Abbott Vascular  Version 17.[ADDRESS_780559] 16, 2018 .  
PROTOCOL 10 -392 
 
ABSORB III  
RANDOMIZED CONTROLLED TRIAL  
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular 
Scaffold in the Treatment of Subjects with de novo  Native Coronary Artery Lesions  
 
 
Version Number  Version 17.[ADDRESS_780560] 16, 2018  
Principal Investigators and 
Study Chairman  
 Principal Investigators:   
Stephen G. Ellis, MD, Cleveland Clinic, Cleveland OH  
Dean J. Kereiakes, MD, The Christ Hospi[INVESTIGATOR_307], Cincinnati, OH  
Study chairman:   
Gregg W. Stone, MD, Columbia University Medical Center, [LOCATION_001], 
NY 
Planned Number of Sites and 
Region(s)  A maximum of 220 sites in the [LOCATION_002] and  
outside the [LOCATION_002]  
Abbott Vascular Medical 
Expert  [INVESTIGATOR_592225], Divisional Vice President Medical Affairs, Chief Medical 
Office  
Trial Type  Prospective, randomized, single -blind, multi -center trial  
Sponsor / Data Monitoring/  
Data Management/Data 
Analysis  Abbott Cardiovascular Systems, Inc.  
[ADDRESS_780561]  
Santa Clara, CA  [ZIP_CODE]  
Trial Monitor  Abbott Vascular  
Enrollment/Randomization 
Service  Bracket  
[ADDRESS_780562]  
Angiographic Core Laboratory  Beth Israel Deaconess Medical Center, Angiographic Core Laboratories, 
[LOCATION_011], MA  
Intravascular Ultrasound 
(IVUS) Core Laboratory  Cardiovascular Core Analysis Laboratory (CCAL), Stanford, CA  
Optical Coherence 
Tomography  (OCT) 
Laboratory  University Hospi[INVESTIGATOR_591946], Cleveland, 
OH 
Clinical Events Committee  Cardiovascular Research Foundation, [LOCATION_001], NY  
Data Safety Monitoring Board  Axio  Research , Seattle, WA    
Protocol Author  Karine Pi[CONTACT_297112] -Ruster , Ph.D.  
  

Abbott Vascular  Version 17.[ADDRESS_780563] 16, 2018 . TABLE OF CONTENTS  
Compliance Statement:  ................................ ................................ ................................ .................... 8 
PROTOCOL SUMMARY  ................................ ................................ ................................ ............... 9 
1. INTRODUCTION  ................................ ................................ ................................ ................ 30 
2. BACKGROUND INFORMATION  ................................ ................................ ..................... 32 
2.1 Summary of Investigational Device  ................................ ................................ ............... 32 
2.1.1  Name [CONTACT_196600]  ................................ ................................ ........... 32 
2.1.2  Intended Indication  ................................ ................................ ................................ ....32 
2.1.3  Absorb BVS Features  ................................ ................................ ................................ 32 
2.1.4  Description of the Investigational Device  ................................ ................................ ..34 
2.1.5  Description of the Control Device  ................................ ................................ ............. 40 
2.1.6  Investigational Device Accountability  ................................ ................................ .......41 
2.1.7  Summary of Pre -Clinical Studies ................................ ................................ ............... 41 
2.1.8  Previous Clinical Studies  ................................ ................................ ........................... 43 
2.1.9  ABSORB TRIALS ................................ ................................ ................................ .....44 
2.1.10  SPI[INVESTIGATOR_591947]  ................................ ................................ ................................ ........ 48 
2.1.11  Patient Reported Outcomes (PRO)  ................................ ................................ ............ 49 
2.2 Trial Rationale  ................................ ................................ ................................ ............... 49 
3. TRIAL  OBJECTIVE  ................................ ................................ ................................ ............ 50 
4. CLINICAL TRIAL/INVESTIGATION FLOW AND FOLLOW -UP SCHEDULE  ........... 50 
4.1 Number of Subjects to be Registered ................................ ................................ ............. 50 
4.2 ABSORB Physician Training  ................................ ................................ ........................ 50 
4.3 Lead -In Phase ................................ ................................ ................................ ................. 52 
4.4 ABSORB III Treatment Flow and Lesion Selection  ................................ ..................... 53 
4.5 Measures Taken to Avoid and Minimize Bias  ................................ ............................... 55 
4.5.1  Randomization  ................................ ................................ ................................ ........... 56 
4.5.2  Blinding ................................ ................................ ................................ ...................... 56 
4.6 Early Termination of the Clinical Trial  ................................ ................................ ......... 57 
5. ENDPOINTS  ……………………………………………………………………………… 57 
5.1 Primary Endpoint  ................................ ................................ ................................ ........... 57 
5.2 Powered Secondary Endpoint(s)  ................................ ................................ .................... 57 
5.3 Additional Secondary Endpoint(s)  ................................ ................................ ................. 59 
5.4 Informational Endpoints (Patient Reported Outcomes)  ................................ ................. [ADDRESS_780564] 16, 2018 . 7.2 Pre-Procedure  ................................ ................................ ................................ ................. 72 
7.2.1  Pre-Procedure Laboratory Assessment  ................................ ................................ ......72 
7.2.2  Dual Anti -Platelet Medications ................................ ................................ .................. 72 
7.2.3  Anti-Coagulation Medications  ................................ ................................ ................... 73 
7.3 Index Procedure  ................................ ................................ ................................ ............. 73 
7.3.1  Baseline (Pre -Procedure) Angiography  ................................ ................................ .....73 
7.3.2  Imaging Guidance Document  ................................ ................................ .................... 73 
7.3.3  Treatment of the Non -target Lesion(s)  ................................ ................................ ......73 
7.3.4  Treatment Rules of the Target Lesion(s)  ................................ ................................ ...74 
7.3.5  Bailout Stenting or Alternative Procedures  ................................ ............................... 80 
7.3.6  Final (Post -procedure) Angiography  ................................ ................................ ......... 81 
7.3.7  Final (Post -procedure) IVUS and OCT  ................................ ................................ .....[ADDRESS_780565]–procedure  ................................ ................................ ................................ ............... [ADDRESS_780566]-procedure Laboratory and Clinical Tests  ................................ ........................... 83 
7.4.3  Follow -up Antiplatelet Medications  ................................ ................................ .......... 84 
7.4.4  Other Chronic Concomitant Medications  ................................ ................................ ..84 
7.5 Clinical and Imaging Follow -up for All Subjects  ................................ .......................... 85 
7.6 Additional Follow -up Visits for All Subjects  ................................ ................................ 86 
8. ADVERSE EVENTS  ................................ ................................ ................................ ............ 87 
8.1 Definitions ................................ ................................ ................................ ...................... 87 
8.1.1  Adverse Event  ................................ ................................ ................................ ............ 87 
8.1.2  Serious Adverse Event  ................................ ................................ ............................... 87 
8.1.3  Device Deficiency/Product Experience  ................................ ................................ .....[ADDRESS_780567]  ................................ ........................... 88 
8.3 Adverse Event/Device Deficiency/Product Experience Reporting  ............................... 89 
8.3.1  Adverse Event and Serious Adverse Event Reporting  ................................ .............. 89 
8.3.2  UADE/[LOCATION_003]DE Reporting to Sponsor and IRB  ................................ ........................ 90 
8.3.3  Device Deficiency/Product Experience Reporting  ................................ .................... [ADDRESS_780568]  ................................ ................... 90 
9. ADJUDICATION OF EVENTS ................................ ................................ ........................... 91 
9.1 The Clinical  Events Committee (CEC) ................................ ................................ .......... [ADDRESS_780569] ACCESS TO SOURCE DATA/DOCUMENTS  ................................ ................... [ADDRESS_780570] Device  ................................ ................... 100 
12.2.3  Training of Sponsor’s Monitors  ................................ ................................ ............... 100 
12.3  Monitoring  ................................ ................................ ................................ ................... 100 
12.3.1 Desig nated Monitors  ................................ ................................ ................................ .100 
12.3.2 Visits  ................................ ................................ ................................ ......................... 101 
12.4  Deviations from Protocol  ................................ ................................ ............................. 101 
12.5  Quality Assurance Audits  ................................ ................................ ............................ 102 
12.6  Sponsor Support to Clinical Trial/Investigation Site for Regulatory Body Inspection
 [ADDRESS_780571] (DSMB)  ................................ ................................ ..103 
12.7.4  Clinical Events Committee (CEC)  ................................ ................................ ........... [ADDRESS_780572]/Medical Ethics Committee Review  ................................ .[ADDRESS_780573] 16, 2018 . 17. Special Populations  ................................ ................................ ................................ ............. 111 
Appendix I: ABBREVIATIONS AND ACRONYMS  ................................ ................................ 113 
APPENDIX II:  DEFINITIONS  ................................ ................................ ............................. 116 
APPENDIX III:  SCHEDULE OF EVENTS  ................................ ................................ ........... 133 
APPENDIX IV:  ENROLLMENT AND REGISTRATION PROCESS  ................................ .133 
APPENDIX V:  VESSEL TREATMENT & RANDOMIZATION  ................................ .......136 
APPENDIX VI:  IMAGING FLOW AND SCHEDULE  ................................ ........................ 139 
APPENDIX VII:  evaluation of lead -in phase  ................................ ................................ ........... 140 
APPENDIX VIII: RISK STRATIFICATION OF Cardiac Catheterization, Stenting and 
Percutaneous Transcatheter Coronary Angioplasty  ................................ ............................ 142 
APPENDIX IX:  CONTACT [CONTACT_7533]  ................................ ................................ ......143 
APPENDIX X:  REFERENCES  ................................ ................................ ............................. 144 
Addendum A:  Pharmacokinetics Sub -study Synopsis  ................................ ......................... 147 
PROTOCOL SUMMARY FOR ABSORB IV  ................................ ................................ ............ 156 
1. INTRODUCTION  ................................ ................................ ................................ .............. 181 
2. BACKGROUND INFORMATION  ................................ ................................ ................... 182 
2.1.1  Name [CONTACT_196600]  ................................ ................................ ......... 182 
2.1.2  Intended Indication  ................................ ................................ ................................ ..182 
2.1.3  Background Information  ................................ ................................ .......................... 182 
2.1.4 Absorb GT1  ................................ ................................ ................................ ................ 182 
2.2 Trial Rationale  ................................ ................................ ................................ ............. 183 
3. TRIAL OBJECTIVE  ................................ ................................ ................................ .......... 183 
4. CLINICAL TRIAL/INVESTIGATION FLOW AND FOLLOW -UP SCHEDULE  ......... 184 
4.1 Number of Subjects to be Registered ................................ ................................ ........... 184 
4.2 ABSORB Physician Training  ................................ ................................ ...................... 184 
4.3 ABSORB IV Treatment Flow and Lesion Selection  ................................ ................... 184 
4.4 Measures Taken to Avoid and Minimize Bias  ................................ ............................. 186 
4.4.1  Randomization  ................................ ................................ ................................ ......... 186 
4.4.2  Blinding ................................ ................................ ................................ .................... 187 
4.5 Early Termination of the Clinical Trial  ................................ ................................ .......188 
5. ENDPOINTS .. ................................ ................................ ................................ .................... 188 
5.1 Primary Endpoints  ................................ ................................ ................................ .......188 
5.2 ABSORB IV Major Secondary Endpoint  ................................ ................................ ....188 
5.3 Additional Secondary Endpoint(s)  ................................ ................................ ............... [ADDRESS_780574] 16, 2018 . 7.1.3  Patient -Reported Outcomes Assessment  ................................ ................................ .192 
7.2 Pre-Procedure  ................................ ................................ ................................ ............... 192 
7.2.1  Pre-Procedure Laboratory Assessment  ................................ ................................ ....192 
7.2.2  Dual Anti -Platelet Medications ................................ ................................ ................ 193 
7.2.3  Anticoagulation Medications  ................................ ................................ ................... 195 
7.2.4  Statin Therapy  ................................ ................................ ................................ .......... 195 
7.3 Index Procedure  ................................ ................................ ................................ ........... 195 
7.3.1  Baseline (Pre -Procedure) Angiography  ................................ ................................ ...195 
7.3.2  Imaging Guidance Document  ................................ ................................ .................. 195 
7.3.3  Treatment Rules of the Target Lesion(s)  ................................ ................................ .195 
7.3.4  Treatment Rules of Unplanned Non -Target Lesion(s)  ................................ ............ 196 
7.3.5  Bailout Stenting or Alternative Procedures  ................................ ............................. 196 
7.3.6  Final (Post -procedure) Angiography  ................................ ................................ .......197 
7.3.7  Final (Post -procedure) IVUS and OCT  ................................ ................................ ...[ADDRESS_780575]–procedure  ................................ ................................ ................................ ............. [ADDRESS_780576]-procedure Laboratory and Clinical Tests  ................................ ......................... 197 
7.4.3  Assessment of perception bias.  ................................ ................................ ................ 198 
7.4.4  Follow -up Antiplatelet Medications  ................................ ................................ ........ 199 
7.4.5  Other Chronic Concomitant Medications  ................................ ................................ 199 
7.5 Clinical Follow -up for All Subjects  ................................ ................................ ............. 199 
7.6 Additional Follow -up Visits for Al l Subjects  ................................ .............................. 200 
8. ADVERSE EVENTS  ................................ ................................ ................................ .......... 201 
8.1 Definitions ................................ ................................ ................................ .................... 201 
8.1.1 Adverse Event  ................................ ................................ ................................ ............. 201 
8.1.2 Serious Adverse Event  ................................ ................................ ................................ 201 
8.1.3 Device Deficiency/Product Experience  ................................ ................................ ......[ADDRESS_780577] ([LOCATION_003]DE)  ................................ ........ 202 
8.3 Adverse Event/ Device Deficiency/ Product Experience Reporting  ........................... [ADDRESS_780578] Reporting to Sponsor and IRB  ......... 204 
8.3.3  Device Deficiency/Product Experience Reporting  ................................ .................. [ADDRESS_780579]  ................................ ................. 205 
9. ADJUDICATION OF EVENTS ................................ ................................ ......................... 205 
9.1 The Clinical Events Committee (CEC) ................................ ................................ ........ 205 
9.2 Angiographic Core Laboratory  ................................ ................................ .................... 205 
10. STATISTICAL ANALYSIS  ................................ ................................ .............................. 205 
10.1  Statistical Overview  ................................ ................................ ................................ .....205 
10.2  Analysis Populations  ................................ ................................ ................................ ....206 
10.2.1  Intent -to-Treat (ITT) Population  ................................ ................................ .............. 206 
10.2.2  As-Treated (AT) Population  ................................ ................................ .................... [ADDRESS_780580] 16, 2018 . 10.4.3  Secondary Endpoint Analyses  ................................ ................................ ................. 209 
10.4.4  Additional Analyses  ................................ ................................ ................................ .210 
10.4.5  Informational Endpoint Analyses  ................................ ................................ ............ 210 
10.4.6  Subgroup Analysis  ................................ ................................ ................................ ...210 
10.4.7  Handling of Multiplicity Issues  ................................ . Error! Bookmark not defined.  
10.4.[ADDRESS_780581] Access to Source Data/Documents Addendum  ................................ ................ 210 
12. ABSORB -RESOLVe: REduction in iSchemia with BiOresorbale Vascular Scaffolds —An 
Imaging Sub -study to ABSORB IV  ................................ ................................ .................... [ADDRESS_780582] Angiography (CCTA)  ................................ ................................ ........ [ADDRESS_780583] Perfusion (CTP)  ................................ ................................ ................................ .[ADDRESS_780584] ................................ ................................ ................................ ....................... 214 
12.1.5.  The Pr esent Study  ................................ ................................ ................................ ....214 
12.2.  Rationale and Design of ABSORB -RESOLVe  ................................ ........................... 214 
12.3.  ABSORB -RESOLVe Study Objectives:  ................................ ................................ .....216 
12.3.1.  Primary Objective (Myocardial Ischemia by [CONTACT_370168]).  ................................ ............ 216 
12.3.2.  Powered Secondary Objective (Myocardial Ischemia by [CONTACT_4654]).  ............................... 216 
12.3.3.  Tertiary Objectives:  ................................ ................................ ................................ .[ADDRESS_780585] Visits  ................................ ................................ ............. 219 
12.4.3.  Procedural Assessments and Treatment Strategy  ................................ .................... 226 
12.5.  References  ................................ ................................ ................................ .................... 227 
Appendix I : ABBREVIATIONS AND ACRONYMS  ................................ ................................ 231 
APPENDIX II:  DEFINITIONS  ................................ ................................ ............................. 232 
APPENDIX III:  SCHEDULE OF EVENTS  ................................ ................................ ........... 236 
APPENDIX IV:  ENROLLMENT AND REGISTRATION PROCESS  ................................ .238 
APPENDIX V:  VESSEL TREATMENT & RANDOMIZATION  ................................ .......240 
APPENDIX VI: RISK STRATIFICATION OF CARDIAC CATHERIZATION, STENTING 
AND PERCUTANEOUS TRANSCATHETER CORONARY ANGIOPLASTY  ............ 243 
APPENDIX VII:  CONTACT [CONTACT_7533]  ................................ ................................ ......[ADDRESS_780586] 16, 2018 . COMPLIANCE STATEMENT :  
This trial will be conducted in accordance with this Protocol/Clinical Investigational Plan, the 
declaration of Helsinki, applicable good clinical practices and regulations (e.g., US 21 CFR Part 
50, 21 CFR Part 56, and 21 CFR Part 812, OUS ISO14155) and the appropriate local 
legislation(s). The most stringent requirements, guidelines or regulations must always be 
followed.  The conduct of the trial w ill be approved by [CONTACT_221456] (IRB)/ Ethics Committee (EC) of the respective investigational site and by [CONTACT_111723] (e.g., FDA, PMDA, MHRA, etc.)  
Sponsor Signatory Representative:  
Approval for this protocol and any subsequent amendments shall be obtained per Abbott 
Vascular Standard / Detailed Operating Procedure(s).
Abbott Vascular  Version 17.[ADDRESS_780587] 16, 2018 . PROTOCOL SUMMARY  
Trial Name [CONTACT_592226]: 10 -392 
Title  THE ABSORB III RANDOMIZED CONTROLLED TRIAL 
(RCT)  
Investigational 
Device  Absorb™ Bioresorbable Vascular Scaffold (BVS) System1: 
• Scaffold diameters: 2.5, 3.0 and 3.5 mm  
• Scaffold lengths2: 8, 12, 18, and 28 mm  
The 3.0 x 18 mm Absorb BVS will be used for the Lead -In.  
Control Device  Commercially approved XIENCE Family Stent System, inclusive of 
XIENCE V, XIENCE PRIME , XIENCE Xpedition , XIENCE Alpi[INVESTIGATOR_050], 
XIENCE P ro (OUS only),and XIENCE P roX (OUS only)3 
• Stent diameters:  2.5, 2.75, 3.0, 3.25*, 3.5 and 4.0 mm  
• Stent lengths:  8, 12, 15, 18, 23, and 28 mm  
XIENCE Family Stent System will hereinafter be called “XIENCE” in 
this study.  
*The 3.25 mm is only available for XIENCE Xpedition  
Objectives  • ABSORB III Primary Objective: The pi[INVESTIGATOR_591948] -market approval (PMA) of Absorb BVS. ABSORB III will 
evaluate the safety and effectiveness of the Absorb BVS System 
compared to the XIENCE in the treatment of subjects, including 
those with diabetes mellitus, with is chemic heart disease caused by 
[CONTACT_592082][INVESTIGATOR_218709].  
• ABSORB III Secondary Objectives:  
• Lead -In Phase Objective: To evaluate the applicability and 
transferability of the didactic Absorb BVS physicia n training 
plan to US clinical practice.  
• Imaging Cohort Objective:  To evaluate long -term vascular 
function and patency of the Absorb BVS treated segments 
compared to XIENCE treated segments in the treatment of 
subjects with ischemic heart disease caused by  [CONTACT_592083] 
                                                           
1 The commercially approved CE marked device will be used in geographies where it is commercially available.  
2 Both the 8 mm and 12 mm length s will be available for the 2.5/3.[ADDRESS_780588] 16, 2018 . novo  native coronary artery lesions in separate epi[INVESTIGATOR_591949].  
Study Design  A prospective, randomized (2:1 Absorb BVS to XIENCE), single -
blind, multi -center trial, registering approxi mately 2250 subjects.  
• The primary endpoint data from this trial will support US premarket 
approval (PMA) of Absorb BVS  and label claims of non -inferiority 
of Absorb BVS as compared to XIENCE in 1 -year target lesion 
failure (TLF).  
The ABSORB III trial also includes a Lead -In Pha se and an Imaging 
Cohort:  
• Lead -In Phase:   
A non -randomized, single -arm, open label group of up to 50 
subjects treated with Absorb BVS at up to 35 US sites. The Lead -In 
phase will enroll/register subjects prior to the randomization  phase 
of ABSORB III.  
• Imag ing Cohort:  
A prospective, randomized (2:1 Absorb BVS to XIENCE), single -
blind, multi -center trial, registering approximately 200 subjects. 
This includes 150 subjects for the angiographic/IVUS endpoints 
analysis and approximately [ADDRESS_780589] endpo ints analysis. 
The 200 subjects are separate from the 2000 subjects inc luded in 
the primary analysis.  
The powered secondary endpoint data from this cohort will support 
label claims of superiority of Absorb BVS as compared to XIENCE 
specific to vasomot ion a nd late lumen enlargement  
The Lead -In Group and Imaging Cohort will operate under the 
ABSORB III trial. The Lead -In Group will enroll/register first. After 
the completion of Lead -In, the rest of ABSORB III subjects (including 
Imaging Cohort) will start to  enroll/register. All trial elements will 
apply to ABSORB III, including the Lead -In Group and the Imaging 
Cohort, unless otherwise specified.  
ABSORB III 
Primary Endpoint  ABSORB III Primary Endpoint  
1. TLF at 1 year, non -inferiority (NI) against the control.  
• TLF is defined as composite of Cardiac Death, Myocardial 
Infarction attributable to Target Vessel (TV -MI), or Ischemia -
Driven Target Lesion Revascularization (ID -TLR).  
• This analysis will include ~[ADDRESS_780590] 16, 2018 . Powered Imaging 
Cohort Secondary 
Endpoints  Imaging secondary endpoints are based on the pooled subjects from the 
Imaging Cohort of ABSORB III (~ 200 angiographic subjects and ~150 
IVUS subjects) and subjects from the ABSORB Japan RCT (~ 400 
angiographic subjects, and ~150 IVUS subjects).  
1. The in -stent/scaffold mean lumen area change, from post -
procedure to 3 years by [CONTACT_427741] (mean lumen area measured after 
nitrate infusions, superiority test, ~300 pooled subjects).  
2. The in -stent/scaffold mean lumen diameter change, between pre - 
and post -nitrate infusion  at 3 years by [CONTACT_89320] (superiority 
test, ~600 pooled subjects).  
Powered 
Secondary 
Endpoint for 
Angina  Angina at [ADDRESS_780591] for superiority of Absorb BVS to XIENCE.  
• Angina  is defined as the first adverse event resulting in the site 
diagnosis of angina.  
• The analysis will exclude angina following the index procedure 
through discharge, not to exceed a period of 7 days  
This analysis will include ~[ADDRESS_780592] for superiority of Absorb BVS to 
XIENCE.  
This analysis will include ~[ADDRESS_780593] ing for 
superiority of Absorb BVS to XIENCE  
This analysis will include ~ 2000 subjects.  
Powered 
Secondary 
Endpoint for 
Diabetic Indication  The powered secondary endpoint will be used to support  a diab etic 
indication for Absorb BVS.  
Patient Reported 
Outcome (PRO) 
Informational 
Endpoints  Patient -reported outcomes are informational endpoints to assess Health -
Related Quality of Life at baseline, 30 days, 1, 2, 3  and 5 years follow -
up. The following questionnaires will be used in this study:  
• EuroQoL 5D (EQ -5D) survey to assess overall health status  
• Seattle Angina Questionnaire (SAQ) to assess disease -specific 
Quality of Life  
• Rose Dyspnea Scale (RDS) to assess sev erity of dyspnea . 
• Generalized Anxiety Disorder scale (GAD -7) to assess anxiety.  
Note s:  
Abbott Vascular  Version 17.[ADDRESS_780594] 
Enrollment, 
Randomization 
and Registration  • Subjects are considered enrolled  in ABSORB III after signing 
the Informed Consent.  
• Subjects are considered randomized  in ABSORB III after the 
interactive voice response system (IVRS) has been called and a 
device (Absorb BVS or XIENCE) has been assigned.  
• Subjects are considered registered  in the ABSORB III upon 
randomization.  
• Enrolled subjects not randomized in the trial will be considered 
screen failures and will not be followed.  
• Lead -In subjects will be considered registered upon calling 
IVRS.  
Refer to Figure 1 in Appendix IV.  
Clinical Follow -Up All subjects in the ABSORB III (including the Lead -In and Imaging 
Cohort)  will receive the following clinical follow -up: 
o 30  [ADDRESS_780595]/office visit  
o 180  [ADDRESS_780596]/office visit  
o 1 year  28 days office visit and electrocardiogram (ECG)  
o Annual visits: 2 -5 years  [ADDRESS_780597]/ 
office visit  
Imaging Follow -
Up for the Imaging 
Cohort  A select number of sites with intravascular ultrasound (IVUS) only or 
IVUS and optical coherence tomography (OCT) capabilities will be 
selected to enroll the [ADDRESS_780598] additional evaluations:  
o Post-procedure: angiography and IVUS (~150 subjects) or 
angiography and OCT (~50 subjects)  
o  3 years  28 days: angiography, IVUS and ECG for 
approximately 150 subjects, OR  
o 3 years  28 days: angiography, OCT and ECG for 
approximately [ADDRESS_780599] received the assigned device.  
Imaging Cohort subjects are required to undergo imaging at 3 years.  
Patient Reported 
Outcome (PRO) 
Follow -Up All 2,000 subjects in the primary analysis will receive the following 
PRO follow -up assessments:  
Abbott Vascular  Version 17.[ADDRESS_780600] 16, 2018 .  o 30  [ADDRESS_780601]/office visit (EQ -5D, 
SAQ, RDS, GAD -7) 
o 1, 2 and 3  year  28 days office visit (EQ -5D, SAQ, RDS, 
GAD -7) 
o 5 year  [ADDRESS_780602]/ office visit  (EQ-
5D, SAQ)  
ABSORB III 
Primary Analysis 
Sample Size 
Justification  ABSORB III Primary Analysis:  
Sample size of this study is based on primary endpoint of 1 year TLF 
using the following assumptions:  
• True rate of 1-year TLF is 7.0% f or both Absorb BVS and XIENCE  
• One-sided alpha = 0.025  
• Non-inferiority margin = 4.5%  
• Power = 96%  
Sample size of 1900 subjects is required for the study (2:1 
randomization); 1267 subjects for Absorb BVS arm and 633 subjects 
for XIENCE arm . Assuming a 5% dropout rate approximately 2,000 
subjects will be required.  
Imaging Cohort 
Analysis Sample 
Size Justification  Imaging Cohort Secondary Endpoint Analysis :  
The assumptions of sample size of this study are detailed in Section 
10.3.2.  
Inclusion Criteria  General Inclusion Criteria  
1. Subject must be at least [ADDRESS_780603] evidence of myocardial ischemia (e.g., 
stable, unstable angina, post -infarct angina or silent ischemia) 
suitable for elective PCI.  Subjects with stable angina or silent 
ischemia and < 70% diameter stenosis must have objectives 
sign of ischemia as determin ed by [CONTACT_080], 
echocardiogram, nuclear scan, ambulatory ECG or stress ECG). 
In the absence of noninvasive ischemia, fractional flow reserve 
(FFR) must be d one and indicative of ischemia.  
4. Subject must be an acceptable candidate for coronary art ery 
by[CONTACT_9292] (CABG) surgery.  
5. Female subject of childbearing potential who does not plan 
pregnancy for up to [ADDRESS_780604] agrees to not participate in an y other investigational or 
invasive clinical study for a period of 1 year following the index 
procedure.4 
Angiographic Inclusion Criteria  
1. One or two de novo  target lesions:  
a. If there is one target lesion, a second non -target lesion may 
be treated but the non-target lesion must be present in a 
different epi[INVESTIGATOR_196518], and must be treated first with a 
successful, uncomplicated result prior to randomization of 
the target lesion.  
b. If two target lesions are present, they must be present in 
different epi[INVESTIGATOR_591950].  
c. The definition of epi[INVESTIGATOR_591951], LCX 
and RCA and their branches. Thus, the patient must not have 
lesions requiring treatment in e.g. both the LAD and a 
diagonal bran ch. 
2. Target lesion(s) must be located in a native coronary artery with 
a visually estimated or quantitatively assessed %DS of ≥ 50% 
and < 100% with a TIMI flow of ≥ 1 and one of the following: 
stenosis ≥ 70%, an abnormal functional test (e.g., fractional fl ow 
reserve, stress test), unstable angina or post -infarct angina.   
a. Lesion(s) must be located in a native coronary artery with 
RVD by [CONTACT_592084]   ≥ 2.50 mm and ≤ 3.75 mm.  
b. Lesion(s) must be located in a native coronary artery with 
length by [CONTACT_592084] ≤ 24 mm.  
c. For Lead -In subjects with 3.0x18 mm Absorb BVS: lesions 
(s) must be located in a native coronary artery with RVD by 
[CONTACT_592084] ≥ 2.75 mm and ≤ 3.25 mm. The lesion 
length by [CONTACT_592085] ≥ 8 mm and ≤ [ADDRESS_780605] 16, 2018 . 1. Any surgery requiring general anesthesia or discontinuation of 
aspi[INVESTIGATOR_34251]/or an ADP antagonist is planned within [ADDRESS_780606] has known hypersensitivity or contraindication to 
device material and its degradants (everolimus, poly (L -lactide), 
poly (DL -lactide), lactide, lactic acid) and cobalt, chromium, 
nickel, platinum, tungsten, acrylic and fluoro polymers that 
cannot be adequately pre -medicated. Subject has a known 
contrast sensitiv ity that cannot be adequately pre -medicated.  
3. Subject has known allergic reaction, hypersensitivity or 
contraindication to aspi[INVESTIGATOR_248]; or to clopi[INVESTIGATOR_591952]; or to heparin and bivalirudin, and therefore cannot be 
adequately treated wit h study medications.  
4. Subject had an acute myocardial infarction (AMI; STEMI or 
NSTEMI) within [ADDRESS_780607] not returned to within normal limits at the 
time of index procedure; or subject with stable angina or s ilent 
ischemia has CK -MB that is greater than normal limits at the 
time of the index procedure.  
5. Subject is currently experiencing clinical symptoms consistent 
with new onset AMI (STEMI or NSTEMI), such as nitrate -
unresponsive prolonged chest pain with isc hemic ECG changes.  
6. Subject has a cardiac arrhythmia as identified at the time of 
screening for which at least one of the following criteria is met:[ADDRESS_780608] has a left ventricular ejection fraction (LVEF) < 30% 
assessed by [CONTACT_592086], including but not limited 
to echocardiography , MRI, Multiple -Gated Acquisition 
(MUGA) scan, contrast left ventriculography, PET scan, etc. 
LVEF may be obtained within [ADDRESS_780609] be assessed during the index  hospi[INVESTIGATOR_059] 
(which may include during the index procedure by [CONTACT_592087]) but prior to randomization in order to confirm 
the subject’s eligibility.   
8. Subject has undergone prior PCI within the target vessel during 
the last 12 months . Prior PCI within the non -target vessel or any 
peripheral intervention is acceptable if performed anytime >[ADDRESS_780610] requires future peripheral interventions < [ADDRESS_780611] is receiving immunosuppressant therapy or has known 
immunosuppressive or severe autoimmune disease that requires 
chronic immunosuppressive therapy (e.g., human 
immunodeficien cy virus, systemic lupus erythematosus, etc.). 
Note: corticosteroids are not included as immunosuppressant 
therapy.  
13. Subject has previously received or is scheduled to receive 
radiotherapy to a coronary artery (vascular brachytherapy), or 
the chest/mediasti num.  
14. Subject is receiving or will require chronic anticoagulation 
therapy (e.g., coumadin, dabigatran, api[INVESTIGATOR_3822], rivaroxaban or 
any other agent for any reason).   
15. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 
cells/mm3.  
16. Subject has a docum ented or suspected hepatic disorder as 
defined as cirrhosis or Child -Pugh ≥ Class B.  
17. Subject has renal insufficiency as defined as an estimated GFR 
< 30 ml/min/1.73m2 or dialysis at the time of screening.[ADDRESS_780612] is high risk of bleeding for any reason; has a history of 
bleeding diathesis or coagulopathy; has had a significant gastro -
intestinal or significant urinary bleed within the past six months.  
19. Subject has had a cerebrovascular accident or transient ischemic 
neurological attack (TIA) within the past  six months, or any 
prior intracranial bleed, or any permanent neurologic defect, or 
any known intracranial pathology (e.g. aneurysm, arteriovenous 
malformation, etc.).  
20. Subject has extensive peripheral vascular disease that precludes 
safe 6 French sheath i nsertion. Note: femoral arterial disease 
does not exclude the patient if radial access may be used.  
                                                           
6 Estimated GFR can be based on Modification of Diet in Renal Dis ease (MDRD) equation or Cockcroft -Gault 
equation (CCG).   
Abbott Vascular  Version 17.[ADDRESS_780613] has life expectancy < [ADDRESS_780614] is part of a vulnerable population who, in the judgment 
of the investigator, is unable to give Informed Consent for 
reasons of incapacity, immaturity, adverse personal 
circumstances or lack of autonomy.  This may include:  
Individuals with mental disability, persons in nursing homes, 
children, impoverished persons, persons in emergency 
situations, homeless persons, nomads, refugees, and those 
incapable of giving informed consent. Vulnerable populations 
also may include members o f a group with a hierarchical 
structure such as university students, subordinate hospi[INVESTIGATOR_400092], employees of the Sponsor, members of 
the armed forces, and persons kept in detention.  
 
Angiographic Exclusion Criteria  
All exclusion criteri a apply to the target lesion(s) or target vessel(s).  
1. Lesion which prevents successful balloon pre -dilatation, defined 
as full balloon expansion with the following outcomes:  
▪ Residual %DS is a maximum < 40% (per visual 
estimation), ≤ 20% is strongly recomme nded.  
▪ TIMI Grade -3 flow (per visual estimation).  
▪ No angiographic complications (e.g. distal embolization, 
side branch closure).  
▪ No dissections NHLBI grade D -F.  
▪ No chest pain lasting > 5 minutes.   
▪ No ST depression or elevation lasting > 5 minutes.  
2. Lesion  is located in left main.  
3. Aorto -ostial RCA lesion (within 3 mm of the ostium).  
4. Lesion located within [ADDRESS_780615] 16, 2018 . 5. Lesion involving a bifurcation with a:  
a. side branch ≥ 2 mm in diameter, or  
b. side branch with either an ostial or non -ostial lesion with 
diameter stenosis > 50%, or  
c. side branch requiring dilatation  
6. Anatomy proximal to or within the lesion that may impair 
delivery of the Absorb  BVS or XIENCE stent:  
a. Extreme angulation (≥ 90°) proximal to or within the 
target lesion.  
b. Excess ive tortuosity (≥ two 45° angles) proximal to or 
within the target lesion.  
c. Moderate or heavy calcification proximal to or within 
the target lesion. If IVUS used, subject must be excluded 
if calcium arc in the vessel prior to the lesion or within 
the lesion  is ≥ 180°.   
7. Vessel contains thrombus as indicated in the angiographic 
images or by [CONTACT_592088].  
8. Lesion or vessel involves a myocardial bridge.  
9. Vessel has been previously treated with a stent at any time prior 
to the index procedure such that the Absorb BVS or XIENCE 
would need to cross the stent to reach the target lesion.  
10. Vessel has been previously treated and the target lesion is within 
[ADDRESS_780616] 16, 2018 . Lesion Selection  Prior to treatment with the assigned device (Absorb BVS or XIENCE), 
vessel sizing by [CONTACT_592089].  Quantitative methods such as 
on-line QCA, IVUS or OCT can be used if deemed necessary per 
physician discretion, but are not required. Details on the vessel sizing 
methods can be found in  the Imaging Guidance Document.  
Table 1.0 provides the device sizes, the reference vessel diameter 
(RVD) and lesion length for ABSORB III.  
Table 1.0 Absorb BVS and XIENCE Sizes  
Device  Lesion and Device Sizes  
RVD 1 Lesion Length1 
Lead -In 
Absorb BVS  
(Target lesion)  RVD  2.75 mm -  3.25 mm  
 
Scaffold diameter: 3.0 mm  Lesion length  8- 14 mm  
Scaffold length: [ADDRESS_780617] Absorb 
BVS  
(Target lesion)  RVD  2.50 mm -  3.75 mm  
 
Scaffold diameter: 2.5, 3.0 and 
3.5 mm  Lesion length  24 mm  
Scaffold Length2: 8, 12, [ADDRESS_780618] 
XIENCE5  
(Target lesion)  
 RVD  2.50 mm -  3.75 mm  
 
Stent diameter: 2.5, 2.75, 3.0, 
3.25 3.5, 4.0 mm  Lesion length  24 mm  
Stent Length: 8, 12, 15, 18, 23 
and 28 mm 3  
 
XIENCE  
(Non -target 
lesion)  Per IFU (RVD ≥ 2.25 mm - ≤ 
4.25 mm can be treated)  
All available sizes  Per IFU (lesion ≤ 32 mm) 4  
All available sizes  
1 Reference vessel diameter (RVD) and lesion length are based on visual estimation.  
2 Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 diameter Absorb 
BVS.  Only the 12 mm length will be available for the 3.5 mm diameter. The 
commercially approved CE marked 23mm Absorb BVS device will not be used in 
this study.  
3 For target lesion, p lanned overlappi[INVESTIGATOR_411418] (i.e. the lesion must be eligible 
for treatm ent with a single stent) . However, bailout overlappi[INVESTIGATOR_591953].  
4 For non -target lesion, planned overlappi[INVESTIGATOR_591954].  
5 XIENCE V, XIENCE Prime, XIENCE Xpedition, XIENCE Alpi[INVESTIGATOR_050], XIENCE Pro, 
and XIENCE ProX are used in this study.  
A minimum of  2 mm (by [CONTACT_142184] ) of normal or nearly normal 
reference vessel at both proximal and distal edge should be covered by 
[CONTACT_8121].  
Treatment 
Strategy  • Treatment of a maximum of two de novo  native coronary artery 
lesions, each in a different epi[INVESTIGATOR_196518].  
o If a single target lesion is treated, it m ust be treated by [CONTACT_592090] (Absorb BVS or XIENCE). For Lead -In 
subject, the target lesion will be treated only with Absorb BVS.  
o If two lesions are treated, possible combinations are as follows:  
Abbott Vascular  Version 17.[ADDRESS_780619] 16, 2018 . o Two target lesions:  
▪ If both lesions satisfy angiographic inclusion/exclusion 
criteria, then both lesions must be treated by [CONTACT_592091] (test device: 
Absorb BVS or control device: XIENCE),  
▪ For Lead -In subjects, both target lesions will be treated 
with Absorb BVS  
OR 
o One target lesion and one non -target lesion:  
▪ If only one lesion satisfies angiographic inclusion and 
exclusion criteria then this lesion must be treated by [CONTACT_592090] (test device: Absorb BVS or control 
device: XIENCE) as a target lesion and the other lesion 
must be treated by [CONTACT_592092] a no n-target lesion per 
the instructions for use  (IFU).  
▪ The non -target lesion must be treated first (before 
randomization) with a XIENCE and the patient may 
then only be randomized if treatment of the non -target 
lesion was successful and uncomplicated, defined as 
final diameter stenosis ≤ 10% with final TIMI -3 flow, 
with no residual dissection NHLBI grade ≥ type B, and 
no transient or sustained angiographic complications 
(e.g., distal embolization, side branch closure) , no chest 
pain lasting > [ADDRESS_780620] segment elevation or 
depression lasting > 5 minu tes. Refer to Figure 2 in 
Appendix V.  
▪ For Lead -In subjects, treatment of one target lesion and 
one non -target lesion is allowed. The target lesion must 
be treated by [CONTACT_592093], and the non -target lesion 
must be treated by [CONTACT_592094]. The non -target lesion mus t 
be treated first and successfully (as defined above) 
before treating the target lesion with Absorb BVS.  
 
Access Site and Guide Catheter Size:  
• Either femoral or radial access may be used.  
• A minimum 6F guide catheter or greater must be used during the 
index procedure per requirements for Absorb B VS implantation 
(refer to IFU).  
o Minimum guiding catheter compatibility (inner diameter) for 
Absorb BVS is 0.070”/1.8 mm (6F).  
o Devices (i.e., guide sheaths such as the Guide Liner) that 
decrease the inner diameter of  the guide catheter outside of the 
Abbott Vascular  Version 17.[ADDRESS_780621] meet or 
exceed the above minimum guiding catheter requirements for 
Absorb BVS (i.e.,  only the 7 -in-8 GuideLiner provides an 
adequate inner diameter (0.071” ID), 8F guiding catheter would 
be required).  
o For XIENCE, please follow IFU for guiding catheter size.  
 
Baseline Angiogram and Identification of the potential target 
lesion:  
• Assessment of the potential target lesion(s) to be treated must be  
done to ensure angiographic criteria are met; this must occur prior 
to pre -dilatation and vessel sizing.  
 
Pre-dilatation of potential target lesion  
• Pre-dilatation of the potential target lesions(s) must be performed.  
• Pre-dilatation must be performed with an angioplasty balloon; 
cutting or scoring balloons may be used per physician discretion, if 
the lesion appears to be mildly calcified.  
• The pre -dilatation balloon should be sized 1:1 to the visually 
estimated RVD or 0.25 mm smaller than RVD. It cannot be m ore 
than 0.5 mm smaller than the visually estimated RVD of the target 
vessel. If the pre -dilatation balloon is sized 1:[ADDRESS_780622] be equal in length or shorter than 
the planned scaffol d/stent length.  
Important: Full balloon expansion with the pre -dilatation balloon 
must be achieved before the patient is randomized into the study. If 
there is any question that the target lesion was not fully dilated or 
that any significant resistance to expansion from the lesion remains, 
the lesion should be re -dilated with a non -compliant balloon (sized 
1:1 to the RVD) at higher pressure. Absorb BVS or XIENCE must 
not be implanted in a lesion in which full balloon expansion has not 
been achieved.  
• The pot ential target lesion must continue to meet angiographic 
criteria following adequate pre -dilatation, to be regarded as 
“successful pre -dilatation”.  
Abbott Vascular  Version 17.[ADDRESS_780623] 16, 2018 . o For randomized subjects, RVD remains ≥ 2.50 mm - ≤ 3.75 
mm, and length of the lesion that will be covered by [CONTACT_8121] 
(including any edge dissections) is still ≤ 24 mm.  
o For Lead -In subjects, RVD remains ≥ 2.75 mm - ≤ 3.25 mm , 
and length of the lesion that will be covered by [CONTACT_8121] 
(including any edge dissections) is still ≥8 - ≤ 14 mm . 
o Residual %DS is a maxi mum of < 40% (per visual estimation),  
≤ 20% is strongly recommended.  
o TIMI Grade -3 flow (per visual estimation).  
o No angiographic complications (e.g. distal embolization, side 
branch closure).  
o No dissections NHLBI grade D -F. 
o No chest pain lasting > [ADDRESS_780624] depression or elevation lasting > 5 minutes.  
• For two potential target lesions, the lesion with the higher 
possibility of failing vessel sizing criteria (per investigator’s 
assessment) should be identified as the first target lesion and pre -
dilated first before randomization.  
o If pre -dilatation of the 1st target lesion fails, the patient may not 
be randomized, and the interactive voice response system 
(IVRS) must not be called.  
o If the 1st target lesion was successfully pre -dilated and vessel 
sizing criteria are still met, the IVRS is called to randomize the 
subject. Once the first lesion is successfully treated8 with the 
assigned device (and only at this time), the second target lesion 
must be pre -dilated, and then tr eated with the assigned devi ce. 
o If the 1st target lesion was successfully pre -dilated but did not 
meet vessel sizing criteria, treat as a non -target lesion. Once the 
first lesion is successfully treated as a non -target lesion, the 
second lesion must be treated as the target lesion in  which 
successful  pre -dilatation and vessel sizing criteria must be met 
after which IVRS must be called and the target lesion treated 
per assignment. If 2nd target lesion fails pre -dilatation and vessel 
sizing criteria, it should be treated as non -target lesion and 
subject must not be randomized.  
• Each target vessel and lesion should  also be such that the operator 
believes either the Absorb BVS or XIENCE devices could be 
delivered to and cross the target lesion without additional lesion 
                                                           
8 Successful lesion treatment is defined as final diameter stenosis ≤ 3 0% with final TIMI -3 flow, with no residual 
dissection NHLBI grade ≥ type B, and no transient or sustained  angiographic complications (e.g. distal 
embolization, side branch closure), no chest pain lasting > [ADDRESS_780625] segment elevation or depression 
lasting > [ADDRESS_780626] 16, 2018 . preparation (e.g. ab sence  of excessive vessel or lesio n tortuosity or 
calcification).  
 
Vessel Sizing  
• Following the use of nitroglycerine (at least 100 µg intracoronary 
nitroglycerine, >150 µg preferred)9 and successful pre -dilatation of 
the potential target lesion(s), vessel sizing must be conducted by 
[CONTACT_142184]. Quantitative methods such as on -line QCA, 
IVUS or OCT may be used per physician discretion but are not 
required , taking into account tha t QCA tends to under -estimate 
RVD compared to visual estimation, whereas IVUS tends to over -
estimate lumen RVD compared to visual estimation. Follow core 
laboratory guidelines for the use of each modality.  
• Prior to randomization, IVUS or OCT can be used to  evaluate the 
vessel if there is question regarding the eligibility of the vessel 
either before or after pre -dilatation.  
• A subject must not be randomized in ABSORB III if : 
o Vessel size or lesion length before or after pre -dilatation does 
not satisfy eligibi lity criteria.  
o Moderate or heavy calcification, tortuosity or other conditions 
are present proximal or within the target segment, reducing the 
likelihood that the Absorb BVS or XIENCE can be either 
delivered to or expanded at the lesion.  
o Complications and/ or adverse events were identified during 
IVUS or OCT usage (e.g. vessel dissection NHLBI grade D -
F).10 
• Table 2.0 provides the guidance of vessel and device sizing during 
the procedure, which are detailed as the following:  
o First, assess RVD based on visual e stimation  
o Then, select a pre -dilatation balloon sized 1:1 to RVD or 0.25 
mm smaller than RVD. For example, for RVD of 2.5 mm, a 
pre-dilatation balloon of 2.25 -2.5 mm should be used.  
o Use the size of the inflated pre -dilatation balloon, as well as the 
results after pre -dilatation, to reassess the RVD for appropriate 
vessel sizing for the scaffold or stent. If the reassessed RVD 
after pre -dilatation exceeds the specified range for a specific 
                                                           
9 If the patient’s blood pressure is so low that ≥ 100 ug of nitroglycerine canno t be administered, the patient should 
not be randomized. It is suggested that ≥200 µg of nitroglycerine be administered if the systolic blood pressure is 
>[ADDRESS_780627]: side -branch occlusion, persistent S -T abnormalities, 
prolonged  chest pain , flow limiting dissections  etc. 
Abbott Vascular  Version 17.[ADDRESS_780628] -dilatation balloon has 
a length short enough so it is inflated within the scaffold 
margins to avoid edge dissectio n. 
Table 2.0  Vessel and Device Sizing [1]  
Closest RVD 
by [CONTACT_592095]-dilatation 
Balloon Diameter  Reassessed 
Closest RVD 
after Pre -
dilatation  Absorb BVS 
Diameter  
2.5 mm  2.25 or 2.5 mm  2.5 mm  2.5 mm  
2.75 mm  2.25 – 2.75 mm  2.75 mm  3.0 mm  
3.0 mm  2.5 – 3.0 mm  3.0 mm  3.0 mm  
3.25 mm  2.75 – 3.25 mm  3.25 mm  3.5 mm  
3.5 mm  3.0 – 3.5 mm  3.5 mm  3.5 mm  
3.75 mm  3.25 – 3.75 mm  3.75 mm  3.5 mm  
 
Randomization  
• Upon successful treatment of the non -target lesion (if any) and 
completion of successful pre -dilatation and vessel sizing of the  first 
target lesion, interactive voice response system (IVRS) can be 
called.  
• A subject is considered registered and in the ITT populatio n at the 
time of randomization.  
• Lead -In subjects will not be randomized but are assigned to Absorb 
BVS treatment in tar get lesion(s).  
 
Lesion Treatment  
• The length of the Absorb BVS and XIENCE stent should be 
selected to allow at least 2 mm of normal or nearly normal 
reference vessel at each edge.  
• If the Absorb BVS cannot reach or cross the lesion or additional 
lesion prepa ration is required, the Absorb BVS must be removed 
and a new Absorb BVS must be introduced after subsequent pre -
dilatation(s) with the same sized or larger non -compliant balloon at 
higher pressure. Note: the Absorb BVS should not be “Dottered” 
across the lesion if it does not cross easily.  
Abbott Vascular  Version 17.[ADDRESS_780629] 16, 2018 . • If the Absorb BVS is unable to reach or cross the target lesion after 
multiple attempts (maximum of two Absorb BVS; including 
additional lesion preparation ), a XIENCE stent must be used.  
• If XIENCE is unable to reach or c ross the target lesion after 
multiple attempts (including additional lesion preparation) , the 
investigator should treat the lesion per standard of care . 
• In the case of two target lesions assigned to the Absorb BVS, if the 
first lesion is unsuccessfully tre ated with the Absorb BVS the 
following must occur:  
o First target lesion must be treated with XIENCE. If the 
treatment of the 1st target lesion is successfully treated with 
XIENCE, treat the 2nd target lesion with Absorb BVS.  
o  If the treatment of the 1st target lesion is unsuccessfully treated 
with XIENCE, treat the 1st lesion and 2nd lesion per standard of 
care. The subject must not be treated with Absorb BVS.  
o Every attempt must be made that the two lesion treatments 
occur at the same index procedure as  staged procedures are not 
allowed. However, if a staged procedure does occur, Absorb 
BVS must not  be used.  
Successful lesion treatment is defined as final diameter stenosis ≤ 
30% with final TIMI -3 flow, with no residual dissection NHLBI 
grade ≥ type B, a nd no transient or sustained angiographic 
complications (e.g. distal embolization, side branch closure) , no 
chest pain lasting > [ADDRESS_780630] segment elevation or 
depression lasting > 5 minutes.   
• For Absorb BVS, the scaffold should be deployed slo wly, by 
[CONTACT_592096] 2 atm increments each over 5 
seconds, until the scaffold is completely expanded. Pressure should 
be maintained for 30 seconds if tolerated by [CONTACT_102].  
• For the Absorb BVS and XIENCE delivery balloon, do not ex ceed 
the rated burst pressure (RBP) per the IFU for the individual device.  
• Post-dilatation of target lesion or non -target lesion treated with 
XIENCE should be per standard of care.  
• If post -dilatation of the target lesion treated with Absorb BVS is 
necessar y the following guidance is given:  
o A low profile, high pressure, non -compliant, balloon dilatation 
catheter that has not been previously inflated must be used.  
o The post -dilatation balloon length should be selected such that 
the balloon stays within the mar gins of the scaffold so as to 
avoid an edge dissection.  
o The expanded diameter of the post dilatation balloon must be 
within the allowable expansion limits of the scaffold. Do not 
Abbott Vascular  Version 17.[ADDRESS_780631] -dilatation.  
• During randomization, if a bailout device is required for a target 
lesion (e.g., for edge dissection), the same device as the implanted 
device must be used.  
o Absorb BVS if target lesion is treated with Absorb BVS.  
o XIENCE if target lesion is treated with XIENCE.  
o If a bailout with an Absorb BVS device cannot be delivered to 
the site of the lesion, the device should be carefully withdrawn 
and a XIENCE used.  
o If an appropriate size Absorb BVS is not available XIENCE can  
be used.  
• If during the Lead -In phase a bailout is required, the investigator 
should use an appropriately sized XIENCE stent and not an Absorb 
BVS.  
• Overlap of the bailout stent/scaffold with the implanted 
stent/scaffold should be 1 -2 mm; gaps should be av oided.  
• IVUS or OCT guidance may be used as per standard of care in all 
patients.  
• Please refer to the physician training deck for user guidance in 
handling procedural issues (e.g., difficult in recrossing an implanted 
scaffold for purposes such as intravascular imaging or post -
dilatation if needed).  
 
Imaging Cohort  
If subject is in the Imaging Cohort (See Appendix VI and Imaging 
Guidance Document for further details):  
Abbott Vascular  Version 17.[ADDRESS_780632] 16, 2018 . • Post-procedure angiography, IVUS and OCT are required based on 
respective imagin g groups.  
• If post -dilatation was performed, post -procedure imaging must be 
conducted following last balloon inflation.  
• If two target lesions are treated, post -procedure imaging must be 
done on the first target lesion after its successful treatment, and the n 
after successful treatment of the 2nd target lesion.    
Antiplatelet11 
Therapy  Antiplatelet Medication Loading Dose:  
• Aspi[INVESTIGATOR_248]: Subjects must receive a loading dose of ≥ 300 mg of 
aspi[INVESTIGATOR_103838] 24 hours before the procedure, regardless of whether 
the patient was previously taking aspi[INVESTIGATOR_248]  
• Adenosine diphosphate (ADP) antagonist: either clopi[INVESTIGATOR_7745], 
prasugrel or ticagrelor may be used as per standard of care and per 
label indications. A loading dose of the ADP antagonist  must be 
given within 24 hours prio r to the index procedure (preferred) but in 
all cases no greater than 1 hour after the end of the procedure.  
o Clopi[INVESTIGATOR_7745]: a peri -procedural loading dose 600 mg is 
required  
o Prasugrel: a peri -procedural loading dose of 60 mg is 
required  
o Ticagrelor: a peri -procedural loading dose of 180 mg is 
required.  
• For patients with recent ACS prior to admission, it is strongly 
recommended that the loading dose be given at least 6 hours before 
the procedure (clopi[INVESTIGATOR_7745] 600 mg), or 1 hour prior to the procedure 
(prasugrel  60 mg or ticagrelor 180 mg), but in all cases no greater 
than 1 hour after the end of the procedure.  
• The prasugrel or ticagrelor loading dose may be omitted for those 
subjects on chronic prasugrel (5 or 10 mg daily) or ticagrelor (90 
mg twice daily) for ≥ [ADDRESS_780633] be administered. A loading dose of prasugrel 
or ticagrelor may be safely given to patients maintained on chronic 
clopi[INVESTIGATOR_7745] t herapy, or even in those in whom a clopi[INVESTIGATOR_591955].  
• Ticlopi[INVESTIGATOR_591956] a substitute at a dose in accordance with 
standard hospi[INVESTIGATOR_591957] 
                                                           
[ADDRESS_780634] 16, 2018 . hypersensitivity or intolerance to clopi[INVESTIGATOR_126865], prasugrel, or 
ticagrelor.  
• Refer to respective prescribing information for ADP Antagonist for 
further details regarding loading practice.  
 
Antiplatelet Medication Post -Procedure Daily Dose:  
• All subjects will be maintained at a minimum of 75 mg of 
clopi[INVESTIGATOR_196511] 5 or 10  mg of prasugrel daily ([ADDRESS_780635] patients*) or 90 mg twice daily of ticagrelor for a minimum 
of 12 months following the procedure.  
• All subjects must receive ≥75 to ≤100 mg of aspi[INVESTIGATOR_196514] 5 
years follow -up during the study and should continue to take aspi[INVESTIGATOR_591958].  
*For prasugrel subjects < 60 kg in weight or ≥ [ADDRESS_780636] for 
further details regarding maintenance dose.  
Cardiac 
Biomarker 
Collection  Between Baseline and Discharge  
• Pre-procedure CK and CK -MB draw*  
• First post -procedure CK and CK -MB draw at [ADDRESS_780637] -
procedure.  
• Second post -procedure CK and CK -MB draw at [ADDRESS_780638] -procedure.**  
• If either of the post -procedure CK -MB levels are ≥ [ADDRESS_780639] be drawn until they are falling.  
• A [ADDRESS_780640] procedure  
* If the patient has stable coronary artery disease, the pre -procedure 
level can be obtained during procedure but prior to stent/scaffold 
deployment. If the patient has a recent acute coronary syndrome, the 
pre-procedure level must be obtained prior to the procedure and the 
CK-MB shown to be within normal limits prior to the patient being 
randomized.  
CK and CK -MB levels are required at all  time points. If troponin is 
collected at the pre -procedure or post -procedure time points, this should 
also be documented in the electronic case report forms.   
Abbott Vascular  Version 17.[ADDRESS_780641] 16, 2018 . ** For hospi[INVESTIGATOR_591959] [ADDRESS_780642] 16, 2018 . 1. INTRODUCTION  
The ABSORB III Randomized Controlled Trial (RCT) evaluates the safety and effectiveness of 
the Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System12. The Absorb 
BVS System13 will be compared to the commercially approved, control stent XIENCE. 
ABSORB III also includes a Lead -In phase and an Imaging Cohort and includes a maximum of 
220 sites in the [LOCATION_002] and outside the [LOCATION_002]. The ABSORB III primary endpoint 
is target lesion failure (TLF) (cardiac death, target vessel myocardial infarction and ischemia -
driven target lesion revascularization) at 1 year.  
The Absorb BVS used in the ABSORB III trial is the Absorb BVS System manufactured in 
Temecula [LOCATION_004] [Absor b BVS System (mfg TEM)]13.  Clinical trials in the ABSORB 
Clinical Program have utilized the Absorb BVS System manufactured in Mountain View 
[LOCATION_004] (mfg MTV).  The Absorb BVS System (mfg TEM) introduces eight additional sizes to 
the Absorb BVS System p roduct matrix for ABSORB III (Refer to Table 4.1).  Concurrent with 
the manufacturing site transfer, Abbott Vascular has implemented design and manufacturing 
enhancements to increase product robustness and product ease of use (Refer to Section [IP_ADDRESS]). 
Hereinafter, Absorb BVS System (mfg TEM)13 will be known as Absorb BVS, unless specified.  
ABSORB III is a prospective, randomized (2:1 Absorb BVS to XIENCE), single -blind, multi -
center trial, registering approximately 2250 subjects. This is the pi[INVESTIGATOR_141370] l to support the US 
PMA approval of Absorb BVS. The primary objective of ABSORB III is to evaluate the safety 
and effectiveness of the Absorb BVS System compared to the XIENCE in the treatment of 
subjects with ischemic heart disease caused by [CONTACT_592097][INVESTIGATOR_218709]. The primary endpoint data from this trial will be based on 
approximately 2000 subjects and will support label claims of non -inferiority of Absorb BVS as 
compared to XIENCE in 1 -year TLF. T he ABSORB III will also include a Lead -In Phase and an 
Imaging Cohort. The ABSORB III will also support a diabetes indication for Absorb BVS.  
Lead -In Phase  
A non -randomized, single -arm, open label group of up to 50 subjects treated with Absorb BVS at 
up to 35 US sites. The objective of the Lead -In is to evaluate the applicability and transferability 
of the didactic Absorb BVS physician training plan to US cli nical practice. The Lead -In Phase 
will enroll/register subjects prior to the randomization in ABSORB III.  
Imaging Cohort  
A prospective, randomized (2:1 Absorb BVS to XIENCE), single -blind, multi -center cohort, 
registering approximately 200 subjects. The 200 subjects are separate from the 2000 subjects 
included in the primary endpoint analysis. The objective of the Imaging Cohort is to evaluate 
long-term vascular function and patency of the Absorb BVS treated segments compared to 
XIENCE treated segments. D ata from two powered secondary endpoints from this cohort will 
                                                           
12 The commercially approved CE marked devic e will be used in geographies where it is commercially available.  
13 The A bsorb ™ Bioresorbable Vascular Scaffold (BVS) System is the trade name [CONTACT_592227]. During the 
course of development, multiple product names were used to describe this product inc luding, Bioresorbable 
Vascular Scaffold (BVS) System, Bioabsorbable Vascular Stent, BVS Everolimus Eluting Coronary Stent System 
(EECSS), Abbott Vascular Bioabsorbable Device (AVBD) EECSS, BVS Cohort A (used in the ABSORB Cohort A 
trial) and BVS Cohort B ( used in the ABSORB Cohort B trial).  
Abbott Vascular  Version 17.[ADDRESS_780643] 16, 2018 . support label claims of superiority of Absorb BVS as compared to XIENCE specific to 
vasomotion and late lumen enlargement.  
After the completion of Lead -In Phase, enroll/registration of the 2000  subjects for the primary 
analysis and the 200 subjects in the Imaging Cohort will begin. All trial elements will apply to 
Lead -In Phase and the Imaging Cohort , unless otherwise specified.  
Figure 1.1  provides the complete ABSORB III design.  
  
Figure 1.1:  ABSORB III  Overall Design  
In addition, all 2,000 primary analysis subjects in ABSORB III will complete patient -reported 
outcome (PRO) self -administered questionnaires at baseline, 30 days,  1, 2 and 3 years  (EQ-5D, 
SAQ, RDS, GAD -7) and  at 5 years (EQ-5D, SAQ) .  
The Lead -In Phase allows the treatment of up to two de novo  native coronary artery lesions in 
different epi[INVESTIGATOR_591960] ≥ 2.75 mm to ≤ 3.25 mm and lesion lengths ≥ 8 to ≤ 14 
mm. All other subjects in ABSORB III  unless specified w ill receive  treatment of up to two de 
novo  native coronary artery lesions in different epi[INVESTIGATOR_591960] ≥ 2.5 mm to ≤ 3.75 
mm and lesion lengths ≤ 24 mm.  
All subjects (including Lead -In) will be screened per the protocol inclusion and exclusion  criteria 
and registered subjects will have clinical follow -up at [ADDRESS_780644].  
ABSORB III 
Randomized 2:1 (BVS :XIENCE) 
N=2250   
Primary EP:1 yr TLF Non-inferiority of Absorb BVS vs. XIENCE
 
ABSORB 
Imaging  Cohort
                   
Randomized 2:1 (BVS :XIENCE) 
N=200
Powered Secondary EPs: Superiority of 
Absorb BVS to XIENCE at: 
1) 3 yrs with vasomotion (n=200)  
2) 3 yrs late lumen enlargement (n=150)
Descriptive assessment of target lesion by 
[CONTACT_63396] (n=50)Non-randomized: 
Absorb BVS only
Primary objective:                           
Evaluation of physician training
N= up to [ADDRESS_780645] device is referred to as “the Absorb BVS”. The Absorb BVS 
System is manufactured by [CONTACT_592098], Inc., [LOCATION_004], an affiliate of 
Abbott Vascular, Inc. 
2.1.2  Intended Indication  
The Absorb Bioresorbable Vascular Scaffold (BVS) is a temporary scaffold that will fully resorb 
over time and is indicated for improving coronary luminal diameter in patients, including those 
with diabetes mellitus, with ischemic heart disease due to de novo  native coronary artery lesions 
(length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.[ADDRESS_780646] therapeutic catheterization for coronary artery stenosis was performed by [CONTACT_592099] 1977. Percutaneous transluminal coronary angioplasty (PTCA) with a balloon was 
the first therapy which became commonly performed. After a vessel is treated by [CONTACT_592100], which may require additional treatment, can occur due to 1) acute recoil, 2) 
remodeling, and/or 3) neointimal proliferation. A stent can minimize the occurrence of recoil and 
remodeling by [CONTACT_592101]. However, the vessel support is 
required only for approximately three - six months to prevent recoil and remodeling [2-4] , and 
an imp lanted stent after this period may no longer be necessary.  
The Absorb BVS is designed to revascularize obstructed coronary arteries and ultimately restore 
the implanted vessel to an unconstrained state potentially capable of dilating and contracting in 
response to changes in blood flow requirements.  The performance of the Absorb BVS is 
described by [CONTACT_592102], namely revascularization, restoration, and 
resorption ( Figure 2.1 ).  These stages parallel the well -known description of P LA degradation, 
whereby [CONTACT_317664], strength, and mass loss decrease progressively one after the other [5].  
It is important to note that Figure 2.[ADDRESS_780647] 16, 2018 .   
 
Figure 2.1:  Schematic Drawing of the Minimum Design Objectives for the Three Phases of 
Absorb BVS performance  
The revascularization phase is the first phase, in which the Absorb BVS most closely mimic the 
design considerations of metallic DES. Specifically, it is necessary that the device be deliverable 
to the target site, the scaffold deploy with a minimum of rec oil and provide adequate acute radial 
strength, and the therapeutic agent be delivered to abluminal tissue at a controlled rate.  The 
critical performance attribute of the Absorb BVS during the revascularization stage is to provide 
luminal support for the period of time necessary for the vessel lumen to stabilize.  Percutaneous 
transluminal coronary angioplasty (PTCA) data for mean lumen diameter and percent diameter 
stenosis suggest that this time scale is approximately three months [4] . 
The restoration phase characterizes the transition from active support of the lumen to a passive 
implant consisting of discontinuous structural elements.  The aggregate of luminal scaffolding 
and structural continuity is represented by [CONTACT_592103] “Support” in Figure 2.[ADDRESS_780648] ic acid, which is readily converted to lactate.  Lactate is in turn 
metabolized into CO 2 and H 2O via the Krebs Cycle and also serves as a source of energy in 
anaerobic metabolism [6-8].    
Revascularization Restoration Resorption
[ADDRESS_780649] 16, 2018 . 2.1.4  Description of the Investigational Device  
The Absorb B VS System is a balloon -expandable, drug -eluting bioresorbable vascular scaffold, 
where the components of the Absorb BVS System include:  
• A bioresorbable poly(L -lactide) (PLLA) scaffold backbone.  
• A coating comprised of the active pharmaceutical ingredient ev erolimus and 
bioresorbable poly(D,L -lactide) (PDLLA).  
• Four platinum marker beads, two each embedded at the proximal and distal ends 
of the scaffold for radiopacity.  
• A delivery system similar in design, materials, and performance to that of the 
MULTI -LINK V ISION® Rapid Exchange (RX) Coronary Stent System (CSS) 
and MULTI -LINK MINI VISION® CSS (P020047 and supplements).  
[IP_ADDRESS]  Polylactide  
Bioresorbable polymers have been the subject of extensive scientific research and commercial 
development in fields as dive rse as food packaging and biomedical devices.  Polylactide (PLA) 
and its copolymers have a long history of use in medical devices starting with bioresorbable 
sutures in the 1960s. These polymers are now used in a wide range of bioresorbable implants, 
inclu ding:  orthopedic devices such as plates, pi[INVESTIGATOR_591961]; drug delivery systems such as 
solid implants and gel based systems; suture anchors; peripheral bioabsorbable stents; and 
surgical mesh and clips. Prior experience with bioresorbable polymers in hum an applications 
includes the Angio -Seal™ vascular closure device (St. Jude Medical) [9], BioMatrix™ drug -
eluting stent (Biosensors International Ltd.) [10], the Bio -Corkscrew™ full -threaded suture 
anchor (Arthrex, Inc.) [11], (Longo) and the Igaki -Tamai® bioabsorbable stent (Kyoto Medical 
Planning Co Ltd.) [12].  The Angio -Seal device, fabricated in part from poly(lactide -co-
glycolide) (PLGA), reveals that the release of degradation products from a bioresorbable device 
is well tolerated by a blood vessel. The BioMat rix DES contains a PDLLA coating, which 
controls the drug release into the coronary tissue and bloodstream.  The Bio -Corkscrew suture 
anchor exemplifies the safe use of PDLLA to fix sutures (soft tissue) to bone in rotator cuff 
repair.  The Igaki -Tamai ste nt, made completely from PLLA, demonstrates the intrinsic safety of 
that material when used in coronary arteries, and this stent received CE mark for peripheral 
vascular application.  Finally, the Absorb  BVS System is currently CE Marked as a temporary 
scaffold indicated for improving coronary luminal diameter that will eventually resorb and 
potentially facilitate normalization of vessel function in patients with ischemic heart disease due 
to de novo  native coronary artery lesions.  
PLA is a member of the al iphatic polyester family of materials. The lactide monomer from which 
PLA is synthesized is a cyclic di -ester of lactic acid, which is a chiral molecule with two optical 
isomers, L -lactic acid and D -lactic acid.  When lactide is prepared from a racemic mix ture of 
lactic acid, one obtains three isomers, namely D -lactide, L -lactide, and meso -lactide.  The meso -
lactide isomer is readily separated from the other two isomers.  Polymerization of pure L -lactide 
or D-lactide leads to the optically active and crysta llizable PLLA and poly(D -lactide) (PDLA), 
respectively.  Polymerization of a racemic mixture of L -lactide and D -lactide leads to the 
Abbott Vascular  Version 17.[ADDRESS_780650] 16, 2018 . optically inactive and amorphous PDLLA, which is a random copolymer containing equal 
numbers of L - and D -lactide monomer su bunits.  
PLLA is a semicrystalline polymer whose degree of crystallinity and crystalline microstructure 
are dependent upon the thermal and deformation history during processing.  The high tensile 
strength and modulus of PLLA make it suitable for load beari ng applications.  PLLA has a 
maximum crystallinity of approximately 70%, a melting temperature ( Tm) of 170 - 180°C, and a 
glass transition temperature ( Tg) of 55 - 65°C [13, 14]. 
PDLLA is a ra ndom copolymer derived from an equimolar mixture of D - and L -lactide.  PDLLA 
is characterized by a lower tensile strength and higher elongation than PLLA due to its 
amorphous structure.  Because amorphous polymers lack crystalline structure, they do not ha ve 
melting temperatures but instead begin to flow at temperatures in excess of Tg [13, 14].  
[IP_ADDRESS]  PLLA Scaffold  
The Absorb BVS is a bioresorbable balloon -expandable scaffold with a drug and bioresorbable 
polymer coating.  The Absorb BVS is fabricated from PLLA and is comprise d of a series of 
circumferentially oriented sinusoidal rings connected by [CONTACT_592104] ( Figure 2.2 ).  The design is 
based upon the same principles as metallic balloon expandable stents (MULTI -LINK family of 
coronary stent systems) with permanent deformatio n of the device being achieved by [CONTACT_592105].  Two permanent platinum markers are embedded at each end 
ring to enable fluoroscopic visualization.  
  
Abbott Vascular  Version 17.[ADDRESS_780651] 16, 2018 .  
 
Figure 2.2: BVS Strut Pattern  
[IP_ADDRESS]  Absorb BVS Bioresorbable Coating  
The Absorb BVS bioresorbable polymer drug coating is a single drug/polymer matrix layer 
comprised of the amorphous random copolymer PDLLA, which contains and controls the release 
of the drug, everolimus.  Everolimus is an anti -proliferative (Afinit or, [COMPANY_001] Pharmaceuticals 
Corp.) that is blended with PDLLA in a 1:1 (w:w) proportion and applied to the entire surface 
(i.e., sidewalls, luminal and abluminal) of the PLLA scaffold.  
Neither a primer coat nor a topcoat layer is utilized for the Absorb B VS. A study has shown that 
the amount of drug transferred to the balloon (Pebax polymer) is less than 0.01 wt% of the label 
claim for total content.15 
[IP_ADDRESS]  Everolimus  
Everolimus [40 -O-(2-hydroxyethyl) -rapamycin], which is provided to Abbott Vascular by 
[CONTACT_591650], is a novel semisynthetic macrolide immunosuppressant, 
                                                           
[ADDRESS_780652] 16, 2018 . obtained through chemical modification of Rapamycin.  Rapamycin (INN: sirolimus) is a 
secondary macrolide metabolite that is produced by [CONTACT_592106] .  The oral 
formulation of everolimus16 known as Certican® ([COMPANY_001] Pharmaceuticals Corporation), 
outside the [LOCATION_002] and as Zortress® in the U.S., is for the prevention of organ transplant 
rejection.  [COMPANY_001] Pharmaceuticals Corporation has granted  Abbott Vascular the right to 
reference Certican’s IND 52,003, NDA No. 21 -560 and NDA No. 21 -638.  Additionally, the oral 
formulation of everolimus known as Afinitor® ([COMPANY_001] Pharmaceuticals Corporation) is 
approved as of March 30, 2009, in the U.S. for the treatment of patients with advanced renal cell 
carcinoma after failure of treatment with sunitinib or sorafenib.  Everolimus has also been used 
in similar dosing on the CE Marked and FDA approved XIENCE permanent vascular implants ..   
The nominal drug dose per scaffold size of BVS and XIENCE is given in Table 2.1 . 
  
                                                           
16 AFINITOR Highlights of Prescribing Information, [COMPANY_001] Pharma Stein AG, March 2009; Zortress Prescribing 
Information, [COMPANY_001] Pharma Stein AG, 2010; Certican Investigator’s Brochure [COMPANY_001]. October 2, 2009.  
Abbott Vascular  Version 17.[ADDRESS_780653] 16, 2018 . Table 2.1  Nominal Drug Dose Comparisons  
Nominal 
Expanded 
Stent 
Diameter 
(mm)  Nominal 
Unexpanded 
Stent Length 
(mm)  XIENCE 
PRIME , 
Xpedition , 
Alpi[INVESTIGATOR_050],  and 
ProX†† 
Nominal 
Drug Dose 
(µg) XIENCE 
V and Pro  
Nominal 
Drug 
Dose ( µg) Cohort A 
Device* 
Nominal 
Drug Dose 
(µg) Absorb 
BVS 
System ** 
(mfg MTV)  
Nominal 
Drug Dose  
(µg) Absorb BVS 
System† (mfg 
TEM)  
Nominal 
Drug Dose 
(µg) 
2.25, 2.5, 
2.75, 3.0, 
3.25 8 40 37 NA NA 76 
3.5, 4.0  50 53 NA NA NA 
2.25, 2.5, 
2.75, 3.0, 
3.25 12 60 56 98 NA 114 
3.5, 4.0  75 75 NA NA 135 
2.25, 2.5, 
2.75, 3.0, 
3.25 15 74 75 NA NA NA 
3.5, 4.0  91 98 NA NA NA 
2.25, 2.5, 
2.75, 3.0, 
3.25 18 88 88 148 160 181 
3.5, 4.0  116 113 NA NA 197 
2.25, 2.5, 
2.75, 3.0, 
3.25 23 109 113 NA NA NA 
3.5, 4.0  141 151 NA NA NA 
2.25, 2.5, 
2.75, 3.0, 
3.25 28 137 132 NA 235 276 
3.5, 4.0  174 181 NA NA 308 
 
      
      
 
      
      
* In the ABSORB BVS Cohort A trial, the Cohort A device was only available in 3.0 mm diameter and 12, 18 mm  
length.  
** In the ABSORB BVS Cohort B trial, the Absorb BVS System (mfg MTV)  was only available in 3.0 mm diameter 
and 18 mm length.  
† In ABSORB III, the BVS System (mfg TEM) will only be available in 2.5, 3.0, 3.5 mm.  
†† The 3.[ADDRESS_780654] 16, 2018 . [IP_ADDRESS]  Delivery System  
The Absorb BVS delivery system is similar in design, materials, and performance to that of 
MULTI -LINK VISION RX CSS (P020047 and supplements), which is commercially approved 
in more tha n 80 countries, including the [LOCATION_002], Canada and European Union. That 
delivery system is also similar to that of XIENCE V RX Stent System (P070015) and MULTI -
LINK RX ZETA CSS (P070020/S042).  
Like other Abbott Vascular RX Coronary Stent Systems and C oronary Dilatation Catheters, the 
Absorb BVS delivery system combines a single lumen proximal shaft with a dual lumen mid -
shaft and a co -axial lumen distal shaft to create the rapid exchange capability.  The single lumen 
proximal shaft connects the interme diate/distal shaft with the inflation port of the catheter.  The 
guide wire exit notch is located at the proximal end of the junction between the intermediate 
shaft and the mid -shaft support.  The annular space between the distal outer member and the 
centr al distal lumen provides a fluid passage path from the proximal lumen to the balloon.  The 
shaft of the catheter, the tip, and tapers of the balloon are coated with HYDROCOAT 
Hydrophilic Coating.  The overall length of the catheter is [ADDRESS_780655] -deployment 
dilation, if necessary.  Two non -radiopaque markers are attached to the proximal end of the shaft 
of the Absorb BVS delivery system, specifically 95 cm a nd 105 cm proximal to the distal tip.  
These two markers indicate when the distal tip of the catheter exits the tip of a brachial or 
femoral guiding catheter, respectively.  
A single arm adapter is attached to the proximal end of the catheter and accesses the 
inflation/deflation lumen.  The proximal shaft is thermally bonded to a nylon adaption cup, 
which is mechanically sealed to the single arm adapter with a polycarbonate nosepi[INVESTIGATOR_13959].  The 
nosepi[INVESTIGATOR_591962], and these are bon ded together with methylene 
chloride.  
A 0.014 inch (0.36 mm) or smaller diameter guide wire can be used in the guide wire lumen.  
The guide wire exits the guide wire lumen at the guide wire exit notch, which is formed at the 
junction of the mid -shaft and the intermediate shafts.  Proximal to this point, the guide wire runs 
externally alongside the proximal shaft of the catheter.  
[IP_ADDRESS]  Absorb BVS Device Comparisons  
During development of the current Absorb BVS System, the product has undergone multiple 
design, process, and manufacturing control changes.   The scaffold pattern was modified from the 
initial hourglass pattern used in the Absorb Cohort A trial to a sinusoidal rings with three links 
design (based on the MULTI -LINK family of patterns) for the A bsorb Cohort B trial.   The 
Absorb Cohort B pattern, manufactured in the Mountain View facility and also described here as 
Absorb BVS System (mfg MTV), has been further improved as part of the transition to 
manufacturing at Abbott Vascular's Temecula facili ty.  The Absorb BVS (mfg TEM) scaffold 
pattern remains based on the MULTI -LINK family of patterns, but with increased overall crest 
and bar arm length, which creates a larger theoretical maximum expanded 
Abbott Vascular  Version 17.[ADDRESS_780656] 16, 2018 . diameter.  Optimization of the scaffold strut width and thickness maintains radial strength while 
balancing other functional attributes.   The Absorb Cohort A BVS System and the Absorb BVS 
System (mfg MTV and mfg TEM) share the same material composition, drug dose density (100 
µg/cm2), and drug release profi les.  Absorb BVS (mfg TEM) has a slightly increased surface area 
and thus a slight increase in total drug dose as compared to the same size Absorb BVS (mfg 
MTV).  Additional device sizes were designed for the Absorb BVS System (mfg TEM).   The 
Absorb BVS (m fg MTV) and Absorb BVS (mfg TEM) delivery systems are identical in 
materials, with minor dimensional adjustments to accommodate the Absorb BVS, to that of 
MULTI -LINK VISION RX CSS, which is commercially approved in more than 80 countries, 
including the Uni ted States, Canada, and within the European Union.  
The principles of operation for the Absorb BVS (mfg MTV) and the Absorb BVS (mfg TEM) 
are identical, i.e. the Absorb BVS, regardless of site of manufacture or scaffold pattern, is 
designed to revascularize  obstructed coronary arteries and ultimately restore the implanted vessel 
to an unconstrained state. The Absorb BVS System (mfg TEM) meets or exceeds all the essential 
performance requirements of the Absorb BVS System (mfg MTV) and is available in sizes 
shown in Table 2.2.  
Table 2.[ADDRESS_780657] Length (mm)  
Product Diameter (mm)  8 12 18 28 
2.5 X X X X 
3.0 X X X X 
3.5  X X X 
A = Anticipated additional size.  
X = Size currently available.  
 
Please note that the commercially approved CE marked 23mm Absorb  BVS device  will not be 
used in this study.  
2.1.5  Description of the Control Device  
The commercially available XIENCE V, XIENCE PRIME , XIENCE Xpedition , XIENCE 
Alpi[INVESTIGATOR_050] , XIENCE Pro , and  XIENCE ProX 17 Stent System s will serve as the control device. 
Hereinafter, these devices will be called “XIENCE” in this trial.  
XIENCE Pro  is a rebranding (re -labelling) of the commercially available XIENCE V and 
XIENCE PRIME . XIENCE ProX is a rebranding of the commercially available XIENCE 
Xpedition . XIENCE Pro and XIENCE ProX are only approved for use outside the US.  
The XIENCE is composed of a drug coated stent and balloon expandable delivery system. The 
drug coating is composed of two polymers and the anti-proliferative drug everolimus. The 
delivery system used in this trial utilizes the same principle of operation as other Abbott 
Vascular Rapid Exchange (RX) coronary stent systems and coronary dilation catheters. The 
XIENCE is fabricated from a single pi[INVESTIGATOR_591963] L -605 Cobalt Chromium (CoCr) 
                                                           
[ADDRESS_780658] 16, 2018 . alloy.  This alloy can be formed into thinner stent struts than traditional stainless steel stents, and 
provides a more flexible, low delivery system profile while maintaining adequate radiopacity and 
strength.  For more details on the XIENCE please refer to the X IENCE V , XIENCE PRIME , 
XIENCE A lpi[INVESTIGATOR_050] , XIENCE P ro, and XIENCE P roX IFUs.  
2.1.6  Investigational Device Accountability  
The Sponsor will ship the investigational devices (Absorb BVS System) to the Pri mary 
Investigator (or designee) only at each site. In geographies using the commercially available CE 
marked device , the i nvestigators  will acquire the product through their normal commercial 
vendors. The Primary Investigator will maintain adequate records  of the receipt and disposition 
of the investigational device, including part number and serial number, date implanted, patient 
identification [ID] number and implanting physician. An Inventory Accountability Report will be 
generated for this purpose. In geographies not using the commercially available CE marked 
device , any unused investigational devices will be returned to the Sponsor and a completed 
Inventory Accountability Report will be generated for the site  when the enrollment phase of the 
study is complete . The Inventory Accountability Report must document the disposition of all 
investigational devices including those that have been returned to the Sponsor. Use of any 
investigational device outside of the protocol (e.g., compassionate use) is strict ly forbidden and 
may constitute grounds for removal of the investigator/site from the study. In geographies using 
the commercially available CE marked device, the commercial device may be used in non -trial 
patients. The sites will manage the XIENCE and the  commercially available  CE marked Absorb 
BVS device supplies for this trial without sponsor oversight and the device should be used in 
accordance with the IFU.  In sites using commercially available CE marked devices (XIENCE 
and Absorb BVS), the primary inv estigator will maintain records of device usage for the study 
subjects. The records will contain device part number and serial number, date implanted, patient 
identification number, and implanting physician.  
2.1.[ADDRESS_780659] been conducted to demonstrate safety of the 
Absorb™ Bioresorbable Vascular Scaffold (BVS) System18.  The studies collectively evaluate 
the BVS Cohort A device and the Absorb BVS System manufactured in Mountain Vie w [Absorb 
BVS System (mfg MTV)], and the Absorb BVS System manufactured in Temecula [(Absorb 
BVS System (mfg TEM)], the latter of which is the investigational device to be used in this 
clinical trial. The BVS Cohort A device and the Absorb BVS (mfg MTV and  mfg TEM) share 
the same materials composition, drug dose density, and drug release profiles. Absorb BVS (mfg 
TEM) has a slightly increased surface area and thus a slight increase in total drug dose (13% 
based on 2.5/3.0 x 18 mm). Other subtle changes invo lved in the manufacturing site transfer for 
optimization and scale -up to improve consistency, throughput, yields, and overall process 
robustness have no impact on the preclinical performance of the Absorb BVS System. Consistent 
preclinical safety has been demonstrated among the BVS Cohort A device (1 to 48 months), the 
                                                           
18 The Absorb ™ Bioresorbable Vascular Scaffold (BVS) System is the trade name [CONTACT_592227].  During the 
course of development, multiple product names were use d to describe this product including, Bioresorbable 
Vascular Scaffold (BVS) System, Bioabsorbable Vascular Stent, BVS Everolimus Eluting Coronary Stent System 
(EECSS), Abbott Vascular Bioabsorbable Device (AVBD) EECSS, BVS Cohort A  (Gen. 1.0) (used in the 
ABSORB  Cohort A trial) and BVS Cohort B  (Gen.1.1)  (used in the ABSORB  Cohort B trial).  
Abbott Vascular  Version 17.[ADDRESS_780660] 16, 2018 . Absorb BVS (mfg MTV) (3, 28, 90, 180 days and 12, 18, 24, and 30 months), and the Absorb 
BVS (mfg TEM) (28, 90, and 180 days).   
Experience in the preclinical setting has been cumulative amon g these devices because of the 
similarities they share. Studies conducted using the Cohort A device include a 90 -day 
pharmacokinetics study, a safety study at 28 and 90 days, a safety study from 1 to 48 months, 
and a degradation study at 10, 12, 18, 24 and  36 months. These studies were conducted in 
porcine coronary arteries. Additionally, a 3 to 36 months safety study was conducted in rabbit 
iliac arteries. Studies conducted for the Absorb BVS (mfg MTV) include an up to 90 -day 
pharmacokinetics study; two sa fety studies with collective evaluations at 3, 28, 90, 180 days and 
12, 18, 24, and 30 months; a 28 -day and a 90 -day overlap safety study; and two in vivo  
degradation studies with collective evaluations at 28, 90, and 180 days and at 12, 18, 24, and 30 
months.  These studies were conducted in porcine coronary arteries.  Studies conducted for the 
Absorb BVS (mfg TEM) include an up to 90 -days pharmacokinetics study and three safety 
studies (28, 90, and 180 days).  
With respect to pharmacokinetics, studies con ducted demonstrate bioequivalence of Absorb BVS 
(mfg MTV) and Absorb BVS (mfg TEM) with 78 -79% of everolimus being released at 28 days 
and 96% at 90 days.  Bioequivalence of the drug release profiles was not only demonstrated 
between the Absorb BVS (mfg MT V) and the Absorb BVS (mfg TEM), but also between the 
Absorb BVS (mfg MTV and mfg TEM) and the XIENCE V Everolimus Eluting Coronary Stent.  
Therapeutic concentrations of everolimus were maintained in target vessels for at least 28 days 
following implantati on of Absorb BVS (mfg MTV and mfg TEM).  A systemic safety profile of 
Absorb BVS (mfg MTV and mfg TEM) was also demonstrated in the PK studies.  
Safety of the BVS Cohort A device was demonstrated in two studies in porcine coronary arteries 
using CYPHER (1 to 48 months) and VISION (28, 90 days) controls and in rabbit iliac arteries 
using a CYPHER control (3 to 36 months).  Safety of the Absorb BVS ( mfg MTV) was 
confirmed in single configuration at 3, 28, 90, 180 days and at 12, 18, 24, and 30 months and in 
overlappi[INVESTIGATOR_591964] 28 and 90 days in porcine coronary arteries using XIENCE V 
(single and overlappi[INVESTIGATOR_007]) as the respective control. Absorb  BVS (mfg TEM) demonstrated safety 
in porcine coronary arteries at 28, 90, and 180 days. Collectively, comparable safety to the 
respective control device(s) was demonstrated through the maintenance of lumen patency, 
sequestration of struts in a benign neoi ntima, near to complete endothelialization by 28 days 
(single) and 90 days (overlappi[INVESTIGATOR_007]), and inflammation that was within pre -established safety 
acceptance criteria.  Luminal thrombosis, medial necrosis, and medial thinning were not 
observed in any of the se studies.  From 24 to 48 months in arteries implanted with BVS Cohort 
A device, resorption sites representing pre -existing struts were benignly integrated into the 
arterial wall. Degradation studies conducted for Absorb BVS (mfg MTV) demonstrate up to 74 % 
resorption by 30 months with no adverse responses, and Absorb BVS (mfg TEM) is expected to 
have similar jn vivo  degradation based on the similar material composition and in vitro 
degradation rates through 180 days shared by [CONTACT_592093] (mfg MTV) and Absor b BVS (mfg 
TEM).  
The Absorb Cohort A BVS System and the Absorb BVS (mfg MTV and mfg TEM) demonstrate 
commensurate safety and function at revascularization, which relates to both luminal support and 
everolimus suppression of neointimal hyperplasia. Collect ively the results from this series of 
animal studies support the validity of commencing clinical studies using the Absorb BVS in this 
trial. 
Abbott Vascular  Version 17.[ADDRESS_780661] as a  vehicle for local therapy and are amenable to 
non-invasive cardiovascular imaging. There is angiographic and clinical evidence from a small 
number of recent studies demonstrating that the bioresorbable stent/scaffold is associated with 
low restenosis and adverse event rates.  However, due to the limited number of studies, small 
sample size, and short -term follow -up, long -term studies are warranted evaluating the 
bioresorbable scaffold.  
[IP_ADDRESS]  Bioresorbable Stent/Scaffold  
Early Bioresorbable Stent/Scaffol d Prototypes  
The first bioresorbable stent was developed at Duke University in the early 1980s. The stents 
made from PLLA were implanted in canine femoral arteries. The strut surface was completely 
endothelialized at [ADDRESS_780662] -implantation. No 
inflammatory response and no thrombosis were observed [15, 16]. This technology subsequently 
was acquired by [CONTACT_592107], and now Abbott Vascular.  
Igaki -Tamai Stent  
Tamai et al were the first group to provide clinical investigation data with PLLA implant in 
humans.  A prospective, unblinded Clinical Investigation was carried out to assess the feasibility 
and safety of the Igaki -Tamai stents. Fifty subjects electively underwent percutaneous coronary 
artery intervention (PCI) for coronary artery stenosis with the Igaki -Tamai stent over a period of 
[ADDRESS_780663] 19 lesions at 3 months and 6 months and the percent diameter 
stenosis (%DS) was 33% at both of the follo w-up time points [12]. This was comparable to the 
%DS at [ADDRESS_780664] -implantation of BMS (29.2% in  VISION stent; 34.6% in TETRA stent). 
Clinical follow -up was performed at up to 4 years, and MACE rate at 4 years was reported as 
18%[17]. Stent struts were not visible during IVUS follow -up at three years [18]. Additionally, 
one subject was followed at [ADDRESS_780665] ( Figure 2.3 ) [19]. Recently, 10 year plus follow -up data was presented on the 
50 patients that received Igaki -Tamai stents. Survival rates for freedom from all -cause death, 
cardiac death and MACE (all death , non -fatal MI and target lesion revascularization/target vessel 
revascularization (TLR/TVR)) were 87%, 98% and 50%, respectively [20]. The 10 year TLR 
rate was 28% and there were 2 cases of definite scaffold thromboses in which one was subacute 
and one was very late (10 years after implant) in which the patient had a sirolimus eluting stent 
proximal to two Igaki -Tamai stents. Angiographic data from 6 months to 3 years showed an 
increase in minimum lumen diameter (1.76±0.74 mm to 2.22±0.56 mm) and a decrease in % 
diameter stenosis (%) (38±22 to 2 5±18). IVUS evaluation of the target vessel found that after 36 
months the  Igaki -Tamai stents struts had disappeared and from 6 months to 3 years the 
minimum lumen area  (3.64±1.68 mm2 to 5.18±2.09 mm2) and the vessel area (external elastic 
membrane) incr eased.  The balloon -expandable (i.e., heating not required) Igaki -Tamai 
Abbott Vascular  Version 17.[ADDRESS_780666] 16, 2018 . peripheral stent was evaluated in the PERSEUS clinical trial [21], of which results supported 
approval for CE mark (November 29, 2007).  
 
Figure 2.3:  OCT Images of Igaki -Tamai Stent at 9 Years  
 
A: Proximal marker; C: Distal marker; B: Bifurcation  
The lumen was smooth and strut footprints were not observed.  
 
2.1.[ADDRESS_780667] been significant improvements in 
PCI clinical outcomes [22-27]. The next endeavor into PCI is the use of polymeric scaffolds, 
such as the Absorb BVS System.  Early evidence with the first iteration of the Absorb BVS 
System (Absorb Cohort A BVS System) demonstrates similar performance to that of DES, a s 
well as similar physiological and functional changes to the treated region of the vessel. The First 
in Man ABSORB Cohort A Trial represents the first clinical evaluation of the safety and 
performance of the Absorb Cohort A BVS System. The ABSORB Cohort A  Trial enrolled 30 
subjects from 4 clinical sites (the Netherlands, Poland, Denmark, and New Zealand) from March 
7, 2006 to July 18, 2006. Subjects with visually estimated nominal vessel diameters of 3.0 mm 
and lesion(s) length ≤ 14 mm were enrolled.  They  received a single 3.0 x 12 mm or 3.0 x 18 mm 
Absorb Cohort A BVS System. The 6 -month angiographic in -device late loss (LL) of the Absorb 
Cohort A BVS System was 0.[ADDRESS_780668] trial  (0.10 mm), but superior to bare metal stents (0.85 mm). The 
greater late loss associated with the Absorb Cohort A BVS System device was due to scaffold -
area loss, suggesting that the scaffold may have prematurely lost the ability to provide luminal 
suppor t [28] . Contrarily, neointimal proliferation observed in IVUS was smaller compared to the 
XIENCE V stent (mean neointimal area of the Absorb Cohort A BVS System: 0.30  ± 0.44 mm2 
vs. XIENCE V: 0.61  ± 0.75 mm2) [29]. Average lumen area significantly decreased between 
post-procedure and [ADDRESS_780669] 16, 2018 . treated segment as well as in the distal and proximal segments [30]. Currently, [ADDRESS_780670] been no changes in the endpoint event rates 
between 6 months and 5 years, in which only one ischemic MACE event (NQMI) was reported 
in the first [ADDRESS_780671] occurred in the Cohort A through 
5 years of follow -up. 
ABSORB Cohort B  
Based upon the safety results of the BVS Cohort A device, Cohort B of the ABSORB trial was 
initiated on March 19, 2009 to evaluate Absorb BVS System ( mfg MTV), and completed 
enrollment on November 6, 2009 with 101 subjects split into two groups: Group 1, n=45 
(imaging follow -up at 180 days and 2 years) and Group 2, n=56 (imaging follow -up at 1 year and 
3 years).  The BVS Absorb BVS System (mfg MTV), is similar to the Cohort A BVS System 
that was evaluated in Cohort A, but has undergone modifications to the scaffold design and 
manufacturing processes to improve its mechanical performance and prolong the duration of 
effective scaffolding.   Cohort B is a pr ospective, open -labeled, multi -center registry that enrolled 
subjects with up to two de novo  native coronary artery lesions in separate epi[INVESTIGATOR_591965] 3.0 mm and lesion(s) length ≤ [ADDRESS_780672] 
trial and compares favorably with the 0.43 mm late loss from Cohort A. At 180 days, the IVUS 
results from Cohort B Group 1 showed limited intra -scaffold neo -intimal hyperplasia, the 
volume obstruction (VO) was 1.2% and the neointimal hype rplasia (NIH) area was 0.[ADDRESS_780673] (VO of 8.0% and NIH area 
of 0.56 mm2) and with Cohort A (VO of 5.3% and NIH area of 0.29 mm2).  As observed in 
Cohort A, the 6 -month IVUS results showed a significant reduction in the average lumen area 
(6.60 ± 1.22 mm2 after procedure vs. 6.37 ± 1.12 mm2 at 180 -day, p=0.0048). This was much 
lower than that found for the Cohort A BVS System (6.08 ± 1.13 mm2 after procedure vs. 5.07 ± 
1.22 mm2, p=0.0001, at 180 -day).  The vessel area remained comparable between baseline and 
180-day follow -up (14.22 ± 3.75 mm2 vs. 14.49 ± 3.67 mm2) demonstrating the absence of 
negative remodeling . 
QCA and IVUS results from baseline, post procedure and 2 year are available for the  patients in 
Cohort B Group 1. The 2 -year angiographic results from Cohort B Group 1 demonstrated a late 
loss of 0.27 mm which compares well to the SPI[INVESTIGATOR_591966] V 2 year late loss of 0.33 mm. 
Furthermore, in Cohort B Group 1 (n=33) IVUS data demonstrat ed lumen, scaffold and vessel 
enlargement between 6 months and 2 years ( Table  2.3).  
Table 2. 3: ABSORB Cohort B Group 1: IVUS Results through [ADDRESS_780674] 
vs. 2 years  p-value 6 m vs. 
2 years  
Average vessel area 
(mm2) 14.04 ± 3.80  14.44 ± 3.82  15.35 ± 
4.05 < 0.0001  < 0.0001  
Average scaffold 
area (mm2) 6.53 ± 1.23 (33)  6.42 ± 1.17  7.08 ± 1.73  0.0035  < 0.0001  
Average lumen 
area  6.53 ± 1.24  6.36 ± 1.18  6.85 ± 1.[ADDRESS_780675] 16, 2018 . Table 2. 4 shows clinical outcomes through 2 years for all subjects (n=100)[ADDRESS_780676] been no cardiac deaths through 1 year and the MI rate has remained 
low at 3% from [ADDRESS_780677] been 6 
TLRs, resulting in an overall 2 -year MACE rate of 9%. As of  [ADDRESS_780678] been reported.   
Table 2. 4: ABSORB Cohort B clinical endpoint event rates through 2 Years  
 30 Days  6 Months  12 Months  24 Months  
 N=101  N=101  N=101  N=100  
Cardiac Death %  0 0 0 0 
Myocardial Infarction 
% (n)  2.0(2)  3.0(3)  3.0(3)  3.0(3)  
 Q-wave MI  [ADDRESS_780679] MI (n)  2.0(2)  3.0(3)  3.0(3)  3.0(3)  
Ischemia driven TLR 
%  0 2.0(2)  4.0(4)  6.0(6)  
  CABG  0 0 0 0 
  PCI (n)  0 2.0(2)  4.0(4)  6.0(6)  
Hierarchical MACE % 
(n) 2.0 (2)  5.0 (5)  6.9 (7)  9.0 (9)  
MACE: Cardiac death, MI, ischemia -driven TLR  
TVF: Cardiac death, MI, ischemia -driven TLR, ischemia -driven TVR  
MI per protocol definition used in SPI[INVESTIGATOR_591967] B Group 1 (N=44) have been presented at TCT 2012.20  
At 3 years, the MACE rate was 6.8%, the MI rate was 2.3%, and the ID -TLR rate was 4.5%; all 
of these were unchanged from 2 years, reflecting that there were no new MACE in this 
population between 1 year and 3 years.  In addition, there were no scaffold t hrombosis events by 
[CONTACT_592108], and there were no cardiac death.  There was one new non -TLR 
TVR between 2 and 3 years that contributed to a 3 year hierarchical TVF rate of 9.1%.  
Vasomotion measurements conducted at 1 year (Cohort B Group 2, N = 32) and at 2 years 
(Cohort B Group 1, N = 33) showed preliminary indications of restoration of vessel movement in 
the treated segment.[ADDRESS_780680] of the ABSORB trials to allow planned overlappi[INVESTIGATOR_591968] (mfg 
MTV). Subjects registered can be treated with a maximum of two de novo  native coronary artery 
lesions each located in different epi[INVESTIGATOR_218709]; the target lesion length must be  ≤ [ADDRESS_780681] did not complete the 2 year follow -up.  
20 Smits, P. et. al. ABSORB Cohort B Trial: Evaluation of the Absorb Everolimus Eluting Bioresorbable Vascular 
Scaff old (Absorb BVS) in the treatment of patients with de novo native coronary artery lesions, in TCT 2012. 2012 
(presentation): Miami, FL.  
[ADDRESS_780682] be sui table to be treated with an Absorb BVS System (mfg MTV).  
The device sizes used thus far in the study that have generated data summarized here have been 
the 3.0 x 18 mm, 3.0 x 28 mm and 2.5 x 18 mm scaffolds.  
Clinical follow -up will be conducted on all su bjects registered in the trial for up to 3 years.  
Interim data snapshot with the cutoff date of 11 -January -2012 (n=469)22 and 18 -September -2012 
(6 month data n=500 and 1 year data n=250)23. Data out to 30 days were available for 451 
subjects in ABSORB EXTEN D as of 11 -January -2012. The MACE rate for ABSORB EXTEND 
through 11 -January -2012 was 2.2% (10/451) out to 30 days, which was driven by [CONTACT_51866]. The 
hierarchical and non -hierarchical MI rates were the same at 30 days; both were 2.2% (10/451). 
There were no cardi ac deaths through 30 days and the ID -TLR rate during the 30 -day period was 
0.2% (1/451). The scaffold thrombosis rate out to 30 days, as defined using the ARC definition 
in which the subacute (1 -30 days) and acute/subacute (0 -30 days) rates were both 0.4% (2/451) 
according to the definite + probable ARC definitions. Data out to 6 -months were available for 
269 subjects in ABSORB EXTEND as of 11 -January -2012. The MACE rate was 3.0% (8/269) 
[1 cardiac death and 7 MI] at [ADDRESS_780683] that did not 
receive an Absorb BVS. The 6 month ID -TLR rate was 0.4% (1/269) and the overall (0 -194 
days) scaffold thrombosis rate was 0.7% (2/268) according to the definite + probable ARC 
definitions. Data out to 1 year was available for 120 su bjects in ABSORB EXTEND as of 11 -
January -2012. The MACE rate was 5.0% (6/120) [1 cardiac death, 4 MI, and 1 ID -TLR] at 1 
year.  The overall (0 -393 days) scaffold thrombosis rate was 0.8% (1/119) according to the 
definite + probable ARC definitions.  
Six mo nth follow -up data were available for 500 subjects and 1 year follow -up data were 
available for 250 subjects through 18 -September -2012.  The MACE rate was 3.0% (15/500) at 6 
months and 4.4% (11/250) at 1 year.  The overall MI rate was 2.8% (14/500) at 6 mo nths and 
2.8% (7/250) at 1 year.  The cardiac death rate was 0.2% (1/500) at 6 months and 0.4% (1/250) 
at [ADDRESS_780684] that did not receive the Absorb BVS. The 6 
month ID -TLR rate was 0.6% due to the occurrence of three I D-TLR events and the 1 year ID -
TLR rate was 2.0% due to the occurrence of 5 ID -TLR events. The overall 6 month  scaffold 
thrombosis rate was 0.6%, and the overall 1 year scaffold thrombosis rate was 0.8% according to 
the definite + probable ARC definitions .  
ABSORB II  
ABSORB II is a post -approval RCT occurring outside the [LOCATION_002] (OUS) that will be the 
first comparison of the Absorb BVS System against an active control of a metallic DES 
(XIENCE PRIME).  The ABSORB II trial is the first to have powered , co-primary endpoints 
evaluating both the morphological and functional responses at 2 or 3 years when the device has 
resorbed (depending on the results of the ABSORB Cohort B trial 3 -year imaging follow -up 
data). The ABSORB II RCT will enroll approximatel y 501 subjects at approximately 40 
investigational sites OUS.   
                                                           
22 ABSORB EXTEND Annual Progress Report, report dated March 14, 2012 . 
23 Bartorelli, A. L. et. al., ABSORB EXTEND: An interim report on the [ADDRESS_780685] 2012. 2012, (p resentation): Miami, FL ; Bartorelli, A. L. et. al., ABSORB EXTEND: 
An interim report on the [ADDRESS_780686] 2012. 2012, 
(presentation): Miami, FL.  
Abbott Vascular  Version 17.[ADDRESS_780687] 16, 2018 . ABSORB PHYSIOLOGY  
The ABSORB PHYSIOLOGY trial will evaluate one of the key potential benefits of the Absorb 
BVS System, which is coronary vessel functionality after bioresorption.  The trial w ill be 
dedicated to comparing the vascular responses of Absorb BVS treated vessel segments versus 
metallic DES (XIENCE V or XIENCE PRIME) treated segments, to measure how the vessel 
accommodates changes in blood flow following physiological stimuli.   
2.1.[ADDRESS_780688], SPI[INVESTIGATOR_591969], SPI[INVESTIGATOR_591970], SPI[INVESTIGATOR_591971], all of which demonstrated the safety and effectiveness of XIENCE V, 
which uses the same drug (Everolimus) and has the same drug density (100  µg/cm2) and release 
profile (80%/28 days) as the Absorb BVS.  
The pi[INVESTIGATOR_591972], which supported the US approval of XIENCE V, was a 2:[ADDRESS_780689] 
with the primary endpoint of in -segment LL at 240 days. XIENCE V was found to be non -
inferior (p<0.0001) and superior (p=0.0037) to TAXUS in this primary endpoint, with values of 
0.14±0.41 (301) and 0.28±0.48 (134), respectively. The 1 -year MACE rates were 6.0% (39/655) 
and 10.3% (33/319) for the XIENCE V arm and TAXUS arm, respectively, and the stent 
thrombo sis rates (definite/probable per ARC) were 1.1% for XIENCE V and 0.6% TAXUS 
(p=NS).  The SPI[INVESTIGATOR_591973] V 
through 5 years.  
The SPI[INVESTIGATOR_591974] a 2:[ADDRESS_780690] TAXUS designed to 
continue to evaluate the safety and efficacy of the XIENCE V. At 1 year, the XIENCE V arm 
demonstrated non -inferiority and superiority to the TAXUS arm in terms of TLF (4.2% and 
6.8%, respectively, PNI  < 0.0001,  PSUP = 0.0012), and the s tent thrombosis rates per ARC 
(definite/probable) were lower in the XIENCE V arm (0.3%)  compared to the TAXUS arm 
(1.1%; p=0.04). SPI[INVESTIGATOR_591975] V 
through 3 years.  
The SPI[INVESTIGATOR_591976], which suppor ts the US approval of XIENCE PRIME, was a 
prospective, open -label, non -randomized study consisting of two registries with approximately 
500 subjects at up to 75 global sites: the Core Size Registry (stent diameters 2.25. 2.5, 3.0, 3.5, 
4.0 mm with stent le ngth 8, 18, and 28 mm) and the Long Lesion Registry (stent diameters 2.5, 
3.0, 3.5, 4.0 mm with stent lengths 33 and 38 mm). Each subject was to receive treatment in up 
to two de novo  native coronary lesions, each lesion in a different epi[INVESTIGATOR_196518]. SPI[INVESTIGATOR_591977] -specified PGs with statistical 
significance. The observed TLF rate at one year was 4.5% (18/399) (per protocol -defined MI) 
and 6.5% (26/399) (per ARC -defined MI) in the Core Size Registry, and 7. 7% (8/104) (per 
protocol -defined MI) and 12.5% (13/104) (per ARC -defined MI) in the Long Lesion Registry, 
respectively.   
Further details on the SPI[INVESTIGATOR_591978] V IFU and XIENCE 
PRIME IFU.  
Abbott Vascular  Version 17.[ADDRESS_780691] 16, 2018 . 2.1.11  Patient Reported Outcomes  (PRO)  
In clinical trials, patient reported outcome instruments can be used to measure the impact of an 
intervention on several aspects of patient health status and quality of life.  Since improvements in 
clinical measures may not necessarily correlate wit h how the patient feels or functions, 
understanding the patient perspective on treatment effectiveness can be extremely valuable. 
Obtaining the patient’s perspective may also provide additional information that may not be fully 
captured through clinician -centered evaluations.  
In addition, as health expenditures have continued to rise, it is no longer sufficient for new 
therapi[INVESTIGATOR_591979]. 
Today, physicians, payers, and policy -makers have become incre asingly interested in 
understanding the overall value of therapi[INVESTIGATOR_014]. Patients’ self -reported health -related quality of life 
outcomes help to determine the full impact of treatment benefit and serve as key inputs when 
assessing the value of this impact.   
Patient Reported Outcome instruments will be incorporated in the 2,000 primary analysis subjects 
in ABSORB III to provide a complementary evaluation of the effectiveness of the Absorb BVS 
system. The following instruments will be administered during this stu dy at pre -implantation, 30 
days, 1, 2, 3  and 5 years follow -up:  
• EuroQoL 5D (EQ -5D) survey to assess overall health status  
• Seattle Angina Questionnaire (SAQ) to assess disease -specific QoL  
• Rose Dyspnea Scale (RDS) to assess severity of dyspnea * 
• Generalize d Anxiety Disorder scale (GAD -7) to assess anxiety * 
*RDS and G AD-7 will only be used through 3  years.  
2.2 Trial Rationale  
As mentioned in Section 2.1.9,  the Absorb BVS System is being evaluated in ABSORB Cohort 
B and ABSORB EXTEND, all single arm, non -randomized clinical trials. Currently, only 
retrospective descriptive comparisons provide insight into the performance of the Absorb BVS 
System (mfg MTV) co mpared to XIENCE V. In the Cohort B trial, Absorb BVS System (mfg 
MTV) showed a similar 1 -year (BVS 0.27 mm and XIENCE V 0.23 mm) and 2 -year LL 
measurement (BVS 0.27 mm and XIENCE V 0.33 mm) compared to XIENCE V and the 1 - year 
(6.9%), 2 -year (8.9%) and 3 -year (8.9%) MACE rates (Kaplan Meier estimate) for Absorb BVS 
System (mfg MTV) were comparable to the 3.0 x18 mm XIENCE V 1 -year (7.5%), 2 -year 
(8.5%) and 3 -year (11.4%) MACE rates (Kaplan Meier estimate) from pooled SPI[INVESTIGATOR_591980] 
(SPI[INVESTIGATOR_591981], SPI[INVESTIGATOR_591982] d SPI[INVESTIGATOR_591983]). ABSORB III provides the first robust head -to-
head comparisons of the Absorb BVS to XIENCE, and is designed to demonstrate non -
inferiority for the 1 -year clinical endpoint of TLF with Absorb BVS compared to XIENCE. 
Furthermore, ABSORB III  will provide the opportunity to evaluate the long term benefits of 
Absorb BVS compared to XIENCE in regards to potential functional as well as dynamic (i.e ., 
vessel movement) and morphological (i.e ., late lumen enlargement) changes to the treated vessel.    
Abbott Vascular  Version 17.[ADDRESS_780692] 16, 2018 . 3. TRIAL OBJECTIVE  
ABSORB III Primary Objective: The pi[INVESTIGATOR_591984] -market approval 
(PMA) of Absorb BVS.  ABSORB III will evaluate the safety and effectiveness of the Absorb 
BVS System compared to the XIENCE in the treatment of subj ects, including those with 
diabetes mellitus,  with ischemic heart disease caused by [CONTACT_592109][INVESTIGATOR_218709].  
ABSORB III Secondary Objectives:  
• Lead -In Phase Objective: To evaluate the applicability a nd transferability of the didactic 
Absorb BVS physician training plan to US clinical practice.  
• Imaging Cohort Objective: To evaluate long -term vascular function  and patency of the 
Absorb BVS treated segments compared to XIENCE treated segments in the treatment of 
subjects with ischemic heart disease caused by [CONTACT_592109][INVESTIGATOR_218709].  
4. CLINICAL TRIAL/INVESTI GATION FLOW AND 
FOLLOW -UP SCHEDULE  
4.1 Number of Subjects to be Registered  
Approximately 2250 subjects will be registered in ABSORB III. Of this total number, up to 50 
subjects will be registered in the Lead -In phase, 2000 subjects will support the primary endpoint 
analysis and 200 subjects will be registered in the Imaging Cohort.  
4.2 ABSORB Physician Training  
The ABSORB  III training program is a two -phased approach that will combine 1) didactic 
learning and 2) vessel sizing test -runs with corresponding retrospective core laboratory analysis.  
All investigators (primary investigators and sub -investigators) will be required to undergo 
didactic training.  The didactic learning will involve both self -learning of provided materials, 
meeting -based peer to peer learning or site learning conducted by [CONTACT_592110].  
The investigators w ill receive an Absorb BVS training package that will include the training on 
the following elements:  1) technology overview, which includes the rationale and goals for a 
bioresorbable scaffold and the description of the Absorb BVS, with specifics on the p olymer, 
delivery system and the three phases of functionality (revascularization, resorption and 
restoration) associated with Absorb BVS.  2) Update on the most current ABSORB program pre -
clinical and clinical data.  3) Patient and lesion selection which i ncludes the indication, 
contraindications and warnings for the use of Absorb BVS.  There will also be a review of the 
general and angiographic inclusion and exclusion criteria, with emphasis on the avoidance of 
specific lesion criteria that could result in  adverse outcomes.  4) Lesion preparation and 
treatment strategy, which will detail the ABSORB III protocol -required criteria on the 
appropriate preparation of the potential target lesion and sizing of the vessel prior treatment.  5) 
Case reviews specific to lessons learned from the previous ABSORB trials.  6) Device usage and 
logistics which includes details on device storage, sheath removal and general instructions for 
Abbott Vascular  Version 17.[ADDRESS_780693] treatment experience with Absorb BVS and the dos and 
don’ts of treatment.  The ABSORB III didactic learning phase was developed from the learning 
and strategies used in the ABSORB Cohort B, ABSORB EXTEND and ABSORB II trials.  
At the investigator meeting, the didactic training will also include hands -on training through the 
use of simulated arterial models (SAM), in which there will be learning on the device handling 
outside of and within the model coronary vasculature.  The SAM training will be conducted by 
[CONTACT_592111].  The 
physicians will be educated on the scaffold, the delive ry system, the scaffold profile differences 
as compared to XIENCE, and direction on the removal of the Absorb BVS’ protective sheath.  
Physicians will have an opportunity to undergo exercises that will allow them to experience the 
differences in the delive ry and deployment between XIENCE and Absorb BVS in an in vitro 
model.  Discussions will be held regarding proper lesion preparation and specific techniques that 
have been used by [CONTACT_592112]. In the 
SAM training, physicians will also be able to undergo exercises to understand the expansion 
capabilities of the Absorb BVS.   
For those investigators not attending the investigator meeting, Abbott Vascular (AV) staff 
trained on the use of Absorb BVS will pro vide detailed training at site initiations.  The training 
will include the topi[INVESTIGATOR_591985], including but not be limited to, the investigational plan, 
investigational device usage, clinical investigation plan requirements, electronic case report for m 
completion, and clinical investigation personnel responsibilities. Specific to the device usage, the 
clinical research associate (CRA) will train the investigators on appropriate use of the device, 
including (but not limited to) reintroduction of the dev ice, dwell time in the body, use of 
adjunctive devices, removal of the device and expansion/post dila tation guidelines.  
All investigator/clinical investigation personnel that are trained must sign a training log.  No 
investigator/clinical investigation personnel will perform any clinical investigation -related 
procedures prior to signing a training log.  Furthermore, the site primary investigator (or 
designee) that attended the investigator meeting will be asked to serve as the site physician 
expert to pr ovide feedback to his/her sub -investigators on their experience with the hands -on 
training with Absorb BVS and any further learning.  However, if investigators at the site need 
further training regarding Absorb BVS , AV will provide this service.  
Prior to e nrollment in ABSORB III, two angiographic test runs that provide a visual estimation 
of RVD  on non -study PCI patients must be completed by [CONTACT_32366].  Visual RVD 
estimates can be sent to the Angiographic Core Laboratory for review to correlate the 
investigator’s visual estimation of RVD with quantitative angiographic readings by [CONTACT_592113]. The test runs can be performed prior to the clinical sites trial start -up or using 
retrospective PCI cases in which the non -study patient has given cons ent for the data to be used. 
Abbott Vascular  Version 17.[ADDRESS_780694] -runs can be found in the 
physician trai ning slides and the imaging guidance document that wi ll be distributed to each site.  
Supplemental quantitative information from on -line quantitative angiography, intravascular 
ultrasound, or optical coherence tomography can be used to confirm measurements of the vessel, 
if the clinical site chooses. Please review the Imaging Guidance  Document for further details.  
4.3 Lead-In Phase  
ABSORB III will include a Lead -In Phase that will provide an opportunity to evaluate whether 
the Absorb physician training, deve loped from the ABSORB programs outside the US, can be 
applied to US clinical practice.  
The Lead -In Phase will enroll/register subjects prior to the randomization of the [ADDRESS_780695] the change 
in practice that occurs with the use of a polymeric scaffold compared to a metallic stent.  The 
Lead -In Phase will involve up to 35 US sites and up to 50 subjects treated with Absorb BVS.  
There will be  four key areas of evaluation of the Lead -In Phase, 1) angiographic 
inclusion/exclusion, 2) vessel sizing meeting protocol required criteria, 3) treatment strategy per 
protocol requirements and 4) device success.  Each of these variables will provide a mea sure of 
adherence to the physician training program.  The data for each registered subject will be 
collected through the electronic case report forms (eCRFs).  The outcomes will determine 
whether the physician training requires further modification to meet  the needs of the US 
physicians. Details on how the sponsor will evaluate the Lead -In Phase can be found in 
Appendix VII.  
The first Absorb BVS case for each investigator participating in the Lead -In will be attended by 
[CONTACT_592114] (AV) CRA. The obj ective of the CRA -attended cases is to provide an 
opportunity for the investigator to receive guidance on and reinforcement of the Absorb BVS 
teachings (detailed in Section 4.2 ) during their Absorb BVS enrollment.  The CRA field group 
will be trained on De vice Handling Fundamentals and all elements of the protocol.  At the time 
of the procedure, the CRA attendant will be available to provide review of the key protocol 
requirements and device usage elements prior to the start or during the index procedure.  The 
sponsor CRA will make every attempt to ensure that the first Absorb BVS case is attended in 
person. However, a diagnostic angiogram is often not performed on a separate date prior to PCI 
for pre -screening. In these instances, since the diagnostic cathe terization (qualifying cardiac 
catheterization) and the intervention are done at the same setting (with limited amount of time in -
between), AV would be unable to travel to the site and attend in person.   For these sites, AV 
personnel will be available to p rovide telephone guidance and reinforcement prior to the start of 
the index procedure.    
Abbott Vascular  Version 17.[ADDRESS_780696] 16, 2018 . Prior to the index procedure, the CRA will review the 4 variables with the enrolling physician:  
1) angiographic inclusion/exclusion criteria requirements; 2) vessel t reatment strategy; 3) 
appropriate vessel sizing and scaffold selection; and 4) appropriate device preparation and usage.  
If the CRA is at the site in person, once this information is reviewed and the index procedure has 
occurred, the CRA will complete the  Lead -In checklist for the investigator and submit this 
information to AV for filing.  If the CRA is not present, the site will be requested to complete the 
eCRF within [ADDRESS_780697] selection, vessel 
treatment strategy, vessel sizing and Absorb B VS selection as well as appropriate device 
preparation and usage.  
Angiograms should be submitted to the core laboratory within 2 business days following the 
procedure for analysis to ensure appropriate vessel sizing and scaffold usage (for details on 
imagi ng uploading refer to Imaging Guidance Document ).  This feedback will be provided to 
the site within 72 hours of submitting the angiogram.  If discrepancies are identified by [CONTACT_592115] %DS required for analyzing device 
success (< 30%), the angiographic core laboratory and the CRA, respectively, will contact [CONTACT_592116] e issue and any corrective measures necessary to avoid the issue in 
future cases. Investigators not meeting all four criteria (CRA assessed and core laboratory 
assessed), will be retrained on the missed elements by [CONTACT_592117]/or core laboratory if 
necessary prior to their next Absorb BVS case.  Depending on the elements missed, the CRA 
may attend the next Absorb BVS case to ensure criteria are met.  At any time during the Lead -In 
phase, if AV or the site determines that further site/investigator traini ng is required, such training 
will be arranged.  
4.4 ABSORB III Treatment Flow and Lesion Selection  
The same treatment flow and lesion selection applies to all subjects in ABSORB III ( including 
the Lead -In Phase and the Imaging Cohort ).  Either one or two target lesions in two separate 
epi[INVESTIGATOR_591986]. If only one target lesion is intended, a second non -target lesion 
in a different epi[INVESTIGATOR_591987]. For the Le ad-In Phase, only Absorb BVS will be used for target lesion (s).  
  
Abbott Vascular  Version 17.[ADDRESS_780698]: Absorb BVS or 
Control: XIENCE Two Lesions 
Two Target Lesions One Target lesion 
and one Non-target 
lesion
Non-Target
XIENCE 2000 subjects
&
[ADDRESS_780699]: Absorb BVS or 
Control: XIENCE 
Test: Absorb 
BVS or Control: 
XIENCE Target
Test: Absorb BVS or 
Control: XIENCE 
 
Figure 4.[ADDRESS_780700] with a 
XIENCE stent. Despi[INVESTIGATOR_591988], planned staged procedures are not 
allowed in ABSORB III.  
Prior to treatment with the assigned d evice (Absorb BVS or XIENCE), vessel sizing by [CONTACT_592118]. 
Quantitative methods such as on -line QCA, IVUS or OCT may be used if deemed necessary per 
physician discretion, but are not required. Details on the vessel sizing methods can be found in 
Imaging Guidance Document ( detailed in Section 7.3.2) .  
Table 4.1  provides the device sizes, RVD and lesion length for ABSORB III.  
Table 4.1   Absorb BVS and XIENCE Sizes  
Device  Lesion and Device Sizes  
RVD 1 Lesion Length1 
Lead -In Absorb 
BVS  
(Target lesion)  RVD  2.75 mm -  3.25 mm  
Scaffold diameter: 3.0 mm  Lesion length  8- 14 mm  
Scaffold length: [ADDRESS_780701] Absorb BVS  
(Target lesion)  RVD  2.50 mm -  3.75 mm  
Scaffold diameter: 2.5, 3.0 and 3.5 mm  Lesion length  24 mm  
Scaffold Length2: 8, 12, [ADDRESS_780702] XIENCE5  
(Target lesion)  
 RVD  2.50 mm -  3.75 mm  
Stent diameter: 2.5, 2.75, 3.0, 3.25, 3.5, 
4.0 mm  Lesion length  24 mm  
Stent Length: 8, 12, 15, 18, 23 and 28 mm 3 
 
XIENCE  
(Non -target lesion)  Per IFU (RVD ≥ 2.25 mm - ≤ 4.25 mm 
can be treated)  
All available sizes  Per IFU (lesion ≤ 32 mm) 4  
All available sizes  
1 Reference vessel diameter (RVD) and lesion length based on visual estimation  
2 Both the 8 mm and 12 mm length s will be available for the 2.5/3.0 diameter Absorb BVS.  Only the 12 mm length 
will be available for the 3.5 mm diameter.  The commercially approve d CE marked 23 mm Absorb BVS device  will 
not be used in this study.  
3 For target lesion, p lanned overlappi[INVESTIGATOR_411418] (i.e., the lesion must be eligible for treatment with a single 
stent) . However, bailout overlappi[INVESTIGATOR_591953].  
4 For non -target lesion, planned overlappi[INVESTIGATOR_591954].  
5 XIENCE V, XIENCE Prime, XIENCE Xpedition, XIENCE Alpi[INVESTIGATOR_050], XIENCE Pro, and XIENCE ProX are used in 
this study.  
The commercially approved CE marked 23mm Absorb BVS device  will not be used in this 
study.  
A minimum of 2 mm (by [CONTACT_142184]) of minimally diseased tissue should be covered by 
[CONTACT_592119].  
Planned overlap of the target lesion is not allowed. Overlap in the case of bailout is allowed for 
both the target  and non -target lesion. Please refer to Section 7.3.[ADDRESS_780703] 16, 2018 . 4.5.1  Randomization  
Stratified Randomization:  
Approximately 2000 subjects will be randomized 2:1 in the primary analysis ( test device: Absorb 
BVS vs. control device: XIENCE ).  As diabetes and dual lesion  treatment are known risks that 
may influence the rate of the composite endpoint (TLF), subjects will be stratified by [CONTACT_592120] (diabetic vs. non -diabetic) and dual vessel treatment (single target lesion vs. dual target 
lesion vs. one target lesio n and one non -target lesion). Subjects will also be stratified by [CONTACT_592121] -specified sites (expected high -enrolling sites). Other sites will be combined to ensure a 
sufficient number of subjects for the attainment of the desired randomization ratio . In the 
Imaging Cohort for both subjects receiving IVUS and those receiving the OCT, randomization 
(2:1) will be stratified by [CONTACT_192068] (diabetic vs. non -diabetic) and intended dual vessel 
treatment (single target lesion vs. dual target lesion vs . one target lesion and one non -target 
lesion). A centralized randomization service, IVRS, will be used.  
Timing of Randomization:  
Randomization will be done after successful treatment of the non -target lesion (if any) and 
successful and uncomplicated pre -dilatation of the target lesion (or the first target lesion if there 
are two target lesions) and vessel sizing (refer to Section 7.3.4 , Treatment Rules of the Target 
Lesion, for details). Once randomization is completed and a treatment is assigned, crossov er is 
not permitted. Regardless of the actual device the subject received, the subject will be included 
in ITT population per the original randomization assignment. An Absorb BVS scaffold may 
never be used in a patient randomized to XIENCE. However, if the  patient is randomized to 
Absorb BVS and the scaffold cannot be delivered or a complication otherwise develops that 
requires treatment with a XIENCE stent, a XIENCE or any other stent may be used as necessary 
in the best interests of the patient.  
The subj ect is considered to be successfully registered in this study and considered in the ITT 
population at the point of randomization (refer to Section 6.4).  Lead -In subjects will be 
considered registered in the study upon calling IVRS. Refer to Appendix IV (F igure 1 and 2) for 
enrollment and registration timeline and flow chart.  
4.5.[ADDRESS_780704] blinding should be 
maintained until the 5-year follow -up visit  for all subjects is completed.  
The physician performing the procedure will not be blinded to the assigned treatment. Thus, if a 
clinical follow -up with a study physician is deemed necessary at the protocol required follow -up 
time points, a different physician (or designee) than the one who implanted the device(s) should 
conduct follow -up clinical visits in order to maintain subject blinding. However for the Imagi ng 
Cohort, the protocol -required imaging follow up can be done by [CONTACT_592122]. Site personnel will be adequately trained such that the physician (or 
Abbott Vascular  Version 17.[ADDRESS_780705] 16, 2018 . designee) conducting the clinical follow -up is adequately blinded to the tr eatment received by 
[CONTACT_423]. For unscheduled visits, subjects may see the physician who implanted the device(s). 
Treating physicians should conduct all non -protocol related visits with the subject with caution, 
to prevent unblinding of the subject.  
The Clinical Events Committee (CEC) will be blinded to the randomization assignments. The 
angiographic, IVUS and OCT core laboratories cannot be blinded to the device received. The 
Data Safety Monitoring Board (DSMB) will also be blinded to the subject’s rand omization. 
Independent statisticians will generate blinded tables for review by [CONTACT_4318]. The DSMB may 
request unblinded data if a safety signal is observed.  
Sponsor personnel that will be unblinded will be the independent biostatisticians involved in 
gene rating and verifying the randomization code, key Clinical Science and Operations, Clinical 
Safety Monitor, Site Monitors, Clinical Data Management, Electronic Database Programmer, 
Inventory Management staff, and Clinical Information System (IS) personnel w orking on the 
trial. Restricted access of blinded personnel to the clinical database will be maintained until 
unblinding of the study.  
4.[ADDRESS_780706], and notify the Ethics Committee 
and the regulatory authority (if applicable).  All applicable Clinical Investigation documents 
shall be subjec t to the same retention policy as detailed in the Section 13.[ADDRESS_780707] Keepi[INVESTIGATOR_007].  
All subjects registered up to the point of trial discontinuation will continue to be followed up per 
protocol requirements.  
5. ENDPOINTS  
5.1 Primary Endpoint  
ABSORB III Primary Endpoint  
1. TLF at 1 year, non -inferiority (NI) against the control.  
• TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol -
defined MI definition, Appendix II) attributable to Target Vessel (TV -MI), or Ischemia -
Driven Target Lesion Revascularization (ID -TLR).  
• This analysis will include ~2000 subjects.  
5.2 Powered  Secondary Endpoint(s)  
Imaging Cohort Powered Secondary Endpoints  
Abbott Vascular  Version 17.[ADDRESS_780708] 16, 2018 . Imaging Cohort Powered Secondary Endpoints  are based on the pooled subjects from  the 
Imaging Cohort of Absorb III (~ 200 angiographic subjects and ~150 IVUS subjects) and 
subjects from the Absorb Japan RCT (~ 400 angiographic subjects, and ~150 IVUS subjects).  
One of the key attributes that differentiates Absorb BVS from metallic sten ts is the progressive 
mechanical weakening of the scaffold with polymer degradation over time, which allowed for 
vessel movement and gradual outward remodeling (positive) to accommodate any increases in 
the in -scaffold intimal hyperplasia that may limit bl ood flow.   In both the Absorb Cohort A and 
Cohort B trials, Absorb BVS treated vessels have shown evidence of vessel movement and late 
lumen and scaffold enlargement, providing anatomic indication that the vessel can adapt and 
enable the natural Glagov pro cess.24  
The vasomotion endpoint assesses the ability of the in -scaffold segment to move when the vessel 
is no longer mechanically constrained. Angiography will be used for the vasomotion assessment.  
The assessment of late lumen enlargement will be evaluat ed by [CONTACT_106269] -stent/scaffold mean lumen 
area change (ΔMLA) from post -procedure to 3 years by [CONTACT_427741].  
1. The in -stent/scaffold mean lumen area change, from post -procedure to 3 years by [CONTACT_427741] 
(mean lumen area measured after nitrate infusions, superiority test, ~30 0 pooled subjects).  
2. The in -stent/scaffold mean lumen diameter change, between pre - and post -nitrate infusion at 
3 years by [CONTACT_89320] (superiority test, ~600 pooled subjects).  
Powered Secondary Endpoint for Angina  
This powered secondary endpoint is inten ded to assess  angina at [ADDRESS_780709] for superiority of 
Absorb BVS to XIENCE . 
• Angina  is defined as the first adverse event resulting in the site diagnosis of angina.  
• The analysis will exclude angina following the index procedure through discharge, not t o 
exceed a period of 7 days . 
This analysis will include ~[ADDRESS_780710] for 
superiority of Absorb BVS to XIENCE . 
This analysis will include ~[ADDRESS_780711] for s uperiority of Absorb BVS to XIENCE.  
                                                           
24Glagov S, Weisenber W, Zarins CK et al. Compensatory enlargement of human atherosclerotic coronar y arteries. 
N Engl J Med . 1987; 316: [ADDRESS_780712] 16, 2018 . This analysis will include ~ 2000 subjects.  
Powered Secondary Endpoint for Diabetic Indication  
The powered secondary endpoint will be to support a diabetic indication for Absorb BVS.  
5.3 Additional Secondary Endpoint(s)  
In ABSORB III the following clinical secondary endpoints will be analyzed. Secondary imaging 
endpoints will be analyzed in the Imaging Cohort.  
• Acute Success : (Combined Clinical/Angiographic Endpoint)  
o Device success (Lesion level analysis)  
o Procedural success (Subject level analysis)  
• Clinical Endpoint  in hospi[INVESTIGATOR_248525] -up point (30 days; 180 days; 1, 2, 3, 4  
and 5 years ). 
o Component  
▪ Death (Cardiac, Vascular, Non -cardiovascular)  
▪ Myocardial Infarction   
- Attributable to target vessel (TV -MI)  
- Not attributable to target vessel (NTV -MI) 
▪ Target Lesion Revascularization (TLR)  
- Ischemia driven TLR (ID -TLR)  
- Non ID TLR (NID -TLR)  
▪ Target Vessel Revascularization (TVR,)  
- ID TVR  
- Non ID TVR  
▪ All coronary revascularization  
o Composite Endpoints  
▪ Death/All MI  
▪ Cardiac Death/All MI  
▪ Cardiac Death/TV -MI/ID -TLR (TLF)  
Abbott Vascular  Version 17.[ADDRESS_780713] 16, 2018 . ▪ Cardiac Death/All MI/ID -TLR (MACE)  
▪ Cardiac Death/All MI/ID -TLR/ID -TVR, non TL (Target Vessel Failure, TVF)  
▪ Death/All MI/All revascularization  
o Scaffold -Thrombosis / Stent Thrombosis (per ARC definition)  
▪ Timing (acute, sub -acute, late and very late)  
▪ Evidence (Definite and Probable)  
• Imaging Endpoints:  
Imaging endpoints will be analyzed on Imaging Cohort subjects only.  
o Angiography:  
All angiographic endpoints will be collected post -procedure and at 3 years  
▪ In-segment25 late loss (LL)  
▪ In-device26 LL 
▪ Proximal LL (proximal defined as 5 mm of tissue proximal to the device 
placement)  
▪ Distal LL (distal defined as 5 mm of tissue distal to the  device placement)  
▪ In-device/in -segment/proximal/distal minimum lumen diameter  
▪ In-device/in -segment/proximal/distal %Diameter Stenosis (DS)  
▪ In-device/in -segment/proximal/distal angiographic binary restenosis  
▪ In-device net gain (change in minimum lumen diameter between [ADDRESS_780714] -
procedure)  
▪ The magnitude of in -stent/scaffold mean lumen diameter change (absolute value) 
at 3-years follow -up from pre -nitrate to post -nitrate  
▪ The normalized in -stent/scaffold mean lumen diameter change at [ADDRESS_780715] -nitrate, defined as,  
 
                                                           
25 In-device refers to the margins of the stent  or scaffold . Segment refers to the margins of the stent or scaffold and 5 
mm proximal and 5 mm distal t o the stent or scaffold.  
26 Device throughout the protocol summary refers  to XIENCE or A bsorb  BVS System  
%100change)/2 Diameter Lumen Mean  Distal   change Diameter Lumen Mean  (Proximalchange Diameter Lumen Mean  fold Stent/Scaf -In
Abbott Vascular  Version 17.[ADDRESS_780716] -nitrate  
▪ Change in minimum lumen diameter, within treated segment, at [ADDRESS_780717] -nitrate  
▪ Change in in -device %DS at [ADDRESS_780718] -nitrate  
o IVUS (Grey scale):  
All IVUS endpoints will be collected post -procedure and at 3 years (as applicable) and 
within the device and within the treated segment:  
▪ Minimal Lumen Area  
▪ Percentage of subjects with late gain without incomplete apposition by [CONTACT_427741] 
(IVUS minimum lumen area post - procedure post -nitrate - IVUS minimu m lumen 
area [ADDRESS_780719] -nitrate)   
▪ %  change in the tissue area/volume between lumen and external elastic lamina 
(EEL)   
▪ Absolute change in tissue area/volume between lumen and EEL  
▪ Mean/minimal vessel diameter/area/volume  
▪ Mean/minimal device d iameter/area/volume; if analyzable in respect to Absorb 
BVS  
▪ Mean/minimal lumen diameter/area/volume, including change in minimum lumen 
area between post -procedure and follow -up 
▪ Mean/maximal neointima hyperplasia area/volume/percentage at 3 years; if 
analyz able in respect to Absorb BVS  
▪ Incomplete apposition (post -implantation), persisting incomplete apposition, late 
acquired incomplete apposition and resolved incomplete apposition at 3 years; if 
analyzable in respect to Absorb BVS  
• OCT:  
All OCT endpoints wil l be collected post -procedure and 3 years, and for within the 
device and within the treated segment:  
▪ Descriptive analysis of strut, lesion and vessel morphology  
▪ Mean neointimal area (NIA)  
- Apposed to the vessel wall with neointimal coverage  
- Apposed to vessel wall without neointimal coverage  
Abbott Vascular  Version 17.[ADDRESS_780720] 16, 2018 . - Incomplete apposition to vessel wall with neointimal coverage  
- Incomplete apposition to vessel wall without neointimal coverage  
▪ Lumen area/volume stenosis %  
▪ Mean/minimal device area  
▪ Mean/minimal luminal area/volume  
▪ Mean strut area/volume   
▪ Persisting incomplete apposition, late incomplete apposition at 3 years (if 
analyzable)  
▪ OCT analysis for subjects with jailed side branch  
▪ Descriptive analyses from [ADDRESS_780721] reconstructions  
5.4 Informational Endpoints  (Patient Reported Outcomes)  
In the 2000 primary analysis subjects of ABSORB III the following Patient Reported Outcomes 
will be analyzed as informational endpoints.  
• Overall Health Status in hospi[INVESTIGATOR_307] (baseline) and at the specified follow -up contacts (30 
days; 1, 2, 3  and 5 years) assessed using the EuroQoL 5D (EQ -5D) 
• Disease -Specific Quality of Life in hospi[INVESTIGATOR_307] (baseline) and at the specified follow -up 
contacts (30 days; 1, 2, 3  and 5 years) assessed using the Seattle Angina Questionnaire 
(SAQ)  
• Dyspnea se verity in hospi[INVESTIGATOR_307] (baseline) and at the specified fo llow-up contacts (30 days; 
1, 2 and 3 years) assessed using the Rose Dyspnea Scale (RDS)  
• Anxiety in hospi[INVESTIGATOR_307] (baseline) and at the specified fo llow-up contacts (30 days; 1, 2  and 
3years) assessed using t he Generalized A nxiety Disorder scale (GAD -7) 
6. SUBJECT SELECTION  AND WITHDRAWAL  
6.[ADDRESS_780722] signe d an Informed Consent (Refer to Appendix IV , Enrollment and 
Registration Process) are considered enrolled  in ASBORB III.  Subjects who do not satisfy the 
general angiographic inclusion and exclusion criteria and/or have unsuccessful pre -dilatation 
and/or v essel sizing are considered screen failures and will not proceed further in the trial.  These 
subjects will be entered into the eCRF screening log (as applicable; in addition, the reason for 
screen failure as well as supporting data will be entered into th e log).  
6.2.2  Informed Consent  
The Investigator or designee, who has been trained on the protocol, will explain the nature and 
scope of the trial, potential risks and benefits of participation, and answer questions for the 
subjects. All subjects (or legal ly authorized subjects’ representatives, if applicable) must sign and 
date the Institutional Review Board (IRB) /Medical Ethics Committee (MEC) approved 
informed consent prior to any clinical trial/investigation -specific procedures. No patients 
belonging t o a vulnerable population will be enrolled. Vulnerable population is defined as 
subject whose willingness to volunteer in a clinical investigation could be unduly influenced by 
[CONTACT_162161], whether justified or not, of benefits associated with particip ation or of retaliatory 
response from senior members of a hierarchy in case of refusal to participate.  Examples of 
populations which may contain vulnerable subjects include: Individuals with lack of or loss of 
autonomy due to immaturity or through mental disability, persons in nursing homes, children, 
impoverished persons, subjects in emergency situations, ethnic minority groups, homeless 
persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable 
subjects include, for examp le, members of a group with a hierarchical structure such as 
university students, subordinate hospi[INVESTIGATOR_248925], employees of the sponsor, 
members of the armed forces, and persons kept in detention.   
Obtaining of the consent, provision of a copy to the subject, along with the date must be 
documented in the subject’s medical records. The informed consent form must be signed by [CONTACT_592123] . In addition, the signed informed consent must 
be kept in the subject’s medical records/research chart and a copy must be given to the subject or 
the legally authorized representative.  
In addition, an authorization for use and disclosure of the subjects’ protected health information, 
in accordance with the Health Ins urance Portability and Accountability Act (HIPAA), must be 
obtained from the subject or their legally authorized representative (US only).  
For Live cases at congresses the patients need to sign a specific Live Case ICF, approved by [CONTACT_5040]/EC and by [CONTACT_592124], as well as by [CONTACT_185059] (e.g., FDA), as 
applicable. The investigator must request Abbott Vascular approval prior to, performing a Live 
Case.  
Abbott Vascular  Version 17.[ADDRESS_780723] of care. If some of these tests are not included in the site’s standard tests, 
they must be done, but after written Informed Consent has been obtained. Subjects must meet 
ALL of the inclusion criteria to be considered for the clinical evaluation. If ANY of the 
exclusion criteria are met, the subject is excluded from the clinical evaluation and cannot be 
registered.  
[IP_ADDRESS]  General Inclusion Criteria   
1. Subject must be at least [ADDRESS_780724] evidence of myocardial ischemia (e.g., stable, unstable angina, post -
infarct angina or silent ischemia) suitable for elective PCI.  Subjects with st able angina or 
silent ischemia and < 70% diameter stenosis must have objectives sign of ischemia as 
determined by [CONTACT_080], echocardiogram, nuclear scan, ambulatory ECG or 
stress ECG). In the absence of noninvasive ischemia, FFR must be done an d indicative of 
ischemia.  
4. Subject must be an acceptable candidate for coronary artery by[CONTACT_9292] (CABG) 
surgery.  
5. Female subject of childbearing potential who does not plan pregnancy for up to [ADDRESS_780725] 16, 2018 . [IP_ADDRESS]  General Exclusion Criteria  
1. Any surgery requiring general anesthesia or discontinuation of aspi[INVESTIGATOR_34251]/or an ADP 
antagonist is planned within [ADDRESS_780726] has known hypersensitivity or contraindication to device material and its 
degradants (everolimus, poly (L -lactide), poly (DL -lactide) , lactide, lactic acid) and 
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be 
adequately pre -medicated. Subject has a known contrast sensitivity that cannot be 
adequately pre -medicated.  
3. Subject has known allergic reac tion, hypersensitivity or contraindication to aspi[INVESTIGATOR_248]; or to 
clopi[INVESTIGATOR_591989]; or to heparin and bivalirudin, and therefore 
cannot be adequately treated with study medications.  
4. Subject had an acute myocardial infarction (AMI: STEMI or NSTEMI) within [ADDRESS_780727] not returned to within normal 
limits at the time of index procedure; or subject with stable angina or silent ischemia has 
CK-MB that is greater than normal limits at the time of t he index procedure.  
5. Subject is currently experiencing clinical symptoms consistent with new onset AMI 
(STEMI or NSTEMI), such as nitrate -unresponsive prolonged chest pain with ischemic 
ECG changes.  
6. Subject has a cardiac arrhythmia as identified at the ti me of screening for which at least 
one of the following criteria is met:[ADDRESS_780728] has a left ventricular ejection fraction (LVEF) < 30% assessed by [CONTACT_592125], including but not limited to echocardiography, MRI, Multiple -Gated 
Acquisition (MUGA) scan, contrast left ventriculography,  PET scan, etc. LVEF may be 
obtained within [ADDRESS_780729] be assessed during the index hospi[INVESTIGATOR_059] 
(which may include during the index procedure by [CONTACT_592126] t ventriculography) but 
prior to randomization in order to conf irm the subject’s eligibility.  
8. Subject has undergone prior PCI within the target vessel during the last 12 months. Prior 
PCI within the non -target vessel or any peripheral intervention is accep table if performed 
anytime >[ADDRESS_780730] requires 
future  peripheral interventions < [ADDRESS_780731] is receiving immunosuppressant therapy or has known immunosuppressive or 
severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., 
human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: 
corticosteroids are not in cluded as immunosuppressant therapy.  
13. Subject has previously received or is scheduled to receive radiotherapy to a coronary 
artery (vascular brachytherapy), or the chest/mediastinum.  
14. Subject is receiving or will require chronic anticoagulation therapy (e.g. , coumadin, 
dabigatran, api[INVESTIGATOR_3822], rivaroxaban or any other agent for any reason).   
15. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.  
16. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child -
Pugh ≥ Cla ss B.  
17. Subject has renal insufficiency as defined as an estimated GFR < 30 ml/min/1.73m2 or 
dialysis at the time of screening.[ADDRESS_780732] is high risk of bleeding for any reason; has a history of bleeding diathesis or 
coagulopathy; has had a significant gast ro-intestinal or significant urinary bleed within 
the past six months.  
19. Subject has had a cerebrovascular accident or transient ischemic neurological attack 
(TIA) within the past six months, or any prior intracranial bleed, or any permanent 
neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous 
malformation, etc.).  
20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath 
insertion. Note: femoral arterial disease does not exclude the patient if radial access may 
be used.  
21. Subject has life expectancy < [ADDRESS_780733] udy for any reason. This 
includes completion of Patient Reported Outcome instruments.  
                                                           
29 Estimated GFR can be based on Modification of Diet in Renal Disease (MDRD) equation or Cockcroft -Gault 
equation (CCG).  
 
Abbott Vascular  Version 17.[ADDRESS_780734] is part of a vulnerable population who, in the ju dgment of the investigator, is 
unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal 
circumstances or lack of autonomy.  This may include:  Individuals with mental 
disability, persons in nursing homes, children, impoverish ed persons, persons in 
emergency situations, homeless persons, nomads, refugees, and those incapable of giving 
informed consent. Vulnerable populations also may include members of a group with a 
hierarchical structure such as university students, subordina te hospi[INVESTIGATOR_591990], employees of the Sponsor, members of the armed forces, and persons kept in 
detention.  
6.3.[ADDRESS_780735] or on -line QCA may be used if deemed 
necessary by [CONTACT_431].  
[IP_ADDRESS]  Angiographic Inclusion Criteria  
1. One or two de novo  target lesions:  
a. If there is one target lesion, a second non -target lesion may be  treated but the non -
target lesion must be present in a different epi[INVESTIGATOR_196518], and must be treated first 
with a successful, uncomplicated result prior to randomization of the target lesion.  
b. If two target lesions are present, they must be present in d ifferent epi[INVESTIGATOR_591991].  
c. The definition of epi[INVESTIGATOR_591951], LCX and RCA and their 
branches. Thus, the patient must not have lesions requiring treatment in e.g. both the 
LAD an d a diagonal branch.  
2. Target lesion(s) must be located in a native coronary artery with a visually estimated 
or quantitatively assessed %DS of ≥ 50% and < 100% with a TIMI flow of ≥1 and 
one of the following: stenosis ≥ 70%, an abnormal functional test (e.g . fractional flow 
reserve, stress test), unstable angina or post -infarct angina.   
a. Lesion(s) must be located in a native coronary artery with RVD by [CONTACT_592127] ≥ 2.5 mm and ≤ 3.75 mm.  
b. Lesion(s) must be located in a native coronary artery with length by [CONTACT_592127] ≤ [ADDRESS_780736] 16, 2018 . c. For Lead -In subjects with 3.0x18 mm Absorb BVS: lesion(s) must be located in a 
native coronary artery with RVD by [CONTACT_592084] ≥ 2.75 mm and ≤ 3.25 mm. 
The lesion length by [CONTACT_592085] ≥ 8 mm and ≤ 1 4 mm.  
[IP_ADDRESS]  Angiographic Exclusion Criteria  
All exclusion criteria apply to the target lesion(s) or target vessel(s).  
1. Lesion which prevents successful balloon pre -dilatation, defined as full balloon 
expansion with the following outcomes:  
▪ Residual %DS is  a maximum of < 40% (per visual estimation), ≤ 20% is strongly 
recommended.  
▪ TIMI Grade -3 flow (per visual estimation).  
▪ No angiographic complications (e.g. distal embolization, side branch closure).  
▪ No dissections NHLBI grade D -F.  
▪ No chest pain lasting > 5 minutes.   
• No ST depression or elevation lasting > 5 minutes   
2. Lesion is located in left main.  
3. Aorto -ostial RCA lesion (within 3 mm of the ostium).  
4. Lesion located within 3 mm of the origin of the LAD or LCX.  
5. Lesion involving a bifurcation with a:  
a. side branch ≥ 2 mm in diameter, or  
b. side branch with either an ostial or non -ostial lesion with diameter stenosis > 50%, or  
c. side branch requiring dilatation.  
6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb  BVS or 
XIENCE stent:  
a. Extreme angulation (≥ 90°) proximal to or within the target lesion.  
b. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.  
c. Moderate or heavy calcification proximal to or within the target lesion. If IVUS used, 
subject must be exclud ed if calcium arc in the vessel prior to the lesion or within the 
lesion is ≥ 180°.   
7. Vessel contains thrombus as indicated in the angiographic images or by [CONTACT_592088].  
Abbott Vascular  Version 17.[ADDRESS_780737] is considered randomized  after IVRS has been 
called and a device has been assigned (Absorb BVS or XIENCE). The subject is considered 
registered and in the ITT population at the point of randomization. Once randomization is 
completed and a treatment arm is assigned, crossover is not permitted. Regardless of the actual 
device the subject received, the subject will be included in ITT population per the original 
randomization assignment.  
Registered subjects count toward the total sample s ize in ABSORB III.  Refer to Appendix IV  
and Figures [ADDRESS_780738] Discontinuation  
Subjects who do not get registered in ABSORB III will be discontinued from the trial.  
Missed Visits:  
• If a subject misses one or more  non-consecutive follow -up contact [CONTACT_150746], the visit 
will be considered a missed visit and subject is not lost -to-follow -up. 
• Under extenuating circumstances in which a subject cannot be contact[INVESTIGATOR_530] (e.g serious 
illness resulting in institutionalization,  dementia, incarceration) indirect contact [CONTACT_4490] a 
subject’s healthcare provider or immediate family member identified will not be 
considered missed visits. Protocol required data will be collected in the electronic case 
report forms (eCRF).  Subject may th en return for subsequent visits.  
Lost-to-Follow -up:   
If the subject misses two consecutive scheduled follow -up time points, and the attempts to 
contact [CONTACT_35323]’s healthcare provider or immediate family member detailed below 
are unsuccessful , then the subject is considered lost -to-follow -up. Site personnel shall make all 
reasonable efforts to locate and communicate with the subject, including the following, at each 
contact [CONTACT_7206]:  
Abbott Vascular  Version 17.[ADDRESS_780739] 16, 2018 . • A minimum of two telephone calls to contact [CONTACT_332027], including date, time, and initials of site personnel trying to make contact;  
• If these attempts are unsuccessful, a certified letter should be sent to the subject.  
Subject Discontinuation:  
Every subject should  remain in the Clinical Investigation until completion of the required follow -
up period, however, a subject’s participation in any Clinical Investigation is voluntary and the 
subject has the right to withdraw at any time without penalty or loss of benefit.  Conceivable 
reasons for discontinuation may include, but not be limited to, the following:  
• Subject Withdrawal:   Subject participation in a Clinical Investigation is voluntary and 
the subject may discontinue participation (refuse all subsequent testing/fol low-up) at any 
time without loss of benefits or penalty.  
• Investigator Termination:   Investigator may terminate the subject’s participation 
without regard to the subject’s consent if the Investigator believes it is necessary. 
Reasons for an investigator’s t ermination of a subject include the following but are not 
limited to:  
o Per the investigator’s discretion, a subject is unable to be compliant with the 
protocol requirement (e.g., medical conditions such as terminal cancer; subject 
moved out of the country,  etc.) 
o Per the investigator’s discretion, the follow -up study requirements (i.e., 
medications or procedures) may put the subject at risk.  
• Lost -to-Follow -up:  Subject does not complete the scheduled follow -up visits but has not 
‘officially’ withdrawn from t he clinical investigation.   
Sponsor must be notified of the reason for subject discontinuation. The site will record this 
information on the eCRF and source documents.  Investigators must also report this to their 
ethics committee (EC) or IRB as defined b y their institution’s procedure.  Subjects will not be 
replaced.  
The subject is considered to have completed the study upon Clinical Investigation completion of 
the [ADDRESS_780740]'s permission to follow 
his/her status/condition outside of the clinical investigation.  
Abbott Vascular  Version 17.[ADDRESS_780741] history will include demographics (e.g., age, gender)31, cardiac history including but not 
limited to Canadian Cardiovascular Society (CCS) and Braunwald classification of angina, 
history of myocardial infarction, diabetes mellitus, hypertension, hypercholesterolemia, previous 
CABG and PCI,  and concomitant cardiovascular medications (Refer to Appendix II  for 
Definitions).  In addition, measurements of weight, height, and resting blood pressure will be 
collected.  
7.1.3  Patient -Reported Outcomes Assessment  
All 2,000 primary analysis subjects i n ABSORB III will complete the following Patient Reported 
Outcome questionnaires in person at the clinical sit e prior to the index procedure*.  
• EuroQoL 5D (EQ -5D) survey to assess overall health status.  The EQ -5D is a self -
administered two -part instrument.   The first part consists of 5 questions to assess current 
health state in 5 dimensions (mobility, self care, usual activities, pain/discomfort and 
anxiety/depression).  The second part is a 20 cm visual analog scale that ranges from 0 
(worst imaginable he alth state) to 100 (best imaginable health state [31].   
• Seattle Angina Questionnaire (SAQ) to assess disease -specific Quality of Life.  The SAQ 
is a self -administered 19 -item instrument designed t o measure the physical and emotional 
effects of coronary artery disease across five dimensions (physical limitation, angina 
stability, angina frequency, treatment satisfaction, and disease perception) [32]. 
• Rose Dyspnea Scale (RDS) to assess severity of dyspnea.  The RDS is a self -
administered [ADDRESS_780742] of dyspnea on health -related 
quality of life [33]. 
• Generalized Anxiety Disorder scale (GAD -7) to assess anxiety.  The GAD -[ADDRESS_780743] ered 7 -item instrument designed to assess severity of patient’s general anxiety 
disorder [34]. 
*Every effort should be made to have subjects complete all four patient reported outcomes 
questionnaires prior to the procedure.  However, in situations where this is absolutely not 
                                                           
[ADDRESS_780744] -menopausal status, date of birth, race/ethnicity, highest level of 
education, employme nt status and household income.  
 
Abbott Vascular  Version 17.[ADDRESS_780745].  
Table 7.1  Baseline Laboratory Assessment  
Within 21 days prior to 
procedure†  Within 7 days prior to 
procedure  Within 48 hours prior to pro cedure€ 
• Platelet and White Blood 
Count  
• Hemoglobin  
• Serum Creatinine  
• HbA1c‡  
• Estimated GFR*  • Pregnancy test (if 
applicable)  • 12-lead ECG (within 24 hours 
preferred)  
• Creatine kinase (CK)  
• Creatine kinase myocardial -band 
isoenzyme (CK -MB)  
†The [ADDRESS_780746] be known prior to index procedure.  
‡ HbA1c is to be collected in diabetic subjects only, and its result is not needed prior to the index procedure.  
€Within [ADDRESS_780747] be done in cases in which there is evidence of acute or recent (<7  days) myocardial infarction 
(MI) or unstable angina; in these cases CK and CK -MB must be < ULN prior to the index procedure.  For stable 
angina or silent ischemia, CK and CK -MB < ULN within [ADDRESS_780748] able angina 
subjects, if CK is > ULN but CK -MB is < ULN, with no signs of MI or unstable angina, the patient maybe enrolled.  
If the subject does not have a known diagnosis of MI or unstable angina within 96 hours prior to the index 
procedure, assessment o f cardiac enzymes may be obtained from arterial blood drawn after the start of the index 
procedure but prior to device implantation.  However, if CK -MB comes back elevated a protocol deviation will be 
issued.  
* Glomerular Filtration Rate  
 
Both CK and CK -MB must be measured pre -procedure and used to assess subject’s eligibility 
criteria.  
7.2.[ADDRESS_780749] receive a loading dose of ≥ 
[ADDRESS_780750] within 24 
hours prior to the index procedure (preferred), but in all cases no greater than [ADDRESS_780751] 6 hours before the procedure (clopi[INVESTIGATOR_7745] 600 mg), or 1 hour prior 
to the procedure (prasugrel 60 mg or ticagrelor 180 mg), but in all cases no greater than 1 hour 
after the end of the procedure.  
The prasugrel lo ading dose may be omitted for those subjects on chronic prasugrel therapy (5 or 
10 mg daily, or according to prescribing information) for ≥ 7 days prior to the index procedure; 
however, it is recommended that a loading dose (≥ 30 mg) be re -administered. Th e ticagrelor 
Abbott Vascular  Version 17.[ADDRESS_780752] 16, 2018 . loading dose may be omitted for those subjects on chronic ticagrelor therapy (90 mg twice daily).  
For patients maintained on chronic clopi[INVESTIGATOR_7745], the loading dose of an ADP antagonist must be 
administered. A loading dose of prasugrel or ticag relor may be safely given to patients 
maintained on chronic clopi[INVESTIGATOR_60469], or even in those in whom a clopi[INVESTIGATOR_591992]. Ticlopi[INVESTIGATOR_591956] a substitute at a dose in accordance with 
standard hospi[INVESTIGATOR_591993], prasugrel, or ticagrelor.   
Refer to respective prescribing information for ADP antagonist for further details regarding 
loading practice.  
7.2.[ADDRESS_780753] 
hospi[INVESTIGATOR_13707]. Either unfractionated heparin or bivalirudin may be used for procedural 
anticoagulation, as per the discretion of the investigator. Subjects having bee n treated with low 
molecular weight heparin (LMWH) prior to the procedure must receive their last dose more than 
8 hours prior to the index procedure. LMWH and fondaparinux are not permitted as procedural 
anticoagulants in this protocol.  
Use of glycoprote in IIb/IIIa inhibitors will be at the discretion of the investigator. Any change in 
medication regime performed per the protocol, and not as routine hospi[INVESTIGATOR_13707], can only 
occur after obtaining Informed Consent.  
7.3 Index Procedure  
7.3.1  Baseline (Pre -Procedure) Angiography  
Baseline angiography of the target vessel(s) will be completed as per the Angiographic Core 
Laboratory Protocol.  
7.3.[ADDRESS_780754] -procedure and 
follow -up imaging with each respective modality. This document will be separate from the 
protocol.  
7.3.3  Treatment of the Non -target Lesion(s)  
In addition to target lesion , one additional non -target lesion in a different epi[INVESTIGATOR_591994]’s regulatory -approved XIENCE stent (e.g., FDA -approved/CE -
marked stent/Therapeutic Goods Administration (TGA)). A non -target lesion can be treated in  
the case that there are two lesions and one lesion does not meet the angiographic 
inclusion/exclusion criteria. The non -target lesions must be treated first, prior to randomization, 
and the subject may then only be randomized if treatment of the non -targe t lesion was successful 
and uncomplicated, defined as final diameter stenosis ≤ 10% with final TIMI -3 flow, with no 
residual dissection NHLBI grade ≥ type B, and no transient or sustained angiographic 
complications (e.g., distal embolization, side branch c losure) , no chest pain lasting > [ADDRESS_780755] segment elevation or depression lasting > 5 minutes. The non -target lesion will not be 
considered in the primary analysis.  
7.3.4  Treatment Rules of the Target Lesion(s)  
Prior to use, the Absorb BVS System or XIENCE should be inspected and prepared according to 
the IFU. The Absorb BVS System and XIENCE should be delivered and deployed per the IFU. 
The treatment strategy applies to all subjects in ABSORB III, including the Lead -In Phase and 
the Imaging  Cohort.  
• Treatment of a maximum of two de novo  native coronary artery lesions, each in a different 
epi[INVESTIGATOR_196518].  
o If a single target lesion is treated, it m ust be treated by [CONTACT_592128] (Absorb BVS 
or XIENCE). For Lead -In subjects, the target lesion will be treated only with Absorb 
BVS.  
o If two lesions are treated, possible combinations are as follows:  
o Two target lesions:  
▪ If both lesions satisfy angiographic inclusion/exclusion criteria, then both lesions 
must be treated by [CONTACT_592129] (test 
device: Absorb BVS or control device: XIENCE),  
▪ For Lead -In subjects, both target lesions will be treated with Absorb BVS  
OR 
o One target lesion and one non -target lesion:  
▪ If only one lesion satisfies angiographic inclusio n and exclusion criteria then this 
lesion must be treated by [CONTACT_592128] (test device: Absorb BVS or control 
device: XIENCE) as a target lesion and the other lesion must be treated by 
[CONTACT_592092] a non -target lesion per the instructions for use  (IFU) .  
▪ The non -target lesion must be treated first (before randomization) with a 
XIENCE, and the patient may then only be randomized if treatment of the non -
target lesion was successful and uncomplicated, defined as final diameter stenosis 
≤ 10% with final TIM I-3 flow, with no residual dissection NHLBI grade ≥ type B, 
and no transient or sustained angiographic complications (e.g., distal 
embolization, side branch closure) , no chest pain lasting > [ADDRESS_780756] 
segment elevation or depression lasting > 5 minutes. Please refer to Figure 2  in 
Appendix V . 
▪ For Lead -In subjects, one target lesion and one non -target lesion treatment is 
allowed. The target lesion must be treated by [CONTACT_592093], and the non -target 
lesion must be treated by [CONTACT_592094]. The non -target le sion must be treated first and 
successfully (as defined above) before treating the target lesion with Absorb BVS.  
Abbott Vascular  Version 17.[ADDRESS_780757] 16, 2018 . Access Site and Guide Catheter Size:  
• Either femoral or radial access may be used.  
• A minimum 6F guide catheter or greater must be used during the index procedure per 
requirements for Absorb BVS implantation.  
o Minimum guiding catheter compatibility (inner diameter) for Absorb BVS is 0.070”/1.8 
mm (6F) (refer to IFU).   
o Devices (i.e., guid e sheaths such as the Guide Liner) that decrease the inner diameter of 
the guide catheter outside of the Absorb BVS minimum guide catheter compatibility must 
not be used with the Absorb BVS System. Do not insert a [ADDRESS_780758] meet or exceed the above 
minimum guiding catheter requirements for Abs orb BVS (i.e.,  only the 7 -in-8 GuideLiner 
provides an adequate inner diameter (0.071” ID), 8F guide catheter would be required).  
• For XIENCE, please follow IFU for the guiding catheter size.  
Baseline Angiogram and Identification of the potential target lesi on: 
• Assessment of the potential target lesion(s) to be treated must be done to ensure angiographic 
criteria are met; this must occur prior to pre -dilatation and vessel sizing.  
Pre-dilatation of potential target lesion  
• Pre-dilatation of the potential target lesions(s) must be performed.  
• Pre-dilatation must be performed with an angioplasty balloon; cutting or scoring balloons 
may be used per physician discretion, if the lesion appears to be mildly calcified.  
• The pre -dilatation balloon should be sized 1:1 to the visually estimated RVD or 0.25 mm 
smaller than RVD. It cannot be more than 0.5 mm smaller than the visually estimated RVD 
of the target vessel.  If pre -dilatation balloon is sized 1:1, a non -compliant balloon is s trongly 
recommended.  
The pre -dilatation balloon must be equal in length or shorter than the planned scaffold/stent 
length.    
Important: Full balloon expansion with the pre -dilatation balloon must be achieved before the 
patient is randomized into the study . If there is any question that the target lesion was not 
fully dilated or that any significant resistance to expansion from the lesion remains, the lesion 
should be re -dilated with a non -compliant balloon (sized 1:1 to the RVD) at higher pressure. 
Absorb BVS or XIENCE must not be implanted in a lesion in which full balloon expansion 
has not been achieved.  
Abbott Vascular  Version 17.[ADDRESS_780759] 16, 2018 . • The potential target lesion must continue to meet angiographic criteria following adequate 
pre-dilatation, to be regarded as “successful pre -dilatation” . 
o For randomized subjects, RVD remains ≥ 2.50 mm - ≤ 3.75 mm, and length of the lesion 
that will be covered by [CONTACT_8121] (including any edge dissections) is still ≤ 24 mm.  
o For Lead -In subjects, RVD remains ≥ 2.75 mm - ≤ 3.25 mm , and length of the lesion t hat 
will be covered by [CONTACT_8121] (including any edge dissections) is still ≥8 - ≤ 14 mm . 
o Residual %DS is a maximum of < 40% (per visual estimation), ≤ 20% is strongly 
recommended.  
o TIMI Grade -3 flow (per visual estimation).  
o No angiographic complications ( e.g. distal embolization, side branch closure).  
o No dissections NHLBI grade D -F. 
o No chest pain lasting > [ADDRESS_780760] depression or elevation lasting > 5 minutes.  
• For two potential target lesions, the lesion with the higher possibility of failing ves sel sizing 
criteria (per investigator’s assessment) should be identified as the first target lesion and pre -
dilated first before randomization.  
o If pre -dilatation of the 1st target lesion fails, the patient may not be randomized, and the 
interactive voice r esponse system (IVRS) must not be called.  
o If the 1st target lesion was successfully pre -dilated and vessel sizing criteria are still met, 
the IVRS is called to randomize the subject. Once the first lesion is successfully treated32 
with the assigned device ( and only at this time), the second target lesion must be pre -
dilated, and then treated with the assigned device.   
o If the 1st target lesion was successfully pre -dilated but did not meet vessel sizing criteria, 
treat as a non -target lesion. Once the first lesion is successfully treated as a non -target 
lesion, the second lesion must be treated as the target lesion in which success ful  pre -
dilatation and vessel sizing criteria must be met after which IVRS must be called and the 
target lesion treated per assignment. If 2nd target lesion fails pre -dilatation and vessel 
sizing criteria, it should be treated as non -target lesion and sub ject must not be 
randomized.  
•  Each target vessel and lesion should also be such that the operator believes either the Absorb 
BVS or XIENCE devices could be delivered to and cross the target lesion without additional 
lesion preparation (e.g., absence of exc essive vessel or lesion tortuosity or calcification) .  
                                                           
32 Successful lesion treatment is defined as final diameter stenosis ≤ 3 0% with final TIMI -3 flow, with no residual 
dissection NHLBI grade ≥ type B, and no transient or sustained angiographic complications (e.g. distal 
embo lization, side branch closure), no chest pain lasting > [ADDRESS_780761] segment elevation or depression 
lasting > [ADDRESS_780762] 16, 2018 . Vessel Sizing  
• Following the use of nitroglycerine (at least 100 µg intracoronary nitroglycerine, >150 µg 
preferred)33 and successful pre -dilatation of the potential target lesion(s), vessel sizing must 
be conducted by [CONTACT_142184]. Quantitative methods such as on -line QCA, IVUS or OCT 
may be used per physician discretion but are not required; taking into account that QCA 
tends to under -estimate RVD compared to visual estimation, whereas IVUS tends t o over -
estimate lumen RVD compared to visual estimation. Follow core laboratory guidelines for 
the use of each modality.  
• Prior to randomization, IVUS or OCT can be used to evaluate the vessel if there is question 
regarding the eligibility of the vessel either before or after pre -dilatation.  
• A subject must not be randomized in ABSORB III if  
o Vessel size or lesion length befor e or after pre -dilatation does not satisfy eligibility 
criteria.  
o Moderate or heavy calcification, tortuosity or other conditions are present proximal or 
within the target segment, reducing the likelihood that the Absorb BVS or XIENCE can 
be either delivere d to or expanded at the lesion.  
o Complications and/or adverse events were identified during IVUS or OCT usage (e.g., 
vessel dissection NHLBI grade D -F).34   
• Table 7.2 provides the guidance of vessel and device sizing during the procedure, which are 
detailed as the followings:  
o First, assess RVD based on visual estimation  
o Then, select a pre -dilatation balloon sized 1:[ADDRESS_780763] -dilatation balloon has a length short enough so it is inflated within the 
scaffold margins to avoid edge dissectio n. 
                                                           
33 If the patient’s blood pressure is so low that ≥ 100 ug of nitroglycerine cannot be administered, the patient should 
not be randomized. It is suggested that ≥200 µg of nitroglycerine be administered if the systolic blood pressure is 
>[ADDRESS_780764]: side -branch occlusion, persistent S -T abnormalities, 
prolonged  chest pain , flow limiting dissections  etc. 
Abbott Vascular  Version 17.[ADDRESS_780765] RVD 
after Pre -dilatation  Absorb BVS Diameter  
2.5 mm  2.25 or 2.5 mm  2.5 mm  2.5 mm  
2.75 mm  2.25 – 2.75 mm  2.75 mm  3.0 mm  
3.0 mm  2.5 – 3.0 mm  3.0 mm  3.0 mm  
3.25 mm  2.75 – 3.25 mm  3.25 mm  3.5 mm  
3.5 mm  3.0 – 3.5 mm  3.5 mm  3.5 mm  
3.75 mm  3.25 – 3.75 mm  3.75 mm  3.5 mm  
 
Randomization  
• Upon successful treatment of the non -target lesion (if any) and completion of successful pre -
dilatation and vessel sizing of the first target lesion, interactive voice response system (IVRS) 
can be called.  
• A subject is considered registered and in the ITT population at the time of randomization.  
• Lead -In subjects will not be randomized but are assigned to Absorb BVS treatment in target 
lesion(s).  
Lesion Treatment  
• The length of the Absorb BVS and XIEN CE stent should be selected to allow at least 2 mm 
but less than 4 mm of normal or nearly normal reference vessel at each edge.  
• If the Absorb BVS cannot reach or cross the lesion or additional lesion preparation is 
required, the Absorb BVS must be removed and a new Absorb BVS must be introduced after 
subsequent pre -dilatation(s) with the same sized or larger non -compliant balloon at higher 
pressure. Note: the Absorb BVS should not be “Dottered” across the lesion if it does not 
cross easily.  
• If the Absorb BVS is unable to reach or cross the target lesion after multiple attempts 
(maximum of two Absorb BVS; including additional lesion preparation), a XIENCE stent 
must be used.  
• If XIENCE is unable to reach or cross the target lesion after multip le attempts (including 
additional lesion preparation) , the investigator should treat the lesion per standard of care.  
• In the case of two target lesions assigned to the Absorb BVS, if the first lesion is 
unsuccessfully treated with the Absorb BVS the follow ing must occur:  
o First target lesion must be treated with XIENCE. If the treatment of the 1st target lesion is 
successfully treated with XIENCE, treat the 2nd target lesion with Absorb BVS.  
o If the treatment of the 1st target lesion is unsuccessful treated  with XIENCE, treat the 1st 
lesion and 2nd lesion per standard of care. The subject must not be treated with a BVS.  
Abbott Vascular  Version 17.[ADDRESS_780766] not  be used.  
• Successful lesion treatment is defined as final diameter steno sis ≤ 30% with final TIMI -3 
flow, with no residual dissection NHLBI grade ≥ type B, and no transient or sustained 
angiographic complications (e.g. distal embolization, side branch closure) , no chest pain 
lasting > [ADDRESS_780767] segment elevation or depression lasting > 5 minutes.   
• For Absorb BVS, the scaffold should be deployed slowly, by [CONTACT_592130] 2 atm increments each, over 5 seconds, until the scaffold is completely expanded. 
Pressure should be maintained for 30 seconds if tolerated by [CONTACT_102].  
• For the Absorb BVS and XIENCE delivery balloon, do not exceed the rated burst pressure 
(RBP) per the IFU for the individual device.  
• Post-dilatation of target lesion or non -target lesion treated with XIENCE should be per 
standar d of care.  
• If post -dilatation of the target lesion treated with Absorb BVS is necessary the following 
guidance is given:  
o A low profile, high pressure, non -compliant, balloon dilatation catheter that has not been 
previously inflated must be used.  
o The post -dilatation balloon length should be selected such that the balloon stays within 
the margins of the scaffold so as to avoid an edge dissection.  
o The expanded diameter of the post dilatation balloon must be within the allowable 
expansion limits of the scaffol d. Do not dilate the Absorb BVS beyond the dilatation 
limit which is 0.[ADDRESS_780768] -
dilatation  
• IVUS or OCT guidance may be used as per standard of care.  
• Please refer to the physician training deck for user guidance in handling procedural issues 
(e.g., difficult in recrossing an implanted scaffold for purposes such as intravascular imaging 
or post -dilatation if needed).  
Abbott Vascular  Version 17.[ADDRESS_780769] is in the Imaging Group (See Appendix VI and Imaging Guidance Document for 
further details):  
• Post-procedure angiography, IVUS and OCT are required based on respective imaging 
groups.  
• If post -dilatation was performed, post -procedure imaging must be conducted following last 
balloon inflation.  
If two target lesions are treated, pos t-procedure imaging must be done on the first target lesion 
after its successful treatment, and then after successful treatment  of the 2nd target lesion.  
7.3.[ADDRESS_780770] experiences:  
• Dissection requiring intervention  
• Occlusive complication as evidenced by a decrease in target vessel flow  
• Chest pain or ischemic changes measured by [CONTACT_592131], medical therapy or lytic agents  
• Unplanne d additional device is required to cover the target lesion  
In the randomized subjects, if a bailout device is required for a target lesion (e.g., for edge 
dissection), the same device as the implanted device must be used. Overlap of the bailout 
stent/scaff old with the implanted stent/scaffold should be 1 -2 mm. Gaps should be avoided.  
 Use Absorb BVS if target lesion is treated with Absorb BVS.  
 Use XIENCE if target lesion is treated with XIENCE.  
 If a bailout with an Absorb BVS device cannot be delivered to t he site of the lesion, the 
device should be carefully withdrawn and a XIENCE used.  
 If an appropriate size Absorb BVS is not available XIENCE can be used.  
If during the Lead -In phase a bailout is required, the investigator should use an appropriately 
sized  XIENCE stent and not an Absorb BVS.  
The Imaging Cohort subjects that receive metallic stent bailout of an Absorb BVS treated lesion 
will be required to complete imaging follow -up at the protocol specified time points of [ADDRESS_780771]’s 
imaging data will not be included in the imaging study analysis and will not be counted towards 
the associated powered secondary endpoints analysis. These subjects may be replaced by [CONTACT_592132] w ithout metallic stent overlap.  
Abbott Vascular  Version 17.[ADDRESS_780772] 16, 2018 . IMPORTANT:   It is required that the bailout device be placed so that there is no visible gap 
between the Absorb BVS and the bailout device.  In such a case, at least 1 mm (minimum) to 2 
mm (maximum) overlap is required.  
IMPORTANT:  In the rare event of acute occlusion following Absorb BVS placement, the 
bailout device should be XIENCE and deployed within the Absorb BVS such that the Absorb 
BVS is completely covered by [CONTACT_592133].  
Although a bailout procedure is not considered a major adverse cardiac event (MACE) unless the 
subject sustains death, emergent CABG, PCI or MI, such procedures should be avoided unless 
required for safe subject management.  
7.3.6  Final (Post -procedure) Angiography  
Angiographic imaging will also be performed after the Absorb BVS or XIENCE stent 
deployment.  Physicians should follow accepted hospi[INVESTIGATOR_591995].  For angiographic imaging, post -
implantation images should be captured the same orthogonal views that were used for the pre -
procedure images. Intracoronary nitroglycerine should be re -administered before final 
angiography.  
7.3.7  Final (Post -procedure) IVUS and OCT  
For subjects not required to have post -procedure imaging, IVUS and OCT may be performed 
post-procedure if the investigator believes there is incomplete apposition of the device. The 
procedure will be pe rformed according to the site’s standard. However, if malapposition is seen 
and post -dilatation required, a non -compliant balloon should be used and in the case of Absorb 
BVS, do not dilate the Absorb BVS beyond the dilatation limit which is 0.[ADDRESS_780773] be performed after any 
additional inflations.  
7.3.8  Imaging Assessment  
Subjects from the Imaging Cohort will receive angiography (includes vasomotion assessment), 
IVUS and OCT at pre -specifie d time -points ( Section 7.5 ). Imaging assessments should be 
conducted per core lab guidelines in the Imaging Guidance Document distributed to each site. 
Intracoronary nitroglycerine should be given before all imaging runs to avoid spasm and afford 
maximal l uminal dimensions.  
Any Imaging Cohort subject that did not receive the assigned Absorb BVS or XIENCE stent will 
not receive follow -up imaging procedures. These subjects will be clinically followed under the 
study. If an Imaging Cohort subject had a TLR pri or to the imaging follow -up, the imaging data 
at the time of TLR and at the protocol specified later imaging time points will be analyzed but 
not included in the imaging endpoint analysis. If an Imaging Cohort subject had a TVR or 
angiogram prior to the im aging follow -up, the subject will continue to have the protocol 
specified imaging follow -up and will not be replaced. If an Imaging Cohort subject has two 
target lesions but only one target lesion was successfully treated with the assigned device, the 
unsu ccessfully treated target lesion must be imaged post -treatment and at the specified follow -up 
Abbott Vascular  Version 17.[ADDRESS_780774]’s imaging data will 
not be included in the imaging study analysi s and will not be counted the associated powered 
secondary endpoints. These subjects may be replaced by [CONTACT_592134].  
[IP_ADDRESS]   QCA of Target Vessel  
• QCA will be performed pre -procedure, post-procedure and at the 3 -year follow -up for the 
imaging study subjects.  
• Angiography must be performed per the angiographic core laboratory guidelines.  
[IP_ADDRESS]  IVUS Pull -back of Target Vessel  
• IVUS pullback (20 MHz or 40 -45 MHz catheter can be used) is r equired post -procedure 
and at 3 -year follow -up for the imaging study subjects.  
• Pullback of the IVUS catheter should be performed from the distal reference to the 
guiding catheter, per IVUS core laboratory guidelines.  
• If IVUS reveals any findings such that additional PCI is performed, an additional IVUS 
run must be performed after the last intervention.  
• Caution:  It is important to place the IVUS transducer in the center of the lumen to avoid 
lifting or disturbing the device struts during pullback.  
[IP_ADDRESS]   OCT of the Target Vessel  
• OCT pullback is required post -procedure and at 3 -year follow -up for the imaging study 
subjects.  
• OCT pullback should contain at least one recognizable landmark, usually a major side 
branch.  
• Caution:  It is important to place the O CT transducer in the center of the lumen to avoid 
lifting or disturbing the device struts during pullback.  
[IP_ADDRESS]  Vasomotion Assessment  
• At the 3 -year follow -up, assessment of vessel movement in response to nitroglycerin 
infusion will be conducted. Please  see the Imaging Guidance Document for the details of 
this assessment.  
• Vasomotion assessment should not be assessed under the following conditions, and those 
subjects may be replaced for the imaging analysis:  
Abbott Vascular  Version 17.[ADDRESS_780775] 16, 2018 . o Target lesion treated with Absorb BVS with meta llic stent overlap  
o Target lesion undergoing other PCI procedures prior to 3 -year imaging follow -up 
o If target lesion has ≥ 50% stenosis at the time of the 3-year assessment and does 
not clearly require revascularization, FFR should be conducted to determine  if 
lesion is flow limiting. If the lesion is flow limiting and requires revascularization, 
vasomotion assessment should not be done.  
• Details regarding the angiographic assessment of the vessel and timing of nitroglycerine 
infusion are further detailed in the Imaging Guidance Document.   
7.[ADDRESS_780776]–procedure  
7.4.[ADDRESS_780777]-procedure Information to be Recorded  
The following information needs to be obtained between 12 hours following the index procedure 
and hospi[INVESTIGATOR_2345] (in -hospi[INVESTIGATOR_591996] a maximum of 7 days following the 
index procedure).  
Between [ADDRESS_780778] -procedure and discharge  
• Date of discharge  
• Antiplatelet medications  
• Chronic concomitant medications  
• Adverse Events, if  any  
7.4.[ADDRESS_780779] -
proce dure cardiac enzyme collection.  
IMPORTANT:   These tests must be performed whether or not they are considered part of the 
Investigator’s standard of clinical practice.  
Post-procedure and discharge  
• A [ADDRESS_780780] procedure.  
• Both Creatine kinase (CK) and Creatine kinase myocardial -band isoenzyme (CK -MB) must  
be obtained for ALL registered subjects as it will be used for cardiac assessment of subjects 
post-index procedure  
o Pre-procedure CK and CK -MB draw*  
o First post -procedure C K and CK -MB draw at [ADDRESS_780781] -procedure**.  
o If either of the post -procedure CK -MB level s are ≥ [ADDRESS_780782] be drawn until they are falling.  
* If the patient has stable coronary artery disease, the pre -procedure level can be obtained during 
procedure but prior to stent/scaffold deployment. If the patient has a rec ent acute coronary 
syndrome, the pre -procedure level must be obtained prior to the procedure and the CKMB shown 
to be within normal limits prior to the patient being randomized.  
** For hospi[INVESTIGATOR_591959] [ADDRESS_780783] -procedure time points, this should al so be documented in the electronic case report forms  
7.4.3  Follow -up Antiplatelet Medications  
All subjects will be maintained at a minimum of 75 mg of clopi[INVESTIGATOR_196511] 5 or 10 mg of 
prasugrel daily ([ADDRESS_780784] patients)  or 90 mg twice da ily of ticagrelor for a 
minimum of 12 months following the procedure. For prasugrel subjects < 60 kg in weight or ≥[ADDRESS_780785] receive 
between ≥75 to ≤ [ADDRESS_780786] and aspi[INVESTIGATOR_591997]/CIP. Subjects may receive other medications as needed per 
physician’s discretion. These concomitant medications must be recorded if the medications are 
expected to continue for more than [ADDRESS_780787] be 
recorded regardless of duration.  
The use and changes for the following classes of chronic concomitant medications, including 
dosage, frequency an d route of administration should be recorded.   
• Cardiovascular Medications: Angiotensin converting enzyme inhibitors and angiotensin 
receptor blockers, renin inhibitor, beta blockers, calcium channel blockers, diuretics, 
coumadin, other chronic anticoagulan ts or anti -platelet agents (e.g. rivaroxaban, api[INVESTIGATOR_3822], 
dabigatran, cilostazol), vasodilators, statins, and other lipid lowering agents  
Abbott Vascular  Version 17.[ADDRESS_780788] 16, 2018 . • Non-cardiovascular Medications: Systemic anti -inflammatory medications, hormone 
replacement therapy and diabetic medications  
7.5 Clinical and Imaging Follow -up for All Subjects  
Clinical follow -up will be performed periodically at the following intervals for all subjects:  
o 30  [ADDRESS_780789]/office visit  
o 180  [ADDRESS_780790]/o ffice visit  
o 1 year  28 days office visit and ECG35 
o 2 years  [ADDRESS_780791]/office visit  
o 3 years  [ADDRESS_780792]/office visit  
o 4 years  [ADDRESS_780793]/office visit  
o 5 years  [ADDRESS_780794]/office visit   
Registered subjects must be clinically followed even if no assigned device is implanted. Clinical 
follow -up visits can also be conducted by a blinded Nurse Practitioner or Physician Assistant that 
has been trained to the pr otocol.  
For the 2,000 primary analysis subjects of ABSORB III, Patient Reported Outcome follow -up 
assessments will be conducted as the followings:  
o 30  7 days follow -up, in -person, mail, or phone (EQ -5D, SAQ, RDS, GAD -7) 
o 1 year  28 days office visit (EQ -5D, SAQ, RDS, GAD -7) 
o 2 years  28 days follow -up, in -person, mail, or phone (EQ -5D, SAQ, RDS, GAD -7) 
o 3 years  28 days follow -up, in -person, mail, or phone (EQ -5D, SAQ, RDS, GAD -7) 
o 5 years  28 days follow -up, in -person, mail, or phone (EQ -5D, SAQ)  
The questionnaires will be mailed to the subject for completion or can be completed during the 
phone or office visit. If questionnaires are mailed to the subjects, the subjects must mail the 
questionnaires back to the clinical site.  
                                                           
[ADDRESS_780795] 16, 2018 . In addition to the cli nical follow -up, imaging follow -up will be performed at the following 
intervals for the Imaging Cohort:  
▪ Post-procedure: angiography and IVUS (~150 subjects) or angiography and OCT 
(~50 subjects)  
▪ 3 years  28 days follow -up office visit and ECG: subjects in the Imaging Cohort 
(n=150) will receive follow -up angiography and IVUS.  
▪ 3 years  28 days follow -up office visit and ECG: subjects in the Imaging Cohort 
(n=50) will receive follow -up angiography and OCT.    
Imaging Cohort subjects are required to undergo only one of the imaging follow -up time -points.  
The following information will be collected at each of the time points:  
• Any adverse events*, medications, laboratory tests and 12 -lead ECGs, if performed;  
• Any repeat coronary angiography and results of such, if applicable;  
• Details of any subsequent coronary interventions (e.g., repeat PCI or CABG);  
• Use and compliance of medications per clinical investigation plan;  
• Use and changes in concomitant cardiovascular medications.  
* All adverse events must be collected up to and including to the [ADDRESS_780796] visits, such as unscheduled visits, may occur as clinically warranted. The 
following information will be collected:  
• Assessment of angina status  
• Adverse events  
• Deta ils of any subsequent coronary interventions (e.g., repeat PCI or CABG)  
• Use and compliance to protocol medications (aspi[INVESTIGATOR_458135]/clopi[INVESTIGATOR_7745]/ 
ticagrelor/ticlopi[INVESTIGATOR_5325])  
• Use and changes in chronic concomitant medications (Refer to Appendix II  for 
definition)  
For unscheduled visits for suspected ischemic cardiac events, sites should make reasonable 
efforts to obtain cardiac enzymes (Troponin I or T), CK and CK -MB, and/or ECG if the site is 
aware of the visit at the time of its occurrence. In all other scenarios (i.e., site does not become 
Abbott Vascular  Version 17.[ADDRESS_780797]), no protocol deviation will be issued if Troponin I or T, CK and CK -
MB, and/or ECG were not obtained at the time of the unscheduled visit.  
All efforts must be made to obtain follow -up information on subjects who have undergone 
procedures or have been treated for adverse events in a non -trial-related hospi[INVESTIGATOR_307](s).  
All coronary revascularizations must be classified prospectively by [CONTACT_592135] -
driven or not ischemia -driven  (Refer to Appendix II  for definition). If a subject has a coronary 
revascularization, all clinical information such as symptoms or lack of symptoms of ischemia, 
and possible relations with the target lesion/vessel should be fully recorded in the source 
documents prior to angiogram.  
8. ADVERSE EVENTS  
8.[ADDRESS_780798] 
definitions as referenced in these standards and guidelines are included in appendix II.  
8.1.1  Adverse Event  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory f indings) in subjects, users or other 
persons, whether or not related to the investigational medical device.  
NOTE 1: This definition includes events related to the investigational medical device or the 
comparator.  
NOTE 2: This definition includes events rel ated to the procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events related to investigational 
medical devices.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product.  
8.1.2  Serious Adverse Event  
If the adverse event meets any of the criteria below, it is rega rded as a serious adverse event 
(SAE):  
a. led to death,  
b. led to serious deterioration in the health of the subject, that either resulted in  
1. a life -threatening illness or injury, or  
2. a permanent impairment of a body structure or a body function, or  
Abbott Vascular  Version 17.[ADDRESS_780799] and/or may require intervention to prevent one of  the outcomes listed 
in this definition.  
NOTE 1: This includes device deficiencies that might have led to a serious adverse event if a) 
suitable action had not been taken or b) intervention had not been made or c) if circumstances 
had been less fortunate. These are handled under the SAE reporting system.  
NOTE 2: A planned hospi[INVESTIGATOR_5912] -existing condition, or a procedure required by [CONTACT_5941], without a serious deterioration in health, is not considered to be a 
serious adverse  event.  
8.1.3  Device Deficiency/Product Experience  
Device deficiency (DD) is defined as an inadequacy of a medical device related to its identity, 
quality, durability, reliability, safety or performance, such as malfunction, misuse or use error 
and inadequ ate labeling. This includes the failure of the device to meet its performance 
specifications or otherwise perform as intended.  Note: performance specifications include all 
claims made in the labeling of the device.  
Product Experience (PE) is defined as an y expression of customer concern or dissatisfaction, 
including adverse events and patient issues that occurred during or after the use of a 
commercially available medical device.  
8.[ADDRESS_780800] or 
device caused or contributed to an AE is to be determined by [CONTACT_398794]. Determination should be based on assessment of temporal 
relationships, biologic plausibility, a ssociation (or lack of association) with underlying disease 
and presence (or absence) of a more likely cause.  
8.2.[ADDRESS_780801] ([LOCATION_003]DE) refers to any serious adverse device effect 
on health or safety or any life -threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death was not previously ident ified in nature, severity, or 
degree of incidence  in the investigational plan or application (including a supplementary plan or 
application), or any other unanticipated serious problem associated with a device that relates to 
the rights, safety, or welfare  of subjects.  
Abbott Vascular  Version 17.[ADDRESS_780802] 16, 2018 . 8.3 Adverse Event /Device Deficiency/Product Experience  Reporting  
8.3.[ADDRESS_780803] through the 1 -year follow -up visit. After 1 
year, only the followin g will be collected:  
• All serious AEs  
• All cardiovascular events regardless of seriousness or device relationship  
• All trial device -related events and events for which the relationship to the trial device is 
unknown  
• All unanticipated adverse device effects  
• All Cerebral Vascular Accidents ( CVAs ) 
The Investigator will monitor the occurrence of adverse events for each registered subject during 
the course of the clinical trial/investigation. Adverse Events reported by [CONTACT_423], observed by 
[CONTACT_737], or documented in medical records should be recorded on the adverse event 
eCRF, whether believed by [CONTACT_592136].  
A fax form will be made available to allow th e investigator to report SAEs and device 
deficiencies in the event the entry cannot be made in the EDC (FRM2073001 SAE Notification 
Form ). This does not replace the EDC reporting system, however, all information must still be 
entered in the EDC system as s oon as feasible.  
For all registered patients, AEs (any new event/experience that was not present at baseline or 
worsening of an event present at baseline) will be collected  as required by [CONTACT_3181]. The 
reporting of AEs will start  when  the guiding cat heter enters the subject’s vasculature.  Reported 
AEs will be monitored through the course of the trial.  Additional information with regards to an 
AE should be updated within the appropriate case report form.  
Unchanged, chronic, non -worsening or pre-existing conditions are not adverse events and should 
not be reco rded on the adverse event eCRF.  
The investigator should report all SAEs to the Sponsor as soon as possible but no later than 
outlined below.  
Study site  Reporting timelines  
All Study Sites  SAEs must be reported no later than 3 calendar days from the day the study 
personnel becoming aware of the event or as per the investigative site’s local 
requirements if the requirement is more stringent than those outlined.  
The date the site staff became aware that the event met the criteria of a serious adverse event 
must be recorded in the source document.  The investigator will further report the event to the 
IRB/EC according to the institution’s IRB/EC reporting requirements.  
Abbott Vascular  Version 17.[ADDRESS_780804] should 
not be entered in the EDC system. However they need to be reported on the SAE Notification 
Form (FRM2073001) .   
Serious adverse events should be reported on the SAE Notification F orm in the occurrence that 
the EDC System is not available.  This does not replace the EDC reporting system.  All 
information must still be entered in the EDC system once the system is back to normal function.  
8.3.2  UADE/[LOCATION_003]DE Reporting to Sponsor and IRB  
Abbott Vascular requires the Investigator to report any [LOCATION_003]DE to the sponsor within 3 calendar 
days of the investigator’s knowledge of the event , unless local requirements are more stringent, 
and to the IRB/EC per IRB/EC requirements . 
8.3.3  Device Deficien cy/Product Experience Reporting  
All device deficiencies/product experiences should be reported within the EDC System on the 
appropriate eCRF. A fax form will be made available to allow the investigator to report device 
deficiencies in the event that the en try cannot be made in the EDC (FRM2073000 Device 
Deficiency Report Form). This does not replace the EDC reporting system. However, all 
information must still be entered in the EDC system as soon as feasible. In case a device 
deficiency occurred before the patient ID and randomization number has been assigned, the 
device deficiency should be reported to the sponsor via a Device Deficiency Report Form 
(FRM2073000).  
The investigator should report all DDs/PEs to the Sponsor as soon as possible but no later than  
outlined below.  
Study sites  Reporting timelines  
All Study Sites  DDs/PEs must be reported no later than 3 calendar days from the day the 
study personnel becoming aware of the event or as per the investigative 
site’s local requirements if the requirement is more stringent than those 
outlined.  
The device, if not implanted or not remained in the subject, should be returned to Abbott 
Vascular.   
Device deficiencies should be reported to the IRB/EC per the investigative site’s local 
requirements.  
8.3.4  Advers e Event Reporting to Country Regulatory Authorities by [CONTACT_592137]/PEs to the country regulatory authority, per local 
requirements.  
8.[ADDRESS_780805] (DSMB) will serve in an advisory role to Abbott Vascular to 
ensure safety by [CONTACT_592138] -scribed intervals for the 
purpose of safeguarding the interests of trial participants. The composition, guiding polic ies, and 
operating procedures governing the DSMB are described in a separate DSMB charter.  Based on 
safety data, the DSMB may consider a recommendation for modifications or termination of the 
Abbott Vascular  Version 17.[ADDRESS_780806] with Abbott Vascular.  
9. ADJUDICATION OF EVENTS  
9.1 The Clinical Events Committee (CEC)  
The Clinical Events Committee is comprised of qualified physicians who are not investigators in 
the trial.  The Clinical Events Committee is responsible for adjudicating specified clinical 
endpoints based on the specific criteria used for the categorizatio n of clinical events in the trial. 
The composition, guiding policies, and operating procedures governing the CEC are described in 
a separate CEC Manual of Operations.  
9.[ADDRESS_780807] 
MI (per protocol -defined MI definition, Appendix II), or ischemia -driven target lesion 
revascularization (ID -TLR).  
The primary endpoint of  TLF at [ADDRESS_780808] is designed to show non -inferiority of Absorb BVS to 
XIENCE for the primary endpoint with a one -sided alpha of 0.025.  The null (H 0) and altern ative 
(HA) hypotheses are:  
H0:  TLF Absorb   - TLF XIENCE  ≥ PE 
HA:  TLF Absorb   - TLF XIENCE  < PE. 
TLF Absorb  and TLF XIENCE  are the 1 -year TLF rates in the Absorb BVS and XIENCE arms, 
respectively.  PE is the non -inferiority margin for the primary endpoint.  
The likelihood score method by [CONTACT_592139]. A 
successful trial requires a p -value less than 0.[ADDRESS_780809].  
Based on the SPI[INVESTIGATOR_591998] -complex XIENCE V subjects, the 1 -year TLF rate per 
the primary analysis definition is approximately 6.1% (N~2000) for all of the core sizes of 
XIENCE V stents. To account for the variability in this study, the assumed [ADDRESS_780810] 16, 2018 . XIENCE V is set to be the upper limit of the one -sided 95% confidence i nterval based on the 
above SPI[INVESTIGATOR_591999] 7%. The assumed true rate for Absorb 
BVS is also 7%. The NI margin derived per FDA guidance is 4.5%.  
The remaining secondary clinical endpoints in Section  5.3 will be descriptively compared using 
the estimated rates and two -sided 95% confidence limits. P values will be shown for hypothesis -
generating purposes.   
Study Success  
Study success is defined as passing the non -inferiority test of Absorb BVS to XIENCE o n the 
primary endpoint of TLF at 1 year.   
10.2 Analysis Populations  
10.2.1 Intent -to-Treat Population  
The ITT population is defined as the subjects registered in the study at the point of 
randomization, regardless of the treatment actually received. Subjects will be analyzed in the 
treatment group to which they were randomized. Subjects enrolled but not randomized will not 
be included in the ITT population.  
10.2.2 Per Treatment Evaluable Population  
The per -treatment evaluable (PTE) population will co nsist of subjects who have received only 
study device(s) (Absorb BVS or XIENCE) at the target lesion. Analyses based on the per -
treatment -evaluable population will be as “treated”. Subjects will be included in the treatment 
group corresponding to the study  device actually received . The PTE population will exclude 
subjects with the protocol deviations to the following criteria:  
• General inclusion criteria:  
• #[ADDRESS_780811] evidence of myocardial ischemia (e.g., stable, unstable angina, 
post-infarct angin a or silent ischemia) suitable for elective PCI.  Subjects with stable 
angina or silent ischemia and < 70% diameter stenosis must have objectives sign of 
ischemia as determined by [CONTACT_080], echocardiogram, nuclear scan, 
ambulatory ECG or stress  ECG). In the absence of noninvasive ischemia, fractional 
flow reserve (FFR) must be done and indicative of ischemia.  
• General exclusion criteria:  
• #1 Any surgery requiring general anesthesia or discontinuation of aspi[INVESTIGATOR_34251]/or an 
ADP antagonist is planne d within 12 months after the procedure.  
• #[ADDRESS_780812] has known allergic reaction, hypersensitivity or contraindication to 
aspi[INVESTIGATOR_248]; or to clopi[INVESTIGATOR_591989]; or to heparin and bivalirudin, 
and therefore cannot be adequately treated with study medications.  
Abbott Vascular  Version 17.[ADDRESS_780813] 16, 2018 . • #[ADDRESS_780814] had an acute myocardial infarction (AMI: STEMI or NSTEMI) within [ADDRESS_780815] not returned to within 
normal limits at the time of index procedure; or subject with stable angina or silent 
ischemia has CK -MB that is greater than normal limits at the time of the index 
procedure.  
• #[ADDRESS_780816] is currently experiencing clinical symptoms consistent with new onset 
AMI (STEMI or NSTEMI), such as nitrate -unresponsive prolonged chest pain with 
ischemic ECG changes.  
• #[ADDRESS_780817] has a left ventricular ejection fraction (LVEF) < 30% assessed by [CONTACT_592125], requires future staged PCI either in target or non -target vessels.  
• #[ADDRESS_780818] 12 months. 
Prior PCI within the non -target vessel or any peripheral intervention is acceptable if 
performed anytime >30 days before the index procedure, or between 24 hours and 30 
days before the index procedure if successful and uncomplicated .  
• #[ADDRESS_780819] 
requires future peripheral interventions < 30 days after the index procedure.  
• #[ADDRESS_780820] has renal insufficiency as defined as an estimated GFR < 30 
ml/min/1.73m2 or dialysis at the time of screening  
• All angiographic inclusion and exclusion criteria  
• Select treatment strategy:  
o Non-target lesion treatment not per protocol  
o Target lesion treated not per protocol  
o Pre-dilatation not done per protocol  
o ≥1 target lesion (s) in which different devices were used in each lesion – semi -
crossover.  
o Treatment of > [ADDRESS_780821] enrolled after unsuccessful treatment of non -target lesion   
10.3 Sample Size Calculations and Assumptions  
10.3.1 ABSO RB III Primary Endpoint  
The sample size calculation for the primary endpoint of TLF at 1 -year follow -up is based on the 
following assumptions:  
• One-sided non -inferiority test  
Abbott Vascular  Version 17.[ADDRESS_780822] 16, 2018 . • α = 0.025  
• Randomization ratio is 2 (Absorb BVS arm) : 1 (XIENCE arm)  
• The true TLF rate is assumed to be 7.0% for both the Absorb BVS arm and the XIENCE 
arm   
• Non-inferiority margin (delta) of 4.5%  
Based on the above assumptions, a total of 1,900 subjects (1,267 for the Absorb BVS arm and 
633 for the XIENCE arm) will provide approxi mately 96% power. Assuming a 5% dropout rate 
at 1 year (which is a common assumption for contemporary trials), approximately 2,[ADDRESS_780823] of the primary endpoint TLF at 1 year is passed, superiority tests of 
the Powered Secondary Endpoints will be performed based on a pre -specified testing sequence.  
The pre -specified testing sequence will ensure the control of study wise type -I error rate at 0.05.  
For further details refer to the statistical analysis plan (SAP).  
Imaging Cohort Powered Secondary Endpoint 1  
The in -stent/scaffold mean lumen area change (ΔMLA) from post -procedure to 3 yea rs by [CONTACT_427741] 
(mean lumen area is to be measured after nitrate infusions) will be evaluated using the difference 
between the two means of the two treatment arms in the pooled subjects from the Imaging 
Cohort of ABSORB III and ABSORB Japan. Superiority testing  will be performed with a two -
sided alpha of 0.05.  The null (H 0) and alternative (H A) hypotheses for the superiority test are:  
H0:  ΔMLA Absorb   - ΔMLA XIENCE   = 0 
HA:  ΔMLA Absorb  - ΔMLA XIENCE ≠ 0 . 
ΔMLA Absorb and ΔMLA XIENCE  are the in -stent/scaffold mean lumen area changes in the Absorb 
BVS and XIENCE arms, respectively.   
The sample size calculation is based on the following assumptions:  
• The in -stent/scaffold mean lumen area change at 3 years for the Absorb BVS arm is 
assumed to be 0.5 ± 1.69 mm2 
• The in -stent/scaffold mean lumen area change at 3 years for the XIENCE arm is assumed 
to be -0.4 ± 1.17 mm2 
• Two-sided alpha= 0.05  
• ~150 subjects from the Imaging Cohort in ABSORB III, 50% IVUS follow -up rate at [ADDRESS_780824] 16, 2018 . • ~[ADDRESS_780825] s from ABSORB Japan, 70% IVUS follow -up rate at 3 years  
• ~15% of all subjects will have dual target lesion treatment.  
An effective sample size of 207 lesions (138 for the Absorb BVS arm and 69 for the XIENCE 
arm) will provide approximately 99.4% power using  two sample t -test. 
The sample size calculation was performed using NCSS PASS 2008 (Hintze JL, 2002. PASS 
User’s Guide -II. NCSS) . 
Imaging Cohort Powered Secondary Endpoint 2  
The in -stent/scaffold mean lumen diameter change (ΔMLD) between pre - and post -nitrate 
infusion at 3 years by [CONTACT_592140]. Superiority testing will be performed with a two -sided alpha of 0.05.  The null 
(H0) and alternative (H A) hypotheses for the superiority test are:  
H0:  ΔMLD Absorb  - ΔMLD XIENCE  = 0  
HA:  ΔMLD Absorb  - ΔMLD XIENCE ≠ 0 . 
ΔMLD Absorb  and ΔMLD XIENCE  are the in -stent/scaffold mean lumen diameter changes in the 
Absorb BVS and XIENCE arms, respectively.   
The sample size calculation is based on the following assumptions:  
• The in -stent/scaffold mean lumen diameter change at 3 years for the Absorb BVS arm is 
assumed to be 0.054 ± 0.156 mm (based on 3 -year imaging data from the Absorb Cohort 
B trial).  
• The in -stent/scaffold mean lumen diameter change at 3 years for the XIENCE arm is 
assumed to be 0.018 ± 0.052 mm (based on clinical assumptions as no imaging data for 
XIENCE is available)  
• Two-sided alpha= 0.05  
• ~200 subjects from the Imaging Cohort in ABSORB III, 50% angiographic follow -up 
rate at 3 years  
• ~400 subjects from ABSOR B Japan, 80% angiographic follow -up rate at 3 years  
• ~15% of all subjects will have dual target lesion treatment  
An effective sample size of 483 lesions (322 for the Absorb BVS arm and 161 for the XIENCE 
arm) will provide approximately 96.2% power using two  sample t -test. 
The sample size calculation was performed using NCSS PASS 2008 (Hintze JL, 2002. PASS 
User’s Guide -II. NCSS).  
Abbott Vascular  Version 17.[ADDRESS_780826] 16, 2018 . Powered Secondary Endpoint for Angina  
Angina at 1 year (exclude angina  following the index procedure through discharge, not to exc eed 
a period of 7 days) will be evaluated using the difference between the angina  rates of the two 
treatment arms. Superiority test will be performed with a two -sided alpha of 0.05.  The null (H 0) 
and alternative (H A) hypotheses for the superiority test ar e: 
H0:  ANGINA Absorb - ANGINA XIENCE  = 0  
HA:  ANGINA Absorb - ANGINA XIENCE ≠ 0 . 
ANGINA Absorb and A NGINA XIENCE  are the 1 -year angina  rates in the Absorb BVS and XIENCE 
arms, respectively.   
Using a two -sided alpha of 0.05, assuming 5% lost to follow -up at [ADDRESS_780827] 
approximately 90% power to demonstrate superiority with a difference of 6. 3% between the 
Absorb BVS arm and the XIENCE arm (e.g. 16.3% in the Absorb BVS arm vs. 22.6% in the 
XIENCE arm) using Pearson’s Chi -square test.  
The powered  secondary endpoint of angina  at 1 year will be assessed on the primary analysis 
group in ABSORB III, separate from the Lead -In Group and the Imaging Cohort Subjects.  
The sample size calculations were performed using SAS 9.3 (SAS Institute Inc., Cary, NC) . 
Powered Secondary Endpoint for All Revascularization  
All revascularization  at [ADDRESS_780828] will be performed with a two -
sided alpha of 0.05.  The null (H 0) and alternative (H A) hypotheses for the superiority test are:  
H0:  ALLREVASC Absorb  - ALLREVASC XIENCE  = 0  
HA:  ALLREVASC Absorb  - ALLREVASC XIENCE ≠ 0 . 
ALLREVASC Absorb and ALLREVASC XIENCE  are the 1 -year all revascularization  rates in the 
Absorb BVS and XIENCE arms, respectively.   
Using a two -sided alpha of 0.05, assuming 5% lost to follow -up at [ADDRESS_780829] 
approximately 90% power to demonstrate supe riority with a difference of 3. 6% between the 
Absorb BVS arm and the XIENCE arm (e.g. 3.6% in the Absorb BVS arm vs. 7.2% in the 
XIENCE arm) using Fisher’s Exact  test. 
The powered secondary endpoint of all revascularization  at 1 ye ar will be assessed on the 
primary analysis group in ABSORB III, separate from the Lead -In Group and the Imaging 
Cohort Subjects.  
The sample size calculations were performed using NCSS PASS 2008 (Hintz JL, 2002. PASS 
User’s Guide -II NCSS) . 
Powered Secondar y Endpoint for ID-TVR  
Abbott Vascular  Version 17.[ADDRESS_780830] will be performed with a two -sided alpha of 0.05.  The null (H 0) 
and alternative (H A) hypotheses for the superiority test are:  
H0:  IDTVR Absorb  - IDTVR XIENCE  = 0  
HA:  IDTVR Absorb  - IDTVR XIENCE ≠ 0 . 
IDTVR Absorb and IDTVR XIENCE  are the 1 -year ID-TVR  rates in the Absorb BVS and XIENCE 
arms, respectively.   
Using a two -sided alpha of 0.05, assuming 5% lost to fo llow-up at [ADDRESS_780831] 
approximately 8 0% power to demonstrate supe riority with a dif ference of 2.3 % between the 
Absorb BVS arm and the XIENCE arm (e.g. 1.8% in the Absorb BVS arm vs. 4.1% in the 
XIENCE arm) using Fisher’s exact  test. 
The powered secondary endpoint of ID-TVR  at 1 year will be assessed on the primary analysis 
group in ABSORB III, separate from the Lead -In Group and the Imaging Cohort Subjects.  
The sample size calculations were performed using NCSS PASS 2008 (Hintze JL, 2 002. PASS 
User’s Guide -II. NCSS).  
Powered Secondary Endpoint for Diabetic Indication  
To assess the performance of Absorb BVS in the diabetic subgroup by [CONTACT_592141] -specified analysis.  
To support this powered secondary endpoint, A bbott Vascular intends to pool ABSORB family 
studies. Refer to SAP for details.  
10.4 Statistical Analyses  
Non-inferiority testing of the primary endpoints will be one -sided and performed at a 0.025 
significance level for the comparison of the Absorb BVS arm with the XIENCE arm. Superiority 
tests on the powered secondary endpoints will be performed at a two -sided 0.05 significance 
level.  Analyses of other secondary endpoints will be descriptive in nature.  
For binary variables such as TLF, TLR, and clinical procedure success, counts, percentages, and 
95% confidence intervals will be calculated, and p -values may  be presented for hypothesis 
generating purposes. Pearson’s Chi -squared test or Fisher’s exact test will be performed when 
appropriate. In addition, logistic regression will be performed to determine whether the baseline 
characteristics exhibit any trends in predicting TLF.  
For continuous variables such as age, means, standard deviations, and 95% confidence intervals 
for the mean will be calculated and p -values may be presented for hypothesis generating 
purposes. For time -to-event variables, such as time t o TLF, survival curves will be constructed 
using Kaplan -Meier estimates, and log rank test results will be displayed. Unless specified, 
analyses will be performed with pooled data across all study sites.  
For further details refer to the statistical analysi s plan (SAP).  
Abbott Vascular  Version 17.[ADDRESS_780832] should meet the 
pre-specified criterion.   
10.4.2 Powered Secondary Endpoint Analyses  
Analysis of the Powered Secondary Endpoints for angina , for all revascularization,  for ID -TVR, 
and for diabetic indication will includ e subjects from the primary analysis group. Pearson’s Chi -
square test will be used for superiority testing based on the ITT and PTE populations  for the 
powered secondary endpoint for angina. Fisher’s exact test will be used for superiority testing 
based on  the ITT and PTE populations for the powered secondary endpoints for all 
revascularization  and for ID -TVR . Analysis of the Imaging Cohort Secondary Endpoints [ADDRESS_780833] will be used for superiority testing based on the ITT and PTE populations.  
Details of the analyses for the powered secondary endpoints can be found in the statistical 
analysis plan (SAP).  
10.4.3 Secondary Endpoint Analyses  
Secondary endpoin ts other than the powered endpoints described above will be summarized 
descriptively for the ITT population. For further details refer to the statistical analysis plan 
(SAP).  
10.4.4 Additional Analyses  
Adverse Events related to stent/scaffold thrombosis, vascular complications or bleeding 
complications, and their relation with antiplatelet therapi[INVESTIGATOR_592000], if applicable.  
Descriptive analy ses will be provided for the Lead -In subjects.  
For further details refer to the SAP.  
10.4.[ADDRESS_780834] 16, 2018 . 10.4.7 Subgroup Analysis  
Pre-specified subgroups such as diabetes, sex, age will be examined. Further details can be found 
in the SAP.  
Pre-specified pooled analysis will b e performed comparing the diabetic subgroup vs. non -
diabetic subgroup in the Absorb BVS arm by [CONTACT_592142]. Further details can be found in the SAP.  
10.4.8 Handling of Multiplicity Issues  
Methods to handle multiplicity are specified, in the SAP.  
10.4.9 Criteria for Early Termination of the Trial for Effectiveness  
No formal statistical rule for early termination of the trial for effectiveness is defined.  
10.4.10 Procedures for Accounting for Miss ing, Unused or Spurious Data  
All analyses will be based on available data with missing data excluded. Any unused or spurious 
data will be noted as appropriate in the final report. Sensitivity analysis of the primary endpoint 
of TLF at 1 -year follow -up will  be performed using the Kaplan -Meier estimates. If missing data 
for the primary analysis is greater than 5% for any treatment arm, imputation methods may be 
utilized as the sensitivity analyses.  
10.4.11 Pooling Strategy  
Details on pooling strategy can be  found in the SAP.  
10.4.12 Deviations from the Original Statistical Plan  
Any major changes to the statistical plan (available upon request) will be documented in an 
amendment to the statistical plan.  Less significant changes to the planned analyses will be 
documented in the final report.  
11. DIRECT ACCESS TO  SOURCE DATA/DOCUMEN TS 
The Investigator/institution will permit direct access to source data/documents for trial -related 
monitoring, audits, IRB/MEC review, and regulatory inspections.  
Subjects providing Informed Consent agree to allow the Sponsor or designee access and copying 
rights to pertinent information in their medical records relevant to trial participation (the 
Investigator should ensure patient identifiers are removed for medic al records that are copi[INVESTIGATOR_530]). 
The Investigator will obtain, as part of the Informed Consent, permission for trial monitors or 
regulatory authorities to review at the investigative site, in confidence, any records identifying 
the subjects in this clinical tr ial/investigation. This information may be shared with regulatory 
agencies; however, the Sponsor undertakes not to otherwise release the subject's personal and 
private information as per local data protection laws.  
Abbott Vascular  Version 17.[ADDRESS_780835] Investigators who are qualified by [CONTACT_592143]. 
Sites will be selected based upon review of a recent site assessment and the qualifications of the 
Primary Investigator at the site.  
12.2 Training  
12.2.1  Site Training  
All Investigators/trial personnel are required to attend Sponsor training sessions, which  may be 
conducted at an Investigator's meeting, a site initiation visit or other appropriate training 
sessions. Over -the-phone training may take place as required. Training of Investigators/trial 
personnel will include, but is not limited to, the protocol requirements, investigational device 
usage, electronic case report form completion and trial personnel responsibilities. All 
Investigators/trial personnel that are trained must sign a training log (or an equivalent) upon 
completion of the training. Prior t o signing the training log, Investigator/trial personnel must not 
perform any trial -related activities that are not considered standard of care at the site.  
12.2.[ADDRESS_780836] Device  
Investigators will be trained on the use o f the Absorb BVS System.  Please refer to Section 4.2 
ABSORB Physician Training.  
12.2.3  Training of Sponsor’s Monitors  
Sponsor and/or designated monitors will be trained to the protocol, eCRFs and investigational 
device usage (as appropriate).  Documentati on of this training will be according to written 
procedures.  
12.3 Monitoring  
Sponsor and/or designee will monitor the trial over its duration according to the pre -specified 
monitoring plan which will include the planned extent of source data verification  
12.3.1 Designated Monitors  
Study monitors are individuals who are designated to oversee the progress of a study. These 
individuals are appropriately trained and qualified to monitor the progress of a clinical study. 
The study sponsor may designate additiona l monitors at any time during the study. The Sponsor 
should be contact[CONTACT_196581](s) responsible for monitoring 
activities.  
Abbott Vascular  Version 17.[ADDRESS_780837] 16, 2018 . 12.3.2 Visits  
Prior to initiating any procedure, the sponsor monitor (or delegate) will visit each i nvestigator to 
ensure that the following criteria are met:  
The Investigator  understands and accepts the obligation to conduct the research study according 
to the protocol and applicable regulations, and has signed the Investigator Agreement or the 
Clinical Study Agreement.  
The Investigator and his staff have sufficient time and facilities to conduct the study and that 
they have access to an adequate number of appropriate subjects to conduct the study.  
Source documentation must be available to substantiate proper Informed Consent procedures, 
adherence to protocol procedures, adeq uate reporting and follow -up of Adverse Events, accuracy 
of data collected on Case Report Forms, and device information.  
The Investigator/site will permit access to such records. A monitoring visit sign -in log will be 
maintained at the site. The Investiga tor will agree to dedicate an adequate amount of time to the 
monitoring process.  The Investigator and/or Research Coordinator will be available for 
monitoring visits. It is expected that the Investigator will provide the study monitor with a 
suitable working environment for review of study -related documents.  
12.4 Deviations from Proto col 
It is the Investigator's responsibility to ensure that there are no deviations from the protocol 
without prior notification and approval of the sponsor and that all actions are in full 
compliance with all established procedures of the IRB/EC or equival ent committee. The 
Investigator will not deviate from the protocol for any reason without prior written approval from 
Sponsor except in cases of medical emergencies, when the deviation is necessary to protect the 
life or physical well -being of the subject or eliminate an apparent immediate hazard to the 
subject. In that event, the Investigator will notify Sponsor immediately by [CONTACT_231471]. 
All deviations must be reported to the Sponsor. In subject -specific deviations from the protocol, 
a Protocol D eviation Case Report Form will be completed. The occurrence of protocol deviations 
will be monitored by [CONTACT_150756]. Invest igators will inform 
their IRB/EC or equivalent committee of all Protocol Deviations in accordance with their 
specific IRB/EC or equivalent committee reporting policies and procedures.  
In the event that an Investigator does not comply with the Investigator  Agreement or the Clinical 
Study Agreement or protocol, the Investigator will be notified of the site’s non -compliance.  
In the event of repeated non -compliance, as determined by [CONTACT_1034], a Sponsor’s monitor or 
company representative will attempt to se cure compliance by [CONTACT_10980] (and 
not limited to):  
• Visiting the Investigator  
• Telephoning the Investigator  
Abbott Vascular  Version 17.[ADDRESS_780838] 16, 2018 . • Corresponding with the Investigator  
Repeated non -compliance with the signed agreement, the protocol or any other conditions of the 
study may result in further escalation in accordance with the Sponsor’s written procedures 
including  securing compliance or, at its sole discretion, the Sponsor may terminate the 
Investigator's participation in the study.  
12.[ADDRESS_780839] periodic Quality Assurance audits (on -site audits) at various clinical 
trial/investigation sites. A Sponsor representative or designee may request access to all trial 
records, including source documentation, for inspection and dupl ication during a Quality 
Assurance audit. The Investigator and Research Coordinator must be available to respond to 
reasonable requests and queries made during the audit process.  
12.6 Sponsor Support to Clinical Trial/Investigation Site for Regulatory Bod y 
Inspection  
In the event that an Investigator is contact[CONTACT_426] a Regulatory Agency in relation to this clinical 
trial/investigation, the Investigator will notify the Sponsor immediately and IRB/MEC as 
appropriate. The Investigator and Research Coordinator must be available to respond to 
reasonable requests and inspection queries made during the inspection process. The Investigator 
must provide the Sponsor with copi[INVESTIGATOR_592001]/investigatio n (e.g., Form FDA 483, Inspectional Observations, and warning 
letters). The Sponsor may provide any needed assistance in responding to regulatory inspections.  
12.[ADDRESS_780840] one person 
each from the Clinical Science and Clinical Program Management groups. The directors of the 
core laboratories and other Sponsor’s personnel may also participate in the Committee meetings 
if appropriate. Meeting minutes from this committee will be filed with the Sponsor.  
The Steering Committee is responsible for overseeing the scientific and operational aspects of 
the study. This committee will meet regularly to monitor patient enrollment, general data 
collection and non -compliance  with the investigation plan at individual centers, to review and act 
upon recommendations of the Data and Safety Monitoring Board, to review operational issues 
that may arise and warrant a protocol amendment or other corrective action and to determine 
policy regarding any publications arising from data generated from the performance of the study.  
12.7.2  Publications Committee  
The Publication Committee is composed of representatives from Abbott Vascular Clinical 
Research, Steering Committee, Investigators, and other personnel as determined by [CONTACT_131458]. This team will oversee presentation and/or publication aspects of the study. The 
Abbott Vascular  Version 17.[ADDRESS_780841] 16, 2018 . Publication Committee will determine policy and strategies regarding individual presentations 
and/or publications arising from study generated data. The committee will also review all 
external requests for accessing study related data and strategies aligning with Abbott Vascular 
presentation and publication team expectations. The committee will also follow Abbott Vasc ular 
applicable policies and Standard Operating Procedures.  
12.7.[ADDRESS_780842] (DSMB)  
The Data Safety Monitoring Board (DSMB) is an independent multidisciplinary group that does 
not have any affiliation with Abbott Vascular, the Investiga tors or core laboratories.  Details 
regarding the DSMB were reported earlier in Section 8.4 . 
12.7.4  Clinical Events Committee (CEC)  
The Clinical Events Committee (CEC) is an independent adjudication body comprised of 
qualified physicians who are not parti cipants in the trial.  Details regarding the CEC were 
reported earlier in Section 9.[ADDRESS_780843] KEEPI[INVESTIGATOR_592002]. All eCRF data collection will be 
performed through a secure web portal and all authorized personnel with access to  the electronic 
data capture (EDC) system must use an electronic signature [CONTACT_196602], review or 
correct data.  Electronic signature [CONTACT_592228] 21 Part II and the 
ICH Guidelines for Good Clinical Practice (GCP) ( Topic E6, April 2000) Section 5.5.3.  
Passwords and electronic signatures will be strictly confidential.  
All eCRF data will be downloaded from the EDC system and reformatted into a data structure 
acceptable to Abbott Vascular.   The data will be subjected to consistency and validation checks 
within the EDC system and will be subject to supplemental validation following download.  
Completed eCRF images with the date -and-time stamped electronic audit trail indicating the 
user, the data entered, and any reason  for change (if applicable) will be archived at the 
Investigator’s site and a backup copy archived with Abbott Vascular  
For the clinical trial/investigation duration, the Investigator will maintain complete and accurate 
documentation including but not limi ted to medical records, clinical trial/investigation progress 
records, laboratory reports, electronic Case Report Forms, signed Informed Consent Forms, 
device accountability records, correspondence with the IRB/MEC and clinical trial/investigation 
monitor/ Sponsor, Adverse Event reports, and information regarding subject discontinuation or 
completion of the clinical trial/investigation.  
13.[ADDRESS_780844]’s medical 
records that corroborates data collected on the Case Report Forms. In order to comply with these 
regulatory requirements/GCP, the following information should be included in the subject’s 
record, at a minimum, and if applicable to the investigation:  
Abbott Vascular  Version 17.[ADDRESS_780845] 16, 2018 . • Medical  history/physical condition of the subject before involvement in the trial 
sufficient to verify protocol entry criteria  
• Dated and signed notes on the day of entry into the trial referencing the sponsor, protocol 
number, subject ID number and treatment assi gned (does not apply to blinded 
randomized trials) and a statement that informed consent was obtained  
• Dated and signed notes from each subject visit (for specific results of procedures and 
exams)  
• Adverse Events reported and their resolution including suppo rting documents such as 
discharge summaries, catheterization laboratory reports, ECGs, and lab results including 
documentation of site awareness of SAEs and of Investigator’s device relationship 
assessment of SAEs  
• Study -required laboratory reports and 12 -lead ECGs, signed and dated for review and 
annotated for clinical significance of out of range results  
• Notes regarding protocol -required and prescription medications taken during the trial 
(including start and stop dates)  
• Subject’s condition upon completion  of or withdrawal from the trial  
• Any other data  required to substantiate data entered into the eCRF  
13.2 Electronic Case Report Form Completion  
Primary data collection based on source -documented hospi[INVESTIGATOR_3491] /or clinic chart reviews will be 
performed clearly and accurately by [CONTACT_196585]. 
eCRF data will be collected for all patients that are registere d into the trial.  
13.[ADDRESS_780846] obtain permission from Sponsor in writing before destroying or 
transfer ring control of any clinical trial/investigation records.  
13.4  Investigational Devices  
13.4.1 Investigational Device Accountability  
Abbott Vascular ships investigational devices (Absorb BVS System) only to the Principal 
Investigator (the responsible leade r of the investigational site) or his/he r legal designee of each 
site. In geographies using the commercially available CE marked device , the investigators will 
acquire the product through their normal commercial vendors.  
Abbott Vascular  Version 17.[ADDRESS_780847] been returned to Sponsor.  In sites using commercially available 
CE marked devices (XIENCE and Absorb BVS), the primary investigator will maintain  records 
of device usage for the study subjects. The records will contain device part number and serial 
number, date implanted, patient identification number, and implanting physician.  
Use of any investigational device outside of the protocol is strictly f orbidden because the 
Investigator has access to other commercially available PCI catheters and may constitute grounds 
for removal of the Investigator/site from the clinical trial/investigation.  In geographies using the 
commercially available CE marked devi ce, the commercial device may be used in non -trial 
patients.  
All investigational devices that are associated with a device failure or device deficiencies must 
be returned immediately to the Sponsor.  
14. ETHICAL CONSIDER ATION  
14.[ADDRESS_780848] /Medical Ethics Committee Review  
Institutional Review Board (IRB)/Medical Ethics Committee (MEC) approval for the protocol 
and Informed Consent Form /other written information provided to the patient will be obtained 
by [CONTACT_079] [INVESTIGATOR_144109] i nvestigational site prior to participation in this clinical 
trial/investigation. The approval letter must be signed by [CONTACT_1201]/MEC Chairman or authorized 
representative prior to the start of this clinical trial/investigation and a copy must be provided to 
the Sponsor. No changes will be made to the protocol or Informed Consent Form or other written 
information provided to the patient without appropriate approvals, including IRB/MEC, the 
Sponsor, and/or the regulatory agencies.  
Until the clinical trial/inve stigation is completed, the Investigator will advise his/her IRB/MEC 
of the progress of this clinical trial/investigation, per IRB/MEC requirements. Written approval 
must be obtained annually from the IRB/MEC to continue the clinical trial/investigation, 
according to each institution’s IRB/MEC requirements (US studies only). Further, any 
amendments to the protocol as well as associated Informed Consent Form changes will be 
submitted to the IRB/MEC and written approval obtained prior to implementation, accor ding to 
each institution’s IRB/MEC requirements.  
No investigative procedures other than those defined in this protocol will be undertaken on the 
registered subjects without the written agreement of the IRB/MEC and the Sponsor.  
15. PUBLICATION POLICY  
The da ta and results from the trial are the sole property of the Sponsor. The Sponsor shall have 
the right to access and use all data and results generated during the clinical trial. The 
Investigators will not use the clinical trial/investigation -related data wi thout the written consent 
of the Sponsor for any other purpose than for clinical trial/investigation completion or for 
generation of publication material, as referenced in the clinical trial/investigation Site 
Abbott Vascular  Version 17.[ADDRESS_780849] 16, 2018 . Agreement. The publication and/or presentation  of results from a single clinical 
trial/investigation site are not allowed until publication and/or presentation of the multi -center 
results. The Sponsor acknowledges that the trial’s Principal Investigators intend to publish a 
multi -center publication re garding the clinical trial/investigation results, and numerous secondary 
publications. The Sponsor must receive any proposed publication and/or presentation materials at 
least 60 days prior to the proposed date of the presentation or the initial submission  of the 
proposed publication in order for the materials to be reviewed by [CONTACT_592144]’s publication policy set forth in the clinical trial/investigation Site Agreement.  
The Sponsor will be responsible for determining whether to register the Clinical Investigation on 
www.clinicaltrials.gov <<http://www.clinicaltrials.gov>> or any other clinical investigations, in 
accordance with the International Committee of Medical Journal Editors guidelines, or any other 
applicable guideline s. In the event Sponsor determines that the trial should be registered, 
Sponsor shall be responsible for any such registration  and results posting as required by [CONTACT_592145].gov . Institution and/or Principal Investigator(s) shall not take any action to  register the 
trial. 
16. RISK ANALYSIS  
16.1 Potential Risk  
16.1.1  Cardiac Catheterization, Stenting and Percutaneous Transcatheter Coronary 
Angioplasty  
Refer to Investigator Brochure and/or Instructions for Use for this section for both Absorb BVS 
and XIENCE for the associated risks.  
Refer to APPENDIX VIII: for the Risk stratification of Cardiac Catheterization, Stenting and 
Percutaneous Transcatheter Co ronary Angioplasty  
16.1.2  Associated Risks of the Absorb BVS Polymer  
The Absorb BVS is composed of a backbone fabricated from poly (L -lactide) and a drug -eluting 
coating layer which is a mixture of poly (DL -lactide) and the drug, everolimus.  These polymer  
materials were selected based on their long history of use in approved medical devices and their 
mechanical properties. Examples of currently approved bioabsorbable polymers used for clinical 
vascular applications include the Angio -Seal vascular closure d evice and the Igaki -Tamai 
bioabsorbable stent.  In addition, PLA is widely used in orthopedic implants and cosmetic 
treatment.  
The Angio -Seal device is composed of a plug of collagen sponge and an absorbable polymer 
anchor that are connected by [CONTACT_592146].  The Angio -Seal device leaves the 
polymer anchor inside the vessel at the end of the procedure.  The anchor is held in place against 
the vessel wall by [CONTACT_592147].  The polymer anchor is manufactured from a 50/[ADDRESS_780850] that the polymer and its degradation p roducts 
are well tolerated by [CONTACT_514586] [21, 35]. 
Abbott Vascular  Version 17.[ADDRESS_780851] to provide clinical trial data with 
biodegradable PLLA stent in humans [12].  The stent is manufactured from a monofilam ent poly 
(L-lactide) fiber wound into a helical pattern.  The long -term safety data presented by [CONTACT_592148] a safe polymer for use in intravascular applications 
[17, 19]. Igaki -Tamai peripheral stent was evaluated in the PERSEUS clinical trial [21], of which 
results supported approval for CE mark (November 29, 2007).  
The coating polymer, poly (D,L -Lactide), is the same polymer used for the Abbott Vascular 
Champi[INVESTIGATOR_592003] I and FUTURE II human clinical trials 
conducted by [CONTACT_592149].  Safety of this polymer was demonstrated in the FUTURE I and 
FUTURE II trials [36-38],   The Champi[INVESTIGATOR_592004] a substantial body of evidence 
that demonstrated the coating polymer is s afe to use in a vascular application.  
Systemic reaction possibly caused by [CONTACT_592150] [39]. 
Local/regional/systemic delayed adverse effects caused by [CONTACT_592151] [40]. 
In summary, safety and  biocompatibility of the Absorb BVS has been demonstrated based upon 
biocompatibility testing per ISO [ZIP_CODE] -1, numerous preclinical animal safety studies, and the 
long use of these polymers in medical implants.  While the long -term outcome of the Absorb 
BVS is unknown at present, follow -up through 5 years from the ABSORB Cohort A and 2 -year 
follow -up from ABSORB Cohort B, has shown a low occurrence of clinical events.  
16.1.3  Everolimus  
Refer to Investigator Brochure and/or Instructions for Use for this section for both Absorb BVS 
and XIENCE for the associated risks.  
16.1.4  Drug Interaction of Everolimus  
Refer to Investigator Brochure and/or Instructions for Use for this section for both  Absorb BVS 
and XIENCE for the associated risks.  
16.1.[ADDRESS_780852] not been 
evaluated; however, long term carcinogenicity and te ratology studies were performed with the 
XIENCE V, a similar Everolimus -eluting coronary stent system. In the carcinogenicity studies, 
XIENCE V was implanted subcutaneously in transgenic mice. Based on the results of this 
study, XIENCE V does not appear to  be carcinogenic when implanted in transgenic mice for 
[ADDRESS_780853] on their fertility or reproductive capability. Additionally, there were no teratogenic 
effects in the offspring in this study.  
There is no carcinogenicity, genotoxicity, and reproductive toxicity in PLA, lactide, and lactic 
acid.  
Pregnancy/Fertility  
Abbott Vascular  Version 17.[ADDRESS_780854] 16, 2018 . There are no adequate studies in pregnant women or men intending to father children regarding 
the safety of  everolimus or the Absorb BVS.  Everolimus when administered at oral doses of 0.1 
mg/kg and above showed effects on pre - and post -natal rat development limited to slight body 
weight changes and fetal survival without any specific toxic potential.  
Therefore, pregnant and nursing subjects and those planning pregnancy up to one year following 
the index procedure are excluded from this study. Female subjects with childbearing potential 
enrolled in this study must have a negative pregnancy test done wit hin [ADDRESS_780855]’s values with adequate medical 
information on the effectiveness and safety of the method. Except for surgical removal of the 
uterus and ovaries or total abstinence, all methods of birth control have a failure rate. Intrauterine 
devices (IUD), hormonal contraceptives (birth control pi[INVESTIGATOR_3353], injections or implants), tubal ligation 
or partner’s vasectomy and barrier contraceptives (condoms, diaphragms, and cervical caps) are 
available means of birth control. The primary care provider or a gynecologist should be 
consulted concerning the best birth control method for the subject given his/her medical history 
and lifestyle choices.  
Lactation  
It is unknown whether everolimus is distributed in human milk. Everolimus pharmacokinetic and 
safety profiles have not been determined in infants. Consequently, mothers should be advised of 
potential serious adverse reactions to everolimus in nursing infants. Prior to the implantation of 
Absorb BVS , a decision should be made regarding whether to discon tinue nursing or conduct an 
alternate percutaneous coronary intervention procedure.  
16.1.[ADDRESS_780856] during the index procedure. 
Complication rates of IVU S range from 1 to 3%, transient spasm being the most common which 
is treated with intracoronary nitroglycerin. The rate of major complications, dissection or MI, is 
less than 0.5%. Examination of imaged vessels compared with non -imaged vessels shows no 
significant damages or disease progression at 1 year follow -up [41, 42]. Other complications 
include bleeding at the entry puncture site, injury to the vascular wall, thrombosis of the vessel, 
and peripheral embolization. Retrospective studies of cardiac patients show no increa se in 
complications between non -imaged vessels and imaged vessels and IVUS is demonstrated to be 
safe for multiple uses (up to 6) after sensitive procedures [42].  
OCT is not commonly associated with major adverse  events; most events can be minimized 
through appropriate training. Procedural planning and full education of risks associated with 
investigating vulnerable plaques will further minimize risk [43].   
Intracoronary nitroglycerin will be used d uring the index procedure in ABSORB III. 
Intracoronary nitroglycerin (NTG) is usually routinely administered to these patients in order to 
prevent coronary spasm for optimum imaging results. It has been shown that coronary dilatation 
occurs with as little as 5 μg of intracoronary NTG and that moderate doses of 50 -200 μg can still 
produce vasodilatation without systemic effects such as hypotension or reflex tachycardia [44]. 
The known contraindications to n itroglycerin include among others hypersensitivity, recent use 
Abbott Vascular  Version 17.[ADDRESS_780857] 16, 2018 . of phosphodiesterase -5 inhibitors like sildenafil (Viagra), narrow angle glaucoma, and 
symptomatic hypotension. Further information about the risks of nitroglycerin can be found in its 
Summary of Product Characteristics (SPC).  
16.[ADDRESS_780858] shown similar results between Absorb BVS and XIENCE V ( Section 
2.2). Further studies are needed to confirm this. The long term pathology of the coronary artery 
lesion after treatment with  the Absorb BVS continues to be evaluated and the long -term benefits 
of Absorb BVS are not fully understood and continue to be evaluated.  
Subjects will receive 75 mg of clopi[INVESTIGATOR_133731] (Plavix®) daily or 10 mg of prasugrel daily 
or 90 mg twice daily of ticagrelor (or according to prescribing information [45]) for a minimum 
of 1 year to reduce the risk of thrombosis and to provid e extended protection to compensate for 
potentially delayed endothelialization after implant. Subjects will also receive aspi[INVESTIGATOR_248] ≥ 75 to  
100 mg to be taken indefinitely. The side effects from aspi[INVESTIGATOR_592005]; gastrointestinal irritation such as stomach pain, dyspepsia, 
gastritis; and bleeding.  
Prasugrel [46] can cause significant, sometimes fatal bleeding.  The use of prasugrel in subjects 
at increased risk of bleeding should only be considered when the benefits in terms of prevention 
of ischemic events are deemed to outweigh the risk of serious bleedings. Th is concern applies 
especially to subjects who:  have a propensity to bleed, are ≥ 75 years of age, a body weight < [ADDRESS_780859] concomitant use of medications that increase the risk of bleeding, or are likely to 
undergo urgent coronary artery by[CONTACT_9292] s urgery.  Compared to patients weighing  60 kg, 
patients weighing < [ADDRESS_780860] an increased exposure to the active metabolite of prasugrel and 
an increased risk of bleeding on a 10 mg once daily maintenance dose. The label recommends 
that patients weighing  < [ADDRESS_780861]:  hypersensitivity to the active substance or to any of the 
excipi[INVESTIGATOR_840], active pathological bleeding, history of stroke or transient ischaemic attack ( TIA), or 
severe hepatic impairment (Child -Pugh class C).  Further information about the risks of prasugrel 
can be found in its Summary of Product Characteristics (SPC).   
Abbott Vascular  Version 17.[ADDRESS_780862] 16, 2018 . Ticagrelor [47] can cause significant, sometimes fatal bleeding. Compared to clopi[INVESTIGATOR_7745], 
ticagrelor increased the overall risk of bleeding to a somewhat greater extent. In general, risk 
factors for bleeding include older age, a history of bleeding disorders,  performance of 
percutaneous invasive procedures, and concomitant use of medications that increase the risk of 
bleeding (e.g., anticoagulant and fibrinolytic therapy, higher doses of aspi[INVESTIGATOR_248], and chronic 
nonsteroidal anti -inflammatory drugs).  The increase  in bleeding risk was seen for non -CABG -
related bleeding, but not for CABG -related bleeding.  Fatal and life -threatening bleeding rates 
were not increased. Dyspnea was reported more frequently with ticagrelor than with clopi[INVESTIGATOR_7745].  
Ticagrelor is contraind icated for subjects who have: history of intracranial hemorrhage, active 
pathological bleeding, and severe hepatic impairment.  Further information about the risks of 
ticagrelor can be found in its Summary of Product Characteristics.  
Prasugrel and ticagrel or are indicated for patients with acute coronary syndrome. The use of 
these medications outside the approved conditions may be associated with risks. Subjects will be 
monitored closely throughout the trial duration.  
The device should only be used by [CONTACT_592152]. The selected investigators will be trained on the device prior to participating in the 
study. In addition, they and other hospi[INVESTIGATOR_592006] a clinical trial will 
be trained  on the IFU and clinical trial protocol.  
The patients will be screened against the inclusion and exclusion criteria before enrollment in the 
trial. The patients will be evaluated clinically with or without imaging at pre -determined time 
points per clinica l trial protocol requirements to assess their clinical status.  
Corrective and preventative actions will be implemented by [CONTACT_196551], as necessary, if 
deviations from recommendations in the protocol or IFU are observed.  
All device deficiencies, commercial complaints, and adverse events from clinical trials are 
monitored internally by [CONTACT_196551]. An independent Data Safety Monitoring Board 
(DSMB) will monitor safety throughout the clinical trial.  Stoppi[INVESTIGATOR_592007].  
16.3 Potential Benefit  
The Absorb BVS is intended to revascularize the vessel like a conventional metallic stent, 
provide controlled elution of anti -proliferative drug to minimize neointimal growth and th en 
resorb naturally into the body after vessel healing and remodeling are complete.   
The imaging and vasomotion data from ABSORB Cohort A at 2 years and ABSORB Cohort B at 
1 year showed the potential for vessel movement with the ABSORB BVS in response to 
pharmacological stimuli ( Section 2.1.9 ). Lumen patency was maintained as shown with an 
increase in IVUS average lumen area in ABSORB Cohort A at 2 years and maintained average 
lumen area in ABSORB Cohort B at 2 years ( Section 2.1.9 ).  
Another benefit of Ab sorb BVS is that non -invasive imaging can be done using multislice 
computed tomography (MSCT) to evaluate stenosis of treated lesion. The Absorb BVS scaffold 
is radiolucent and was undetected by [CONTACT_592153].  In [ADDRESS_780863] results for the full ABSORB Cohort B 
trial (Cohort B1 and B2, 101 patients) were reported at the TCT congress in Nov ember, 2011. 
Unlike metal stents, on MSCT scans at [ADDRESS_780864] low PCI utilization [48] . Recent statistics 
show that from [ADDRESS_780865] lower PCI utilization compared to men [48]. There are also data to support that 
women have a higher risk of PCI related mortality compared to men [49, 50] . The poorer 
outcomes among women have been related to delayed onset of disease, co -morbidities, vessel 
size associated with smaller body surface area, and premature coronary ar tery disease [49]. 
However, in the advent of advanced PCI technolog y, outcomes have improved among women 
and benefits of stenting can be applied to both women and men [49, 51, 52]. In SPI[INVESTIGATOR_592008] -analysis women treated with XIENCE V and TAXUS had worse MACE outcomes 
compared to men [52].  However, the difference in 1 year MACE rates between women and men 
was not significant in the XIENCE arm (p=0.146) but was significant in the TAXUS arm 
(p=0.019) [52].  A recent XIENCE V [LOCATION_003] gender sub -analysis, which consisted of a larger 
population than SPI[INVESTIGATOR_591970], found comparable ARC stent thrombosis (0.85% vs. 0.82%), cardiac 
death and MI (3 .7% vs. 2.9%), and TLR (5.0% vs. 4.2%) rates among women compared to men 
treated with XIENCE V.  
Certain minority populations are found to have a higher rate of heart disease and associated risk 
compared to whites in the US. The prevalence of coronary hear t disease (CHD) and MI is 
highest in black males and females compared to white males and other minority groups [53] . 
Among the US minority population, blacks and Hispanics compared to whites and Asian, ha ve 
the lowest PCI utilization rates [48]. Blacks and  Hispanics that undergo PCI are found to be 
younger, and have co -morbidities such as diabetes, hypertension, obesity, and renal failure, 
compared to whites  [54]. There has been some limited evidence that indicated these differences 
did not result in different angioplasty outcomes across minority groups [54]. However, a recent  
retrospective analysis in a small population (n=1438) which was 47.4% black, reported a higher 
MACE (death, MI and TVR) rate (21.7%) at 2.9 years compared to non -blacks (13.6%) [55]. 
Furthermore, after adjusting for age, comorbidities and socioeconomic status,  black race 
remained an independent predictor of MACE [55].  
Overall women and minorities in the US have been identified as populations shouldering a 
greater coronary artery disease burden but ironically lower PCI utilization. However,  there is 
evidence, albeit limited, to demonstrate that these populations may have poorer outcomes 
compared to other groups, while still benefiting from PCI utilization. Based on the discordance 
between disease burden and PCI utilization, it becomes impera tive for PCI clinical trials to 
increase women and minority participation.   
To increase recruitment of special populations in ABSORB III, Abbott Vascular will implement 
several strategies. The first being a recruitment brochure that will educate patients on heart 
disease risk and the difference in heart disease burden across ethnicity and genders. This 
brochure will also inform patients that they can speak to their physician about whether they are 
Abbott Vascular  Version 17.[ADDRESS_780866] 16, 2018 . eligible to enroll in ABSORB III. Patients interested in th e trial will also be shown a detailed 
flip-chart, presented by [CONTACT_592154].   
A second recruitment strategy will be compensation to subjects for their participation in 
ABSOR B III  (US only) . Abbott Vascular will provide payments to subjects in order to 
compensate them for their time and effort in returning to the hospi[INVESTIGATOR_592009] -related follow -up questions. Subjects’ participation in -person in the vis its at the time points 
indicated below will be compensated as set forth below.  Payment will be made to Institution as a 
pass-thru to the subject on a per -subject per -time point basis, following completion of all eCRF 
data entry for the given procedure or receipt of imaging films at the core laboratory, depending 
on the nature of the visit, receipt of an invoice from Institution and evidence of the payment by 
[CONTACT_592155].  Institution will make payment by [CONTACT_592156].  This reimbursement is subject to IRB approval.  All subjects at the baseline visit will be 
paid $50.00.  Subjects who complete the 1 -year follow -up will receive $100.  IVUS imaging 
subjects who complete the 3 -year follow -up will receive $ 500.  OCT i maging subjects who 
complete the 3 -year follow -up will receive $ 500. 
Lastly, subjects enrolled in the trial identified by [CONTACT_592157] a financial hardship will be reimbursed for the protocol -required antiplatelet 
(Clopi[INVESTIGATOR_7745], Prasugrel, Ticagrelor, or Ticlopi[INVESTIGATOR_5325]) regimen.   
Abbott Vascular believes these strategies may aid in the recruitment of patients from special 
populations that may not traditionally participate in a clinical trial.  
  
Abbott Vascular  Version 17.[ADDRESS_780867] 16, 2018 . APPENDIX I: ABBREVIA TION S AND ACRONYMS  
Acronym or Abbreviation  Complete Phrase or Definition  
%DS  percent diameter stenosis  
ACS  Acute Coronary Syndrome  
AE adverse event  
AMI  acute myocardial infarction  
BVS  bioresorbable vascular scaffold  
CABG  coronary artery by[CONTACT_592158] (Canada)  
CEC  Clinical Events Committee  
CFR  Code of Federal Regulations  
CI clinically -indicated  
CIP Clinical Investigation Plan (EU)  
CK creatine kinase  
CK-MB creatine kinase myocardial -band  isoenzyme  
CoCr  cobalt chromium  
CRA  Clinical Research Associate  
CRF  case report form  
CSA  cyclosporine A  
CSS coronary stent system  
CVA  cerebrovascular accident (or stroke)  
DES  drug eluting stent  
DLPLA  poly (DL -lactide)  
DSMB  Data Safety Monitoring Board  
EC Ethics Committee (EU)  
ECG  Electrocardiogram  
eCRF  electronic CRF  
EECS  everolimus eluting coronary stent  
EECSS  everolimus eluting coronary stent system   
EQ-5D Euro -QoL 5D  
FDA  Food and Drug Administration  
F/U follow up (verb); follow -up (noun, adjective)  
GAD -[ADDRESS_780868] (US and Japan)  
ITT Intent -to-Treat  
IVRS  interactive voice response service  
IVUS  intravascular  ultrasound  
LAD  left anterior descending coronary artery  
LCX  left circumflex coronary artery  
LL late loss  
LVEF  left ventricular ejection fraction  
MACE  major adverse cardiac event  
MEC  Medical Ethics Committee (EU)  
g microgram  
Mg milligram  
MI myocardial infarction  
mL milliliter  
ML MULTI -LINK  
MLD  minimum lumen diameter  
MLA  mean lumen area  
mm millimeter  
N sample size; also N 
NIH neointimal hyperplasia  
NQMI  non-Q wave myocardial infarction  
OUS  Outside  [LOCATION_002]  
PCI percutaneous coronary intervention  
PK pharmacokinetics  
PLA  poly lactic acid  
PLLA  poly (L -lactide)  
PMA  pre-marketing approval  
PTCA  percutaneous transluminal coronary angioplasty  
PTE per treatment evaluable  
PRO  patient reported outcomes  
QCA  quantitative coronary angiography  
QOL  quality of life  
RBC  red blood cell  
Abbott Vascular  Version 17.[ADDRESS_780869] 16, 2018 . APPENDIX II:  DEFINIT IONS  
CLINICAL ENDPOINT DEFINITIONS  
DEATH (Per ARC Circulation 2007; 115: 2344 -2351)  
All deaths are considered cardiac unless an unequivocal non -cardiac cause can be established. 
Specifically, any unexpected death even in patients with coexisting potentially fatal non -cardiac 
disease (e.g. cancer, infection) should be classified as cardiac .  
Cardiac death (CD):  
Any death due to proximate cardiac cause (e.g. MI, low -output failure, fatal arrhythmia), 
unwitnessed death and death of unknown cause, all procedure related deaths including those 
related to concomitant treatment.  
Vascular death:  
Death due to non -coronary vascular causes such as cerebrovascular disease, pulmonary 
embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.  
Non-cardiovascular death:  
Any death not covered by [CONTACT_354457], malignancy, 
sepsis, pulmonary causes, accident, suicide or trauma.  
  
Abbott Vascular  Version 17.[ADDRESS_780870] 16, 2018 . MYOCARDIAL INFARCTION (MI)  
Protocol MI Definition  
Classification  Biomarker Criteria  Additional Criteria  
Periprocedural PCI  CK-MB > [ADDRESS_780871]  Baseline value* < ULN; see also 
** 
Periprocedural CABG  CK-MB > [ADDRESS_780872]  Baseline value* < ULN; see also 
**  
Spontaneous  Troponin >ULN or CK -MB > ULN  One or more of the following must 
also be present:  
- Symptoms of ischemia;   
- ECG changes  indicative of new 
ischemia -  (new ST -T changes or 
new LBBB),   
- Development of pathological Q 
waves;   
 - Imaging evidence of a new loss 
of  viable myocardium or a new 
regional wall  motion abnormality  
Reinfarction (not 
related to a proce dure)  If the Troponin or CKMB values are stable 
or decreasing on 2 consecutive samples > 6 
hours, a 20% or greater increase [ADDRESS_780873] be 
present:   
- ECG changes  indicative of new 
ischemia -  (new ST -T changes or 
new LBBB),   
- Development of pathological Q 
waves  
- Imaging evidence of a new loss of  
viable myocardium or a new 
regional wall  motion abnormality  
ULN=Upper limits of the local laboratory normal (will be collected from each hospi[INVESTIGATOR_592010]);  
LBBB=Left Bundle -branch Block  
* Baseline CKMB va lue is required before study procedure and presumes a typi[INVESTIGATOR_592011] a peri procedure MI  
** Whenever at least one baseline and one post procedure CK -MB measure are available, adjudication 
of MI will be based solely on thes e biomarker values. If the patient has stable ischemic heart disease 
and the baseline CK -MB measure are not available, they will be assumed to be within normal limits 
and MI will be adjudicated by [CONTACT_592159] -MB measur es. 
TROPONINS WILL NOT BE USED TO DIAGNOSE PERI -PROCEDURAL MI.  
If the patient had an elevated CK -MB at baseline (protocol violation), and/or no post procedure CK -
MB measures are available (protocol violation), adjudication of a post procedure MI will be b ased on 
presence of two of the following three:  
1) New ST elevation or ST depression ≥0.1mV in ≥2 contiguous leads on ECG ≥30 min. and ≤[ADDRESS_780874]-PCI (Note: ST elevation should be measured at the J point, and ST depression must be horizontal 
or down -slopi[INVESTIGATOR_007]), Or New pathological Q -waves in ≥2 contiguous leads, or new LBBB;  
2) Post procedure TIMI 0/1 flow in a coronary artery or a side branch with reference vessel diameter 
≥2.0 mm which had TIMI 2 -3 flow at baseline, or TIMI 2 flow in a major coronary ar tery or a side 
branch with reference vessel diameter ≥3.0 mm which had TIMI 3 flow at baseline (core laboratory 
assessed);  
3) Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality.  
 
Abbott Vascular  Version 17.[ADDRESS_780875] 16, 2018 . Note: Patients with stable coronar y artery disease syndromes may have the baseline CKMB drawn 
from the arterial sheath during the PCI procedure. If this value is elevated (expected in 1 -2% of 
patients with stable CAD, a post -PCI MI will be diagnosed if the post -procedure CK -MB shows a 20% 
or greater CK -MB increase on the second sample drawn [ADDRESS_780876] procedure (meeting the 
threshold of CKMB > [ADDRESS_780877]), and at least 1 of the following are present:  
1) ECG changes  indicative of new ischemia -  (new ST -T changes or new LBBB),   
2) Development of pathological Q waves;  
3) Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality.  
In the absence of any of the above evidence, a > 50% increase in CK -MB over the baseline value, 
meeting the threshold  of CKMB > [ADDRESS_780878], will also qualify for a periprocedural MI.  
• Periprocedural MI After PCI:  
The periprocedural period includes the first 48 hours after PCI.  
• Periprocedural MI After CABG:  
The periprocedural period includes the first 48 hours after coronary artery by[CONTACT_15806] 
(CABG).  
• Spontaneous MI:  
MI after the periprocedural period may be secondary to late stent complications or 
progression of native disease. Performance of ECG and angiography supports 
adjudication to either a target or non -target vessel in most cases.  
With the unique issues and pathophysiological mechanisms associated with these later 
events as well as the documented adverse impact on short and long -term prognosis, a 
more sensitive definition than for periprocedural MI of any  elevation of troponin or 
CKMB above the 99th percentile of the upper range limit (or ULN if URL is not 
available) is used. All late events that are not associated with a revascularization 
procedure will be considered simply as spontaneous.  
Myocardial infa rctions  will also be adjudicated based on the following classification:  
• Q wave MI  
Development of new, pathological Q wave on the ECG (≥ 0.04 seconds in duration and ≥ 
1 mm in depth) in ≥ 2 contiguous precordial leads or ≥ 2 adjacent limb leads)  
• Non-Q wav e MI  
Those MIs which are not Q -wave MI.  
Myocardial infarctions  will also be adjudicated as to their relation to the Target Vessel  
All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be 
considered related to the tar get vessel.  
Universal Myocardial Infarction Definition. As a secondary analysis, MI will be adjudicated 
according to the [ADDRESS_780879] 16, 2018 .  
Modified World Health Organization (WHO) MI Definition. As a secondary analysis, MI 
will be adjudicated according to the modified WHO MI definition.  
• Q wave MI  
 Development of new, pathological Q wave on the ECG  
• Non-Q wave MI  
o Elevation of CK levels to  two times the upper limit of normal (ULN) with elevated 
CK-MB in the absence of new pathological Q waves  
o Non-Q wave MI definition will be used for both peri -procedural MI definition (≤ [ADDRESS_780880] -procedure) and spontaneous (> [ADDRESS_780881] -procedure).  
  

Abbott Vascular  Version 17.[ADDRESS_780882] 16, 2018 . REVASCULARIZATION (Per ARC Circulation 2007; 115: 2344 -2351)  
Target Lesion Revascularization (TLR)  
TLR is defined as any repeat percutaneous intervention of the target lesion or by[CONTACT_592160]. All TLR 
should be classified prospectively as ischemia driven or not ischemia driven by [CONTACT_592161]. An independent angiographic core laboratory should verify that the 
severity of percent diamete r stenosis meets requirements for clinical indication and will overrule 
in cases where investigator reports are not in agreement. The target lesion is defined as the 
treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent.  
Target Ve ssel Revascularization (TVR)  
TVR is defined as any repeat percutaneous intervention or surgical by[CONTACT_592162]. The target vessel is defined as the entire major coronary vessel proximal and distal 
to the target lesion  which incl udes upstream and downstream branches and the target lesion 
itself. The above two definitions will be used in this protocol.  
The above two definitions will be used for CEC adjudication.  
Non Target Lesion Revascularization (Non -TLR)  
Any revascularization i n the target vessel for a lesion other than the target lesion is considered a 
non-TLR.  
Non Target Vessel Revascularization (Non -TVR)  
Revascularization of the vessel identified and treated as the non -target vessel at the time of the 
index procedure.  
Non-Treated Vessel  
Vessel not treated at the time of the index procedure.  
Non-Treated Vessel Revascularization  
Revascularization of the non -treated vessel.   
Ischemia Driven [ID] Revascularization (TLR/TVR)  
A revascularization is considered ischemia driven if ass ociated with any of the following:  
• Positive functional ischemia study including positive FFR  
• Ischemic symptoms and angiographic diameter stenosis ≥ 50% by [CONTACT_354471]  
• Angiographic diameter stenosis ≥ 70% by [CONTACT_592163] 17.[ADDRESS_780883] 16, 2018 . CORONARY ARTERY BY[CONTACT_592164] [CABG]  
Acute CABG is defined as immediate transfer from the cath lab to the operative room for 
emergent by[CONTACT_592165].  
CABG during follow -up is only considered as a Clinical -indicated Target Lesion 
Revascularization if coronary angiography indicates a diameter of stenosis greater than 50% of 
the stented coronary segment (core lab QCA assessment) associated with one of the following 
conditions:  
• A positi ve history of recurrent angina pectoris presumably related to the target vessel.  
• Objective signs of ischemia ([ADDRESS_780884] or equivalent) presumably 
related to the target vessel,  
• Abnormal results of any invasive functional diagnostic test (e .g. Doppler flow velocity 
reserve, fractional flow reserve).  
• A TLR/TVR with a diameter stenosis ≥70% (core lab QCA assessment) in the absence of 
the above mentioned ischemic signs or symptoms.  
STENT THROMBOSIS (Per ARC Circulation 2007; 115: 2344 -2351)  
Stent Thrombosis should be reported as a cumulative value at the different time points and with 
the different separate time points. Time [ADDRESS_780885] left the Catheterization lab.  
Timing:  
Acute stent thrombosis*:   [ADDRESS_780886] stent implantation  
Subacute stent thrombosis*:  >[ADDRESS_780887] stent implantation  
Late stent thrombosis†:   [ADDRESS_780888] stent implantation  
Very late stent thrombosis†:  >[ADDRESS_780889] stent implantation  
*  Acute/subacute can also be replaced by [CONTACT_196591]. Early stent thrombosis (0 - 
30 days) - this definition is currently used in the community.  
† Including “primary” as well as “secondary” late stent thrombosis; “secon dary” late stent 
thrombosis is a stent thrombosis after a target segment revascularization.  
  
Abbott Vascular  Version 17.[ADDRESS_780890] 16, 2018 . Categories (Definite, Probable, and Possible):  
Definite stent thrombosis  
Definite stent thrombosis is considered to have occurred by [CONTACT_592166].  
Angiographic confirmation of stent thrombosis*  
The presence of a thrombus† that originates in the stent or in the segment [ADDRESS_780891] 1 of the following criteria within a 48 -hour 
time window:  
o Acute onset of ischemic symptoms at rest  
o New ischemic ECG changes that suggest acute ischemia  
o Typi[INVESTIGATOR_196543] (refer to definition of spontaneous MI)  
o Nonocclusive  thrombosis  
o Thrombus Intracoronary thrombus is def ined as a (spheric, ovoid, or 
irregular) noncalcified filling defect or lucency surrounded by [CONTACT_196593] (on 3 sides or within a coronary stenosis) seen in multiple 
projections, or persistence of contrast material within the lumen, or a 
visible embo lization of intraluminal material downstream.  
o Occlusive thrombus  
o TIMI [ADDRESS_780892] adjacent 
proximal side branch or main branch (if or iginates from the side branch).  
Pathological confirmation of stent throm bosis  
Evidence of recent thrombus within the stent determined at autopsy or via examination of 
tissue retrieved following thrombectomy.  
* The incidental angiographic documentation of stent occlusion in the absence of 
clinical signs or symptoms is not con sidered a confirmed stent thrombosis (silent 
occlusion).  
† Intracoronary thrombus.  
  
Abbott Vascular  Version 17.[ADDRESS_780893] occurred after 
intracoronary stenting in the following cases:  
o Any unexplained death within the first 30 days‡  
o Irrespective of the time after the index procedure, any MI that is related to 
documented acute ischemia in the territory of the implanted stent without 
angiographic confirmation of stent thrombosis and in the ab sence of any other 
obvious cause  
‡ For studies with ST -elevation MI population, one may consider the exclusion of 
unexplained death within [ADDRESS_780894] occurred with any 
unexplained death from 30 days after intracoronary stenting until end of trial follow -up. 
For the present study the principal definition of stent thrombosis will be ARC definite or 
probable stent thrombosis.  
ANGIOGRAPHIC ENDPOINT DEFINITIONS  
ANGIOGRAPHIC BINARY RESTENOSIS (ABR)  
Re-narrowing of the artery defined as %DS ≥ 50%.   
  
Abbott Vascular  Version 17.[ADDRESS_780895] 16, 2018 . ACC/AHA Classification Scheme of Coronary Lesions: Lesion -Specific Characteristics  
Type A Lesions (High Success, >85%; Low Risk)  
• Discrete (< 10 mm length)  • Little or no calcification  
• Concentric  • Less than totally occlusive  
• Readily accessible  • Not ostial in location  
• Nonangulated segment, < 45  • No major branch involvement  
• Smooth contour  • Absence of thrombus  
Type B Lesions* (Moderate Success, 60 -85%; Moderate risk)  
• Tubular (10 -20 mm length)  • Moderate -to-heavy calcification  
• Eccentric  • Total occlusions < 3 mo old  
• Moderate tortuosity of proximal segment  • Ostial in location  
• Moderately angulated segment, > 45 , < 90 • Bifurcation lesions requiring double guide 
wires  
• Irregular contour  • Some thrombus present  
* Type B1 lesions: One adverse characteristic  
* Type B2 lesions:  two adverse characteristics  
Type C Lesions (Low Success, <60%; High Risk)  
• Diffuse (> 2 cm length)  • Total occlusions > 3 mo old  
• Excessive tortuosity of proximal segment  • Inability to protect major side branches  
• Extremely angulated segments > 90  • Degenerated vein grafts with friable lesions  
 
CHRONIC OCCLUSION  
Total Occlusion:  
An occlusion with no antegrade filling of contrast to the distal segment (TIMI grade 0)  
Sub-total Occlusion:  
TIMI grade 1, and with collateral filling of the distal segment  
MAXIMUM DIAMETER (Dmax)  
Dmax  refers to maximum lumen diameter evaluated after pre -dilatation within the boundaries of 
intended scaffold segment.  
IN-STENT  
Within the margins of the stent.  
IN-SCAFFOLD  
Within the margins of the scaffold.  
  
Abbott Vascular  Version 17.[ADDRESS_780896] 16, 2018 . IN-SEGMENT  
Within the margins of the stent or scaffold and 5 mm proximal and 5 mm distal to the stent or 
scaffold.  
LATE LOSS (LL)  
General definition: Calculated as MLD post -procedure – MLD at follow -up 
• In-segment Late Loss: in -segment MLD post -procedure – in segment MLD at follow -up 
• Proximal Late Loss : proximal MLD post -procedure – proximal MLD at follow -up 
(proximal defined as within 5 mm of healthy tissue proximal to the device placement)  
• Distal Late Loss: distal MLD post -procedure – distal MLD at follow -up (distal defined as 
within 5 mm of healthy t issue distal to the device placement)  
• In-device Late Loss: in -device MLD post -procedure – in-device MLD at follow -up 
PERCENT DIAMETER STENOSIS [%DS]  
The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views 
(when possible)  by [CONTACT_13775].  
REFERENCE VESSEL DIAMETER [RVD]  
Average diameter of proximal and distal healthy segments by [CONTACT_13775]. 10 mm “normal” reference 
segments are selected proximal and distal to the stenosis and averaged to define the reference 
vessel diameter (User defined  method).  A computer -defined interpolated normal segment will 
be used to calculate percent diameter stenosis.  
RESTENOSIS  
Re-narrowing of the artery following the removal or reduction of a previous narrowing.  
TIMI (THROMBOSIS IN MYOCARDIAL INFARCTION) FLO W GRADES  
0. No contr ast flow through the stenosis.  
1. A small amount of contrast flows through the stenosis but fails to fully opacify the artery 
beyond.  
2. Contrast material flows through the stenosis to opacify the terminal artery segment. 
However, contrast enters the terminal segment perceptibly more slowly than more 
proximal segments. Alternatively, contrast material clears from a segment distal to a 
stenosis noticeably more slowly than from a comparable segment not preceded by a 
significant stenosis.  
3. Anter ograde flow into the terminal coronary artery segment through a stenosis is as 
prompt as anterograde flow into a comparable segment proximal to the stenosis. Contrast 
Abbott Vascular  Version 17.[ADDRESS_780897] 16, 2018 . material clears as rapi[INVESTIGATOR_592012], more proximal 
segment.  
ACUTE SUCCESS DEFINITIONS  
Clinical Device Success (Lesion Basis)  
Successful delivery and deployment of the study scaffold/stent at the intended target lesion and 
successful withdrawal of the delivery system with attainment of final in -scaffold/sten t residual 
stenosis of less than 30% by [CONTACT_13775] (by [CONTACT_592167]). When bailout 
scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment 
is not one of the criteria for device success.  
Clinical  Procedure Success (Patient Basis)  
Achievement of final in -scaffold/stent residual stenosis of less than 30% by [CONTACT_13775] (by [CONTACT_592168]) with successful delivery and deployment of at least one study 
scaffold/stent at the intended targe t lesion and successful withdrawal of the delivery system for 
all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during 
the hospi[INVESTIGATOR_4408] (maximum of 7 days). In dual target lesion setting both lesions must meet 
clinical procedure success criteria to have a patient level procedure success.  
 Successful 
Deployment  No Device 
Deficiencies  QCA requirement  In-hospi[INVESTIGATOR_592013]*  Yes In-stent %DS < 30%  Not applicable  
Procedure 
Success**  Yes Yes In-segment %DS <  30% No TLF  
* Deployment success with any device is a condition of device success, as “can’t cross the lesion” is 
regarded as device deficiencies  
** Patient basis. If a patient has multiple lesions, all the lesions must satisfy the success criteria.  
 
DEVICE DEFICIENCY [ ISO14155 3.15]  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety 
or performance ISO14155 3.15  
Note: Device deficiencies include malfunctions, use errors, and inadequate labeling  
  
Abbott Vascular  Version 17.[ADDRESS_780898] 16, 2018 . ADVERSE EVENT DEFINITIONS  
General Definition  
ADVERSE EVENT [AE]  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or other 
persons,  whether or not related to the investigational medical device.   
UNANTICIPATED SERIOUS ADVERSE DEVICE EFFECT  
Unanticipated serious adverse device effect ([LOCATION_003]DE) refers to any serious adverse device effect 
which by [CONTACT_5942], incidence, severity or outcome  has not been identified in the current version 
of the risk analysis report (BS EN ISO [ZIP_CODE]:2011).  
SERIOUS ADVERSE EVENT [SAE]  
If the adverse event meets any of the criteria below, it is regarded as serious adverse event 
(SAE).  
a. led to death,  
b. led to seri ous deterioration in the health of the subject, that either resulted in  
1. a life -threatening illness or injury, or  
2. a permanent impairment of a body structure or a body function, or  
3. in-patient or prolonged hospi[INVESTIGATOR_059], or  
4.  medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function,  
c. led to fetal distress, fetal death or a congenital abnormality or birth defect  
NOTE: Planned hospi[INVESTIGATOR_272]  a pre -existing condition, or a procedure required by [CONTACT_10396], 
without serious deterioration in health, is not considered a serious adverse event.  
ANTICIPATED ADVERSE EVENT  
Any undesirable experience (sign, symptom, illness, abnormal laboratory value, or o ther medical 
event) occurring to a patient, whether or not considered related to the investigational product(s) 
or drug regimen prescribed as part of the protocol, predefined in the protocol and/or IFU, that is 
identified or worsens or occurs in frequency that is not considered normal during a clinical trial.  
  
Abbott Vascular  Version 17.[ADDRESS_780899], problem, or death was not previously identified in 
nature, severity, or degree of incidence in the investigational plan or application (including a 
supplementary plan or application), or any other unanticipated serious problem as sociated with a 
device that relates to the rights, safety, or welfare of subjects (21 CFR 812.3).  
SPECIFIC EVENT DEFINITIONS (ALPHABETIC ORDER)  
ANGINA PECTORIS  
Braunwald Classification of Unstable Angina:  
I. New onset of severe or accelerated angina. Patients with new onset (< 2 months in 
duration) exertional angina pectoris that is severe or frequent (> 3 epi[INVESTIGATOR_1841]/day) or patients 
with chronic stable angina who develop accelerated angina (that is, angina distinctly more 
frequent, severe, longer in dur ation, or precipi[INVESTIGATOR_592014]) but who have not experienced pain at rest during the preceding [ADDRESS_780900] within the 
preceding 48 hours.  
Canadian Cardiovascular Society [CCS] Classification of Stable Angina:  
I. Ordinary physical activity does not cause angin a; for example walking or climbing stairs, 
angina occurs with strenuous or rapid or prolonged exertion at work or recreation.  
II. Slight limitation of ordinary activity; for example, angina occurs walking or stair 
climbing after meals, in cold, in wind, under emotional stress or only during the few 
hours after awakening, walking more than two blocks on the level or climbing more than 
one flight of ordinary stairs at a normal pace and in normal conditions.  
Abbott Vascular  Version 17.[ADDRESS_780901] 16, 2018 . III. Marked limitation of ordinary activity; for example, ang ina occurs walking one or two 
blocks on the level or climbing one flight of stairs in normal conditions and at a normal 
pace.  
IV. Inability to carry on any physical activity without discomfort - angina syndrome may be 
present at rest.  
CEREBROVASCULAR ACCIDENT/ STROKE  
Stroke is defined as a sudden onset of focal neurological deficits due to vascular lesions of the 
brain that persists >24 hours. Any neurological symptom that lasts < 24 hours is classified as 
TIA. Stroke results from either of two types of cerebral  vascular disturbance: ischemia or 
hemorrhage.  
DISCONTINUITY  
Use when geometry of an implanted Absorb BVS has perceived or observed discontinuiti es 
(such as gaps, breaks or misalignment) on or after (≥) [ADDRESS_780902] occurred or reported during use or prior to (<) [ADDRESS_780903] -
procedure (whichever is earliest)  
DISSECTION  
• National Heart, Lung, and Blood Institute [NHLBI] Dissection Classification 
System:  
A. Minor  radiolucencies within the lumen during contrast injection with no 
persistence after dye clearance.  
B. Parallel tracts or double lumen separated by a radiolucent area during contrast 
injection with no persistence after dye clearance.  
C. Extraluminal cap with per sistence of contrast after dye clearance from the lumen.  
D. Spi[INVESTIGATOR_196547].  
E. New persistent filling defects.  
F. Non-A-E types that lead to impaired flow or total occlusion.  
Note:  Type E and F dissections may represent thrombus.  
VASCULAR COMPLICATIONS (Am Heart J 2003; 145: 1022 -9) 
Access site injury requiring invasive treatment associated with protocol required procedures and 
unscheduled cardiac catheterizations. A vascular complication may include access site 
hematoma, pseudoaneurysm, ar teriovenous fistula, peripheral ischemia or nerve injury.  
Abbott Vascular  Version 17.[ADDRESS_780904] adverse event resulting in the site diagnosis of angina.  
ASSIGNED DEVICE  
In ABSORB III the assigned device for subjects in the Lead -In group is the investigational 
device Absorb BVS. For subjects in the randomized portion of ABSORB III (including the 
Imaging  Cohort), the assigned device will be either the investigational Absorb BVS or the FDA 
approved XIENCE V, based on a 2:1 randomization.    
BLEEDING CLASSIFICATION   
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)  
Major Bleeding endpoint will be defined by [CONTACT_592169] “Severe” or “Moderate” as 
defined below:  
Severe or life -
threatening  Either intracranial hem orrhage or bleeding that causes 
hemodynamic compromise and requires intervention  
Moderate  Bleeding that requires blood transfusion but does not result in 
hemodynamic compromise  
Mild  Bleeding that does not meet criteria for either severe or moderate 
bleeding  
Bleeding events that are medically important, but that do not meet the severe or moderate levels (e.g. 
require laboratory testing, evaluation by a physician, ER visit, or cessation of either study medication 
or other antithrombotic therapi[INVESTIGATOR_014]) wil l be collected.  Bleeding complications will be site reported.  
CHRONIC CONCOMITANT MEDICATIONS  
Chronic concomitant medication refers to the following:  
a) medication that has been prescribed or is over the counter, that has been taken or will 
continue to be taken regularly for at least a period of 3 months; or  
b) medication that is required to be taken indefinitely by [CONTACT_102]; or  
c) medication that has been prescribed or taken multiple times (each time for at least 3 
months).  
ENROLLED SUBJECT  
Subject has sign ed the Informed Consent.  
DWELL TIME  
Start date and time the device was inserted into the sheath. Start date and time the device was 
deployed.  
Abbott Vascular  Version 17.[ADDRESS_780905] 16, 2018 . Family History of Coronary Artery Disease (CAD)  
Family history of CAD is defined as CAD occurring in male 1st de gree relatives (father, 
brothers) < [ADDRESS_780906] degree relatives (mother, sisters) < 65 years old.  
INTENT TO TREAT [ITT] POPULATION  
The ITT population is defined as the subjects registered in the study at the point of 
randomization.  
LEGA L AUTHORIZED REPRESENTATIVE  
An individual or judicial or other body authorized under applicable law to consent on behalf of a 
prospective subject to the subject’s participation in the procedure(s) involved in the research. (21 
CFR Part 50.3)  
MAJOR EPI[INVESTIGATOR_592015]  
• Left anterior descending artery [LAD] with septal and diagonal branches;  
• Left circumflex artery [LCX] with obtuse marginal and/or ramus intermedius branches;  
• Right coronary artery [RCA] and any of its branches.  
NO-REFLOW  
An acute reduction in co ronary flow (TIMI grade 0 -1) in the absence of dissection, thrombus, 
spasm, or high -grade residual stenosis at the original target lesion.  
PERCUTANEOUS CORONARY INTERVENTION [PCI]  
Refers to all interventional cardiology methods for treatment of coronary a rtery disease.  
PRINCIPAL INVESTIGATOR  
A physician -specialist, related to the study, who is responsible for the overall conduct of the trial 
at all sites and compliance with protocol and relevant.  
PRIMARY INVESTIGATOR  
A physician responsible for conducting  the clinical trial at each investigational site.  
PROCEDURE START DATE AND TIME  
Procedure start date and time is recorded as the date and time the first guiding catheter was 
inserted into the subject.  
PROCEDURE END DATE AND TIME  
Procedure end date and time  is recorded as the time the last guiding catheter was removed from 
the subject.  
Abbott Vascular  Version 17.[ADDRESS_780907] 16, 2018 . SUCCESSFUL PRE -DILATATION  
Pre-dilatation has been successfully completed without complications if all of the following 
apply:  
o For randomized subjects: RVD remains ≥ 2.50 mm - ≤ 3.75 mm and length of the lesion 
that will be covered by [CONTACT_8121] (including any edge dissections) is still ≤ 24 mm  
o For Lead -In subjects: RVD remains ≥ 2.75 mm - ≤ 3.25 mm and length of the lesion that 
will be covered by [CONTACT_8121] (including any edge dissections) is still ≥ 8 mm - ≤ 14 mm  
o Residual %DS is a maximum of < 40% (per visual estimation), ≤ 20% is strongly 
recommended.  
o TIMI Grade -3 flow (per visual estimation),  
o No angiographic complications (e.g. distal embolization, side branch closure),  
o No dissections NHLBI grade D -F  
o No chest pain lasting > [ADDRESS_780908] depression or elevation lasting > 5 minutes.  
TARGET LESION (Analysis Definition)  
The target lesion is defined as the lesion that has met the angiographic inclusion and exclusion 
criteria in a registered subject upon calling IVRS.  
Under these conditions, the lesion will be considered the target lesion regardless of the device 
implantat ion and treatment actually received.  
TARGET VESSEL  
The entire epi[INVESTIGATOR_592016].  
RANDOMIZED SUBJECT  
Subject is considered randomized after the interactive voice response system (IVRS) has been 
called and a device (Abs orb BVS or XIENCE) has been assigned.  
REGISTERED SUBJECT  
Subject is considered registered upon randomization. Lead -In subjects will be considered 
registered upon calling IVRS.  
UNSTABLE CARDIAC ARRYTHMIA  
Any irregularity in the heart's natural rhythm associated with hemodynamic instability that has 
not been controlled in spi[INVESTIGATOR_592017].  
Abbott Vascular  Version 17.[ADDRESS_780909] 16, 2018 . APPENDIX III:  SCHEDU LE OF EVENTS  
PROCEDURE/TEST  
Baseline  
Baseline  
(within 7 days)  
Pre-Procedure  
(within 24 hours)  
Procedure  
Post-Procedure  
30 days (  7 d)   
Telephone contact 
[CONTACT_592170]  
180 days (  28 d)  
Telephone contact 
[CONTACT_592170]  
1 yr ( 28 d)  
 office visit  
2, 3, 4, 5 yrs  
( 28 d)  
Telephone contact 
[CONTACT_592171]/Clinical History 
(Age, Sex, Risk Factors, Angina 
Status, Cardiac History)  ✓          
Subject Informed Consent (Must be 
obtained prior to any study related 
testing or procedures)  ✓          
General Inclusion/Exclusion 
Criteria  ✓          
Angiographic Inclusion/Exclusion 
Criteria     ✓[ADDRESS_780910] (if applicable)   ✓         
Hgb, Platelet Count, Creatinine, 
HbA1c, eGFR, WBC  ✓1          
CK and CK -MB    ✓2  ✓3     ✓6 
Troponin I or T           ✓6 
ECG    ✓2  ✓4   ✓ ✓8 ✓[ADDRESS_780911]     ✓7     ✓8  
Study device information     ✓       
Per Protocol Medications5   ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Concomitant Medications  ✓   ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Adverse Events     ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Patient Reported Outcome 
Instruments9 ✓10     ✓  ✓ ✓11  
1. The 21 day labs should be known prior to index procedure. HbA1c is to be collected in diabetic subjects only, and its result is not 
needed prior to the index procedure.  
2. Within 48 hours pre -procedure will be acceptable except when there is evidence of acute  or recent (<7  days) myocardial infarction or 
unstable angina prior to the procedure, in which case pre -procedure draws/assessments must be within [ADDRESS_780912] a known diagnosis of AMI or unstable a ngina within 96 hours prior to the index 
procedure, assessment of cardiac enzymes may be obtained after the start of the index procedure but prior to device implantat ion.  
3. Three draws required: 1) Pre -procedure (prior to stent deployment); 2) [ADDRESS_780913]-procedure; 3) [ADDRESS_780914] -procedure (for hospi[INVESTIGATOR_592018] [ADDRESS_780915] to retu rn to the enrolling institution for their second 
biomarker draw) . If either of the post -procedure CK -MB levels are ≥ [ADDRESS_780916] be given for a minimum of  
12 months, and Aspi[INVESTIGATOR_248] ≥ 75 mg to ≤ [ADDRESS_780917].  
7. Baseline (prior to pre -dilatation) and final (after stenting/post dilatation) angiogram must be obtained and sent to the core laboratory. 
For imaging sites enrolling an imaging subject, if vessel si zing is conducted using IVUS, OCT or on -line QCA, these images must  
also be sent to their respective core laboratory. For subjects in imaging study group, post -implantation angiogram and IVUS, or 
angiogram and OCT will be conducted and images sent to their  respective core laboratory. Images will be sent to respective core 
laboratory.  
8. Subjects in the imaging study group will receive either at [ADDRESS_780918].   
9. Patient Reported Outcome instruments (EQ -5D, SAQ, RDS, GAD -7) will be  administered to the [ADDRESS_780919] -procedure should base their responses on their condition prior to the procedure.  
 EQ-5D, SAQ, RDS, GAD -7 will be administered throu gh 3 years; only EQ -5D and SAQ will be administered at [ADDRESS_780920] 16, 2018 . APPENDIX IV:  ENROLLMENT AND REGIS TRATION 
PROCESS  
 
Figure 1.  Enrollment, Randomization and Registration  
Subject was screened and met general 
inclusion/exclusion criteria
Enrollment ICF signed*
Angiographic inclusion/exclusion met
Successful  pre-dilatation and vessel 
sizing
RandomizationCall IVRS
Registered in TrialYes
Yes
Yes
Yes
Yes
YesNo Screen failure, 
don’t enroll
No Subject not eligible, 
don’t enroll
No Screen failure, 
don’t call IVRS
ITT populationPRO Questionnaires 
Completed
    YesNoComplete after 
index procedure 
prior to discharge
1Lead -In subjects will be randomized and will be considered registered in the trial upon calling IVRS.  
* The ICF can be signed before or after the general inclusion criteria screening. Once signed, a subject is considered 
enrolled.
Abbott Vascular  Version 17.[ADDRESS_780921] 16, 2018 . Figure 2. Enrollment through Treatment Flow  
Angiographic inclusion/
exclusion met Yes
YesNo
No
Call IVRS
Identify # TL lesionsDocument in eCRFYes
ABSORB BVS arm XIENCE arm Subject 
randomized
Subject is considered registered 
in ITT populationSubject a 
screen failure 
Subject RegistrationNo
Subject is clinically followed:
Telephone/office visit 30 days, 180 days, 1 
through 5 years
Imaging subjects: 
Also includes 3 year
 imaging follow-upYesIf Non-target lesion 
(NTL) present, must be 
treated 1stSubject Enrollment
YesMet vessel sizingNTL treatment 
successful?
Don’t randomize 
subjectNoYes
If subject in imaging 
study perform post-
treatment imaging 
assessments per 
guidance
Appendix VIYes
No2nd TL?Treat 2nd TL per protocol 
requirements for the 
assigned deviceIf single TL only or if 2nd TL, 
follow protocol treatment 
strategy before proceeding No1st TL treatment 
successful ?Informed Consent Signed
Complete PRO Questionnaire Must Complete prior 
to discharge
Successful Pre-dilatation of the 
1st target  lesion (TL)
Can treat  as NTL if 
there is 2nd eligible 
lesion*
Note:  
* If there are two lesions and vessel sizing of the intended 1st target lesion fails, this lesion can be treated as a non -
target lesion and the second lesion can be treated as the 1st target lesion, only after meeting the pre -dilatation and 
vessel sizing criter ia. If a single intended target lesion and vessel sizing criteria not met, then subject cannot be 
registered in trial.  
For the Lead -In subjects, randomization is substituted by [CONTACT_592172].  
The ICF can be signed before or after the general inclu sion criteria screening. Once signed, a subject is considered 
enrolled.  
If two target lesions, the same vessel sizing modality and treatment requirements must be used on both target 
lesions.  
Subjects will be clinically followed up to [ADDRESS_780922] 16, 2018 . APPENDIX V:  VESSEL T REATMENT & RANDOMIZA TION  
Figure 1. Single Vessel Treatment  
Visual assessment of lesion to 
be treated
Single Lesion
Vessel Size
Call IVRS 
randomizationMeets size 
Criteria?YesSuccessful 
pre-dil of 
lesion?No
Yes
YesDon’t call IVRS, subject 
is a screen failureIf subject in imaging study perform 
post-treatment imaging 
assessments per guidance
Appendix VI
NoDon’t call IVRS, subject 
is a screen failure
ABSORB BVS arm XIENCE  arm Subject 
randomized
Subject is considered registered 
in ITT population
Assigned device 
reach/cross TL?Proceed 
with 
subject 
follow-upYes
If assigned BVS, treat w/
XIENCE; If assigned XIENCE 
treat per standard of careSuccessful 
implant? 
No No
 
[ADDRESS_780923].  
Note:   
• Due to pre-dilatation being required prior to vessel sizing and randomization, there is the possibility of an 
“unstable” target lesion. Therefore, time period between p re-dilatation and vessel sizing should be 
minimized to being as brief as possible.  
• For Lead -In subjects randomization is substituted by [CONTACT_592172].  
• Vessel sizing is done by [CONTACT_142184].   
Abbott Vascular  Version 17.[ADDRESS_780924] 16, 2018 . Figure 2. Vessel Sizing: Two Vessel Treatment1  
 
NoVisual Assessment of two 
lesions to be treated
NTL treatment 
successful?
Successful 
pre-dil of 1st 
TL?yes
Vessel Size 1st TL1 st TL
yesNon-TL?
YesNo
1st TL meets 
size criteria?No
Yes
ABSORB BVS arm XIENCE  arm Subject 
randomizedCall IVRS 
randomizationNo
Don’t 
randomize 
subjectDon’t 
randomize 
subject
Assigned device 
reach/cross TL?
Successful 
implant? Treat NTL Yes
If assigned to BVS treat 
with XIENCE, if assiged 
to XIENCE treat per 
standard of care and 
proceed to 2nd TL 
treatment per protocolNoYes
YesSubject is considered registered 
in ITT population
Proceed to 2nd TL 
treatment per protocol*Treat as  
NTLNo
 
Abbott Vascular  Version 17.[ADDRESS_780925] 16, 2018 . 
Successful 
pre-dil of 2nd 
TL?
Yes2nd TL
Vessel Size 2nd TL
yes2nd TL meets 
size criteria?YesNo 
No
Assigned device 
cross TL?
Successful 
implant? yes
Subject is clinically followed:
Telephone/office visit 30 days, 180 
days, 1 through 5 years
Imaging subjects: 
[ADDRESS_780926] of care**NoTreat 2nd TL with XIENCE 
regardless of assignment** 
 
[ADDRESS_780927] lesion is a non -target lesion, follow single vessel treatment flow.  
Note:  
• *If there are two lesions and vessel sizing of the intended 1st target lesion fails, this lesion can be treated as 
a non -target lesion and the second lesion can be treated as the 1st target lesion, only after meeting the pre -
dilatation and vessel sizing criteria. Subject cannot be randomized if the 2nd lesions fail to meet pre -
dilatation and sizing criteria.  
• **If assigned to BVS and 1st lesion treatment fails with BVS and treatmen t with XIENCE is unsuccessful, 
then treatment of the 1st and 2nd lesion is per standard of care.  
• Due to pre -dilatation being required prior to vessel sizing and randomization, there is the possibility of an 
“unstable” target lesion. Therefore, time period  between p re-dilatation and vessel sizing should be 
minimized to being as brief as possible.  
• For Lead -In subjects randomization is substituted by [CONTACT_592172]  
• Vessel sizing is done by [CONTACT_142184].  
• In the case of two target lesions assigned t o the Absorb BVS and the first lesion is unsuccessfully treated 
with the Absorb BVS, if the first lesion can be successfully  treated with a XIENCE or other stent, the 
second target lesion should be treated with an Absorb BVS; if the first lesion is unsuccessfully  treated with 
a XIENCE or other stent, the second target lesion should be treated per standard of care (XIENCE stent 
preferred) but NOT with an Absorb BV, at another session.    
Abbott Vascular  Version 17.[ADDRESS_780928] 16, 2018 .  APPENDIX VI:  IMAGING  FLOW AND SCHEDULE  
 
Note:  
[ADDRESS_780929] 16, 2018 . APPENDIX VII:  EV ALUA TION OF LEAD -IN PHAS E 
The ABSORB III Lead -In Phase will begin immedia tely prior to the randomization phase of the 
ABSORB III.  The main objective of the Lead -In Phase will be the evaluation of the applicability 
and transferability of the didactic Absorb BVS physician training plan to US clinical practice.  
The primary area of learning in the usage of Absorb BVS is in the vessel sizing, lesion 
preparation, and device delivery and deployment, as these variables reflect the change in practice 
that occurs with the use of a polymeric scaffold compared to a metallic stent.  The Le ad-In Phase  
will involve up to [ADDRESS_780930] had previous experience with 
Absorb BVS, therefore will be limited to US sites on ly.  As the Absorb physician training will be 
used to train all physicians in the usage of Absorb BVS, and the Lead -In Phase is intended to 
evaluate the training program, 35 sites are deemed sufficient.  
During the Lead -In phase, there will be four key areas specific to lesion/vessel selection, lesion 
preparation and device delivery and deployment that will be measured during the time of and 
following the index procedure.  The four variables are as follows:  
1. Angiographic inclusion/exclusion:  At the time o f the index procedure all angiographic 
inclusion/exclusion must be met. Selection of the appropriate target vessel and lesion 
criteria has been found to be important in the proper delivery and deployment of Absorb 
BVS. The expected adherence to the angiogr aphic inclusion/exclusion will be set at the 
success criteria of 95%. The criteria is based on ASBORB EXTEND data in which out of 
469 patients, there were 24 angiographic inclusion/exclusion deviations (5% 
angiographic inclusion/exclusion deviation rate).  
2.  Vessel sizing met protocol required criteria:  Retrospective analysis will be completed 
by [CONTACT_592173].  Appropriate vessel sizing is important in the 
selection of the correct Absorb BVS diameter.  The RVD will be visually assessed by  
[CONTACT_592174], and will be sent to angiographic core 
laboratory to assess if vessel sizing was done appropriately. The targeted Dmax 36 range 
as assessed by [CONTACT_592175] ≥ 2.5 to ≤ 3.3 mm, with an a cceptable 
range between 2.25 to ≤ 3.3 mm. This criterion is based on ABSORB EXTEND data in 
which an angiographic core laboratory retrospective analysis conducted on 108 target 
lesions  that were selected by [CONTACT_592176] -line QCA 
(Quantitative Coronary Angiography)  [56]. The ac ceptable range identified above is 
considered appropriate based on ABSORB EXTEND data in which out of 108 lesions 
69.4% of vessels treated with the 3.0x18 mm Absorb BVS fell within the Dmax range of 
≥ 2.5 to ≤ 3.3 mm and 26.9% of vessels had a Dmax range <  2.5 mm [56].Furthermore, 
preliminary analysi s from ABSORB Cohort B has demonstrated that the placement of the 
3.0 mm Absorb BVS in a vessel < 2.5 mm has not resulted clinical and angiographic 
differences as compared to vessels > 2.5 mm [57].  
3. Treatment strategy followed per the protocol: All treatment strategy requirements 
must be met at the time of the index procedure.  Proper delivery and deployment of the 
Absorb BVS is also dependent on variables such as appropriate guide catheter choice, 
                                                           
[ADDRESS_780931] -dilatation strategy. Therefore, 
the expected adherence to the treatment strategy will be set at the success criteria of 95%.  
This is based on ABSORB EXTEND data in which there were 32 treatment deviations 
out of 469 subjects registered in the t rial (7% treatment deviation rate).                            
4. Device success: The device success criteria will be based on the protocol definition that 
is detailed in Appendix II .  The expected device success will be 90%.  
Each of these variables can be e valuated acutely and will provide the sponsor with a measure of 
adherenc e to the physician training program.  Subject registration will be conducted in [ADDRESS_780932] enrollment/registration to the sites can occur.  Regarding the vessel sizing 
criteria, after the first missed vessel sizing by [CONTACT_2413], they will receive im mediate 
feedback from the sponsor and core laboratory, and retraining if needed.  
The data for each enrolled subject will be collected through the electronic case report forms  
(eCRFs).  Sites will be required to enter the Lead -In data within [ADDRESS_780933] 16, 2018 . APPENDIX VIII: RISK STRATIFICATION OF CA RDIAC 
CATHETERIZATION, STE NTING AND PERCUTANEO US 
TRANSCATHETER CORONA RY ANGIOPLASTY  
Potential risks associated with the study device and everolimus were described in the original 
protocol. Based on additional clinical and commercial experience, Abbott Vascular has updated 
the BVS IDE IFU. The below section provides a consolidated list of anticipated adverse events 
and, in alignment with ISO14155:[ADDRESS_780934] ed that the risks will not be significantly different with 
the use of the Absorb BVS and XIENCE V stent in this trial .  The incidence rates of the known 
complications that may arise from a ste nting procedure were obtained from the pooled XIENCE 
V trials  c onducted by [CONTACT_12227] (Spi[INVESTIGATOR_592019], Spi[INVESTIGATOR_592020], Spi[INVESTIGATOR_592021], Spi[INVESTIGATOR_592022], Spi[INVESTIGATOR_592023] 4.0 mm, 
Spi[INVESTIGATOR_592024], Spi[INVESTIGATOR_17040] V Diabetic, Spi[INVESTIGATOR_17040] V Registry, Spi[INVESTIGATOR_592025], XV [LOCATION_003], XV DAPT, and XV 
India using MedDRA Preferred Terms of site -reported 1 year adverse events reg ardless of 
relationship to device or procedure ) and were classified using the frequency categories as below. 
Death and stent thrombosis within [ADDRESS_780935] been observed in < 2.0% of the patients enrolled 
in these trials.  
1. Very common: ≥ 10%: Unstable or stable angina pectoris  
2. Common: ≥ 1.0% to < 10 %: Cardiac, pulmonary or renal failure; a ccess site 
complications including pain, hematoma, or hemorrhage; vascular complication including 
at the entry site, which may require ves sel repair; coronary artery dissection; arrhythmia 
including atrial and ventricular; myocardial infarction, including acute myocardial 
infarction; nausea and vomiting; hypotension; hypertension; restenosis  
3. Uncommon: ≥ 0.1% to < 1.0%:  Cardiac arrest;  emergent or non -emergent surgery; 
allergic or hypersensitivity reactions  to contrast agent or platinum, polymer poly (L -
lactide) (PLLA), polymer poly (D,L -lactide) (PDLLA), and drug reactions to everolimus, 
antiplatelet drugs or contrast agent; bleeding com plications which may require 
transfusion; coronary artery spasm; distal emboli; fever; catheter site infection or pain; 
myocardial ischemia; palpi[INVESTIGATOR_814]; coronary artery perforation; pericarditis, peripheral 
ischemia (due to vascular injury); pseudoaneury sm; pulmonary edema; stroke /CVA/TIA ; 
total occlusion of coronary artery; ventricular tachycardia;  ventricular fibrillation; vessel 
dissection  
4. Rare: ≥ 0.01% to < 0.1%: Arteriovenous fistula; cardiac tamponade; coronary artery 
embolism; arterial injury; proc edural nausea; shock; peripheral artery dissection;  
peripheral nerve injury; renal insufficiency ; pericardial effusion  
5. Very Rare: < 0.01% (including not reported AEs): Abrupt coronary artery closure; 
coronary artery aneurysm; arterial rupture;  everolimus I FU risks.  
Some IFU risks, including everolimus ri sks have not been observed in Abbott Vascular  clinical 
studies. These risks are listed in the very rare category. There may be risks related to the device 
that are unknown at present.  Likewise the exact freq uency of the risk might be unknown.  
Abbott Vascular  Version 17.[ADDRESS_780936] 16, 2018 . APPENDIX IX:  CONTACT  [CONTACT_7533]  
A list of investigational site co -ordinates can be obtained upon request from the Clinical Project 
Manager for the study. The Clinical Project Manager can be reached at [ADDRESS_780937] 16, 2018 . APPENDIX X:  REFERENC ES 
 
1. Gomez -Lara, J., et al., Serial analysis  of the malapposed and uncovered struts of the new 
generation of everolimus -eluting bioresorbable scaffold with optical coherence tomography.  
Jounal of the American College  of Cardiology: Cardiovascular Interventions, 2011. 4(9): p. 992 -
1001.  
2. Kimura, T., et al., Three -year follow -up after implantation of metallic coronary -artery stents.  The 
New England Journal of Medicine, 1996. 334(9): p. 561 -566. 
3. Nobuyoshi, M., et al ., Restenosis after successful percutaneous transluminal coronary 
angioplasty: serial angiographic follow -up of 229 patients.  Journal of the American College of 
Cardiology, 1988. 12(3): p. 616 -623. 
4. Serruys, P.W., et al., Incidence of restenosis after su ccessful coronary angioplasty: a time -related 
phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 
months.  Circulation, 1988. 77(2): p. 361 -371. 
5. Pi[INVESTIGATOR_58628], W.S., M.L. Verstynen, and D.R. Sarver, Bioabsorbable fixati on devices: status for the 
craniomaxillofacial surgeon.  Journal of Craniofacial Surgery, 1997. 8(2): p. 92 -96. 
6. Gladden, L.B., Lactate metabolism: a new paradigm for the third millennium.  Journal of 
Physiology, 2004. 558(Pt 1): p. 5 -30. 
7. Philp, A., A.L . Macdonald, and P.W. Watt, Lactate --a signal coordinating cell and systemic 
function.  Journal of Experimental Biology, 2005. 208: p. 4561 -4575.  
8. Robergs, R.A., F. Ghiasvand, and D. Parker, Biochemistry of exercise -induced metabolic 
acidosis.  American Journal of Physiology, 2004. 287(3): p. R502 -R516.  
9. Lupattelli, T., et al., Efficacy and safety of antegrade common femoral artery access closure 
using the Angio -Seal device: experience with 1889 interventions for critical limb ischemia in 
diabetic patients.  Journal of Endovascular Therapy, 2010. 17(3): p. 366 -375. 
10. Barlis, P., et al., An optical coherence tomography study of a biodegradable vs. durable polymer -
coated limus -eluting stent: a LEADERS trial sub -study.  European Heart Journal,  2010. 31(2): p. 
165-176. 
11. Longo, U.G., et al., The low -profile Roman bridge technique for knotless double -row repair of 
the rotator cuff.  Archives of Orthopaedic and Trauma Surgery, 2011. 131(3): p. 357 -361. 
12. Tamai, H., et al., Initial and 6 -month r esults of biodegradable poly -l-lactic acid coronary stents 
in humans.  Circulation, 2000. 102(4): p. 399 -404. 
13. Garlotta, D., A literature review of poly(lactic acid).  Journal of Polymers and the Environment, 
2001. 9(2): p. [ADDRESS_780938] of molecular weight and crystallinity on poly(lactic 
acid) mechanical properties.  Journal of Applied Polymer Science, 1996. 59(1): p. 37 -43. 
15. Chapman, G.D., et al., A bioabsorbable stent: Initial experimental results.  Circula tion, 1990. 
1990 (82 (Suppl II)): p. III - 541. 
16. Gammon, R.S., et al., Mechanical features of the Duke biodegradable stent.  Journal of the 
American College of Cardiology, 1991. 1991 (17): p. 235A.  
17. Tsuji, T., et al., Four -year follow -up of the biodegra dable stent (IGAKI -TAMAI Stent).  
Circulation Journal, 2004. 68(Suppl 1): p. 135.  
18. Tsuji, T., et al., Three -year clinical follow -up results of the Igaki -Tamai biodegradable stent.  
Circulation Journal, 2003. 67(Suppl. I): p. 351.  
19. Onuma, Y., et al., Ten-year follow -up of the IGAKI -TAMAI stent. A posthumous tribute to the 
scientific world of [CONTACT_592231].  EuroIntervention Supplement, 2009. 5(Suppl. F): p. F109 -
F111.  
20. Nishio, S., et al., Long -Term (>10 Years) clinical outcomes of first -in-human biodegradable poly -
l-lactic acid coronary stents: Igaki -Tamai stents.  Circulation, 2012. 125(19): p. 2343 -53. 
21. Biamino, G. and D. Schreinhert, Treatment of SFA lesions with PLLA biodegradable stents: 
results of the PERSEUS study.  Journal of Endovascular  Therapy, 2005. 12(Suppl. I): p. 5.  
Abbott Vascular  Version 17.[ADDRESS_780939] 16, 2018 . 22. Colombo, A., et al., Randomized study to assess the effectiveness of slow - and moderate -release 
polymer -based paclitaxel -eluting stents for coronary artery lesions.  Circulation, 2003. 108(7): p. 
788-794. 
23. Morice, M.C., et al., A randomized comparison of a sirolimus -eluting stent with a standard stent 
for coronary revascularization.  The New England Journal of Medicine, 2002. 346(23): p. [ADDRESS_780940] ste nts in patients with stenosis in a 
native coronary artery.  The New England Journal of Medicine, 2003. 349(14): p. 1315 -1323.  
25. Serruys, P.W., et al., A randomised comparison of an everolimus -eluting coronary stent with a 
paclitaxel -eluting coronary stent : the SPI[INVESTIGATOR_592026].  EuroIntervention, 2006. 2(3): p. 286 -294. 
26. Stone, G.W., et al., A polymer -based, paclitaxel -eluting stent in patients with coronary artery 
disease.  The New England Journal of Medicine, 2004. 350(3): p. 221 -231. 
27. Stone, G.W., et  al., Comparison of an everolimus -eluting stent and a paclitaxel -eluting stent in 
patients with coronary artery disease: a randomized trial.  Journal of the American Medical 
Association, 2008. 299(16): p. 1903 -1913.  
28. Tanimoto, S., et al., Comparison of i n vivo acute stent recoil between the bioabsorbable 
everolimus -eluting coronary stent and the everolimus -eluting cobalt chromium coronary stent: 
insights from the ABSORB and SPI[INVESTIGATOR_592027].  Catheterization and Cardiovascular Interventions, 
2007. 70(4): p. 5 15-523. 
29. Ormiston, J.A., et al., A bioabsorbable everolimus -eluting coronary stent system for patients with 
single de -novo coronary artery lesions (ABSORB): a prospective open -label trial.  Lancet, 2008. 
371(9616): p. 899 -907. 
30. Serruys, P.W., et al., A bioabsorbable everolimus -eluting coronary stent system (ABSORB): 2 -
year outcomes and results from multiple imaging methods.  Lancet, 2009. 373(9667): p. [ADDRESS_780941] iac 
rehabilitation.  Heart, 2006. 92(1): p. 62 -7. 
32. Spertus, J.A., et al., Development and evaluation of the Seattle Angina Questionnaire: a new 
functional status measure for coronary artery disease.  J Am Coll Cardiol, 1995. 25(2): p. [ADDRESS_780942] of dyspnea on health -related quality of life in patients with 
coronary artery disease: results from the PREMIER registry.  American Heart Journal, 2009. 
157(6): p. 1042 -9 e1.  
34. Spi[INVESTIGATOR_626], R.L., et al., A brief measure for as sessing generalized anxiety disorder: the GAD -7. Arch 
Intern Med, 2006. 166(10): p. 1092 -7. 
35. Aksoy, M., et al., The safety and efficacy of angioseal in therapeutic endovascular interventions.  
European Journal of Vascular and Endovascular Surgery, 2006. 32(1): p. [ADDRESS_780943] human experience using everolimus -
eluting stents with bioabsorbable polymer.  Circulation, 2004. 109(18): p. 2168 -2171.  
37. Storger, H., et al., Clinical experiences using everolimus -eluting stents in patients with coronary 
artery disease.  Journal of Interventional Cardiology, 2004. 17(6): p. 387 -390. 
38. Grube, E. FUTURE II: Multicenter evaluation of the bioabsorbable polymer -based everolimus -
eluting stent . 2003.  
39. Mastro kalos, D.S. and H.H. Paessler, Allergic reaction to biodegradable interference poly -L-
lactic acid screws after anterior cruciate ligament reconstruction with bone -patellar tendon -bone 
graft.  Arthroscopy, 2008. 24(6): p. 732 -733. 
40. Alijotas -Reig, J., V. G arcia -Gimenez, and M. Vilardell -Tarres, Late-onset immune -mediated 
adverse effects after poly -L-lactic acid injection in non -HIV patients: clinical findings and long -
term follow -up. Dermatology, 2009. 219(4): p. 303 -308. 
41. Nissen, S.E. and P. Yock, Intra vascular ultrasound: novel pathophysiological insights and 
current clinical applications.  Circulation, 2001. 103(4): p. 604 -616. 
42. Ramasubbu, K., et al., Repeated intravascular ultrasound imaging in cardiac transplant 
recipi[INVESTIGATOR_592028].  Journal of the American 
College of Cardiology, 2003. 41(10): p. [ADDRESS_780944] 16, 2018 . 43. Barlis, P., et al., A multicentre evaluation of the safety of intracoronary optical coherence 
tomography.  EuroIntervention, 2009. 5(1): p. 90 -95. 
44. Feldman, R.L., et al., Analysis of coronary responses to various doses of intracoronary 
nitroglycerin.  Circulation, 1982. 66(2): p. 321 -327. 
45. Partnership, B. -M.S.S.P., Plavix Highlights of Prescribing Information.  2011.  
46. Daiichi Sankyo, I. and E.L.a. Company, Effient Highlights of Prescribing Information.  2009.  
47. [COMPANY_008], Brilinta Highlights of Prescribing Information.  2011.  
48. Movahed, M.R., et al., Nationwide trends in the utilisation of percutaneous coronary inte rvention 
(PCI) in the [LOCATION_002] of America based on gender and ethnicities.  EuroIntervention, 2009. 
5(3): p. 343 -348. 
49. Lansky, A.J., Outcomes of percutaneous and surgical revascularization in women.  Progress in 
Cardiovascular Diseases, 2004. 46(4): p. 305 -319. 
50. Singh, M., et al., Mortality differences between men and women after percutaneous coronary 
interventions. A 25 -year, single -center experience.  Journal of the American College of 
Cardiology, 2008. 51(24): p. 2313 -2320.  
51. Abbott, J.D., et a l., Gender -based outcomes in percutaneous coronary intervention with drug -
eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry).  American 
Journal of Cardiology, 2007. 99(5): p. 626 -31. 
52. Lansky, A.J., et al., Gender -based e valuation of the XIENCE V everolimus -eluting coronary stent 
system: clinical and angiographic results from the SPI[INVESTIGATOR_592029].  Catheterization 
and Cardiovascular Interventions, 2009. 74(5): p. 719 -727. 
53. Lloyd -Jones, D., et al., Heart diseas e and stroke statistics --2009 update: a report from the 
American Heart Association Statistics Committee and Stroke Statistics Subcommittee.  
Circulation, 2009. 119(3): p. e21 -e181.  
54. Minutello, R.M., et al., Impact of race and ethnicity on inhospi[INVESTIGATOR_592030] (report from the 2000 -2001 [LOCATION_001] State Angioplasty Registry).  
American Heart Journal, 2006. 151(1): p. 164 -167. 
55. Napan, S., et al., Racial difference in cardiovascular outcomes following percutaneous coro nary 
intervention in a public health service patient population.  Journal of Invasive Cardiology, 2010. 
22(4): p. 168 -173. 
56. Farooq, V., et al., Proximal and distal maximal luminal diameters as a guide to appropriate 
deployment of the ABSORB everolimus -eluting bioresorbable vascular scaffold: a sub -study of 
the ABSORB Cohort B and the on -going ABSORB EXTEND Single Arm Study.  Catheterization 
and Cardiovascular Interventions, 2012. 79(6): p. 880 -888. 
57. Diletti, R., et al., 6-month clinical outcomes followi ng implantation of the bioresorbable 
everolimus -eluting vascular scaffold in vessels smaller or larger than 2.5 mm.  Journal of the 
American College of Cardiology, 2011. 58(3): p. [ADDRESS_780945] 16, 2018 . ADDENDUM A:  PHARMACOKINETICS SU B-STUDY 
SYNOPSIS  
 
 
PROTOCOL 10-[ADDRESS_780946]  
PHARMACOKINETICS (PK) SUB -STUDY SYNOPSYS  
Date  August 16, 2018  
Sub-Study Co-Primary 
Investigator s David G. Rizik, MD  
Scottsdale Healthcare  
Scottsdale, AZ  
 
Louis A. Cannon, MD  
Cardiac and Vascular Research Center of Northern Michigan  
Petoskey, MI  
Planned Number of Sites 
and Region(s)  A maximum o f 5 sites in the [LOCATION_002]  
Abbott Vascular Medical 
Expert  [INVESTIGATOR_592225], Divisional Vice President Medical Affairs, Chief 
Medical Office  
Study Type  Prospective, open -label, non -blinded  study  
Sponsor / Data Monitoring/  
Data Management/Data 
Analysis  Abbott Cardiovascular Systems, Inc.  
[ADDRESS_780947]  
Santa Clara, CA  [ZIP_CODE]  
Study Monitor  Abbott Vascular  
Enrollment/Randomization 
Service  Bracket  
[ADDRESS_780948]  
Blood Sample Analysis 
Core Laboratory  Eurofins │ ADME Bioanalyses  
Vergeze, [LOCATION_009]  
Data Analysis Core 
Laboratory  Kinesis Pharma BV  
Breda, The Netherlands  
Clinical Events Committee  Cardiovascular Research Foundation, [LOCATION_001], NY  
Sub-study Author  Maureen Kennedy, MN  
Senior Manager – Clinical Science  
 
  

Abbott Vascular  Version 17.[ADDRESS_780949] 16, 2018 . Study Name  [CONTACT_592229] -study: 10 -392 
Investigational 
Device  Absorb™ Bioresorbable Vascular Scaffold (BVS) System :  
• Scaffold diameters: 2.5, 3.0 and 3.5 mm  
• Scaffold lengths: 8, 12, 18, and 28 mm  
Objective  To determine the pharmacokinetics of everolimus delivered by [CONTACT_592177] a separate and non -randomized cohort of subjects who 
only receive Absorb BVS with a maximum of two de novo  native 
coronary artery lesions after implantation of the Absorb BVS.  (Note: 
The ABSORB III PK subjects will not contribute to the determination of 
the ABSORB III RCT primary endpoint.)  
Sub-study 
Design  A prospective, open -label, non -blinded study enroll ing approximately [ADDRESS_780950] Number  Total number of patients: Approximately 12 (as distributed below)  
Table 1: Drug Content in Absorb BVS  
Absorb BVS Diameter  
(mm)  Absorb BVS Length  
(mm)  Drug Dose  
(µg) 
2.5, 3.0  8 76 
2.5, 3.0  12 114 
2.5, 3.0  18 181 
2.5, 3.0  28 276 
3.5 12 135 
3.5 18 197 
3.5 28 308 
Table 2: Treatment Group and Drug Dosage  
Treatment Groups  Drug Dose (µg)  
Single Scaffold  76-308 
≥ 2 Scaffolds+ ≥ 152++ 
+Two lesions in two separate vessels or bailout  
++Minimum dosage a subject can receive based on use of two of the smallest 
scaffold sizes (2.5/3.0 x 8 mm)  
To ensure the PK measurements reflect everolimus exposure due to 
Absorb BVS only, the PK sub -study will not allow non -target lesion 
treatment.   
Subjects will be included in the PK analysis only if all intended Absorb 
BVS are implanted and no other device is used/implanted.  
Abbott Vascular  Version 17.[ADDRESS_780951] 16, 2018 . Blood Sampling 
Timing  • Pre-Absorb BVS implantation : Baseline  
• Baseline is defined as prior to implantation of the first Absorb 
BVS; the blood sample will be drawn on the day of the index 
procedure either through a heparin lock, venous sheath, or 
venipuncture.  
• Post-Absorb BVS implantation : 10 and 30 minutes, 1 hr, 2 hrs, 4 hrs, 
6 hrs , 12 hrs, 24 hrs (1 day), 48 hrs (2 days), 72 hr s (3 days), 96 hrs 
(4 days), 120 hrs (5 days), 168 hrs (7 days), 336 hrs (14 days), and 
720 hrs (30 days)  
• Post-implantation blood samples will be drawn at the time 
intervals stated above; timing of the post -implantation sampling 
will begin when the last A bsorb BVS is deployed , i.e. last Absorb 
BVS delivery catheter is removed from the body . 
Follow -up • Refer to Section 7.5 Clinical and Imaging Follow -Up for All Subjects  
• Note: Follow -up for PK sub -study subjects will not include 
administration of the PRO too ls nor imaging follow -up. 
PK Parameters  • tmax 
• Cmax 
• AUC 0-24h 
• AUC 0-t 
• AUC 0-∞ 
• z  
• t1/2term   
• CL 
Safety 
Monitori ng Refer to Section 9.[ADDRESS_780952] 
Enrollment  Unlike the ABSORB III primary analysis group and Imaging cohort, 
IVRS will not be called for PK subjects until after a) successful pre -
dilatation and b) completion of the index procedure.  
Abbott Vascular  Version 17.[ADDRESS_780953] 16, 2018 . Exclusion from 
Analysis and 
Follow -up • Subjects in whom an Absorb BVS enters the body but is not 
implanted will be excluded from the sub -study analysis and will 
require 30 -day safety follow -up. 
• Subjects in whom an Absorb BVS and a non -Absorb BVS device are 
implanted will be excluded from the sub -study analysis and will 
require the full 5 -year follow -up as described in Section 7.5 Clinical 
and Imaging Follow -Up for All Subjects.  (Note: Completion of the 
PRO tools and imaging follow -up will not be required.)  
• In all of the above cases, subjects will be replaced in the PK sub -
study.  
Inclusion 
Criteria  General Inclusion Criteria: Refe r to Section [IP_ADDRESS] General Inclusion 
Criteria for complete list  
Angiographic Inclusion Criteria  
1. One or two de novo target lesions:  
a. If two target lesions are present, they must be present in 
different epi[INVESTIGATOR_592031].  
b. The definition of epi[INVESTIGATOR_591951], LCX and 
RCA and their branches. Thus, the patient must not have 
lesions requiring treatment in e.g. both the LAD and a 
diagonal branch.  
2. Target lesion(s) must be located  in a native coronary artery with a 
visually estimated or quantitatively assessed %DS of ≥ 50% and < 
100% with a TIMI flow of ≥ 1 and one of the following: stenosis 
≥ 70%, an abnormal functional test (e.g., fractional flow reserve, 
stress test), unstable a ngina or post -infarct angina.   
a. Lesion(s) must be located in a native coronary artery wit h 
RVD by [CONTACT_592084] ≥ 2.50 mm and ≤ 3.75 mm.  
b. Lesion(s) must be located in a native coronary artery with 
length by [CONTACT_592084] ≤ 24 mm.  
Exclusion 
Criteria  General Exclusion Criteria:  Refer to Section [IP_ADDRESS]. General 
Exclusion Criteria for the complete list; the following 
change/modification applies to criterion #8:  
Abbott Vascular  Version 17.[ADDRESS_780954] has undergone prior PC I within the target vessel(s)  during 
the last 12 mo nths.  
a. Prior PCI to a non -target vessel not using drug -eluting/coated 
devices (e.g. balloon, stent) is acceptable if performed 
anytime > 30 days before the index procedure .   
b. Prior PCI to a non -target vessel using drug -eluting/coated 
devices is acceptable i f performed >6 months before the index 
procedure.  
c. Peripheral interventions not using drug -eluting/coated devices 
are acceptable if performed anytime > 30 days before the 
index procedure or between 24 hours and 30 days before the 
index procedure if successf ul, uncomplicated.  
d. Peripheral interventions using drug -eluting/coated devices are 
acceptable if performed > 6 mont hs before the index 
procedure.   
Angiographic Exclusion Criteria: Refer to Section [IP_ADDRESS] 
Angiographic Exclusion Criteria for the complete lis t 
Lesion Selection  Refer to Section 4.4 ABSORB III Treatment Flow and Lesion Selection 
(Please note again that non -target lesion treatment is no t allowed in the 
PK sub -study.)  
Treatment 
Strategy  Refer to Section 7.3.4 Treatment Rules of the Target Lesion(s) with the 
following exceptions:  
• In the PK sub -study, all target lesions are to be treated with the 
Absorb BVS only  
• Subjects in the PK sub -study will not be randomized; any 
references to randomization should be disregarded  
Cardiac 
Biomarker 
Collection  Refer to Section 7.4.[ADDRESS_780955] 16, 2018 .  
PROTOCOL 10 -392 
 
ABSORB IV  
RANDOMIZED CONTROLLED TRIAL  
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in 
the Treatment of Subjects with de novo  Native Coronary Artery Lesions  
Date  August 16, 2018  
Principal Investigators and 
Study Chairman  
 Principal Investigator & Study Chairman:   
Gregg W. Stone, MD, Columbia University Medical Center, [LOCATION_001], 
NY  
Co-Principal Investigators:   
Stephen G. Ellis, MD, Cleveland Clinic, Cleveland OH  
Dean J. Kereiakes, MD, The Christ Hospi[INVESTIGATOR_307], Cincinnati, OH  
Planned Number of Sites and 
Region(s)  Approximately  140 sites in the [LOCATION_002] and  
outside the [LOCATION_002]  
Trial Type  Prospective, randomized, single -blind, multi -center trial  
Sponsor / Data Monitoring/  
Data Management/Data 
Analysis  Abbott Cardiovascular Systems, Inc.  
[ADDRESS_780956]  
Santa Clara, CA  [ZIP_CODE]  
Angiographic Core Laboratory  Cardiovascular Research Foundation, [LOCATION_001], NY  
Ischemia Substudy Core 
Laboratory  (SPECT and CT)  Cardiovascular Research Foundation, [LOCATION_001], NY  
Clinical Events Committee  Cardiovascular Research Foundation, [LOCATION_001], NY  
Data Safety Monitoring Board  Axio  Research , Seattle, WA    
  

Abbott Vascular  Version 17.[ADDRESS_780957] 16, 2018 . TABLE OF CONTENTS  
PROTOCOL SUMMARY FOR ABSORB IV  ................................ ................................ ............ 156 
1. INTRODUCTION  ................................ ................................ ................................ .............. 181 
2. BACKGROUN D INFORMATION  ................................ ................................ ................... 182 
2.1.1  Name [CONTACT_196600]  ................................ ................................ ......... 182 
2.1.2  Intended Indication  ................................ ................................ ................................ ..182 
2.1.3 Background Information  ................................ ................................ .......................... 182 
2.2 Trial Rationale  ................................ ................................ ................................ ............. 183 
3. TRIAL OBJECTIVE  ................................ ................................ ................................ .......... 183 
4. CLINICAL TRIAL/INVESTIGATION FLOW AND FOLLOW -UP SCHEDULE  ......... 184 
4.1 Number of Subjects to be Registered ................................ ................................ ........... 184 
4.2 ABSORB Physician Training  ................................ ................................ ...................... 184 
4.3 ABSORB IV Treatment Flow and Lesion Selection  ................................ ................... 184 
4.4 Measures Taken to Avoid and Minimize Bias  ................................ ............................. 186 
4.4.1  Randomization  ................................ ................................ ................................ ......... 186 
4.4.2  Blinding ................................ ................................ ................................ .................... 187 
4.5 Early Te rmination of the Clinical Trial  ................................ ................................ .......188 
5. ENDPOINTS  …………………………………………………………………………….. 188 
5.1 Primary Endpoints  ................................ ................................ ................................ .......188 
5.2 ABSORB IV Major Secondary Endpoint  ................................ ................................ ....188 
5.3 Additional Secondary Endpoint(s)  ................................ ................................ ............... [ADDRESS_780958] History ................................ ................................ ................................ ......... 192 
7.1.3  Patient -Reported Outcomes Assessment  ................................ ................................ .192 
7.2 Pre-Procedure  ................................ ................................ ................................ ............... 192 
7.2.1  Pre-Procedure Laboratory Assessment  ................................ ................................ ....192 
7.2.2  Dual Anti -Platelet Medications ................................ ................................ ................ 193 
7.2.3  Anticoagulation Medications  ................................ ................................ ................... 195 
7.2.4  Statin Therapy  ................................ ................................ ................................ .......... 195 
7.3 Index Procedure  ................................ ................................ ................................ ........... 195 
7.3.1  Baseline (Pre -Procedure) Angiography  ................................ ................................ ...195 
7.3.2  Imaging Guidance Document  ................................ ................................ .................. 195 
7.3.3  Treatment Rules of the Target Lesion(s)  ................................ ................................ .195 
7.3.4  Treatment Rules of Unplanned Non -Target Lesion(s)  ................................ ............ 196 
7.3.5  Bailout Stenting or Alternative Procedures  ................................ ............................. 196 
7.3.6  Final (Post -procedure) Angiography  ................................ ................................ .......[ADDRESS_780959] 16, 2018 . 7.3.7  Final (Post -procedure) IVUS and OCT  ................................ ................................ ...[ADDRESS_780960]–procedure  ................................ ................................ ................................ ............. [ADDRESS_780961]-procedure Laboratory and Clinical Tests  ................................ ......................... 197 
7.4.3  Assessment of perception bias.  ................................ ................................ ................ 198 
7.4.4  Follow -up Antiplatelet Medications  ................................ ................................ ........ 199 
7.4.5  Other Chronic Concomitant Medications  ................................ ................................ 199 
7.5 Clinical Follow -up for All Subjects  ................................ ................................ ............. 199 
7.6 Additional Follow -up Visits for All Subjects  ................................ .............................. 200 
8. ADVERSE EVENTS  ................................ ................................ ................................ .......... 201 
8.1 Definitions ................................ ................................ ................................ .................... 201 
8.1.1 Adverse Event  ................................ ................................ ................................ ............. 201 
8.1.2 Serious Adverse Event  ................................ ................................ ................................ 201 
8.1.3 Device Deficiency/Product Experience  ................................ ................................ ......[ADDRESS_780962] ([LOCATION_003]DE)  ................................ ........ 202 
8.3 Adverse Event/ Device Deficiency/ Product Experience Reporting  ........................... [ADDRESS_780963] Reporting to Sponsor and IRB  ......... 204 
8.3.3  Device Deficiency/Product Experience Reporting  ................................ .................. [ADDRESS_780964]  ................................ ................. 205 
9. ADJUDICATION OF EVENTS ................................ ................................ ......................... 205 
9.1 The Clinical Events Committee (CEC) ................................ ................................ ........ 205 
9.2 Angiographic Core Laboratory  ................................ ................................ .................... 205 
10. STATISTICAL ANALYSIS  ................................ ................................ .............................. 205 
10.1  Statistical Overview  ................................ ................................ ................................ .....205 
10.2  Analysis Populations  ................................ ................................ ................................ ....206 
10.2.1  Intent -to-Treat (ITT) Population  ................................ ................................ .............. 206 
10.2.2  Per Treatment Evaluable Population  ................................ ................................ .......206 
10.3.1  ABSORB IV Primary Endpoints  ................................ ................................ ............. 206 
10.3.2 Powered Secondary Endpoint  ................................ ................................ ................... 207 
10.4  Statistical Analyses  ................................ ................................ ................................ ......208 
10.4.1 Primary Endpoint Analyses  ................................ ................................ ..................... 209 
10.4.2  Powered Secondary Endpoint Analysis  ................................ ................................ ...209 
10.4.3  Secondary Endpoint Analyses  ................................ ................................ ................. 209 
10.4.4  Additional Analyses  ................................ ................................ ................................ .210 
10.4.5  Informational Endpoint Analyses  ................................ ................................ ............ 210 
10.4.6  Subgroup Analysis  ................................ ................................ ................................ ...210 
10.4.7  Handling of Multiplicity Issues  ................................ . Error! Bookmark not defined.  
10.4.[ADDRESS_780965] Access to Source Data/Documents Addendum  ................................ ................ 210 
12. ABSORB -RESOLVe: REduction in iSchemia with BiOresorbale Vascular Scaffolds —An 
Imaging Sub -study to ABSORB IV  ................................ ................................ .................... [ADDRESS_780966] Angiography (CCTA)  ................................ ................................ ........ [ADDRESS_780967] Perfusion (CTP)  ................................ ................................ ................................ .[ADDRESS_780968] ................................ ................................ ................................ ....................... 214 
12.1.5.  The Pr esent Study  ................................ ................................ ................................ ....214 
12.2.  Rationale and Design of ABSORB -RESOLVe  ................................ ........................... 214 
12.3.  ABSORB -RESOLVe Study Objectives:  ................................ ................................ .....216 
12.3.1.  Primary Objective (Myocardial Ischemia by [CONTACT_370168]).  ................................ ............ 216 
12.3.2.  Powered Secondary Objective (Myocardial Ischemia by [CONTACT_4654]).  ............................... 216 
12.3.3.  Tertiary Objectives:  ................................ ................................ ................................ .[ADDRESS_780969] Visits  ................................ ................................ ............. 219 
12.4.3.  Procedural Assessments and Treatment Strategy  ................................ .................... 226 
12.5.  References  ................................ ................................ ................................ .................... 227 
Appendix I : ABBREVIATIONS AND ACRONYMS  ................................ ................................ 231 
APPENDIX II:  DEFINITIONS  ................................ ................................ ............................. 232 
APPENDIX III:  SCHEDULE OF EVENTS  ................................ ................................ ........... 236 
APPENDIX IV:  ENROLLMENT AND REGISTRATION PROCESS  ................................ .238 
APPENDIX V:  VESSEL TREATMENT & RANDOMIZATION  ................................ .......240 
APPENDIX VI: RISK STRATIFICATION OF CARDIAC CATHERIZATION, STENTING 
AND PERCUTANEOUS TRANSCATHETER CORONARY ANGIOPLASTY  ............ 243 
APPENDIX VII:  CONTACT [CONTACT_7533]  ................................ ................................ ......[ADDRESS_780970] 16, 2018 . PROTOCOL SUMMARY FOR  ABSORB IV  
 
Investigational 
Device  Absorb™ Bioresorbable Vascular Scaffold (BVS) System37: 
• Scaffold diameters: 2.5, 3.0 and 3.5 mm  
• Scaffold lengths38: 8, 12, 18, and 28 mm  
Once Absorb GT1™ BVS System is commercially available, it can 
also be used in the ABSORB IV trial (see section 2.1.4 for available 
sizes).  
Control Device  Commercially approved XIENCE Family Stent System, inclusive of 
XIENCE V, XIENCE PRIME , XIENCE Xpedition , XIENCE Alpi[INVESTIGATOR_050] , 
XIENCE P ro (OUS only) , and XIENCE P roX (OUS only)39. 
• Stent diameters:  2.5, 2.75, 3.0, 3.25*, 3.5 and 4.0 mm  
• Stent lengths: 8, 12, 15, 18, 23, and 28 mm  
XIENCE Family Stent System will hereinafter be called “XIENCE” in 
this study.  
*The 3.25 mm is only available for XIENCE Xpedition.  
Objectives  • ABSORB IV Primary Objective s:  
o To evaluate 30-day clinical outcomes of the Absorb BVS 
compared to XIENCE in the treatment of subjects with ischemic 
heart disease caused by [CONTACT_592178] a maximum of two epi[INVESTIGATOR_218709] , with a 
maximum of two lesions per epi[INVESTIGATOR_196518].  
o To evaluate long -term clinical outcomes of Absorb BVS 
compared to XIENCE in the treatment of subjects with ischemic 
heart disease caused by [CONTACT_592178] a maximum of two epi[INVESTIGATOR_218709] , with a 
maximum of two  lesions per epi[INVESTIGATOR_196518].  
• ABSORB IV Secondary Objective s: 
                                                           
37 The commercially approved CE marked device will be used in geographies where it is commercially available.  
38 Both the 8 mm and 12 mm length s will be available for the 2.5/3.[ADDRESS_780971] 16, 2018 . • To evaluate 1-year clinical outcomes of the Absorb BVS 
compared to XIENCE in the treatment of subjects with ischemic 
heart disease caused by [CONTACT_592179] a maximum of two epi[INVESTIGATOR_218709], with a 
maximum of two lesions per epi[INVESTIGATOR_592032].  
o To evaluate the incidence of angina occurring within  1 year, 
with treatment of Absorb BVS compared to XIENCE.  
Study Design  ABSORB IV is a prospective, randomized (1:1, Absorb BVS to 
XIENCE), single -blind, multi -center study, registering approximately 
2600  subjects at approximately 140 sites.  
The enrollment of the ~2600  subjects in ABSORB IV will start after 
enrollment completion of the 2000 primary analysis subjects in 
ABSORB III.  
Primary Endpoint  TLF through 30-day, tested for non -inferiority of Absorb BVS to 
XIENCE.  
• This analysis will consist of ~ 2600  subjects in ABSORB IV.  
Powered 
Secondary 
Endpoint s  1. TLF through 1 ye ar, tested for non -inferiority of Absorb BVS to 
XIENCE.  
2. Angina Powered Secondary  Endpoint: The percentage of patients 
who experienced angina within [ADDRESS_780972] for non -inferiority of 
Absorb BVS to XIENCE with reflex testing to superiority.  
• Angina is defined as any angina or angina equivalent symptoms 
determined by [CONTACT_430183]/or research coordinator after 
interview of the patient, and as adjudicated by a clinical events 
committee (CEC).   
• This analysis will exclude angina or angina equivalent 
symptoms that occurred following the index procedure through 
hospi[INVESTIGATOR_53767] [ADDRESS_780973] of ~ 2600  subjects in ABSORB  IV 
Patient Reported 
Outcome (PRO) 
Informational 
Endpoints  Patient -reported outcomes (PRO) are informational endpoints to assess 
Health -Related Quality of Life . PRO assessments will be conducted  at 
baseline, 1  and 6 months , and at  1, 3 and 5 years . The following 
questionnaires  will be used in this study:  
• Seattle Angina Questionnaire -7 (SAQ -7) to assess disease -
specific Quality of Life  
• EuroQoL 5D (EQ -5D) survey to assess overall health status  
(Note: PRO endpoints will be evaluated in the ~2600  subjects of 
ABSORB IV)  
The PROs will be analyzed  to evaluate the relationship between quality 
of life and cardiovascular events that occurred post -PCI and to 
substantiate the clinical impact of the angina events identified in the 
trial. 
Health Economics 
Informational 
Endpoints  The prima ry analysis is to compare the resource utilization and costs 
between the two treatment groups at 1, [ADDRESS_780974] 
Enrollment, 
Randomization 
and Registration  • Subjects are considered enrolled  in ABSORB IV after signing 
the Informed Consent.  
• Subjects are considered randomized  in ABSORB IV after the 
interactive voice response system (IVRS) has been called and a 
device (Absorb BVS or XIENCE) has been assigned.  
• Subjects are considered registered  in the ABSORB IV upon 
randomization.  
• Enrolled subjects not randomized in the trial will be considered 
screen failures and will not be followed.   
Clinical Follow -Up All registered subjects in ABSORB IV will receive the following 
clinical follow -up: 
o 30  [ADDRESS_780975]/office visit  
o 90  [ADDRESS_780976]/office visit  
Abbott Vascular  Version 17.[ADDRESS_780977] 16, 2018 . o 180  [ADDRESS_780978]/office visit  
o 270  [ADDRESS_780979]/office visit  
o 1 year  [ADDRESS_780980]/office visit  
o 2 years  [ADDRESS_780981]/office visit  
o 3 years  [ADDRESS_780982]/office visit  
o 4 years  [ADDRESS_780983]/office visit  
o 5 years  [ADDRESS_780984]/office visit  
Patient Rep orted 
Outcome (PRO) 
Assessments  All registered subjects of ABSORB IV will receive the following PRO 
assessments:  
o Baseline: SAQ -7, EQ-5D 
o 30  7 days: SAQ -7, EQ-5D 
o 180  28 days: SAQ -7, EQ-5D 
o 1 year  28 days: SAQ -7, EQ-5D 
o SAQ -7, EQ -5D will also be administered to all registered 
subjects at 3 and 5 years  (± 28 days)  visits . 
Primary Analysis 
Sample Size 
Justification  The sample size was originally based on a powered landmark analysis. 
The powered landmark analysis has since been removed, howe ver, the 
sample size was sufficient to support the testing of the powered [ADDRESS_780985] evidence of myocardial ischemia (e.g., silent 
ischemia, stable or unstable angina, non -ST-segment elevation 
MI (NSTEMI) , OR recent  ST-segment elevation MI (STEMI). 
Patients with stable coronary syndromes can be enrolled any 
time after symptom onset if eligibility criteria are otherwise 
Abbott Vascular  Version 17.[ADDRESS_780986] 16, 2018 . met. Patients with acute coronary syndrome can be enrolled 
under the following conditions:  
a. Unstable angina or NSTEMI within 2 weeks of the 
index procedure.  
b. STEMI > 72 hours ≤ 2 weeks prior to the index 
procedure.  
Note: Subjects with UA or NSTEMI or STEMI occurring > [ADDRESS_780987] be suitable for PCI.  Subjects with stable angina 
or silent ischemia and < 70% diameter stenosis must have 
objective signs of ischemia as determined by [CONTACT_31806] o f the 
following: abnormal stress echocardiogram, nuclear scan, ECG, 
PET, MRI, and/or fractional flow reserve (FFR).  
(Note: subject with silent ischemia must have a prior history 
of typi[INVESTIGATOR_592033] , angina -equivalent symptoms , or atypi[INVESTIGATOR_592034] p ast year to be included in the trial.)  
5. Subject must be an acceptable candidate for coronary artery 
by[CONTACT_9292] (CABG) surgery.  
6. Female subject of childbearing potential who does not plan 
pregnancy for up to [ADDRESS_780988] 15 mm apart per visual estimation ; 
otherwise this is considered as a single target lesion for lesion (and 
stent ) length determination  and must be treated with a single study 
device . 
1. Target lesion(s) must be located in a native coronary artery with 
a visually estimated or quantitatively assessed %DS of  ≥50% 
and < 100% , with a TIMI flow of ≥ 1 , and one of the following: 
stenosis ≥ 70%, an abnormal functional test (e.g., fractional flow 
reserve ≤0.80 AND/OR a positive stress test), or presentation 
with an acute coronary syndrome (unstable angina or NSTEMI 
within 2 weeks of ind ex procedure, or STEMI >72 hours but ≤ 2 
weeks prior to the index procedure).   
a. Target lesion(s) must be located in a native coronary artery 
with RVD by [CONTACT_592084]   ≥ 2.50 mm and ≤ 3.75 
mm.*  
b. Target lesion(s) must be located in a native coronary artery 
with length by [CONTACT_592084] ≤ 24 mm.  
Note: Subjects with UA or NSTEMI or STEMI occurring > 2 
weeks of the index procedure can be included in the trial but 
should be categorized based on their current angina class.  
*Note: To exclude enrollment of excessively small vessels, if  
the operator believes that  based on visual angiographic 
assessments, the distal reference vessel diameter is ≤ 2.75 mm 
such that the plan is to implant a 2.5 mm device (stent or 
scaffold) in a  target lesion, it is strongly recommended  that 
either on -line QCA or intravascular imaging (ultrasound or 
optical coherence tomography) is used and demonstrates that the 
measured distal RVD for this target lesion is ≥ 2.50 mm (by [CONTACT_592180]). This measurement may 
be performed before or after pre -dilatation, but before 
randomization. If the distal RVD measures <2.[ADDRESS_780989] 16, 2018 . Exclusion Criteria  General Exclusion Criteria  
1. Any surgery requiring general anesthesia or discontinuation of 
aspi[INVESTIGATOR_34251]/or a P2Y12 receptor inhibitor is planned within [ADDRESS_780990] has known hypersensitivity or contraindication t o 
device material and its degradants (everolimus, poly (L -lactide), 
poly (DL -lactide), lactide, lactic acid) and cobalt, chromium, 
nickel, platinum, tungsten, acrylic and fluoro polymers that 
cannot be adequately pre -medicated. Subject has a known 
contrast  sensitivity that cannot be adequately pre -medicated.  
3. Subject has known allergic reaction, hypersensitivity or 
contraindication to any of the following: aspi[INVESTIGATOR_248]; or clopi[INVESTIGATOR_592035]; or heparin and bivalirudin, and 
therefore cannot be adequately treated with study medications.  
4. Subject had an acute STEMI (appropriate clinical syndrome 
with ≥[ADDRESS_780991] -segment elevation in ≥2 contiguous leads) 
within [ADDRESS_780992] one of the following criteria is 
met:[ADDRESS_780993] has a left ventricular ejection fraction (LVEF) < 30% 
assessed by [CONTACT_592086], including but not limited 
to echocardiography, MRI, multiple -gated acquisition (MUGA) 
scan, contrast left ventriculogr aphy, PET scan, etc. LVEF may 
be obtained within [ADDRESS_780994]’s eligibility.   
                                                           
[ADDRESS_780995] 12 months. Prior PCI within the non -target vessel or an y 
peripheral intervention is acceptable if performed anytime >[ADDRESS_780996] requires future staged PCI of any lesion other than a 
target lesion identified at the time of index procedure; or subject 
requires future peripheral vascular interventions < [ADDRESS_780997] is receiving immunosuppressant therapy or has known 
immunosuppressive or severe autoimmune disease that requires 
chronic immunosuppressive therapy (e.g., human 
immunodeficiency virus, systemic lupus erythematosus, etc.). 
Note: corticosteroids are not included as immunosuppressant 
therapy.  
12. Subject has previously received or is scheduled to receive 
radiot herapy to a coronary artery (vascular brachytherapy), or 
the chest/mediastinum.  
13. Subject is receiving or will require chronic anticoagulation 
therapy (e.g., coumadin, dabigatran, api[INVESTIGATOR_3822], rivaroxaban, 
edoxaban or any other related agent for any reason).   
14. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 
cells/mm3.  
15. Subject has a documented or suspected hepatic disorder as 
defined as cirrhosis or Child -Pugh ≥ Class B.  
16. Subject has renal insufficiency as defined as an estimated GFR 
< 30 ml/min/1.[ADDRESS_780998] is high risk of bleeding for any reason; has a history of 
bleeding diathesis or coagulopathy; has had a significant 
                                                           
43 Estimated GFR can be based on Modification of Diet in Renal Disease (MDRD) equation or Cockcroft -Gault 
equation (CCG).   
 
Abbott Vascular  Version 17.[ADDRESS_780999] has ha d a cerebrovascular accident or transient ischemic 
neurological attack (TIA) within the past six months, or any 
prior intracranial bleed, or any permanent neurologic defect, or 
any known intracranial pathology (e.g. aneurysm, arteriovenous 
malformation, et c.). 
19. Subject has extensive peripheral vascular disease that precludes 
safe 6 French sheath insertion. Note: femoral arterial disease 
does not exclude the patient if radial access may be used.  
20. Subject has a life expectancy <[ADDRESS_781000] is part of a vulnerable population who, in the judgment 
of the investigator, is unable to give Informed Consent for 
reasons of incapacity, immatu rity, adverse personal 
circumstances or lack of autonomy.  This may include:  
Individuals with a mental disability, persons in nursing homes, 
children, impoverished persons, persons in emergency 
situations, homeless persons, nomads, refugees, and those 
incapable of giving informed consent. Vulnerable populations 
also may include members of a group with a hierarchical 
structure such as university students, subordinate hospi[INVESTIGATOR_400092], employees of the Sponsor, members of the 
armed forces, a nd persons kept in detention.  
Angiographic Exclusion Criteria  
All exclusion criteria apply to the target lesion(s) or target vessel(s).  
                                                           
[ADDRESS_781001] 16, 2018 . 1. Unsuccessful pre -dilatation, defined as the presence of one or 
more of the following (note: successful pre-dilatation o f at least 
one target lesion is required prior to randomization):  
a. Residual %DS after pre -dilatation is ≥ 40% (per visual 
estimation). Note: achieving a %DS ≤ 20% prior to 
randomization is strongly recommended.  
b. TIMI flow grade <3 (per visual estimation).  
c. Any angiographic complication (e.g. distal embolization, 
side branch closure).  
d. Any dissection NHLBI grade D -F.  
e. Any chest pain lasting > [ADDRESS_781002] -segment depression or elevation lasting > 5 
minutes.  
2. Lesion is located in left main or there is a ≥ 30% diameter 
stenosis in the left main  (unless  the left main lesion is a 
protected left main (i.e. a patent by[CONTACT_592181]/or 
LCX arteries is present), and there is no intention to treat the 
protected left main lesion) . 
3. Aorto -ostial RCA lesion  (within 3 mm of the ostium).  
4. Lesion located within 3 mm of the origin of the LAD or LCX.  
5. Lesion involving a bifurcation with a:  
a. side branch ≥ 2 mm in diameter, or  
b. side branch with either an ostial or non -ostial lesion with 
diameter stenosis >50%, or  
c. side branch requiring dilatation  
6. Anatomy proximal to or within the lesion that may impair 
delivery of the Absorb  BVS or XIENCE stent:  
a. Extreme angulation (≥ 90°) proximal to or within the 
target lesion.  
b. Excessive tortuosity (≥ two 45° angles) proximal to or 
within the target lesion.  
c. Moderate or heavy calcification proximal to or within 
the target lesion. If IVUS used, subject must be excluded 
Abbott Vascular  Version 17.[ADDRESS_781003] 16, 2018 . if calcium arc in the vessel prior to the lesion or within 
the lesion is ≥ 180°.   
7. Lesion or vessel involves a myocardi al bridge.  
8. Vessel has been previously treated with a stent and the target 
lesion is within 5 mm proximal or distal to a previously stented 
lesion.  
9. Target lesion located within an arterial or saphenous vein graft 
or distal to any arterial or saphenous vein graft.  
 
Lesion Selection  Prior to treatment with the assigned device (Absorb BVS or XIENCE), 
vessel sizing by [CONTACT_592089]. Quantitative methods such as 
on-line QCA, IVUS or OCT may be used if the site is experienced with 
these techniques. Specifically, use of pre -PCI and post-PCI IVUS or 
OCT is strongly recommended to optimize device sizing and results . 
Details on the vessel s izing methods can be found in the Imaging 
Guidance Document. Table 1.0 provides the device sizes, the reference 
vessel diameter (RVD) and lesion length for ABSORB IV.  
Table 1.0 Absorb BVS and XIENCE Sizes in ABSORB IV  
Device  Lesion and Device Sizes  
RVD 1 Lesion Length1 
   
Absorb BVS  
(Target lesion)  RVD  2.50 mm -  3.75 mm  
 
Scaffold diameter: 2.5, 3.0 and 
3.5 mm  Lesion length  24 mm  
Scaffold Length2: 8, 12, 18 and 
28 mm 3    
 
XIENCE4  
(Target lesion)  
 RVD  2.50 mm -  3.75 mm  
 
Stent diameter: 2.5, 2.75, 3.0, 
3.25 3.5, 4.0 mm  Lesion length  24 mm  
Stent Length: 8, 12, 15, 18, 23 
and 28 mm 3  
 
1 Reference vessel diameter (RVD) and lesion length are based on visual estimation.  
2 Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 diameter Absorb 
BVS.  Only the 12 mm length will be available for the 3.5 mm diameter. The 
commercially approved CE marked 23mm Absorb BVS device will not be used in 
this study.  
3 For target  lesion, p lanned overlappi[INVESTIGATOR_411418] (i.e. the lesion must be eligible 
for treatment with a single stent) . However, bailout overlappi[INVESTIGATOR_591953].  
4 XIENCE V, XIENCE Prime, XIENCE Xpedition, XIENCE Alpi[INVESTIGATOR_050], XIENCE Pro, 
and XIENCE ProX will be used in this study.  
It is highly recommended that a minimum of 2 mm (by [CONTACT_592182]) of normal or nearly normal reference vessel at both 
proximal and distal edge be covered by [CONTACT_8121].  
Abbott Vascular  Version 17.[ADDRESS_781004] 16, 2018 . Treatment 
Strategy  • Treatment of up to three de novo  lesions in a maximum of two 
epi[INVESTIGATOR_218709], with a maximum of two lesions per 
epi[INVESTIGATOR_196518]45.  
•  If only a single lesion is to be treated, it must be a target lesion , 
treated with  the assigned device  (Absorb or XIENCE) . 
• Non-target lesion treatment can occur only in a non-target 
vessel.  
• The treatment possibilities are:  
o Single target lesions  
o Two or three target lesions  
o One target lesion and one non -target lesion  
o Two target lesions and one non -target lesion  
• All target lesions must meet angiographic inclusion/exclusion 
criteria.  
• The non -targe t lesion must be treated first  with a XIENCE , 
before randomization , per the instructions for use (IFU). A non -
target lesion cannot be considered for a staged procedure.  T he 
patient may then only be randomized if treatment of the non -
target lesion was successful and uncomplicated, defined as : 
 
o  final diameter stenosis ≤ 10% with final TIMI -3 flow,  
o with no residual dissection NHLBI grade ≥ type B, and  
o no transient or sustained angiographic complications 
(e.g., dis tal embolization, side branch closure) ,  
o no chest pain lasting > [ADDRESS_781005] segment elevation or depression lasting > 5 
minutes.  
• If there are two target lesions within the same epi[INVESTIGATOR_196518], 
the two target lesions must be at least 15 mm apart ; otherwise 
this should be considered a single target lesion for lesion (and 
stent) length determination  and must be treated with a single 
study device .  
 
Access Site and Guide Catheter Size:  
• Either femoral or radial access may be used.  
                                                           
[ADDRESS_781006] 16, 2018 . • A minimum 6F guide catheter or greater must be used during 
the index procedure per requirements for Absorb BVS 
implantation (refer to IFU).  
o Minimum guiding catheter compatibility (inner 
diameter) for Absorb BVS is 0.070”/1.8 mm (6F).  
o Devices (i.e., guide sheaths such as the GuideLiner) that 
decrease the inner diameter of the guide catheter outside 
of the Absorb BVS minimum guide catheter 
compatibility must not be used with the Absorb BVS 
System. Do not insert a [ADDRESS_781007] 
meet or exceed the above minimum guiding catheter 
requirements for Absor b BVS (i.e.,  only the 7 -in-8 
GuideLiner provides an adequate inner diameter (0.071” 
ID), 8F guiding catheter would be required).  
o For XIENCE, please follow IFU for guiding catheter 
size. 
Baseline angiogram and identification of the potential target lesion:  
• Assessment of the potential target lesion(s) to be treated must 
be done to ensure angiographic criteria are met; this must occur 
prior to pre -dilatation and vessel sizing. Refer to the Imaging 
Guidance Document.  
• To exclude enrollment of excessively small vessels, if  the 
operator believes that  based on visual angiographic 
assessments, the distal reference vessel diameter is ≤ 2.75 mm 
such that the plan is to implant a 2.5 mm device (stent or 
scaffold) in a target  lesion, it is strongly recommended  that 
either on -line QCA or intravascular imaging (ultrasound or 
optical coherence tomography) is used and demonstrates that 
the measured distal RVD for this target lesion is ≥ 2.50 mm (by 
[CONTACT_592183]). This measurement 
may be performed before or after pre -dilatation, but before 
randomization. If the distal RVD measures <2.5 mm, that lesion 
IS NOT ELIGIBLE for randomization. Such a lesion may be 
treated as  a non -target lesion .  
Pre-dilatation o f potential target lesion(s)  
Abbott Vascular  Version 17.[ADDRESS_781008] 16, 2018 . • Pre-dilatation of at least one of the planned target lesions(s) 
must be performed  and be successful before calling IVRS . 
However, each target lesion must be pre -dilated  before device 
implantation  in that lesion .  
• Pre-dilatation  must be performed with an angioplasty balloon; 
cutting or scoring balloons may be used per physician 
discretion.  
• The pre -dilatation balloon should be sized 1:1 to the visually 
estimated RVD and should be no more than 0.25 mm smaller 
than RVD. If the pre -dilatation balloon is sized 1:[ADDRESS_781009] be equal in length or shorter than 
the planned scaffold/stent length.  
Important: Full balloon expansion with the pre -dilatation balloon 
must be achieved before the patient is randomized into the study. If 
there is any question that the target lesion was not fully dilated or 
that any significant resistance to expansion from the lesion remains, 
the lesion should be re -dilated with a non -compliant  balloon (sized 
1:1 to the RVD) at higher pressure. Absorb BVS or XIENCE must 
not be implanted in a lesion in which full balloon expansion has not 
been achieved.  
• The potential target lesion (s) must continue to meet 
angiographic criteria following adequate pre-dilatation, to be 
regarded as “successful pre -dilatation”.  
o RVD remains ≥ 2.50 mm - ≤ 3.75 mm, and length of the 
lesion that will be covered by [CONTACT_8121] (including any 
edge dissections) is still ≤ 24 mm.  
o Residual %DS is a maximum of < 40% (per visual 
estimation ); ≤ 20% is strongly recommended.  
o TIMI Grade  3 flow (per visual estimation).  
o No angiographic complications (e.g. distal embolization, 
side branch closure).  
o No dissections NHLBI grade D -F.  
o No chest pain lasting > [ADDRESS_781010] -segment depr ession or elevation lasting > [ADDRESS_781011] 16, 2018 . • For two or three potential target lesions, the lesion with the 
highest possibility of failing eligibility criteria after pre -
dilatation (per investigator’s assessment) should be identified as 
the 1st target lesion and pre -dilated first before randomization.  
o If the 1st target lesion was successfully pre -dilated and 
eligibility criteria are still met, the operator may at this 
point choose to randomize the patient, or pre -dilate other 
lesions. If other lesions are pre -dilated, all such pre -
dilatations must be considered successful according to 
the above criteria prior to randomization. If there are 
two target lesions in a single epi[INVESTIGATOR_131270], 
it is strongly recommended that both be successf ul pre -
dilated before the patient is randomized. The IVRS is 
called to randomize the subject. All target lesions must 
be treated with the assigned device.  
o If the 1st target lesion was successfully pre -dilated but 
did not meet vessel sizing criteria, treat  as a non -target 
lesion. Once the first lesion is successfully treated as a 
non-target lesion, the second lesion  or third lesion  must 
meet successful predilatation and vessel sizing criteria. 
Afterwards IVRS must be called and the target lesion(s) 
will be treated per assignment.  
o If pre -dilatation of the 1st target lesion fails (or if pre -
dilatation of any lesion fails if multiple lesions are pre -
dilated prior to randomization), the patient may not be 
randomized, and the interactive voice response system 
(IVRS) must not be called.  The lesion will be treated 
with XIENCE or standard of care.  
o If the 1st target lesion was successfully pre -dilated but no 
longer met eligibility criteria (or if any lesion after pre -
dilatation no longer met eligibility criteria if multiple 
lesions are pre -dilated prior to randomization), the 
patient may not be randomized, and  the interactive voice 
response system (IVRS) must not be called.  
o If after successful pre -dilatation, randomization and 
treatment of the 1st target lesion  with the assigned 
device , and pre-dilatation of the 2nd or 3rd target lesion 
failed, the patient is t o be treated with XIENCE. For any 
lesion in which pre -dilatation did not meet the success  
definition , the default device is XIENCE.  
• Each target vessel and lesion should  also be such that the 
operator believes either the Absorb BVS or XIENCE devices 
could be delivered to and cross the target lesion after pre -
Abbott Vascular  Version 17.[ADDRESS_781012] 16, 2018 . dilatation  (e.g. absence  of excessive vessel or lesion tortuosity 
or calcification).  
Vessel Sizing  
• Following the us e of nitroglycerine (at least 100 µg 
intracoronary nitroglycerine, >150 µg preferred)46 and 
successful pre -dilatation of the potential target lesion(s), vessel 
sizing must be conducted by [CONTACT_142184]. If nitroglycerine 
is not available, intravenous ni troprusside or intravenous 
calcium channel blocker may  be used per physician discretion . 
• Quantitative methods such as on -line QCA, IVUS or OCT may 
be used if the site is experienced with these techniques , taking 
into account that QCA tends to under -estimate RVD compared 
to visual estimation and OCT, whereas IVUS tends to over -
estimate lumen RVD compared to visual estimation and OCT. 
Specifically, use of pre -PCI and post -PCI IVUS or OCT is 
strongly recommen ded to optimize device  sizing and results. 
Follow core laboratory guidelines for the use of each modality.  
• Prior to randomization, IVUS or OCT can be used to evaluate 
the vessel if there is question regarding the eligibility of the 
vessel either before or after pre -dilatation. Specifically,  to 
exclude enrollment of excessively small vessels, if  the operator 
believes that  based on visual angiographic assessments, the 
distal reference vessel diameter is ≤ 2.75 mm such that the plan 
is to implant a 2.5 mm device (stent or scaffold) in a target 
lesion, it is strongly recommended that either on -line QCA or 
intravas cular imaging (ultrasound or optical coherence 
tomography) is used and demonstrates that the measured distal 
RVD for this target lesion is ≥ 2.50 mm (by [CONTACT_592184]). This measurement may be performed 
before or after pre -dilata tion, but before randomization. If the 
distal RVD measures <2.[ADDRESS_781013] not be randomized in ABSORB IV if : 
o Vessel size or lesion length before or  after pre -dilatation 
does not satisfy eligibility criteria.  
o Moderate or heavy calcification, tortuosity or other 
conditions are present proximal or within the target 
                                                           
46 If the patient’s blood pressure is so low that ≥ 100 ug of nitroglycerine cannot be administered, the patient should 
not be randomized. It is suggested that ≥200 µg of nitroglycerine be administered if the systolic blood pressure is 
>[ADDRESS_781014] 16, 2018 . segment, reducing the likelihood that the Absorb BVS or 
XIENCE can be either delivered to  or expanded at the 
lesion.  
o Complications and/or adverse events were identified 
during IVUS or OCT usage (e.g. vessel dissection 
NHLBI grade D -F).47   
• Table 2.0 provides the guidance of vessel and device sizing 
during the procedure, which are detailed as the following:  
o First, assess RVD based on visual estimation  
o Then, select a pre -dilatation balloon sized 1:[ADDRESS_781015] always be performed with a non-
compliant balloon , sized 1:[ADDRESS_781016]: side -branch occlusion, persistent S -T abnormalities, 
prolonged  chest pain , flow limiting dissections  etc. 
Abbott Vascular  Version 17.[ADDRESS_781017] RVD 
after Pre -
dilatation  Absorb BVS 
Diameter  
2.5 mm  2.25 or 2.5 mm  2.5 mm  2.5 mm  
2.75 mm  2.5 – 2.75 mm  2.75 mm  3.0 mm  
3.0 mm  2.75 – 3.0 mm  3.0 mm  3.0 mm  
3.25 mm  3.0 – 3.25 mm  3.25 mm  3.5 mm  
3.5 mm  3.25 – 3.5 mm  3.5 mm  3.5 mm  
3.75 mm  3.5 – 3.75 mm  3.75 mm  3.5 mm  
 
Randomization  
• Upon completion of successful pre -dilatation and vessel sizing 
of the first target lesion (or of multiple target lesions, at operator 
discretion as described above), the interactive voice response 
system (IVRS) can be called.  
• A subject is considered regist ered and in the ITT population at 
the time of randomization.  
Lesion Treatment  
• It is highly recommended that t he length of the Absorb BVS 
and XIENCE stent be selected to allow at least 2 mm of normal 
or nearly normal reference vessel at each edge.  
• If the A bsorb BVS cannot reach or cross the lesion or additional 
lesion preparation is required, the Absorb BVS must be 
removed and a new Absorb BVS must be introduced  after 
subsequent pre -dilatation(s) with the same sized or larger non -
compliant balloon at higher pressure. Note: the Absorb BVS 
should not be “Dottered” across the lesion if it does not cross 
easily.  
• If the Absorb BVS is unable to reach or cross the targe t lesion 
after multiple attempts (maximum of two Absorb BVS; 
including additional lesion preparation), a XIENCE stent must 
be used.  
• If XIENCE is unable to reach or cross the target lesion after 
multiple attempts (including additional lesion preparation) , the 
investigator should treat the lesion per standard of care . 
• In the case of two or three target lesions assigned to the Absorb 
BVS, if any of the target lesions is unsuccessfully treated with 
Absorb BVS, XIENCE must be used  for that lesion . If the target  
lesion that failed treatment of Absorb BVS is treated 
Abbott Vascular  Version 17.[ADDRESS_781018] 16, 2018 . successfully with XIENCE, the remaining target lesion(s) must  
be treated with Absorb BVS.  
• In the case of two or three target lesions assigned to XIENCE,  if 
any of the target lesions is unsucc essfully treated with XIENCE , 
the investigator should treat the lesion per standard of care. If 
the target lesion that failed treatment with XIENCE i s treated 
successfully with standard of care , the remaining target lesion(s) 
must  be treated  with XIENCE . 
• For patients in whom [ADDRESS_781019] intervention (depending on the 
complexity, contrast and radiation use of the first procedure). If 
a staged procedure becomes necessary, it is strongly 
recommended that the staged procedure occurs within [ADDRESS_781020] be used for 
staged procedures. To avoid having to cross a previously 
implanted study device, it is strongly recommend ed that the 
staged lesion (s) be located in a separate epi[INVESTIGATOR_592036] (s) previously treated  during the fi rst intervention . 
• Successful lesion treatment is defined as final diameter stenosis 
≤ 30% with final TIMI -3 flow, with no residual dissection 
NHLBI grade ≥ type B, and no transient or sustained 
angiographic complications (e.g. distal embolization, side 
branch closure) , no chest pain lasting > [ADDRESS_781021] 
segment elevation or depression lasting > 5 minutes.   
• For Absorb BVS, the scaffold should be deployed slowly, by 
[CONTACT_592096] 2 atm increments each over 
5 seconds, until the scaffold is completely expanded. Pressure 
should be maintained for 30 seconds if tolerated by [CONTACT_102].  
• For the Absorb BVS and XIENCE delivery balloon, do not 
exceed the rated burst pressure (RBP) per the IFU for the 
individual device.  
• Post-dilatati on of target lesion treated with XIENCE should be 
per standard of care.  
• Post-dilatation of the scaffold is strongly recommended  for all 
Absorb treated lesions , especially  for any implanted 2.[ADDRESS_781022] 16, 2018 . treated with Absorb BVS is performed the following guidance 
is given:  
o If a stent or scaffold cannot be re -crossed easily, 
excessive force with the balloon dilatation catheter or 
imaging catheter should be avoided. If it is necessary to 
re-cross the device,  options to consider include changing 
the guide catheter orientation to reduce wire bias; 
consider use of a different wire or a wiggle wire or a 
buddy wire; attempt to cross the device with a balloon at 
0 atm (rather than negative pressure); or inflate and  
deflate the balloon to wing it to help centralize the tip.  
o A low profile, high pressure, non -compliant, balloon 
dilatation catheter that has not been previously inflated 
must be used.  
o Post-dilatation must always be performed with a non -
compliant balloon, sized 1:[ADDRESS_781023] 16, 2018 . • During randomization, if a bailout device is required for a target 
lesion (e.g., for edge dissection), the same device as the 
implanted device must be used.  
o Absorb BVS if target lesion is treated with Absorb BVS.  
o XIENCE if target lesion is treated with XIENCE.  
o If a bailout with an Absorb BVS device cannot be 
delivered to the site of the lesion, the device should be 
carefully withdrawn and a XIENCE used.  
o If an appropriate size Absorb BVS is not available 
XIENCE can be used.  
• Overlap of the bailout stent/scaffold wi th the implanted 
stent/scaffold should be 1 -2 mm; gaps should be avoided.  
• IVUS or OCT guidance may be used as per standard of care in 
all patients.  
• Please refer to the physician training deck for user guidance in 
handling procedural issues (e.g., difficulty in re -crossing an 
implanted scaffold for purposes such as intravascular imaging 
or post -dilatation if needed).  
• Unplanned Lesions  
o In cases where treatment of a target lesion reveals 
unexpected additional lesion(s), the investigator may 
treat the lesion(s). This is considered an unplanned 
lesion.  
o If the lesion meets enrollment criteria both before and 
after pre -dilatation, the lesion must be treated with the 
assigned device. This lesion will be considered to be an 
unplanned target lesion.  
o If the le sion does not meet the enrollment criteria (either 
before or after pre -dilatation), the lesion must be treated 
with XIENCE. This lesion will be considered to be an 
unplanned non -target lesion.  
o Planned treatment of more than two lesions per 
epi[INVESTIGATOR_592037] l or planned treatment of more than three 
lesions per subject is not  allowed . 
Abbott Vascular  Version 17.[ADDRESS_781024] 16, 2018 . Antiplatelet48 
Therapy  Antiplatelet Medication Loading Dose:  
• Aspi[INVESTIGATOR_248]: Subjects must receive a loading dose of ≥ [ADDRESS_781025] been 
prescribed daily aspi[INVESTIGATOR_354374] , no aspi[INVESTIGATOR_592038].  
• P2Y12 receptor inhibitors: either clop idogrel, prasugrel or 
ticagrelor may be used as per standard of care and per label 
indications.  
o Clopi[INVESTIGATOR_7745]: a peri -procedural loading dose 600 mg is 
required  
o Prasugrel: a peri -procedural loading dose of 60 mg is 
required  
o Ticagrelor: a peri -procedural loa ding dose of 180 mg is 
required.  
• For patients with stable coronary symptoms, silent ischemia, or 
acute coronary syndromes in whom all measured troponin and CK -
MB values were within normal limits, pre -loading with clopi[INVESTIGATOR_592039] [ADDRESS_781026] receives less 
than the required amount of the loading dose for a P2Y12 receptor 
inhibitor, the investigator is to give the remaining amount of the 
same agent in the next 24 hours and within the protocol required 
timeframe.  
Note:  The biomarker measurements in patients with stable coronary 
symptoms and silent ischemia may be pending at the time of the 
procedure, or may be drawn from the arterial sheath prior to first 
balloon inflation; such patients may still be randomized, and a 
P2Y12 receptor inhibitor must be administered no later than [ADDRESS_781027] be g iven a) a loading dose of  
                                                           
[ADDRESS_781028] 16, 2018 . clopi[INVESTIGATOR_592040] 3 and 24 hours prior to the index procedure  or 
prasugrel or ticagrelor between 1 -24 hours prior to the index 
procedure OR b) an intravenous GP IIb/IIIa inhibitor or cangrelor 
(see below ) prior to and /or during  PCI but prior to first balloon 
inflation, per institution standard of care .. If an intravenous GP 
IIb/IIIa inhibitor is given, a P2Y12 receptor inhibitor must be given 
within [ADDRESS_781029] administration of the 
P2Y12  receptor  inhibitor should be as follows: clopi[INVESTIGATOR_592041]; ticagrelor may be administered before, during , 
or immediately upon discontinuation of  the cangrelor infusion. 
Ticagrelor is the preferred P2Y12  receptor  inhibitor in cangrelor -
treated patients. Cangrelor should be maintained [ADDRESS_781030] label ing. Note: If the subject 
receives less than th e required amount of the loading dose for a 
P2Y12 receptor inhibitor, the investigator is to give the remaining 
amount of the same agent in the next 24 hours and within the 
protocol required timeframe.   
• The protocol required loading dose may be omitted  in a) s table 
CAD or  ACS patients maintained on chronic P2Y12 receptor 
inhibitor for ≥ 7 days, and b) patients who received a P2Y12 
receptor inhibitor loading dose [ADDRESS_781031] be reloaded  with a P2Y12 receptor 
inhibitor i f they did not already receive  a loading dose of 
clopi[INVESTIGATOR_7745], prasugrel, or t icagrelor in the 24 hours prior to the 
procedure  
• Ticlopi[INVESTIGATOR_591956] a substitute at a dose in accorda nce with 
standard hospi[INVESTIGATOR_592042], prasugrel, or 
ticagrelor during the trial.  
• Refer to respective prescribing information for P2Y12 receptor 
inhibitor for further details regarding loading practice.  
• Cangrelor  may be used pre-PCI at operator discretion as per local 
practice  in any patient (but should be used similarly in patients 
randomized to ABSORB and XIENCE) : a pre -PCI loading dose of 
30 μg/kg IV followed by [CONTACT_592185] 4 μg/kg for at least [ADDRESS_781032] -Procedure Daily Dose:  
• All subjects must be maintained at a minimum of 75 mg of 
clopi[INVESTIGATOR_196511] 5 or 10  mg of pr asugrel daily ([ADDRESS_781033] patients*) or 90 mg twice daily of ticagrelor for a minimum 
of 12 months following the procedure.  
• All subjects must receive ≥75 to ≤100 mg of aspi[INVESTIGATOR_196514]  5 
years follow -up during the study and should continu e to take aspi[INVESTIGATOR_591958].  
*For prasugrel subjects < 60 kg in weight or ≥ [ADDRESS_781034] be 
repeated for the staged procedure  in the same manner as done for 
the original index procedure . 
Cardiac 
Biomarker 
Collection  Between Baseline and Discharge  
• All patients admitted with the diagnosis of possibl e acute coronary 
syndrome (including unstable angina, NSTEMI or STEMI) must 
have at least one and preferably 2 or more complete sets of cardiac 
biomarkers (a set consisting of troponin (I or T), CK and CK -MB)  
measured within [ADDRESS_781035] in determination of peri -procedural MI , all patients 
with an acute coronary syndrome (including unstable angina, 
Abbott Vascular  Version 17.[ADDRESS_781036] 16, 2018 . NSTEMI or STEMI) must  have troponin and CK and CK -MB 
drawn from the arterial sheath prior to first balloon inflation.  
o First post -procedure CK and CK -MB draw at [ADDRESS_781037] -procedure.*  
o If either of the post -procedure CK-MB levels are ≥ 5x ULN, 
serial CK and CK -MB levels must be drawn until they are 
falling.  
o A [ADDRESS_781038] procedure  
* For patients  discharge d prior to [ADDRESS_781039] to 
return to the en rolling institution for their second biomarker draw (or a 
visiting nurse may be sent to the patient’s home to collect the blood 
sample).  
CK and CK -MB levels are required at each  time point. Troponins are 
required pre -procedure and from the arterial sheath  prior to first balloon 
inflation during the procedure in patients with acute coronary 
syndromes. All troponin, CK and CK -MB levels collected at any time 
points pre -procedure, during the procedure and post -procedure, should 
be documented in the electronic case report forms.   
For subjects having staged procedures, the protocol required pre -
procedure and post -procedure cardiac en zyme and [ADDRESS_781040] be repeated for the staged procedure  in the same 
manner as done for the original index procedure . 
Primary 
Analytical 
Population  The primary analysis population will be the ITT population.  
 
Note: Protocol 10 -392 Part 1 (ABSORB III) compliance statement also applies to Part 2 
(ABSORB IV).   
Abbott Vascular  Version 17.[ADDRESS_781041] 16, 2018 . 1. INTRODUCTION  
The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the 
safety and effectiveness as well as the potential short and long -term benefits of Abbott Vascular 
Absorb™ Bioresorbable Vascular Scaffold (BVS) System49 , and the Absorb GT1™ BVS 
System, as compared to the commercially approved, control stent XIENCE. In the subsequent 
sections of this protocol , the term “Absorb BVS” will be used to re present both Absorb™ BVS  
and Absorb GT1™ BVS.  
ABSORB IV is a prospective, randomized (1:1 Absorb BVS to XIENCE), single -blind, multi -
center trial, registering approximately 2600  subjects from approximately 140 sites50 in the United 
States and outside the Un ited States. The primary objective of ABSORB IV  is to evaluate  30-day 
and long -term clinical outcomes of the Absorb BVS compared to XIENCE in the treatment of 
subjects with ischemic heart disease caused by [CONTACT_592186] a maximum of two epi[INVESTIGATOR_592043], with a maximum of two lesions per epi[INVESTIGATOR_196518].  
The primary endpoint data of TLF through 30-day, tested for non -inferiority of Absorb BVS to 
XIENCE, will be tested on the ~2600 ABSORB IV subjects. The secondary objective s of 
ABSORB IV will be to evaluate  TLF at 1 -year and  the incidence of angina occurring within 1 
year, with treatment of Absorb BVS compared to XIENCE.   The ABSORB IV protocol trial will 
compare patient reported outc omes, resource utilizations and costs  between the Absorb BVS and 
XIENCE arms. These analyses will be based on all ~[ADDRESS_781042] -procedural 
period, and at 14 months  and 62 months . However, this sub -study had to be s topped due to very 
slow enrollment (see Section 12  for more details).  
The enrollment/registration of ~2600  subjects in ABSORB IV will start after the completion of 
the enrollment/registration of 2000 primary analysis subjects in ABSORB III. All subjects in  
ABSORB IV  will receive  treatment of up to three de novo  native coronary artery lesions  in a 
maximum of two epi[INVESTIGATOR_592044], with a maximum two lesions in the same epi[INVESTIGATOR_592045] ≥ 2.5 mm to ≤ 3.75 mm and lesion lengths ≤ [ADDRESS_781043] clinical follow -
up at 30, 90, 180, 270 days and 1, 2, 3, 4, and 5 years . In addition, all ~2600  subjects in 
ABSORB IV will complete patient -reported outcome self -administered questionnaires at 
baseline, 30, 180 days,  and at 1 year.  Additional PRO assessments may be conducted at 1, 3 and 
5 years.  
                                                           
49 The A bsorb ™ Bioresorbable Vascular Scaffold (BVS) System is the trade name [CONTACT_592227]. During the 
course of dev elopment, multiple product names were used to describe this product including, Bioresorbable 
Vascular Scaffold (BVS) System, Bioabsorbable Vascular Stent, BVS Everolimus Eluting Coronary Stent System 
(EECSS), Abbott Vascular Bioabsorbable Device (AVBD) EEC SS, BVS Cohort A (used in the ABSORB Cohort A 
trial) and BVS Cohort B (used in the ABSORB Cohort B trial).  
[ADDRESS_781044] 16, 2018 . 2. BACKGROUND INFORMATION  
2.1.1  Name [CONTACT_592230]51 and the Absorb 
GT1™ BVS System once it is commercially available . In this protocol, the investigational 
scaffold or test device is referred to as “the Absorb BVS”. The Absorb BVS System is 
manufactured by [CONTACT_592098], Inc., [LOCATION_004], an affiliate of Abbott 
Vascular, Inc.  
2.1.2  Intended Indication  
The Absorb Bioresorbable V ascular Scaffold (BVS) is a temporary scaffold that will fully resorb 
over time and is indicated for improving coronary luminal diameter in patients, including those 
with diabetes mellitus and acute coronary syndromes, with ischemic heart disease due to de  novo 
native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm 
and ≤ 3.75 mm.  
2.1.3  Background Information  
Please refer to section 2.1.3 to 2.1.8  of ABSORB III Protocol (Version 17.0, August 1 6, 2018 ) 
for the detailed  background information of the investigational device Absorb BVS, the control 
device XIENCE V, as well as the summary of pre -clinical and clinical studies.   
2.1.4 Absorb GT1  
 
Once A bsorb  GT1™ BVS System is commercially available, it can also be used in the ABSORB 
IV trial. The Absorb GT1 BVS System is composed of the following components:  
• A bioresorbable poly(L -lactide) (PLLA) scaffold backbone  
• A coating comprised of the active pharmaceut ical ingredient everolimus and 
bioresorbable poly(D,L -lactide) (PDLLA)  
• Four platinum marker beads, two each embedded at the proximal and distal ends of the 
scaffold for radiopacity  
• An optimized delivery system (ODS) that leverages technology advancements o f the 
XIENCE family of products, and incorporates design features from the Absorb BVS, 
XIENC E Xpedition®, and XIENCE Alpi[INVESTIGATOR_592046]1 sizes are detailed in the table below.  
 
                                                           
[ADDRESS_781045] 16, 2018 . Table 2.1: Absorb GT1 BVS System Size Matrix  
 
Scaffold 
Design Product 
Diameter 
(mm)  Product Length (mm)  
8 12 18 23* 28 
Small  2.5 X X X X X 
3.0 X X X X X 
Medium  3.5 N/A X X X X 
* The commercially approved 23mm Absorb BVS GT1 device will not be used in ABSORB IV.  
 
2.2 Trial Rationale  
The Absorb BVS has been evaluated and continues to be evaluated in the ABSORB Family of 
Trials which includes ABSORB Cohort A and Cohort B, ABSORB EXTEND, ABSORB II and 
the ABSORB III Pi[INVESTIGATOR_592047]. Retrospective comparison of Absorb BVS to XIENCE has 
demonstrated compara ble TLF rates through 2 and 3 years (EXTEND 2 -year TLF52: 6.2% vs. 
8.2%; Cohort B 3 -year TLF53: 9.9% vs. 11.4%).  The potential long -term clinical benefit of 
Absorb BVS compared to metallic drug eluting stents has not been prospectively evaluated in 
randomiz ed subject population.  
Recurring angina has been associated with lifestyle limitations and worse self -reported quality of 
life, making the relief of symptoms one of the primary reasons for performing PCI54. However, 
despi[INVESTIGATOR_592048], po st-PCI angina recurrence is a clinically relevant burden 
that impacts patient’s quality of life. Recent retrospective descriptive comparison of Absorb BVS 
to XIENCE has shown preliminary evidence that Absorb BVS may be associated with lower rate 
of angina compared to XIENCE at 1 year (16% vs. 27.9%)55.  As Absorb BVS is a novel 
technology it will be important to evaluate the potential to reduce the recurrence of angina post 
PCI compared to existing DES technologies. The ABSORB IV trial will further evaluate the 
differences between Absorb BVS and XIENCE in the percentage of patients with angina after 
the stenting procedure, as determined by [CONTACT_67353]/or research coordinator after interview of  
the patient, and as adjudicated by a cli nical events committee (CEC).  
3. TRIAL OBJECTIVE  
ABSORB IV Primary Objective:  
                                                           
52 Whitbourn RJ. ABSORB EXTEND: An interim report on the [ADDRESS_781046] report of the three year clinical and multi -modality imaging results 
of the ABSORB trial evaluating the Absorb everolimus eluting bioresorbable vascular scaffold in the treatment of 
patients with De Novo native coronary artery lesions. ACC 2013.  
54 Holubkov R, Laskey WK, Haviland A, et al. Angina 1 year after percutaneous coronary intervention: a report 
from the NHLBI Dynamic Registry. Am Heart J. Nov 2002;144(5):826 -833 
55 Stone GW. Demonstration of Clinical Superiority with a Bioresorbable Vascular Scaffold: The ABSORB IV 
Clinical Trial . http://www.tctmd.com/show.aspx?id=[ADDRESS_781047] 16, 2018 . • To evaluate 30-day clinical outcomes of the Absorb BVS compared to XIENCE in the 
treatment of subjects with ischemic heart disease caused by [CONTACT_592187] a max imum of two epi[INVESTIGATOR_218709] , with a maximum of two  
lesions per epi[INVESTIGATOR_371542]  
• To evaluate long -term clinical outcomes of the Absorb BVS compared to XIENCE in the 
treatment of subjects with ischemic heart disease caused by [CONTACT_592187] a maximum of two epi[INVESTIGATOR_218709] , with a maximum of two 
lesions per epi[INVESTIGATOR_196518].  
ABSORB IV Secondary Objectives:  
• To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the 
treatment of sub jects with ischemic heart disease caused by [CONTACT_592187] a maximum of two epi[INVESTIGATOR_218709] , with a maximum of two  
lesions per epi[INVESTIGATOR_371542]  
• To evaluate the incidence of angina occurring within 1 year with treatment of Absorb BVS 
compared to XIENCE.  
4. CLINICAL TRIAL/INVESTIGATION FLOW AND 
FOLLOW -UP SCHEDULE  
4.1 Number of Subjects to be Registered  
Approximately 2600  subjects will be registered in ABSORB IV from approximately  140 sites in 
the [LOCATION_002] and outside the [LOCATION_002]. The enrollment/registration of ABSORB IV will 
start after the completion of enrollment/registration of the [ADDRESS_781048] not participated in previous ABSORB trials or are not commercial users 
of the Absorb BVS device will participate in the ABSORB  IV physician training program. 
Please refer to section 4.2  of ABSORB III Protocol (Version 17.0, August 09,  2018 ) for the 
detailed information on the didactic training.  
4.[ADDRESS_781049] 15 mm apart. 
One p lanned non-target lesion  is allowed in ABSORB IV  treated with a XIENCE per the IFU . 
However, in situations where treatment of a target lesion reveals additional lesion(s), the 
investigator may treat the lesion(s). This is considered an unplanned lesion. If the lesion meets 
enrollment criteria  both before and after pre -dilatation, the les ion must  be treated with the 
assigned device  and will be considered to be an unplanned target lesion.  If the lesion does not 
Abbott Vascular  Version 17.[ADDRESS_781050] 16, 2018 . meet the enrollment criteria  (either before or after pre -dilatation), the lesion must  be treated with 
XIENCE. This lesion will be c onsidered as an unplanned non -target lesion.  
Figure 4.[ADDRESS_781051]: Absorb or
Control: XIENCEOne Target 
Lesion in 
One Target 
VesselOne Non-
Target Lesion 
in One Non-
Target Vessel
Test: Absorb or
Control: XIENCEXIENCEOne Non-Target 
Lesion in One Vessel 
and Two Target 
Lesions in Another 
Vessel.Two Target Lesions 
in One Vessel and 
One Target Lesion in 
Another Vessel
Test: Absorb or
Control: XIENCETest: Absorb or
Control: XIENCE
Non-Target Lesion: 
XIENCETest: Absorb or
Control: XIENCE
 
Note: For subjects with two or three target lesions  in a maximum of two epi[INVESTIGATOR_218709] , a maximum of two 
target lesion s can be located within one epi[INVESTIGATOR_196518].  
Figure 4.1  Lesion Treatment  
 
Every attempt should be made that the two or three target lesion treatments occur at the same 
index procedure. However, if a staged procedure becomes necessary (e.g. due to  high use of 
contrast or radiation after treatment of the first lesion), it is strongly recommended that the staged 
procedure occurs within 2 weeks of the index procedure using the assigned device, but in all 
cases no more than 35  days from the index proce dure.   To avoid having to cross a previously 
implanted study device, it is strongly recommended that the staged lesion(s) be located in a 
separate epi[INVESTIGATOR_592049](s) previously treated during the first intervention . A 
maximum of one staged procedure is allowed.  Staged procedures must only include target 
lesions identified at the time of the index procedure.  
Prior to treatment with the assigned device (Absorb BVS or XIENCE), vessel sizing by [CONTACT_592188]. 
Quantitative methods such as on -line QCA, IVUS or OCT may be used if the site is experienced 
with these techniques. Specifically, use of pre -PCI and post -PCI IVUS or OCT is strongly 
Abbott Vascular  Version 17.[ADDRESS_781052] 16, 2018 . recommended to optimize device sizing results . Details on the vessel sizing methods can be 
found in Imaging Guidance Document .  
To exclude enrollment of excessively small vessels, if  the operator believes that  based on visual 
angiographic assessments, the distal reference vessel diameter is ≤ 2.75 mm such that the plan is 
to implant a 2.5 mm device (stent or scaffold) in a target lesion, it is strongly recommended  that 
either on -line QCA or intravascular imaging (ultrasound or optical coherence tomography) is 
used and demonstrates that the measured distal RVD for this target lesion is ≥ 2.50 mm (by [CONTACT_592189]). This measurement may be performed before or after pre -
dilatation, but before randomization. If the distal RVD measures <2.5 mm, that lesion IS NOT 
ELIGIBLE for randomization. Such a lesion may be treated as  a non -target lesion .  Table 4.1  
provides the device sizes, RVD a nd lesion length for ABSORB IV.  
Table 4.1   Absorb BVS and XIENCE Sizes  
Device  Lesion and Device Sizes  
RVD 1 Lesion Length1 
Absorb BVS  
(Target lesion)  RVD  2.50 mm -  3.75 mm  
Scaffold diameter: 2.5, 3.0 and 3.5 mm  Lesion length  24 mm  
Scaffold Length2: 8, 12, 18 and 28 mm 3    
XIENCE4  
(Target lesion)  
 RVD  2.50 mm -  3.75 mm  
Stent diameter: 2.5, 2.75, 3.0, 3.25 3.5, 
4.0 mm  Lesion length  24 mm  
Stent Length: 8, 12, 15, 18, 23 and 28 mm 3  
 
1 Reference vessel diameter (RVD) and lesion length based on visual estimation  
2 Both the 8 mm and 12 mm length s will be available for the 2.5/3.0 diameter Absorb BVS.  Only the 12 mm length 
will be available for the 3.5 mm diameter.   
3 For target lesion, p lanned overlappi[INVESTIGATOR_411418] (i.e., the lesion must be eligible for treatment with a single 
stent) . However , bailout overlappi[INVESTIGATOR_591953].  
4 XIENCE V, XIENCE Prime, XIENCE Xpedition, XIENCE Alpi[INVESTIGATOR_050], XIENCE Pro, and XIENCE ProX will be used 
in this study.  
The commercially approved CE marked 23mm Absorb BVS device  will not be used in this 
study.  
It is highly recommended a minimum of 2 mm (by [CONTACT_142184]) of minimally diseased 
tissue be covered by [CONTACT_592119].  
Planned overlap of the target lesion is not allowed. Overlap in the case of bailout is allowed. 
Please refer to Section 7.3.5  for details regarding bailout.  
4.4 Measures Taken to Avoid and Minimize Bias  
In ABSORB IV there will be several measures taken to avoid and minimize bias such as 
randomization and blinding. This process is detailed in the foll owing sections.  
4.4.1 Randomization  
Stratified Randomization:  
Approximately 2600  subjects will be randomized 1:1 in the ABSORB IV trial  (test device: 
Absorb BVS vs. control device: XIENCE). Randomization will be stratified by [CONTACT_192068] 
(diabetic vs. non -diabetic) and ABSORB III -like or not. ABSORB III-like will be determined by 
[CONTACT_592190] 17.[ADDRESS_781053] 16, 2018 . the absence of planned staged procedure, number of ta rget lesions ≤ 2, and no biomarker positive 
ACS or STEMI. Subjects will also be stratified by [CONTACT_592191] -specified expected high -enrolling 
sites. Other sites will be combined to ensure a sufficient number of subjects for the attainment of 
the desired rand omization ratio. A centralized randomization service, IVRS, will be used.  
Timing of Randomization:  
Randomization will be done after successful and uncomplicated pre -dilatation of at least one  
target lesion and vessel sizing (refer to Protocol Summary , Tre atment Strategy , for details).  If 
there is a non -target lesion, it must be successfully treated prior to randomization.  If there are 
two or three target lesions, after the first target lesion was successfully pre -dilated and vessel 
sizing criteria still met, the operator may at this point choose to randomize the patient, or pre -
dilate other lesions. If other lesions are pr e-dilated, all such pre -dilatations must be considered 
successful according to the above criteria prior to randomization. If there are two target lesions in 
a single epi[INVESTIGATOR_131270], it is strongly recommended that both be successfully pre -
dilated before the patient is randomized.  
Once randomization is completed and a treatment is assigned, the assigned device must be used 
for all lesions. An Absorb BVS scaffold may never  be used in a patient randomized to XIENCE. 
However, if the patient is rand omized to Absorb BVS and the scaffold cannot be delivered or a 
complication otherwise develops that requires treatment with a drug-eluting  stent, a XIENCE 
stent must be used. If the XIENCE stent is unable to successfully treat the patient, any 
commercially  available  device approved for use in that geography may be used  as necessary in 
the best interests of the patient. Regardless of the actual device the subject received, the subject 
will be included in ITT population per the original randomization assignme nt. 
The subject is considered to be successfully registered in this study and considered in the ITT 
population at the point of randomization (refer to Section 6.4).  Refer to Appendix IV (Figure 1 
and 2 ) for enrollment and registration timeline and flow ch art. 
4.4.[ADDRESS_781054] blinding should be maintained until the 5-year follow -up visit  for all registered 
subjects is completed.  
The physic ian performing the procedure will not be blinded to the assigned treatment. Thus, if 
clinical follow -up with a study physician is deemed necessary at the protocol required follow -up 
time points, a different physician (or designee) than the one who implante d the device(s) must  
conduct the follow -up clinical visits in order to maintain subject blinding. Similarly, follow -up 
visits with research personnel must be conducted by [CONTACT_592192][INVESTIGATOR_059]. Sit e personnel will be adequately trained such that 
the physician (or designee) conducting the clinical follow -up is adequately blinded to the 
treatment received by [CONTACT_423]. For unscheduled visits, subjects may see the physician who 
Abbott Vascular  Version 17.[ADDRESS_781055] 16, 2018 . implanted the device(s ). Treating physician should prevent unblinding of the subject when  they 
conduct any non -protocol related visits. In addition, hospi[INVESTIGATOR_11533], dictated notes, notes to 
referral physicians, billing information, and other related patient information must ref er to the 
assigned treatment device as “study device” or other non -revealing language, to maintain the 
blind . The only exception to these requirements is if the hospi[INVESTIGATOR_592050] . Sites will be provided with a blinding guidance document that will instruct 
the sites on how to maintain blinding at the clinical sites.  
The Clinical Events Committee (CEC) will be blinded to the randomization assignments. The 
angiographic core laborato ries cannot be blinded to the device received. The Data Safety 
Monitoring Board (DSMB) will also be blinded to the subject’s randomization. Independent 
statisticians will generate blinded tables for review by [CONTACT_4318]. The DSMB may request 
unblinded data i f a safety signal is observed.  
Sponsor personnel that will be unblinded will be the independent biostatisticians involved in 
generating and verifying the randomization code, key Clinical Science and Operations, Clinical 
Safety Monitors, Site Monitors, Clin ical Data Management, Electronic Database Programmer, 
Inventory Management staff, and Clinical Information System (IS) personnel working on the 
trial. Restricted access of blinded personnel to the clinical database will be maintained until 
unblinding of th e study.   
4.5 Early Termination of the Clinical Trial  
Please refer to section 4.6  of ABSORB III Protocol (Version 17. 0, August 09,  2018 ) for the 
relevant information about trial early termination.  
5. ENDPOINTS  
5.[ADDRESS_781056] the control  
• This analysis will consist of ~ 2600  subjects in ABSORB IV.  
• TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol -
defined MI definition, Appendix II) attributable to Target Vessel  (TV-MI), or 
Ischemia -Driven Target Lesion Revascularization (ID -TLR).  
5.2 ABSORB IV Major  Secondary Endpoint  
• TLF through [ADDRESS_781057] the control  
• ABSORB IV Angina Powered Secondary Endpoint : The percentage of patients who 
experi enced angina within [ADDRESS_781058] the control.  
• Angina is defined as any angina or angina equivalent symptoms determined by [CONTACT_592193]/or research coordinator after interview of the patien t, and as 
adjudicated by a clinical events committee (CEC).  
Abbott Vascular  Version 17.[ADDRESS_781059] 16, 2018 . • This analysis will exclude angina or angina equivalent symptoms that occurred 
following the index procedure through hospi[INVESTIGATOR_53767] [ADDRESS_781060]. 
• This analysis will consist  of ~2600  subjects in ABSORB IV.  
 
5.3 Additional Secondary Endpoint(s)  
In ABSORB IV the following clinical secondary endpoints will be analyzed for all the ~2600  
subjects.  
• Acute Success : (Combined Clinical/Angiographic Endpoint)  
o Device success (Lesion level analysis)  
o Procedural success (Subject level analysis)  
• Clinical Endpoint  in hospi[INVESTIGATOR_248525] -up point (30, 90, 180, 270 days; 1, 2, 3, 
4, 5 years ). 
o Component  
▪ Death (Cardiac, Vascular, Non -cardiovascular)  
▪ Myocardial Infarction  
- Attributable to target vessel (TV -MI) 
- Not attributable to target vessel (NTV -MI) 
▪ Target Lesion Revascularization (TLR)  
- Ischemia driven TLR (ID -TLR)  
- Non ID TLR (NID -TLR)  
▪ Target Vessel Revascularization (TVR,)  
- ID TVR  
- Non ID TVR  
▪ All coronary revascularization  
o Composite E ndpoints  
▪ Death/All MI  
▪ Cardiac Death/All MI  
Abbott Vascular  Version 17.[ADDRESS_781061] 16, 2018 . ▪ Cardiac Death/TV -MI/ID -TLR (TLF)  
▪ Cardiac Death/All MI/ID -TLR (MACE)  
▪ Cardiac Death/All MI/ID -TLR/ID -TVR, non TL (Target Vessel Failure, TVF)  
▪ Death/All MI/All revascularization  
o Scaffold -Thrombosis / Stent Thrombosis (per ARC definition)  
▪ Timing (acute, sub -acute, late and very late)  
▪ Evidence (Definite and Probable)  
o Rehospi[INVESTIGATOR_059]  
▪ Coronary artery disease related  
▪ Cardiovascular, non -CAD related  
▪ Non-cardiovascular related  
o Repeat coronary arteriography  
o TLF th rough 5 years based on 4600  subjects (2000 primary analysis subjects of 
ABSORB III and 2600  subjects of ABSORB IV)  
5.4 Informational Endpoints  
5.4.1 Patient Reported Outcomes  
Patient -reported outcomes are informational endpoints to assess Health -Related Quality of Life 
at baseline, 1, 6, 12 months and will be assessed at 3 and 5 years through out the remaining 
duration of the trial . These PRO endpoints will be evaluated in the ~2600  subjects of ABSORB 
IV. The following questionnaires will be used in this study:  
• Seattle Angina Questionnaire -7 (SAQ -7) to assess disease -specific Quality of Life  
• EuroQoL 5D (EQ -5D) survey to assess overall health status  
The PROs will be analyzed to evaluate the relationship bet ween quality of life and 
cardiovascular  events that occurs post -PCI and to substantiate the clinical impact of the angina 
events identified in the trial . 
5.4.2 Health Economics  
During the course of the trial, the Sponsor (or the health economic core laboratory) will collect 
health ec onomic data.  The data may include billing information and claims data for the index 
hospi[INVESTIGATOR_592051] -up period , for sites located 
in the United  States only .  Patients will be asked to provide consent to access billing information 
for the purposes of conducting economic analysis of the trial.  
Abbott Vascular  Version 17.[ADDRESS_781062] 16, 2018 . Additional information regarding medical resource utilization may also be collected throughout 
the trial,  including but not limited to: laboratory services, diagnostic procedures, or pharmacy 
records . 
6. SUBJECT SELECTION  AND WITHDRAWAL  
6.[ADDRESS_781063] Screening and Informed Consent  
Please refer to section 6.2.1 and 6.2.2  of ABSORB III Protocol ( Version 17.0, August 1 6, 2018 ) 
for the relevant information about subject screening and informed consent.   
6.[ADDRESS_781064] of care. If some of the protocol required  tests are not included in the site’s 
standard tests, they must be done, but after written Informed Consent has been obtained. Subjects 
must meet ALL of the inclusion criteria to be considered for the clinical evaluation. If ANY of 
the exclusion criteria ar e met, the subject is excluded from the clinical evaluation and cannot be 
registered. Please see Protocol Summary , Inclusion Criteria and Exclusion Criteria, for details 
of the eligibility criteria of ABSORB IV.  
6.[ADDRESS_781065] is considered randomized  after IVRS has been 
called and a device has been assigned (Absorb BVS or XIENCE). The subject is considered 
registered and in the ITT population at the point of randomization. Once randomization is 
complet ed and a treatment arm is assigned, crossover is not permitted. Regardless of the actual 
device the subject received, the subject will be included in ITT population per the original 
randomization assignment.  
Refer to Appendix IV  and Figures [ADDRESS_781066] Discontinuation  
Please refer to section 6. 5 of ABSORB III Protocol ( Version 17.0, August 16, 2018 ) for the 
relevant information about subject discontinuation.  
Abbott Vascular  Version 17.[ADDRESS_781067] history will include demographics (e.g., age, gender)56, cardiac history including but not 
limited to Canadian Cardiovascular Society (CCS) and Braunwald classification of angina, 
history of myocardial infarction, diabetes mellitus, hypertension, hypercholesterolem ia, previous 
CABG and PCI, and concomitant cardiovascular medications (Refer to Appendix II  for 
Definitions).  In addition, measurements of weight, height, and resting blood pressure will be 
collected.  
7.1.3  Patient -Reported Outcomes Assessment  
All ~2600  subjects in ABSORB IV will complete the following Patient Reported Outcome 
questionnaires prior to  the index procedure*.  
• EuroQoL 5D (EQ -5D) survey to a ssess overall health status.  
• Seattle Angina Questionnaire -7 (SAQ -7) to assess dis ease-specific Quality of Life.  
Please refer to section 7.1.3  of ABSORB III protocol ( Version 17.0, August 1 6, 2018 ) for the 
details regarding each questionnaire.  
*Every effort should be made to have subjects complete all three patient reported outcomes 
questionnaires prior to the procedure.  However, in situations where this is absolutely not 
possible, subjects may complete them post -procedure, prior to discharge. Subjects who complete 
their questionnaires post -procedure should base their responses on their condition prior to the 
procedure.   
7.[ADDRESS_781068] -menopausal status, date of birth, race/ethnicity, highest level of 
education,  employment status and household income.  
 
Abbott Vascular  Version 17.[ADDRESS_781069] 16, 2018 . Within 21 days prior to 
procedure†  Within 7 days prior to 
procedure  Within 48 hours prior to procedure  
Platelet and White Blood 
Count  
Hemoglobin  
Serum Creatinine  
HbA1c‡  
Estimated GFR*  Pregnancy test (if 
applicable)  12-lead ECG (within 24 hours 
preferred)  
Creatine kinase (CK)  
Creatine kinase myocardial -band 
isoenzyme (CK -MB)  
Troponin (if suspected acute coronary 
syndrome, within 24 hours)  
†The [ADDRESS_781070] be known prior to index procedure.  
‡ HbA1c is to be collected in diabetic subjects only, and its result is not needed prior to the index procedure.  
* Glomerular Filtration Rate  
 
The following applies to  cardiac enzyme measurement pre -procedure and during the procedure . 
• All patients admitted with the diagnosis of possible acute coronary syndrome (including 
unstable angina, NSTEMI or STEMI) must have at least one and preferably 2 or more 
complete sets of cardiac biomarkers ( a set consisting of troponin (I or T), CK and CK -MB) 
measured within [ADDRESS_781071] 6 hours apart if 
multiple measurements were taken.    
•  If the patient has stable coronary artery disease or silent ischemia, a pre-procedure CK and 
CK-MB must be drawn, but may be obtained during the procedure from the arterial sheath 
but prior to any angioplasty . The angioplasty procedure may then be performed before the 
results are known.  
• To assist in the determination of peri -procedural MI, d uring the procedure, all patients with  an 
acute coronary syndrome (including unstable angina, NSTEMI or STEMI) must have troponin, 
CK and CK -MB drawn from the arterial sheath prior to first balloon inflation.  
For subjects having staged procedures, the protocol -required pre -procedure and post -procedure 
cardiac enzyme and [ADDRESS_781072] receive a loading dose of ≥ 
[ADDRESS_781073] 16, 2018 . Note:  The biomarker measurements in patients with stable coronary symptoms and silent 
ischemia may be pending at the time of the procedure, or may be drawn from the arterial sheath 
prior to first balloon inflation; such patients may still be randomized, and a P2Y12  receptor 
inhibitor must be administered no later th an [ADDRESS_781074] be used  a) a 
loading dose of  clopi[INVESTIGATOR_592040] [ADDRESS_781075] be given , OR b) an intravenous 
GP IIb/IIIa inhibitor or cangrelor ( see below ) must be administered prior to and/or during PCI 
but prior to first balloon inflation, per institution standard of care. If an intravenous GP IIb/IIIa 
inhibitor is given, a P2Y12 receptor inhibitor must be given within [ADDRESS_781076] administration of the P2Y12 
receptor inhibitor should be as follows: clopi[INVESTIGATOR_592052]; ticagrelor may be administered  before, during , or 
immediately upon discontinuation of  the cangrelor infusion . Ticagrelor is the preferred P2Y12 
receptor inhibitor in cangrelor -treated patients. Cangrelor should be maintained [ADDRESS_781077] 
procedure according to label.  
Note: If the subject  receives less than the required amount of the loading dose for a P2Y12 
receptor inhibitor, the investigator is to give the remaining amount of the same agent in the next 
24 hours and within the protocol required timeframe.   
The protocol required loading d ose may be omitted in a) stable CAD or  ACS patients maintained 
on chronic P2Y12 receptor inhibitor for ≥ 7 days,  and b) patients who  received a P2Y12 receptor 
inhibitor loading dose [ADDRESS_781078] develops hypersensitivity or intolera nce to clopi[INVESTIGATOR_7745], prasugrel, or ticagrelor 
during the trial.  
Refer to respective prescribing information for P2Y12 receptor inhibitor for further details 
regarding loading practice.  
Cangrelor may be used pre -PCI at operator discretion as per local practice in any patient (but 
should be used similarly in patients randomized to ABSORB and XIENCE): a pre -PCI loading 
dose of 30 μg/kg IV followed by [CONTACT_592185] 4 μg/kg for at least 2 hours and for a 
maximum of 4 hours may be used, in conjunction wi th an oral P2Y12 inhibitor. If ticagrelor is 
selected, the ticagrelor loading dose may be given before, during or immediately upon 
discontinuation of the cangrelor infusion. If clopi[INVESTIGATOR_592053], a clopi[INVESTIGATOR_592054], even if a loading dose was given earlier.  
For subjects having staged procedures, the pre -procedure administration regimen of aspi[INVESTIGATOR_34251] 
P2Y12 receptor inhibitor  (dosage requiremen ts and timing)  must be repeated prior to the staged 
Abbott Vascular  Version 17.[ADDRESS_781079]  has not 
been discharged between the index and staged  procedures, and has received daily aspi[INVESTIGATOR_592055], no aspi[INVESTIGATOR_354379] (see above).  
7.2.[ADDRESS_781080] 
hospi[INVESTIGATOR_13707]. Either unfractionated heparin or bivalirudin may be used for procedural 
anticoagulation, as per the discretion of the investigator. Subjects having  been treated with low 
molecular weight heparin (LMWH) prior to the procedure should receive their last dose more 
than 8 hours prior to the index procedure, and then be anticoagulated during the procedure with 
either unfractionated heparin or bivalirudin. LMWH and fondaparinux are not permitted as 
procedural anticoagulants in this protocol.  
Use of glycoprotein IIb/IIIa inhibitors will be at the discretion of the investigator for stable 
patients. Patients with biomarker positive acute coronary syndromes in whom procedural 
anticoagulation is achieved with unfractionated heparin should receive a procedural glycoprotein 
IIb/IIIa inhibitor dosed per standard of care. Glycoprotein IIb/IIIa inhibitors should not routinely 
be used in bivalirudin anticoagulated pati ents unless 1) the patient had an acute coronary 
syndrome and did not receive recommended pre -loading with a P2Y12 receptor inhibitor (and in 
whom cangrelor is not used during the PCI); and/or 2) refractory ischemic and/or thrombotic 
complications develop during the procedure.  
7.2.4  Statin Therapy  
In the absence of absolute contraindications to statin use (e.g. severe allergy with prior use), it is 
strongly recommended to preload with statins [ADDRESS_781081] ory of prior or current statin use . Recommended statin loading dose regimen s 
include atorvastatin 80 mg or rosuvastatin 40 mg.  
7.3 Index Procedure  
7.3.1  Baseline (Pre -Procedure) Angiography  
Baseline angiography of the target vessel(s) will be completed as  per the Angiographic Core 
Laboratory Protocol.  
7.3.2 Imaging Guidance Document  
The Imaging Guidance Document will provide specific details and instructions from the 
angiographic core laboratory regarding vessel sizing. This document will be separate from the 
protocol.  
7.3.3  Treatment Rules of the Target Lesion(s)  
Please see Protocol Summary, Treatment Strategy, for details of the treatment rules of target 
lesion(s).   
Abbott Vascular  Version 17.[ADDRESS_781082] 16, 2018 . 7.3.4 Treatment Rules of Unplanned Non -Target Lesion(s)  
In situations where treatment of a planned target lesion revealed additional lesion(s), the 
additional lesion(s) may be treated. These lesions are considered unplanned lesions. If the lesion 
meets enrollment criteria both before and after pre -dilatation, the lesion must be treated with the 
assigned device and will be considered as an unplanned target lesion. If the lesion does not meet 
the enrollment criteria (either before or after pre -dilatation), the lesion must be treated with 
XIENCE and will be considered as an unplanned non -target lesi on. 
7.3.[ADDRESS_781083] experiences:  
• Dissection requiring intervention  
• Occlusive complication as evidenced by a decrease in target vessel flow  
• Chest pain or ischemic changes me asured by [CONTACT_592131], medical therapy or lytic agents  
• Unplanned additional device is required to cover the target lesion  
During randomization, if a bailout device is required for a target lesion (e.g., for edge dis section), 
the same device as the implanted device must be used. Overlap of the bailout stent/scaffold with 
the implanted stent/scaffold should be 1 -2 mm. Gaps should be avoided.  
 Use Absorb BVS if target lesion is treated with Absorb BVS.  
 Use XIENCE if targ et lesion is treated with XIENCE.  
 If a bailout with an Absorb BVS device cannot be delivered to the site of the lesion, the 
device should be carefully withdrawn and a XIENCE used.  
 If an appropriate size Absorb BVS is not available XIENCE can be used.  
IMP ORTANT:   It is required that the bailout device be placed so that there is no visible gap 
between the Absorb BVS and the bailout device.  In such a case, at least 1 mm (minimum) to 2 
mm (maximum) overlap is required.  
IMPORTANT:  In the rare event of acute o cclusion following Absorb BVS placement  and an 
additional drug -eluting stent is required for treatment , the bailout device should be XIENCE and 
deployed within the Absorb BVS such that the Absorb BVS is completely covered by [CONTACT_592194] b elieved to be in the best interest of the patient.  
Although a bailout procedure is not considered a major adverse cardiac event (MACE) unless the 
subject sustains death, emergent CABG, PCI or MI, such procedures should be avoided unless 
required for safe subject management.  
Abbott Vascular  Version 17.[ADDRESS_781084] 16, 2018 . 7.3.6 Final (Post -procedure) Angiography  
Angiographic imaging will also be performed after the Absorb BVS or XIENCE stent 
deployment.  Physicians should follow accepted hospi[INVESTIGATOR_591995].  For angiographic imaging, post -
implantation images should be captured the same orthogonal views that were used for the pre -
procedure images  (after the guidewire has been withdrawn) . Intracoronary nitroglycerine should 
be re-administered before final angiography.  If nitroglycerine is not available, intravenous 
nitroprusside or intravenous  calcium channel blocker may  be used per physician discretion.  
7.3.7 Final (Post -procedure) IVUS and OCT  
IVUS and OCT may be performed pos t-procedure per site standard of care. If stent or scaffold 
under -expansion or substantial malapposition is seen and post -dilatation required, a non -
compliant balloon should be used. Do not dilate the Absorb BVS beyond the dilatation limit 
which is 0.[ADDRESS_781085]–procedure  
7.4.[ADDRESS_781086]-procedure Information to be Recorded  
The following information needs to be obtained between 12 hours following the index procedure 
and hospi[INVESTIGATOR_2345] (in -hospi[INVESTIGATOR_591996] a maximum of 7 days following the 
index procedure).  
Between [ADDRESS_781087] -procedure and discharge  
• Date of discharge  
• Antiplatelet medications  
• Chronic concomitant medications  
• Adverse Events, if  any  
7.4.[ADDRESS_781088] -
procedure cardiac enzyme collection.  
IMPORTANT:   These tests must be pe rformed whether or not they are considered part of the 
Investigator’s standard of clinical practice.  
Post-procedure and discharge  
• A [ADDRESS_781089] 16, 2018 . • Both Creatine kinase (CK) and Creatine kinase myocardial -band isoenzyme (CK -MB) must  
be obtained for ALL subjects as it will be used for cardiac assessment of subjects post -index 
procedure  
o First post -procedure CK and CK -MB draw at [ADDRESS_781090] -procedure**.  
o If either of the post -procedure CK -MB levels are ≥ 5x ULN, serial CK and CK -MB 
levels must be drawn until they are falling.  
** For subjects discharged  prior to [ADDRESS_781091] to return to the enrolling 
institution for their second biomarker draw.  
Alternatively, a visiting nurse may be sent to the patient’s home to collect the blood sample. CK 
and CK -MB levels are required at all time points. Troponins are required pre -procedure and from 
the arterial sheath prior to first balloon inflation during th e procedure in patients with acute 
coronary syndromes. All troponin, CK and CK -MB levels collected at any time points pre -
procedure, during the procedure and post -procedure, should also be documented in the electronic 
case report forms.  
For subjects havin g staged procedures, the post-procedure cardiac enzyme and [ADDRESS_781092] be repeated following  the staged procedure  in 
the same manner as done for the original index procedure . 
7.4.3 Assessment of perception bias.  
Patients’ perception as to whether they received the control or test device may affect the rate of 
angina. As described in section 4.5.2, comprehensive efforts will be undertaken to maintain 
patient blinding. Nonetheless, for a variety of reasons pat ients may develop a belief as to which 
device they received, even if the blind is maintained.  
To assess any potential perception bias on the secondary endpoint of percentage of patients who 
experienced angina within [ADDRESS_781093]-procedure  in the hospi[INVESTIGATOR_592056]  (≥ 4 hours to ≤ 7 days after the procedure)  and at [ADDRESS_781094] received , and the basis 
of this perception . The following question(s) will be asked:  
1. Do you think you know which treatment you have received?  
a. Yes. 
b. No. 
If answered “Yes” to Question #1, then answer the following questions. If answered 
“No” to Question #1, do not answer the following questions.  
2. Which treatment do you think you have received?  
a. Standard metal stent.  
b. Temporary dissolving stent.  
3. Are you certain?  
a. Yes. 
Abbott Vascular  Version 17.[ADDRESS_781095] 16, 2018 . b. No. 
4. Why do you think you know?  
a. I was told by /overheard the doctor who did the procedure.  
b. I was told by/overheard another person in the procedure room/cath lab.  
c. I was told by/overheard another person in the hospi[INVESTIGATOR_592057].  
d. I was told by/overheard a family member or friend who was told.  
e. I believe so because I am feeling better.  
f. I believe so because I am not feeling better.  
g. Other (write in).  
7.4.[ADDRESS_781096] be maintained at a minimum of 75 mg of clopi[INVESTIGATOR_196511] 5 or 10 mg of 
prasugrel daily ([ADDRESS_781097] patients)  or 90 mg twice daily of ticagrelor for a 
minimum of 12 months following the procedure. For prasugrel subjects < 60 kg in weight or ≥[ADDRESS_781098] receive between ≥75 to ≤ 100 mg of aspi[INVESTIGATOR_196514] 5 years 
follow -up during the study and should continue to take aspi[INVESTIGATOR_592058].  
Refer to respective prescribing information for P2Y12 receptor inhibitor for further details 
regarding maintenance dose. The start of anti -platelet medications, any changes or 
discontinuation of the medications, as well as the reasons for those cha nge will be documented in 
the eCRF.  
For subjects having staged procedures, the follow -up regimen of aspi[INVESTIGATOR_34251] P2Y12 receptor 
inhibitor (dosage requirements and timing) must be maintained following both the  original index 
procedure and the staged procedure.  
7.4.5 Other Chronic Concomitant Medications  
Please refer to section 7.4.4  of ABSORB III Protocol ( Version 17.0, August 16, 2018 ) for the 
relevant information about concomitant medications.  
7.[ADDRESS_781099]-procedure in the hospi[INVESTIGATOR_592056] (≥ 4 hours to ≤ 7 days after the procedure)  and at [ADDRESS_781100] mail the 
questionnaires back to the clinical site.  
The following information will be collected at each of the time points:  
• Any adverse events (including re -hospi[INVESTIGATOR_602])*, repeat coronary angiography, details 
regarding angina, medications, laboratory tests and 12 -lead ECGs, if performed;  
• Any angina events  
o If the subject experiences any symptoms of abnormal chest/arm/neck/jaw 
discomfort or pain, including angina -equivalent or atypi[INVESTIGATOR_592059]/sensation, 
data wil l be solicited and recorded regarding angina and angina -equivalent 
symptoms, including the quality, frequency and severity of discomfort/pain, to 
allow the CEC to adjudicate the symptoms as to angina/angina -equivalent vs. 
non-angina.  This information will  be collected by [CONTACT_592195] 
a standard script . A blinded cardiologist will review the information collected by 
[CONTACT_23164], provide a diagnosis and sign -off on his /her diagnosis.  
• Any repeat coronary angiography and results  of such, if applicable;  
• Details of any subsequent coronary interventions (e.g., repeat PCI or CABG);  
• Use and compliance of medications per clinical investigation plan;  
• Use and changes in concomitant cardiovascular medications.  
* All adverse events must be  collected up to and including to the 1 year follow up for all ~[ADDRESS_781101] visits, such as unscheduled visits, may occur as clinically warranted. The 
following information will be collected:  
• Assessment of angina st atus 
• Adverse events (including re -hospi[INVESTIGATOR_602])  
• Repeat coronary angiography  
• Details of any subsequent coronary interventions (e.g., repeat PCI or CABG)  
• Use and compliance to protocol medications (aspi[INVESTIGATOR_458135]/clopi[INVESTIGATOR_7745]/ 
ticagrelor/ticlopi[INVESTIGATOR_5325])  
Abbott Vascular  Version 17.[ADDRESS_781102] 16, 2018 . • Use and changes in chronic concomitant medications (Refer to Appendix II  for 
definition)  
For unscheduled visits for suspected ischemic cardiac events, sites should make reasonable 
efforts to obtain cardiac enzymes (Troponin I or T), CK and CK -MB, and/or ECG if the site is 
aware of the visit at the time of its occurrence. In all other scenarios (i.e., site does not become 
aware until after the fact), no p rotocol deviation will be issued if Troponin I or T, CK and CK -
MB, and/or ECG were not obtained at the time of the unscheduled visit.  
All efforts must be made to obtain follow -up information on subjects who have undergone 
procedures or have been treated fo r adverse events in a non -trial-related hospi[INVESTIGATOR_307](s).  
All coronary revascularizations must be classified prospectively by [CONTACT_592135] -
driven or not ischemia -driven (Refer to Appendix II  for definition). If a subject has a coronary 
revascula rization, all clinical information such as symptoms or lack of symptoms of ischemia, 
and possible relations with the target lesion/vessel should be fully recorded in the source 
documents prior to angiogram.  
8. ADVERSE EVENTS  
8.[ADDRESS_781103] 
definitions as referenced in these standards and guidelines are included in appen dix II.   
8.1.1 Adverse Event  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or other 
persons, whether or not related to the inve stigational medical device.  
NOTE 1: This definition includes events related to the investigational medical device or the 
comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this defini tion is restricted to events related to 
investigational medical devices.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investiga tional) 
product, whether or not related to the medicinal (investigational) product.  
8.1.2 Serious Adverse Event  
If the AE meets any of the criteria below, it is regarded as serious adverse event (SAE).  
a) Led to a death,  
Abbott Vascular  Version 17.[ADDRESS_781104] 16, 2018 . b) Led to a serious deterioration in health that either:  
1) Resulted in a life -threatening illness or injury, or  
2) Resulted in a permanent impairment of a body structure or a body function, or  
3) Required in -patient hospi[INVESTIGATOR_1081], or  
4) Result ed in medical or surgical intervention to prevent life threatening illness or injury 
or permanent impairment to a body structure or a body function.  
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
d) An important medical event that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_49200], based upon appropriate medical judgment, 
may jeopardize the subject and/or may require intervention to prevent one of the outcomes liste d 
in this definition.  
NOTE 1: This includes device deficiencies that might have led to a serious adverse event if a) 
suitable action had not been taken or b) intervention had not been made or c) if circumstances 
had been less fortunate. These are handled u nder the SAE reporting system.  
NOTE 2: A planned hospi[INVESTIGATOR_5912] -existing condition, or a procedure required by [CONTACT_5941], without a serious deterioration in health, is not considered to be a 
serious adverse event.  
8.1.3 Devic e Deficiency/Product Experience  
Device deficiency (DD) is defined as an inadequacy of a medical device related to its identity, 
quality, durability, reliability, safety or performance, such as malfunction, misuse or use error 
and inadequate labeling. This includes the failure of the device to meet its performance 
specifications or otherwise perform as intended.  Note: performance specifications include all 
claims made in the labeling of the device.  
Product Experience (PE) is defined as any expression of cus tomer concern or dissatisfaction, 
including adverse events and patient issues that occurred during or after the use of a 
commercially available medical device.  
8.[ADDRESS_781105] or 
device caused or contributed to an AE is to be determined by [CONTACT_592196]. Determination should be based on assessment of temporal 
relationships, biologic plausibility, association (or lac k of association) with underlying disease 
and presence (or absence) of a more -likely cause.  
8.2.[ADDRESS_781106] ([LOCATION_003]DE)  
Unanticipated serious adverse device effect ([LOCATION_003]DE) refers to any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, a device, 
Abbott Vascular  Version 17.[ADDRESS_781107], problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a sup plementary plan or 
application), or any other unanticipated serious problem associated with a device that relates to 
the rights, safety, or welfare of subjects.  
8.3 Adverse Event/ Device Deficiency/ Product Experience Reporting  
8.3.[ADDRESS_781108] through the 1 -year follow -up visit. After one 
year, only the following will be collected:  
• All serious adverse events.  
• All cardiac events regardless of seriousness or device relationship.  
• All trial device -related events and events for which the relationship to the trial device is 
unknown.  
• All unanticipated adverse device effects.  
• All Cerebral Vascular Accidents (CVAs).  
The Investigator will monitor the occurrence of adverse ev ents for each registered subject during 
the course of the clinical trial/investigation and report as required by [CONTACT_592197] [ADDRESS_781109], observed by [CONTACT_3786], or documented in medical records should be recorded on the adverse event eCRF, 
whether believed by [CONTACT_592198].  
A fax form will be made available to allow the investigator to  report SAEs and device 
deficiencies in the event the entry cannot be made in the EDC (FRM2073001 SAE Notification 
Form ). This does not replace the EDC reporting system, however, all information must still be 
entered in the EDC system as soon as feasible.  
For all registered patients, AEs (any new event/experience that was not present at baseline or 
worsening of an event present at baseline) will be collected as required by [CONTACT_3181].  The 
reporting of AEs will start when the guiding catheter enters the  subject’s vasculature.  Reported 
AEs will be monitored through the course of the trial.  Additional information with regards to an 
AE should be updated within the appropriate case report form.  
Unchanged, chronic, non -worsening or pre -existing conditions a re not AEs and should not be 
recorded on the AE eCRF page.  
The investigator should report all SAEs to the Sponsor as soon as possible but no later than 
outlined below.  
Study site  Reporting timelines  
Abbott Vascular  Version 17.[ADDRESS_781110] be reported no later than 3 calendar days from the day the study 
personnel becoming aware of the event or as per the investigative site’s local 
requirements if the requirement is more stringent than those outlined.  
The date the site staff became aware that the event met the criteria  of a serious adverse event 
must be recorded in the source document.  The investigator will further report the event to the 
IRB/EC according to the institution’s IRB/EC reporting requirements.  
Serious adverse events that occurred in the user or persons oth er than the study subject should 
not be entered in the EDC system. However they need to be reported on the SAE Notification 
Form (FRM2073001) .   
Serious adverse events should be reported on the SAE Notification Form in the occurrence that 
the EDC System is  not available.  This does not replace the EDC reporting system.  All 
information must still be entered in the EDC system once the system is back to normal function.  
8.3.2. Unanticipated Serious Adverse Device Effect Reporting to Sponsor and IRB  
Abbott Vas cular requires the Investigator to report any [LOCATION_003]DE to the sponsor within 3 calendar 
days of the investigator’s knowledge of the event, unless local requirements are more stringent, 
and to the IRB/EC per IRB/EC requirements  
8.3.3  Device Deficiency/Product  Experience Reporting  
All device deficiencies/product experiences should be reported within the EDC System on the 
appropriate eCRF. A fax form will be made available to allow the investigator to report device 
deficiencies in the event that the entry cannot  be made in the EDC (Device Deficiency Report 
Form). This does not replace the EDC reporting system. However, all information must still be 
entered in the EDC system as soon as feasible. In case a device deficiency occurred before the 
patient ID and random ization number has been assigned, the device deficiency should be 
reported to the sponsor via a Device Deficiency Report Form.  
The investigator should report all DDs/PEs to the Sponsor as soon as possible but no later than 
outlined below.  
Study sites  Repo rting timelines  
All Study Sites  DDs/PEs must be reported no later than 3 calendar days from the day the 
study personnel becoming aware of the event or as per the investigative 
site’s local requirements if the requirement is more stringent than those 
outlined.  
The device, if not implanted or not remained in the subject, should be returned to Abbott 
Vascular.   
Device deficiencies should be reported to the IRB/EC per the investigative site’s local 
requirements.  
8.3.4  Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_592137]/PEs to the country regulatory authority, per local 
requirements.  
Abbott Vascular  Version 17.[ADDRESS_781111] (DSMB) will serve in an advisory role to Abbott Vascular to 
ensure safety by [CONTACT_592138] -scribed intervals for the 
purpose of safeguarding the interests of trial participants. The composition, guiding policies, and 
operating procedures  governing the DSMB are described in a separate DSMB charter.  Based on 
safety data, the DSMB may consider a recommendation for modifications or termination of the 
trial based on any perceived safety concerns regardless of statistical significance. The 
recommendations of the DSMB are not binding, and all final decisions related to trial 
modifications rest with Abbott Vascular.  
9. ADJUDICATION OF EVENTS  
9.1 The Clinical Events Committee (CEC)  
Please refer to section 9.1 of ABSORB III Protocol (Version 17.0, August 1 6, 2018 ) for relevant 
information on CEC. In addition to the events adjudicated in ABSORB III, in ABSORB IV the 
CEC will also adjudicate any patient reported symptoms of abnormal chest/arm/neck/jaw 
discomfort or pain  to angina/angina -equivalent vs.  non-angina l symptoms .   
9.[ADDRESS_781112] MI (per protocol -defined MI definition, Appendix II), or 
ischemia -driven target lesion revascularization (ID -TLR).  
                                                           
[ADDRESS_781113] of the presence and extent of incomplete angiographic revascularization after 
percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Interven tion 
Triage Strategy (ACUITY) Trial”. Circulation. 2012;125:[ADDRESS_781114] of untreated coronary artery disease after percutaneous coronary 
intervention. The residual SYNTAX (Synergy Between PCI with Taxus and Cardi ac Surgery) score. J Am Coll 
Cardiol. 2012 Jun 12;59(24):[ADDRESS_781115] of Absorb BVS to XIENCE on the 
Primary Endpoint of TLF through 30 days . 
10.2 Analysis Populations  
10.2.1  Intent -to-Treat (ITT) Population  
The ITT population is defined as the subjects registered in the study at the point of 
randomization, regardless of the treatment actually received. Subjects will be analyzed in the 
treatment group to which they were  randomized. Subjects enrolled but not randomized will not 
be included in the ITT population.  
10.2.2  As-Treated (AT) Population  
The As-Treated (AT) population will consist of subjects  who were randomized and have 
received at least one study  device  (Absorb BVS or XIENCE) at the target lesion. Subjects who 
have received at least one Absorb BVS device will be included in the Absorb BVS arm; and 
subjects who have received at least one XIENCE device and none of Absorb BVS device will be 
included in the XIENCE arm.   
10.3.1  ABSORB IV Primary Endpoint  
Primary Endpoint : TLF at 30-day Primary  Endpoint  
TLF at 30-day will be tested for non -inferiority. This analysis will consist of ~ [ADDRESS_781116] is designed to show non-inferiority of Absorb BVS to XIENCE for the TLF 
at 30 days  with a one -sided alpha of 0.025.  The null (H 0) and alternative (H A) hypotheses are:  
H0:  TLF Absorb  - TLF XIENCE  ≥ TLF 
HA:  TLF Absorb  - TLF XIENCE  < TLF.  
TLF BVS and TLF XIENCE  are the 30 -Day TLF rates in the Absorb BVS and XIENCE arms, 
respectively.  TLF is the non -inferiority m argin for this powered primary  endpoint.  
The power calculation for the primary endpoi nt of TLF at 30 days is based on the following 
assumptions:  
• The true 30 -Day TLF rate is assumed to be 4.9% for both the Absorb BVS arm and the 
XIENCE arm   
• One-sided alpha: 2.5%  
• Non-inferiority margin ( TLF): 2.9%  
• Randomization ratio (ABSORB IV): 1 (Absorb BVS arm) : 1 (XIENCE arm)  
Abbott Vascular  Version 17.[ADDRESS_781117] 16, 2018 . • 1% loss to follow -up at 30 days  
With the effective sample size 2574  (Absorb: 1287 , XIENCE: 1287 ) at 30 days, the study 
has approximately 92% power to demonstrate non -inferiority of Absorb BVS to XIENCE 
using Farrington and Manning test.  
10.3.2 Powered Secondary Endpoint s 
Powered Secondar y Endpoint 1: TLF through [ADDRESS_781118] of ~ [ADDRESS_781119] is designed to show non -inferiority of Absorb BVS to XIENCE for the TLF 
at 1 year  with a one -sided alpha of 0.0 25.  The null (H 0) and alternative (H A) hypotheses are:  
H0:  TLF Absorb   - TLF XIENCE  ≥ TLF 
HA:  TLF Absorb   - TLF XIENCE  < TLF.  
TLF Abosrb  and TLF XIENCE  are the 1 year TLF rates in the Absorb BVS and XIENCE arms, 
respectively.  TLF is the non -inferiority m argin for this powered secondary  endpoint.  
The power calculation for the secondary  endpoint of TLF at 1 year is based on the following 
assumptions:  
• The true 1 year TLF rate is assumed to be 9.7% for both the Absorb B VS arm and the 
XIENCE arm.  
• One-sided alpha: 2.5% 
• Non-inferiority margin ( TLF): 4.8%  
• Randomization ratio (ABSORB IV): 1 (Absorb BVS arm) : 1 (XIENCE arm)  
• 5% loss to follow -up at 1 year  
With t he effective sample size 2470  (Absorb  BVS : 1235, XIENCE: 1235) at 1 year, the study 
has approximately 98% power to demonstrate non -inferiority of Absorb BVS to XIENCE using 
Farrington and Manning test.  
Power Secondary Endpoint 2: Angina through 1 year  
The Angina Powered Secondary Endpoint of percentage of patients who had angina within 1 
year (excluding an angina blanking period of the index hospi[INVESTIGATOR_592060] [ADDRESS_781120]) will be tested for non -inferiority with reflex testing to superiority. 
This analysis will consist of ~ [ADDRESS_781121] is designed to show non -inferiority of Absorb BVS to XIENCE for angina 
within 1 year  with a one -sided alpha of 0.025 .  The null (H 0) and alternative (H A) hypotheses are:  
H0:  ANGINA Absorb   - ANGINA XIENCE  ≥ ANGINA  
Abbott Vascular  Version 17.[ADDRESS_781122] 16, 2018 . HA:  ANGINA Absorb   - ANGINA XIENCE  < ANGINA.  
ANGINA Absorb  and ANGINA XIENCE  are the percentage of patients with angina within 1 year in 
the Absorb BVS and XIENCE arms, respectively.  ANGINA  is the non -inferiority margin for this 
secondary  endpoint.  
The power calculation for the Angina  Secondary  Endpoint  within 1 year is based on the 
following assumptions:  
• The true percentage of patients with angina within 1 year is assumed to be 22.6% for bo th 
the Absorb BVS arm and the XIENCE arm   
• One-sided alpha: 2.5% 
• Non-inferiority margin ( ANGINA ): 7%  
• Randomization ratio (ABSORB IV): 1 (Absorb BVS arm) : 1 (XIENCE arm)  
• 5% loss to follow -up at 1 year  
With the effective sample size 2470  (Absorb: 1235 , XIENCE: 1235 ) at 1 year, the study has 
approximately 99% power to demonstrate non -inferiority of Absorb BVS to XIENCE using 
Farrington and Manning test.  
If the non -inferiority of Absorb  BVS to XIENCE is demonstrated and the percentage is lower in 
Absorb BVS compared to XIENCE, a superiority test will be performed at the two sided alpha 
0.05 level.  
The null (H 0) and alternative (H A) hypotheses are:  
H0:  ANGINA Absorb   - ANGINA XIENCE   = 0 
HA:  ANGINA Absorb   - ANGINA XIENCE   ≠ 0 
ANGINA Absorb  and ANGINA XIENCE  are the percentage of patients with angina within 1 year in the 
Absorb BVS and XIENCE arms, respectively.   
With the effective sample size 2 470 at 1 year, the study has approximately 86% power to 
demonstrate superiority with a difference of 4.9% between th e Absorb BVS arm and the 
XIENCE arm (e.g. 17.7% in the Absorb BVS arm vs. 22.6% in the XIENCE arm) using 
Pearson’s Chi -square test.  
The sample size calculations were performed using NCSS PASS 11 (Hintze, J., 2011, NCSS, 
LLC. Kaysville, Utah).  
10.4 Statisti cal Analyses  
For binary variables such as TLF, TLR, and clinical procedure success, counts, percentages, and 
95% confidence intervals will be calculated, and p -values may be presented for hypothesis 
generating purposes. Pearson’s Chi -squared test or Fisher’s exact test  will be performed when 
Abbott Vascular  Version 17.[ADDRESS_781123] deviations, and 95% confi dence intervals 
for the mean will be calculated and p -values may be presented for hypothesis generating 
purposes. For time -to-event variables, such as time to TLF, survival curves will be constructed 
using Kaplan -Meier estimates, and log rank test results may be displayed. Unless specified, 
analyses will be performed with pooled data across all study sites.  
For further details refer to the statistical analysis plan (SAP).  
10.4.1  Primary Endpoint Analys es  
The ABSORB IV Primary Endpoint of TLF at 30-day will be analyzed for the  ITT (~ 2600 
subjects of ABSORB IV)  and the AT populations . The primary analysis will be based on the ITT 
population. The non -inferiority hypothesis testing will be performed using non -inferiority test by 
[CONTACT_63541]. Non -inferiority of Absorb BVS to XIENCE will be established if the p -
value for the non -inferiority test is less than 0.025.  
Details of the analyses for the primary  endpoint s can be found in the statistical analysis plan 
(SAP).  
10.4.2  Powered Secondary Endpo int Analys is  
The ABSORB IV Secondary  Endpoint of TLF at 1-year will be analyzed for the  ITT (~ 2600  
subjects of ABSORB IV)  and the AT populations . The primary analysis will be based on the ITT 
population. The non -inferiority hypothesis testing will be performed using non -inferiority test by 
[CONTACT_63541]. Non -inferiority of Absorb BVS to XIENCE will be established if the p -
value for the non -inferi ority test is less than 0.025.  
Analysis of the Angina Powered Secondary Endpoint of the percentage  of patients with angina 
within 1 year will be based on the ITT population (~ 2600  subjects of ABSORB IV) and the AT 
population. The primary analysis will be based on the ITT population. The non -inferiority 
hypothesis testing will be performed using non -inferiority test by [CONTACT_63541]. Non -
inferiority of Absorb BVS to XIENCE will be established if the p -value for the non -inferiority 
test is les s than 0.025.  
If the non -inferiority of Absorb BVS to XIENCE is demonstrated and the percentage is lower  in 
Absorb BVS compared to XIENCE, a superiority test will be performed at the two -sided alpha 
0.05 level.  
10.4.3  Secondary Endpoint Analyses  
Secondary endpoints other than the powered endpoints described above will be summarized 
descriptively for the ITT  population (~2600  subjects of ABSORB IV) . For further details refer to 
the statistical analysis plan (SAP).  
Abbott Vascular  Version 17.[ADDRESS_781124] 16, 2018 . 10.4.4  Additional Analyses  
Adverse Events related to stent/scaffold thrombosis, vascular complications or bleeding 
complications, and their relat ion with antiplatelet therapi[INVESTIGATOR_592000], if applicable.  
For further details refer to the SAP.  
10.4.5  Informational Endpoint Analyses  
Details on informational endpoint  analyses can be found in the S AP. 
10.4.6  Subgroup Analysis  
Pre-specified subgroups such as diabetes, sex, age will be examined. Further details can be found 
in the SAP.  
10.4.7  Criteria for Early Termination of the Trial for Effectiveness  
No formal statistical rule for early termination of the trial for effectiveness is defined.  
10.4.10  Procedures for Accounting for Missing, Unused or Spurious Data  
All analyses will be based on available data with missing data excluded. Any unused or spuri ous 
data will be noted as appropriate in the final report.  
10.4.11  Pooling Strategy  
Details on pooling strategy can be found in the SAP.  
10.4.12  Deviations from the Original Statistical Plan  
Any major changes to the statistical plan (available upon requ est) will be documented in an 
amendment to the statistical plan.  Less significant changes to the planned analyses will be 
documented in the final report.  
11. ADDITIONAL PROTOCOL INFORMATION  
Please refer to section 11 - 17 of ABSORB III Protocol (Version 16.0, March 1 4, 2017 ) for 
relevant information on data access and handling, quality control, ethical consideration, 
publication policy, risk analysis and special population.   
11.[ADDRESS_781125] Access to Source Data/Documents Addendum  
It is possible that during the duration of the trial, subjects may receive medical care from 
institutions other than the study site. In addition to collecting the informed consent from patients, 
the Sponsor strongly recommends that study sites obtain a medical release author ization from the 
subject  to facilitate the collection of relevant medical information from non -study site 
institutions.  
Abbott Vascular  Version 17.[ADDRESS_781126] 16, 2018 . 12. ABSORB -RESOLVE: REDU CTION IN ISCHEMIA WI TH 
BIORESORBALE V ASCULA R SCAFFOLDS —AN 
IMAGING SUB -STUDY TO  ABSORB IV  
12.1. Background  
To date, no randomized controlled trial (RCT) has demonstrated the superiority of percutaneous 
coronary intervention (PCI) over medical therapy for the reduction of death or myocardial 
infarction (MI) in patients with stable coronary artery disease (CAD) [1,2]. Limitations of prior 
studies, however, have included excessively high rates of revascularization failure and 
incomplete coronary revascularization after PCI, and use of older generation stent technology 
(for example, only 2.7% of the COURAGE trial PC I patients received drug -eluting stents) [1,3] . 
Despi[INVESTIGATOR_592061], COURAGE and numerous other RCTs 
have demonstrated that angina frequency and quality of life are significantly improved with PCI 
over medical therapy alone  [4]. In COURAGE, a longitudinal assessment at [ADDRESS_781127] of PCI was noted for patients with 
either sever e or frequent angina. Importantly, approximately half of subjects enrolled into the 
COURAGE study were asymptomatic or experienced minimal angina for a generally short 
duration of ~5 months, and PCI would be expected to be more effective in a more symptoma tic 
group.  
The symptomatic improvements with PCI in the COURAGE trial —despi[INVESTIGATOR_592062]-eluting stents —may be mechanistically explained by [CONTACT_592199] -study in 
which myocardial ischemia was evaluated by [CONTACT_592200] 
(SPECT) [5]. Abnormal single photon emission computed tomography ( SPECT ) findings have 
been strongly associated with adverse prognosis and worsened angina [6].  In the COURAGE 
nuclear sub -study, it was hypothesized that ischemia reduct ion would be greater for patients who 
were randomized to receive PCI over those receiving medical therapy alone [5].  Among [ADDRESS_781128], follow -up ischemia was 
assessed at 6 -18 months (median 12  months). In PCI -treated patients, the mean amount of 
ischemi c myocardium  was reduced from 8.2% at baseline to 5.5% at follow -up-- equating to a 
mean reduction of 2.7% -- which compared favorably to the mean 0.5% reduction that was 
observed in t he medical therapy alone arm (p < 0.001).  These findings are in direct accordance 
with several pi[INVESTIGATOR_592063] 
(ACIP) and SWISSI II studies, each of which demonstrated superior clinical outcomes with PCI 
compared to medical therapy alone in patients with documented ischemia [7-8].  
12.1.1.  Ischemia Assessment by [CONTACT_592201] -invasive imaging tests exist for physiologic assessment of CAD, including 
echocardiography, cardiac magnetic resonance and myocardial perf usion imaging by [CONTACT_592202] (PET) [9,10] . These modalities identify stress -induced 
wall motion abnormalities or regional myocardial perfusion defects as a surrogate for ischemia, 
and serve to identify individuals who may have severe coronary stenoses.  Among the non -
invasive stress modalities, m yocardial perfusion imaging (MPI) by [CONTACT_592203], comprising ~90% of the more than [ADDRESS_781129] 16, 2018 . US annually [11]. MPI [INVESTIGATOR_592064], severity and reversibility of myocardial 
ischemia with high performance [12]. In pooled analyses, the sensitivity and specificity of MPI 
[INVESTIGATOR_592065] 85 -90% and 70 -75%, respectively.  Further, the prognostic value 
of MPI [INVESTIGATOR_592066] -invasive tests, with risk of CAD even ts escalating 
exponentially with increasing magnitude of inducible hypoperfusion [6]. 
12.1.2.  Coronary CT Angiography (CCTA)  
A major goal of imaging is to accurately evaluate the angiographic severity of luminal stenoses. 
Coronary CT angiography (CCTA) has recentl y emerged as an accurate non -invasive method for 
determination of obstructive CAD [13]. In three prospective multicenter studies, the diagnostic 
sensitivity of CCTA for patients with and without known CAD has ranged between 85 -99%, 
with specificities rangi ng between 64 -90% [14-16].  CCTA has been demonstrated to be 
particularly effective in excluding obstructive coronary stenosis and a normal CCTA is 
associated with a very low annual mortality rate of 0.13% [17].  
However, there are limitations of CCTA, par ticularly as it relates to intracoronary stents [18]. 
Owing to blooming artifacts caused by [CONTACT_592204], visualization of the coronary lumen within stents 
by [CONTACT_592205]. Clinical studies 
published so far show low sensitivity to identify in -stent restenosis. The limited spatial resolution 
of CCTA, the type of stent, and stent diameter all contribute  to limited clinical results.  
Importantly, as blooming artifacts are absent in CCTA imaging of bioresorbab le vascular 
scaffolds ( Absorb BVS), the diagnostic performance of CCTA may be improved after  Absorb  
BVS implantation [19]. The coupling of a non -invasive technique for evaluation of symptomatic 
or ischemic patients with suspected in -scaffold restenosis may  be cost -effective compared to 
traditional evaluation of metallic stents [20]. 
12.1.3.  CT Perfusion (CTP)  
Recent advances in technology now enable MPI [INVESTIGATOR_592067], a procedure termed CT perfusion (CTP) 
[21].  Multidetector CT systems can image in a dynamic mode, in which sequential images are 
obtained over a period of time to record the kinetics of iodinated contrast in the arterial blood 
pool and myocardium. George et al, using a [ADDRESS_781130] in a canine is chemia model, 
performed CTP during adenosine infusion [22]. They found strong correlations between the ratio 
of myocardial upslope and left ventricular upslope and microsphere -derived MBF. The authors 
replicated the study in humans with adenosine stress 64 - and 256 -row detector CCTA and CTP. 
In the human study, they calculated the transmural perfusion ratio (sub -endocardial attenuation / 
sub-epi[INVESTIGATOR_592068]), which had a significant inverse linear correlation with percent 
diameter stenosis on quantit ative intracoronary angiography (ICA) [23]. Further, the combination 
of CTP and CCTA was 86% sensitive and 92% specific for identifying patients with 
atherosclerosis causing perfusion abnormalities when compared with the combination of ICA 
and S PECT -MPI [INVESTIGATOR_592069].  
In a prospective multicenter study of chest pain patients entitled the Combined Coronary 
Atherosclerosis and Myocardial Perfusion Evaluation Using 320 Detector Row Computed 
Tomography (CORE320) [24], CCTA with concomitant CTP was as ef fective as sequential 
SPECT -MPI [INVESTIGATOR_592070] -limiting atherosclerotic lesions. The 
clinical utility of CTP may be particularly important in patients with a high coronary risk profile, 
known coronary artery disease, those wit h a high calcium score (e.g. >400 Agatston Units), or 
Abbott Vascular  Version 17.[ADDRESS_781131] 
At present, the “gold” standard assessme nt of the hemodynamic significance of coronary 
stenoses is fractional flow reserve (FFR). Recent advances in computational fluid dynamics 
(CFD) allow for calculation of coronary flow and pressure fields from anatomic image data [25]. 
Applied to CT, these t echnologies enable calculation of FFR (which reflects the ratio of maximal 
myocardial blood flow through a diseased artery to the blood flow in the hypothetical case that 
the artery was normal) without additional imaging or administration of additional med ications. 
Several studies have reported incremental value of FFR CT in the diagnosis of CAD [26-28]. In 
the most contemporary of these prospective multicenter trials, the HeartFlowNXT study of [ADDRESS_781132] data matched 
closely with invasively measured FFR. The area under the receiver operating characteristic curve 
(AUC) was 0.[ADDRESS_781133] (≤ 0.80) vs. 0.63 for CCTA (lumen reduction > 50%) (p < 0.0001) 
with invasive FFR as the reference standard. Per -patient sensitivity and specificity were 86% and 
79% for FFR CT vs. 94% and 34% for CCTA, and 91% and 51% f or ICA (lumen reduction 
>50%).  
FFR CT offers sev eral practical advantages in that it does not require modification of CT 
angiography protocols, does not require administration of additional medications beyond what is 
typi[INVESTIGATOR_592071], and does not result in any additional  radiation exposu re.  
12.1.5.  The Present Study 
In the present proposal, we propose to determine the effects of the Absorb  BVS on reversible 
myocardial and coronary lesion -specific ischemia by [CONTACT_370168], CTP, and FFR CT; and to quantify 
group -to-group differences in myocardial ischemia in individuals undergoing coronary 
intervention with bioabsorbable scaffolds versus latest generation drug -eluting stents. Further, 
we will evaluate the long -term vascular responses to  Absorb BVS by [CONTACT_592206].  
The first subject for the RESO LVe study was enrolled on February 15, [ADDRESS_781134] been enrolled. Therefore, due to this very slow enrollment, this sub-study 
has been stopped and will no longer enroll patients. For patients already enrolled, clinical follow -
up will continue as per protocol ; however subjects will not undergo the ABSORB -RESOLVe 
specific testing specified in the protocol.  
12.2. Rationale and Design of ABSORB -RESOLVe  
Hypothesis -generating clinical observations have  surfaced that Absorb BVS may result in less 
angina than XIENCE. Speci fically, the site -reported recurrence rate of angina after PCI was 
compared at different time periods from the SPI[INVESTIGATOR_592072] (n  = 2,051) and the ABSORB 
EXTEND registry (n  = 375) (data on file, Abbott Vascular). Of note, both studies evaluated  
Abbott Vascular  Version 17.[ADDRESS_781135] 16, 2018 . angina recu rrence at similar intervals and with similar ly designed case report forms . This 
comparison excluded complex patients and lesions from SPI[INVESTIGATOR_592073] (3 -vessel PCI; PCI of 2 
lesions in a single vessel; RCA aorto -ostial lesions; bifurcation lesions) . Non-Japanese  Asian 
patients from ABSORB EXTEND  were excluded because of historically low reported event rates  
and for more appropriate comparison to patients in SPI[INVESTIGATOR_592073] . At 30 days angina had recurred in 
12.5% of XIENCE patients vs. 5.8% of Absorb BVS patients. At 1  year angina had recurred in 
26.7% of XIENCE patients vs. 15.9% of Absorb BVS patients (393 day HR  [95% CI] = 0.55 
[0.42, 0.72], p  < 0.0001). To further correct for baseline differences, a propensity adjusted 
comparison was performed between 602 X IENCE  patients and 287 Absorb BVS patients (data 
on file, Abbott Vascular). In this analysis angina at 30 days had recurred in 11.3% of XIENCE 
patients vs. 7.0% of Absorb BVS patients. At 1 year angina had recurred in 28.1% of XIENCE 
patients vs. 16.0% of Absorb BVS patients (393 day HR  [95% CI] = 0.53 [0.93, 0.74], p  = 
0.0001). It is unknown  to which extent this reduction in angina recurrence is due to reduced 
ischemia with Absorb  BVS compared to XIENCE . 
The ABSORB -RESOLVe sub -study of the parent ABSORB IV trial has been specifically 
designed to address each important stage and mechanism of the ischemic cascade wherein the 
Absorb  BVS may exert salutary anti -anginal effects . The substudy will employ both SPECT and 
CT in patients undergoing a prospective, multicente r, randomized 1:[ADDRESS_781136] available, 
and enables quantifica tion of relative perfusion deficits within myocardial territories, findings 
that can arise  from both epi[INVESTIGATOR_131270] (re -)stenosis as well as microcirculatory 
dysfunction and/or disease.  Additionally, the evaluation of functional capacity throu gh exercise 
testing in those who are capable of it will allow for a direct assessment of the potential beneficial 
effects of Absorb  BVS on reducing exertional angina. Available SPECT images taken within [ADDRESS_781137]. Ischemia provoked by [CONTACT_592207], and the inherent differences in 
vascular responses after Absorb BVS compared to X IENCE  V (including exercise induced 
vasodilation at the treatment site  and restored cyclic pulsatility ) may be optimally differentiated 
with exercise induced hemodynamic changes. Exercise testing also allows between -group 
comparisons of additi onal variables including exercise time/capacity and ECG changes, and 
exercise induced angina.  
CT—inclusive of coronary CT angiography, CT perfusion, and FFR CT—will be performed at 
baseline, after the device has been implanted , and at [ADDRESS_781138].  Both of these tests are “disruptive” methods for CAD 
evaluation. Given the spatial resolution of CT, MPI [INVESTIGATOR_592074] a distinct advantage over 
SPECT for evaluation of sub -endoc ardial ischemia evaluation while FFR CT allows for 
Abbott Vascular  Version 17.[ADDRESS_781139] at 5 -years will be able to characterize changes in plaque 
morphology and extent and vessel dimensions and remodeling  after resorption of the Absorb 
BVS, and correlate such changes to long -term outcomes  in the 2 groups . 
12.3.  ABSORB -RESOLVe S tudy  Objectives : 
12.3.1.  Primary Objective (Myocardial Ischemia by [CONTACT_370168]).  
The primary powered objective is to compare the efficacy of between group differences  in % 
ischemic myocardium  after treatment with  Absorb BVS versus XIENCE at 14 ± [ADDRESS_781140] . Percent ( %) ischemic myocardium will be based upon a summed 
stress score (SSS), which will be calculated for all myocardial segments using a 17 -segment 
AHA model. Each segment will be classified as having normal myocardial perfusion (=0), mild 
perfusion defect (=1), moderate perfusion defect (=2) , severe perfusion defect (=3) , or absence of 
perfusion (=4) . The SSS will be converted as a function of 100, resulting in per -subject % 
ischemic myocardium .  
Sample Size Calculation.  For the between -group analysis using SPECT , an a priori  power 
analysis was performed to test the hypothesis that implantation of Absorb BVS will be associated 
with lower  per-subject  % ischemic myocardium , compared to XIENCE stents  at 14 ± 1 month 
follow -up.  
In the present study, for estimated % ischemic myocardium, we utilized per -patient data from the 
COURAGE nuclear substudy where PCI + OMT therapy resulted in 5.5% ±  5.1% residual % 
ischemic myocardium  at 6-18 month follow -up. Given the uniformity of use of the X IENCE  
drug-eluting stents in the  ABSORB IV  trial that was not present in the COURAGE study, we 
anticipate a lower residual % ischemic myocardium in ABSORB RESOLVe than was observed 
in COURAGE, and have estimated this to be an ~25% relative improvement, or 4.0% ± 3.7%.  
Based upon a 14 ± 1  month per -patient % ischemic myocardium of 4.0% ± 3.7% for XIENCE, 
we assume a 2.7% ± 3.7% per -patient % is chemic myocardium for Absorb BVS , i.e. a 33% 
relative reduction. This 33% reduction is a conservative estimate based on the 47% observed 
reduction i n angina at 1 year in the propensity adjusted  comparis on of Absorb BVS vs. X IENCE  
described in section 12.2 above. With 370 total subjects  (185 per group),   employing a 2 -sided 
alpha = 0.05, and assuming  5% of  patients are lost to follow -up, the statistic al power will be 
90%.  
12.3.2.  Powered Secondary Objective (Myocardial Ischemia by [CONTACT_4654]).  
The secondary powered objective is to compare the efficacy of between -group differences in % 
ischemic myocardium after treatment with Absorb  BVS versus XIENCE at 62 ± [ADDRESS_781141] perfusion.  Percent ( %) ischemic myocardium will be based upon a 
summed stress score in a manner identical to that for SPECT.  
Sample Size Calculation.  For the betwee n-group analysis using CT pe rfusion  at 62 ±  1 month, 
there are no long -term myocardial perfusion studies after PCI on which to base estimates of % 
ischemic myocardium. However, given the durabili ty of long -term freedom from re -intervention 
observed for both Absorb BVS and XIENCE [29-31], it is reasonable to employ the same 
assumptions as used for the primary endpoint for SPECT in accordance with the COURAGE 
study. Based upon a per -patient % ischemic myocardium of 4.0% ± 3.7% for XIENCE, we 
assume a 2.7% ± 3.7% per -patient % ischemic m yocardium for Absorb BVS , i.e. a 33% relative 
reduction. We further assume a non -evaluable CT perfusion study rate at 62 ± 1 month of 10%. 
With 370 total subjects (185 per group), and employing a 2 -sided alpha = 0.05, the statistical 
power will be 83%.  
12.3.3.  Tertiary Objective s: 
[IP_ADDRESS].  Myocardial Ischemia by [CONTACT_370168].  
To compare the effect of revascularization by [CONTACT_592208] -group reversible ischemia differences  at 14 ± [ADDRESS_781142]. Myocardial ischemia 
measures will include:  
1) Per-vessel territory % ischemic myocardium. Vessel territories will include those from 
the left anterior descending artery, left circumflex a rtery and right coronary arter y. 
2) Significant ischemia reduction, as defined by ≥ 5% ischemic myocardium  
3) Rates of myocardial perfusion normalization  
4) Rates of residual ≥10% ischemic myocardium  
5) Reduction in high -risk SPECT findings (e.g., transient ischemic dilatation, increased lung 
uptake, right ventricular dilatation)  
6) Exercise -induced angina  
7) Exercise duration  
8) ST-segment depression during exercise  
9) Improvement in Duke Treadmill Score  
[IP_ADDRESS].  Myocardial Ischemia by [CONTACT_592209] % ischemic myocardium in ABSORB RESOLVe sub -study subjects 
from pre -procedure to 14 ± 1 month follow -up, and to assess between -group differences in the 
reduction of % ischemic myocardium between the Absorb BVS and XIENCE arms. Baseline 
SPECT imaging is not mandated per protocol; this secondary analysis wi ll be performed only on 
subjects who have an available non -study SPECT and will be used for determination of reduction 
in % ischemia myocardium from pre -procedure to 14 ± [ADDRESS_781143] 16, 2018 . [IP_ADDRESS].  Myocardial Ischemia by [CONTACT_592210] -study subjects who 
have met the parent ABSORB IV angina secondary endpoint ( angina group ) in comparison to 
subjects who have not met the angina secondary endpoint ( non-angina group ), and to assess 
between -group differences in the Absorb BVS and XIENCE arms. ABSORB IV angina 
secondary endpoint is  defined in Section 5. 2 of the ABSORB IV portion of the protocol.  
[IP_ADDRESS].  Myocardial Ischemia by [CONTACT_4654].  
To compare the effect of revascularization by [CONTACT_592211] a) the immediate post PCI period (within 7 days 
after the index PCI procedure ) and b) at 62 ± 1 month follow -up. For this tertiary objective, 
myocardial ischemia (for both the tar get vessel territory and global ischemia) will be evaluated 
by [CONTACT_592212]. Myocardial ischemia measures will include:  
1) Between group reversible myocardial ischemia at 7 days.  
2) Within -patient  reversible myocardial ischemia change  from 7 days to 62 ± 1 month  
follow -up. 
3) Rates of myocardial perfusion normalization . 
4) Reduction in reversible myocardial ischemia by [CONTACT_592213] [as classified by [INVESTIGATOR_32522] 
(0%), mild (1 -4%), moderate (5 -9%) and severe (≥  10%) ischemic myocardium . 
5) Rates of residual ≥  10% ischemic myocar dium . 
[IP_ADDRESS].  Lesion -Specific Ischemia by [CONTACT_4654].  
To compare the effect of revascularization by [CONTACT_592214] -specific ischemia reduction in a) the immediate post PCI period (within 7 
days after the PCI period) and b)  at 62 ± 1 month follow -up. For this tertiary objective(s), target 
vessel and lesion -specific ischemia will be evaluated by [CONTACT_592215]. Lesion -specific ischemia 
measures will include  between group (at 7 days and at 62 ± 1 month follow -up) and within –
patient (c hange from 7 days to 62 ± 1 month follow -up): 
1) Differences  in absolute FFR CT value . 
2) Rate of trans -lesion hyperemic pressure difference normalization (as defined by [CONTACT_592215] ≥ 
0.80) . 
12.4.  ABSORB -RESOLVe Study Population and Clinical Site Participation  
The study populations will consist of [ADDRESS_781144] enrollment will be simultaneous; that is, the 370 subjects 
registered in this sub -study will be a part of the ~[ADDRESS_781145] ion of Subjects  
[IP_ADDRESS].  Inclusion Criteria (in addition to standard inclusion criteria from ABSORB IV 
parent trial):  
1) Subjects that received only Absorb BVS or XIENCE as per their assigned 
treatment group.  
2) Successful and uncomplicated PCI procedure, as defined in the main protocol . 
3) Provision of informed, written consent for the ischemia substudy.  
[IP_ADDRESS].  Exclusion Criteria. (The following exclusions are in addition to the general 
exclusion criteria for the ABSORB IV trial.)  
1) Atrial fibrillation . 
2) Contrai ndication to adenosine. Contraindications include including 2nd or 3rd 
degree heart block; sick sinus syndrome; long QT syndrome; severe hypotension, 
severe asthma, severe COPD or bronchodilator -dependent COPD . 
3) Any condition making it unlikely that the pat ient will be unable or unwilling to 
follow all the ischemia substudy procedures . 
12.4.2.  Test Schedule and Subject Visits  
Patients enrolled in the RESOLVE study will not undergo the ABSORB -RESOLVe specific 
testing in the protocol. Clinical follow -up will c ontinue as per protocol and these patients will 
remain in full cohort analysis.  All related imaging analysis will not be conducted.  
[IP_ADDRESS].  Baseline CT  
• Baseline CT (CT#1) performed after registration/randomization and after PCI but 
no later than [ADDRESS_781146] may be performed as an in -patient prior to hospi[INVESTIGATOR_2345], 
or after hospi[INVESTIGATOR_592075] a study approved facility.  
• For subjects in who the randomized PCI procedure is staged, CT#[ADDRESS_781147] staged procedure. Other tests, however (SPECT and 
CT#2) should  be performed at a time course based on completion of the first PCI 
procedure (a similar proce dure to clinical follow -up in the main ABSORB  IV 
randomized trial).  
[IP_ADDRESS].  14 ± 1 months (i.e. 13 -15 months) SPECT  
• A 14 ± [ADDRESS_781148] study will be performed for all eligible subjects, except 
under the following condition s (Figures 12.4.2 a, b):  
o Subjects with stable angina occurring before the 14 ± [ADDRESS_781149] performed at the unscheduled visit shows no evidence of suspected 
ischemia, the following conditions apply:  
▪ If the SPECT exam occurred within ≤ 7 months of the index PCI, the 14 ± 
[ADDRESS_781150] still be performed.  
▪ If the SPECT exam occurred > 7 months after the index PCI, the 14 ± [ADDRESS_781151] to  be performed; the SPECT performed at 
unscheduled visit will be analyzed as having met the 14 ± [ADDRESS_781152] shows evidence of suspected ischemia at the unscheduled visit, it is 
strongly recommended that intracoronary angiography (ICA)  is performed . 
▪ If the ICA demonstrates no in -stent restenosis (ISR) and TLR is not 
performed on all target lesions, the following conditions apply:  
- If the unscheduled visit occurred within ≤ 7 months of the index PCI, 
the 14 ± [ADDRESS_781153] still be performed.  
- If the unscheduled visit occurred > 7 months after the index PCI, the 
14 ± [ADDRESS_781154] to be performed; the SPECT 
performed at the unscheduled visit will be analyzed as having met the 
14 ± [ADDRESS_781155] requirement.  
▪ If the ICA demonstrates ISR (QC A diameter stenosis > 50% as 
determined by [CONTACT_592173]), the following conditions 
apply:  
- If TLR is not performed on all target lesions, the 14 ± [ADDRESS_781156] still be performed.  
- If TLR is performed on all target lesions,  or if ISR (QCA diameter 
stenosis > 50% as determined by [CONTACT_592173]) in 
all target lesions  is present,  the 14 ± [ADDRESS_781157] to 
be performed; the SPECT performed at the unscheduled visit will be 
analyzed as having met the 14 ± [ADDRESS_781158] requirement.  
• Subjects with severe unstable angina or MI and suspected ISR occurring before 
the 14 ± [ADDRESS_781159] who can’t exercise are not required to undergo SPECT 
before the unscheduled ICA.  
o If TLR was not performed on all target lesions, a 14 ± [ADDRESS_781160] 
still be performed.  
o If TLR is performed on all target lesions, or if ISR (QCA diameter stenosis > 
50% as determined by [CONTACT_592173]) in all target lesions  is 
present,  the 14 ± [ADDRESS_781161] does not need to be performed . 
• If subjects miss CT#1, they should still undergo the 14 ± [ADDRESS_781162] 16, 2018 . • All subjects are strongly recommended to discontinue their anti -angina  
medications (i.e., nitrates, calcium channel blockers, and beta -blockers) [ADDRESS_781163] if there are no contraindications to discontinuing. Patients 
with recurrent angina are not required to discontinue their anti -angina  
medications.  
[IP_ADDRESS].  62 ± [ADDRESS_781164]  
• A 62 ± [ADDRESS_781165]  study will be performed for all eligible subjects, except under 
the following conditions  (Figures 12.4.2.a, c):  
o Subjects with stable angina occurring before the 62 ± [ADDRESS_781166] imaging (note: i f only one study can be performed in this time 
period, the SPECT should be given preference). If this event has occurred 
after [ADDRESS_781167] exam 
should be performed (without SPECT).  
o If the CT performed at the u nscheduled visit shows no evidence of suspected 
ischemia, the following conditions apply:  
▪ If the CT exam occurred within ≤ 36 months of the index PCI, the 62 ± [ADDRESS_781168] still be performed.  
▪ If the CT exam occurred > 36 months after the index PCI , the 62 ± [ADDRESS_781169] to performed; the CT performed at 
unscheduled visit will be analyzed as having met the 62  ± [ADDRESS_781170] undergo  intracoronary 
angiography (ICA).  
▪ If the ICA demonstrates no in -stent restenosis (ISR) and TLR is not 
performed on all target lesions, the following conditions apply:  
- If the unscheduled visit occurred within ≤ 36 months of the  index PCI, 
the 62 ± [ADDRESS_781171] still be performed.  
- If the unscheduled visit occurred > 36 months after the index PCI, the 
62 ± [ADDRESS_781172] to performed; the CT exam 
performed at the unscheduled visit will be analyzed as having met the 
62 ± [ADDRESS_781173] requirement.  
▪ If the ICA demonstrates ISR (QCA diameter stenosis > 50% as 
determined by [CONTACT_592173]), the following conditions 
apply:  
Abbott Vascular  Version 17.[ADDRESS_781174] 16, 2018 . - If TLR is not performed on all target lesions, the 62 ± [ADDRESS_781175] still be performed.  
- If TLR is performed on all target lesions,  or if ISR (QCA diameter 
stenosis > 50% as determined by [CONTACT_592173]) in 
all target lesions  is present,  the 62 ± [ADDRESS_781176] 
to perfor med; the CT exam performed at the unscheduled visit will be 
analyzed as having met the 62 ± [ADDRESS_781177] exam requirement.  
• Subjects with severe unstable angina or MI and suspected ISR occurring befor e 
the 62 ± [ADDRESS_781178] exam  who can’t exercise  are not requi red to undergo the CT 
exam before the unscheduled ICA.  
o If TLR was not performed on all target lesions, a 62 ± [ADDRESS_781179] 
still be performed.  
o If TLR is performed on all target lesions, or if ISR (QCA diameter stenosis > 
50% as determined by [CONTACT_592216]) in all target lesions  is 
present,  the 62  ± [ADDRESS_781180] exam does not need to be performed.  
• If subjects miss CT#1, they should still undergo the 62 ± [ADDRESS_781181] exam study.  
• All subjects are strongly recommended to discontinue their anti -angina 
medications (i.e., nitrates, calcium channel blockers, and beta -blockers) [ADDRESS_781182] 
protocols. The baseline and 62 ± [ADDRESS_781183] and 
pharmacologic stress conditions. The 14 ± [ADDRESS_781184] 16, 2018 . Figure 1 2.4.2 a. Sub-study design: Overall Trial Flow   
  
Randomization
ABSORB or XIENCE 
 within 7 days after index procedure14 ± 1 mo
62 ± [ADDRESS_781185]
Within [ADDRESS_781186]
14 ± [ADDRESS_781187]
62 ± [ADDRESS_781188] 16, 2018 . Figure 1 2.4.2 b. Sub-study design: Unscheduled visit to perform SPECT at < [ADDRESS_781189] with Recurrent Stable 
Angina (1st Epi[INVESTIGATOR_1865])
SPECT 
PerformedSPECT Not 
Performed*
Perform ICADo Not Perform 
ICA
[ADDRESS_781190] 
RequiredICA PerformedICA Not 
Performed
Did epi[INVESTIGATOR_592076] 
≤ 7 months after 
index procedure?
[ADDRESS_781191] 
RequiredDid epi[INVESTIGATOR_592076] 
≤ 7 months after 
index procedure?
[ADDRESS_781192] 
Not Required
* No SPECT required if clinically contraindicated or not clinically feasible.
Note: CT#2 (See Protocol Section [IP_ADDRESS]) should also be obtained if SPECT is 
performed before [ADDRESS_781193]: Single Photon Emission Computer TomographyTLR: Target Lesion RevascularizationICA: Invasive Coronary AngiogramISR: In-Stent Restenosis. Defined as QCA diameter stenosis > 50% as determined by [CONTACT_141108].YesNo
Yes NoICA 
Indicated?
Yes No
TLR Performed on All 
Target Lesions or ISR 
Present in All Target 
Lesions?
Yes
NoTLR Performed on 
All Target Lesions or 
ISR Present in All 
Target Lesions?
No Yes
 
Subject with Unstable 
Angina/MI (1st Epi[INVESTIGATOR_1865])
SPECT 
Performed*SPECT Not 
Performed
Perform 
AngiogramDo Not Perform 
Angiogram
[ADDRESS_781194] 
RequiredICA PerformedICA Not 
Performed
Did epi[INVESTIGATOR_592076] 
≤ 7 months after 
index procedure?
[ADDRESS_781195] 
RequiredDid epi[INVESTIGATOR_592076] 
≤ 7 months after 
index procedure?
[ADDRESS_781196] 
Not Required
* SPECT may be performed if clinically indicated.YesNo
Yes NoICA 
Indicated?
Yes No
TLR Performed on All 
Target Lesions or ISR 
Present in All Target 
Lesions?
Yes
NoTLR Performed on 
All Target Lesions or 
ISR Present in All 
Target Lesions?
No Yes
 
Abbott Vascular  Version 17.[ADDRESS_781197] 16, 2018 . Figure 1 2.4.2 c. Sub-study design: Unscheduled visit to perform CTA/CTP at < 62 months.  
* No CTA/CTP required if clinically contraindicated or not clinical feasible.
CTA/CTP: Computer Tomography Angiogram/Computer Tomography PerfusionTLR: Target Lesion RevascularizationISR: In-Stent Restenosis. Defined as QCA diameter stenosis > 50% as determined by [CONTACT_141108].Subject with Recurrent Stable 
Angina
CTA/CTP 
PerformedCTA/CTP Not 
Performed*
Perform 
AngiogramDo Not Perform 
Angiogram
62 Month CTA/CTP 
RequiredICA PerformedICA Not 
Performed
Did epi[INVESTIGATOR_592076] 
≤ 36 months after 
index procedure?
62 Month CTA/CTP 
Not RequiredDid epi[INVESTIGATOR_592076] ≤ 36 months after 
index procedure?
YesNo
Yes NoICA 
Indicated?
Yes No
TLR Performed on All 
Target Lesions or ISR 
present in All Target 
Lesions?
Yes
NoTLR Performed on 
All Target Lesions or 
ISR present in All 
Target Lesions?
No Yes
62 Month CTA/CTP 
Not Required62 Month CTA/CTP 
Required
 
 
Subject with Unstable 
Angina/MI (1st Epi[INVESTIGATOR_1865])
CTA/CTP 
Performed*CTA/CTP Not 
Performed
Perform 
AngiogramDo Not Perform 
Angiogram
62 Month CTA/CTP 
RequiredICA PerformedICA Not 
Performed
Did epi[INVESTIGATOR_592076] 
≤ 36 months after 
index procedure?
62 Month 
CTA/CTP Not 
Required62 Month CTA/CTP 
RequiredDid epi[INVESTIGATOR_592076] ≤ 36 months after 
index procedure?
62 Month CTA/CTP 
Not Required
* CTA/CTP may be performed if clinically indicated.YesNo
Yes NoICA 
Indicated?
Yes No
TLR Performed on All 
Target Lesions or ISR 
Present in All Target 
Lesions?
Yes
NoTLR Performed on 
All Target Lesions or 
ISR Present in All 
Target Lesions?
No Yes
.  
Abbott Vascular  Version 17.[ADDRESS_781198] 16, 2018 . 12.5.  References  
1) Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada 
M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, 
Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; 
COURA GE Trial Research Group. Optimal medical therapy with or without PCI for stable 
coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503 -16.  
2) BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, 
MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones 
TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapi[INVESTIGATOR_36259] 2 
diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11;362(24):2503 -15.  
3) Kereiakes DJ, Teirstein PS, Sarembock IJ, Hol mes DR Jr, Krucoff MW, O'Neill WW, 
Waksman R, Williams DO, Popma JJ, Buchbinder M, Mehran R, Meredith IT, Moses JW, 
Stone GW. The truth and consequences of the COURAGE trial. J Am Coll Cardiol. [ADDRESS_781199] 
16;50(16):1598 -623.  
4) Weintraub WS, Spertus JA, Kolm P , Maron DJ, Zhang Z, Jurkovitz C, Zhang W, Hartigan 
PM, Lewis C, Veledar E, Bowen J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree 
R, Barnett PG, Teo KK, Boden WE; COURAGE Trial Research Group, Mancini GB. Effect 
of PCI on quality of life in patients  with stable coronary disease. N Engl J Med. 2008 Aug 
14;359(7):677 -87.  
5) Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, 
O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, 
Germano G, Gosselin G, Be rger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates 
ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy 
with or without percutaneous coronary intervention to reduce ischemic burden: results from 
the Clinical Outcome s Utilizing Revascularization and Aggressive Drug Evaluation 
(COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283 -91. 
6) Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. 
ACC/AHA/ASNC guidelines for the clinical use o f cardiac radionuclide imaging --executive 
summary: a report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines 
for the Clinical Use of Cardiac Radionuclid e Imaging). Journal of the American College of 
Cardiology. 2003;42(7):1318 -33. 
7) Davies RF, Goldberg AD, Forman S, Pepi[INVESTIGATOR_85375], Knatterud GL, Geller N, Sopko G, Pratt C, 
Deanfield J, Conti CR. Asymptomatic Cardiac Ischemia Pi[INVESTIGATOR_2268] (ACIP) study two -year follow -
up: outcomes of patients randomized to initial strategies of medical therapy versus 
revascularization.Circulation. 1997 Apr 15;95(8):2037 -43. 
8) Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, 
Resink TJ, Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia 
after myocardial infarction: the SWISSI II randomized controlled trial.JAMA. 2007 May 
9;297(18):[ADDRESS_781200] 16, 2018 . 9) Dowsley T, Al -Mallah M, Ananthasubramaniam K, Dwivedi G, McArdle B, Chow BJ. The 
role of noninva sive imaging in coronary artery disease detection, prognosis, and clinical 
decision making. Can J Cardiol. 2013 Mar;29(3):285 -96.  
10) Gershlick AH, de Belder M, Chambers J, Hackett D, Keal R, Kelion A, et al. Role of non -
invasive imaging in the management of coronary artery disease: an assessment of likely 
change over the next 10 years. A report from the British Cardiovascular Society Working 
Group. Heart. 2007;93(4):423 -31.  
11) Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, et al. Why all 
the focus on cardiac imaging? JACC Cardiovascular imaging. 2010;3(7):789 -94. 
12) Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or 
exercise SPECT imaging? A meta -analysis of diagnostic test performance. Journal of nuclear 
cardiology :  official publication of the American Society of Nuclear Cardiology. 
2002;9(1):133 -4. 
13) Min JK, Shaw LJ, Berman DS. The present state of coronary computed tomography 
angiography a process in evolution. Journal of the American College of Cardiology. 
2010;55(1 0):957 -65. 
14) Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic 
performance of 64 -multidetector row coronary computed tomographic angiography for 
evaluation of coronary artery stenosis in individuals without known coronary ar tery disease: 
results from the prospective multicenter ACCURACY (Assessment by [CONTACT_592217]) trial. 
Journal of the American College of Cardiology. 2008;52(21):1724 -32. 
15) Miller JM, Rochitte CE, Dewey M, Arbab -Zadeh A, Niinuma H, Gottlieb I, et al. Diagnostic 
performance of coronary angiography by [ADDRESS_781201]. The New England journal of medicine. 
2008;359(22):2324 -36. 
16) Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, et al. 
Diagnostic accuracy of 64 -slice computed tomography coronary angiography: a prospective, 
multicenter, multivendor study. Journal of the American College of Cardiology. 
2008;52(25):2135 -44. 
17) Min JK, Dunning A, Lin FY, Achenbach S, Al -Malla h M, Budoff MJ, et al. Age - and sex -
related differences in all -cause mortality risk based on coronary computed tomography 
angiography findings results from the International Multicenter CONFIRM (Coronary CT 
Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 
23,854 patients without known coronary artery disease. Journal of the American College of 
Cardiology. 2011;58(8):849 -62. 
18) Kumbhani DJ, Ingelmo CP, Schoenhagen P, Curtin RJ, Flamm SD, Desai MY. Meta -analysis 
of diagnost ic efficacy of 64 -slice computed tomography in the evaluation of coronary in -stent 
restenosis. Am J Cardiol. 2009 Jun 15;103(12):1675 -81. 
19) Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia -Garcia HM, Ormiston JA, 
Serruys PW. Five -year clinical and fu nctional multislice computed tomography angiographic 
Abbott Vascular  Version 17.[ADDRESS_781202] 16, 2018 . results after coronary implantation of the fully resorbable polymeric everolimus -eluting 
scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC 
Cardiovasc Interv. [ADDRESS_781203];6(10):999 -1009.  
20) O’Day K and Min JK. Two -Year Diagnostic Costs Using a Coronary CT Angiographic -
Based Diagnostic Algorithm for Patients with Suspected In -stent Restenosis Previously 
Stented with Bioresorbable Vascular Scaffold versus Metallic Stents. CRT 2014 (Abstract 
accepted).  
21) Ko BS, Cameron JD, Defrance T, Seneviratne SK. CT stress myocardial perfusion imaging 
using multidetector CT --A review. J Cardiovasc Comput Tomogr. 2011Nov -Dec;5(6):345 -
56.  
22) George RT, Jerosch -Herold M, Silva C, Kitagawa K, Bl uemke DA, Lima JA, Lardo AC. 
Quantification of myocardial perfusion using dynamic [ADDRESS_781204] Radiol. 2007 Dec;42(12):815 -22. 
23) George RT, Arbab -Zadeh A, Miller JM, Kitagawa K, Chang HJ, Bluemke DA, Becker L, 
Yousuf O, Texter J, L ardo AC, Lima JA. Adenosine stress 64 - and 256 -row detector 
computed tomography angiography and perfusion imaging: a pi[INVESTIGATOR_592077]. Circ Cardio vasc Imaging. 2009 May;2(3):174 -82. 
24) Rochitte CE, George RT, Chen MY, Arbab -Zadeh A, Dewey M, Miller JM, Niinuma H, 
Yoshioka K, Kitagawa K, Nakamori S, Laham R, Vavere AL, Cerci RJ, Mehra VC, Nomura 
C, Kofoed KF, Jinzaki M, Kuribayashi S, de Roos A, Laule M , Tan SY, Hoe J, Paul N, 
Rybicki FJ, Brinker JA, Arai AE, Cox C, Clouse ME, Di Carli MF, Lima JA. Computed 
tomography angiography and perfusion to assess coronary artery stenosis causing perfusion 
defects by [CONTACT_592218]: the CORE320 study. Eur Heart J. 
2013 Nov 19. [Epub ahead of print]  
25) Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed 
tomography for noninvasive quantification of fractional flow reserve: scientific basis. J Am 
Coll Cardiol.  2013 Jun 4;61(22):2233 -41.  
26) Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, 
Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini 
GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accur acy of fractional flow reserve 
from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237 -45.  
27) Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, Dunning A, De[LOCATION_009] T, Lansky 
A, Leipsic J, Min JK. Diagnosis of ischemia -causing coronary stenoses by [CONTACT_592219]. Results 
from the prospective multicenter DISCOVER -FLOW (Diagnosis of Ischemia -Causing 
Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Ca rdiol. 
2011 Nov 1;58(19):1989 -97.  
28) Nørgaard BL, Leipsic J, Gaur S, Seneviratne S, Ko BS, Ito H, Jensen JM, Mauri  L, De 
Bruyne B, Bezerra H, Osawa K, Marwan M, Naber C, Erglis A, Park SJ, Christiansen EH, 
Kaltoft A, Lassen JF, Bøtker HE, Achenbach S; NXT Trial Study  Group. Diagnostic 
Abbott Vascular  Version 17.[ADDRESS_781205] 16, 2018 . Perfor mance of Noninvasive Fractional Flow Reserve Derived From Coronary  Computed 
Tomography Angiography in Suspected Coronary Artery Disease: The NXT Trial (Analysis 
of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol. 2014 Apr 
1;63(12): 1145 -55.  
29) Chevalier, B. ABSORB Cohort B Trial:  Evaluation of the Absorb Everolimus Eluting 
Bioresorbable Vascular Scaffold (Absorb) in the Treatment of Patients with de novo Native 
Coronary Artery Lesions – 4-Year Clinical Results of Cohort B1.  Chevalier , Bernard.  
Transcatheter Cardiovascular Therapeutics 2013.  
30) Onuma Y, Dudek D, Thuesen L, Webster M, Nieman K, Garcia -Garcia HM, Ormiston JA, 
Serruys PW.  Five -year clinical and functional multislice computed tomography 
angiographic results after coronary i mplantation of the fully resorbable polymeric 
everolimus -eluting scaffold in patients with de novo coronary artery disease: the ABSORB 
cohort A trial.  JACC Cardiovasc Interv. [ADDRESS_781206];6(10):999 -1009.  
31) Gada, Hemal; Kirtane, Ajay J; Newman, William; Sanz, Ma rk; Hermiller, James B; 
Mahaffey, Kenneth W; Cutlip, Donald E; Sudhir, Krishnankutty; Hou, Liming; Koo, Kai; 
Stone, Gregg W.  Five -Year Results of a Randomized Comparison of XIENCE V 
Everolimus -Eluting and TAXUS Paclitaxel -Eluting Stents: Final Results Fro m the SPI[INVESTIGATOR_592078].  JACC. Cardiovascular interventions (Nov 7, 2013).  
  
Abbott Vascular  Version 17.[ADDRESS_781207] 16, 2018 . APPENDIX I: ABBREVIA TIONS AND ACRONYMS  
Please refer to APPENDIX I of ABSORB III Protocol (Version 16.0, March 1 4, 2017 ) for a 
complete list of abbreviations and acronyms.  
  
Abbott Vascular  Version 17.[ADDRESS_781208] 16, 2018 . APPENDIX II:  DEFINIT IONS  
Please refer to Appendix II of ABSORB III Protocol (Version 16.0, March 1 4, 2017 ) for 
complete list of definitions. New or updated definitions are listed below:  
MYOCARDIAL INFARCTION (MI)  
Protocol MI Definition: Periprocedural MI definition is modified from Moussa ID, Klein LW, 
Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. 
Consideration of a new definition of clinically relevant myocardial infarction after coronary 
revascularization: an expert con sensus document from the Society for Cardiovascular 
Angiography and Interventions (SCAI). J Am Coll Cardiol. [ADDRESS_781209] 22;62(17):1563 -70. 
This definition will be used for the primary analysis of ABSORB IV and secondary analysis of 
ABSORB III.  
Classification  Biomarker Criteria  Additional Criteria  
Periprocedural – patients 
with a) stable CAD, or b) 
silent ischemia, or c) 
acute coronary 
syndromes with at least 2 
baseline troponin values 
which remained <ULN, 
or d) acute coronary 
syndromes in whom the 
troponin and/or CK -MB 
levels were elevated but 
all returned to <ULN 
prior to the procedure  Absolute CK -MB rises within 48 hours of 
the procedure to > [ADDRESS_781210] -PCI 
or CK -MB > [ADDRESS_781211] -CABG  Baseline value* < ULN; see also 
** 
Periprocedural – patients 
with stable CAD and 
elevated baseline CK -
MB, or acute coronary 
syndromes in whom at 
least [ADDRESS_781212] 
recent troponin and CK -
MB values were less 
than the preceding 
measures by >25%  Absolute incremen tal CK -MB rise within 
[ADDRESS_781213] 
recent CK -MB level by > [ADDRESS_781214]-PCI or > [ADDRESS_781215] -CABG   
Periprocedural – patients 
with elevated baseline 
CK-MB in whom the 
biomarker levels have 
not been shown to be 
stable or  falling as 
defined above (either 
because only one CK -
MB was measured, or 
the most recent CK -MB 
measure in a series was 
either still increasing or 
had not decreased by [CONTACT_592220] -MB rises within [ADDRESS_781216] recent CK -MB level of  > [ADDRESS_781217] -PCI or > [ADDRESS_781218] also be 
present:  
1. New ST -segment elevation or 
depression,  
2. Plus signs consistent with a 
clinically relevant MI, such as 
new onset or worsening heart 
failure or sustained 
hypotension.  
Abbott Vascular  Version 17.[ADDRESS_781219] 16, 2018 . >25% from the most 
recent measure)  
Spontaneous (before or 
>48 hours after any 
coronary 
revascularization 
procedure)  Troponin >ULN or CK -MB > ULN  
 
  One or more of the following must 
also be present:  
- Symptoms of ischemia;   
- ECG changes  indicative of new 
ischemia -  (new ST -T changes or 
new LBBB),   
- Development of pat hological Q 
waves;   
 - Imaging evidence of a new loss 
of  viable myocardium or a new 
regional wall  motion abnormality  
ULN=Upper limits of the local laboratory normal (will be collected from each hospi[INVESTIGATOR_592010]);  
LBBB=Left Bundle -branch Block  
* Baseline CKMB value is required before study procedure and presumes a typi[INVESTIGATOR_592011] a peri procedure MI  
 
** Whenever at least one baseline and one post procedure CK -MB measure are available  in a patient 
with stable CAD, adjudication of MI will be based solely on these biomarker values. If the patient has 
stable ischemic heart disease and the baseline CK -MB measure are not available, they will be assumed to 
be within normal limits and MI will  be adjudicated by [CONTACT_592221]-MB measures. TROPONINS WILL NOT BE USED TO  DIAGNOSE PERI -PROCEDURAL MI.  
• Periprocedural MI After PCI:  
The periprocedural period includes the first 48 hours after PCI.  
• Periprocedural MI After CABG:  
The periprocedural period includes the first 48 hours after coronary artery by[CONTACT_15806] 
(CABG).  
• Spontaneous MI:  
MI after the periprocedural period may be secondary to late stent complications or 
progression of native disease. Performance of ECG and angiography supports 
adjudication to either a target or non -target vessel in most cases.  
With the unique issues and pa thophysiological mechanisms associated with these later 
events as well as the documented adverse impact on short and long -term prognosis, a 
more sensitive definition than for periprocedural MI of any elevation of troponin or 
CKMB above the 99th percentile of the upper range limit (or ULN if URL is not 
available) is used. All late events that are not associated with a revascularization 
procedure will be considered simply as spontaneous.  
Myocardial infarctions  will also be adjudicated based on the following c lassification:  
• Q wave MI  
Development of new, pathological Q wave on the ECG (≥ 0.04 seconds in duration and ≥ 
1 mm in depth) in ≥ 2 contiguous precordial leads or ≥ 2 adjacent limb leads)  
Abbott Vascular  Version 17.[ADDRESS_781220] 16, 2018 . • Non-Q wave MI  
Those MIs which are not Q -wave MI.  
Myocardial infar ctions  will also be adjudicated as to their relation to the Target Vessel  
All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be 
considered related to the target vessel.  
For Universal  and WHO  MI definitions, please refer to ABSORB III protocol ( Version 17.0, 
August 1 6, 2018 ). These definitions will be used for secondary analysis for ABSORB IV and 
ABSORB III.   
ANGINA  
Angina is defined as any angina or angina equivalent symptoms determined by [CONTACT_592222]/or research coordinator after interview of the patient, and as adjudicated by a clinical events 
committee (CEC).  
ADVERSE EVENT [AE]  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or other 
persons, whether or not related to the investigational medical device.  
NOTE 1: This definition includes events related to the investigational medical device or the 
comparator.  
NOTE 2: This definition includes events related to the procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events related to 
investigational medical devices.  
An AE can therefore be any unfavorable and unintended sign (inclu ding an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product, whether or not related to the medicinal (investigational) product.  
UNANTICIPATED SERIOUS ADVERSE DEVICE EFFECT  
Unanticipa ted serious adverse device effect ([LOCATION_003]DE) refers to any serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, a device, 
if that effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan or application (including a supplementary plan or 
application), or any other unanticipated serious problem associated with a device that relates to 
the rights, safety, or welfare of subjects.  
SER IOUS ADVERSE EVENT [SAE]  
If the AE meets any of the criteria below, it is regarded as serious adverse event (SAE).  
a) Led to a death,  
Abbott Vascular  Version 17.[ADDRESS_781221] 16, 2018 . b) Led to a serious deterioration in health that either:  
1) Resulted in a life -threatening illness or injury, or  
2) Resul ted in a permanent impairment of a body structure or a body function, or  
3) Required in -patient hospi[INVESTIGATOR_1081], or  
4) Resulted in medical or surgical intervention to prevent life threatening illness or injury 
or permanent impairment to a body structure or a body function.  
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
d) An important medical event that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_592079], based upon appropriate medical judgment, 
may jeopardize the subject and/or may require intervention to prevent one of the outcomes listed 
in this definition.  
NOTE 1: This includes device deficiencies that might have led to a serious adverse event if a) 
suitable action had not been taken or b) intervention had not been made or c) if circumstances 
had been less fortunate. These are handled under the SAE reporting system.  
NOTE 2: A planned hospi[INVESTIGATOR_5912] -existing condi tion, or a procedure required by [CONTACT_5941], without a serious deterioration in health, is not considered to be a 
serious adverse event.  
DEVICE DEFICIENCY (DD)  
Device deficiency (DD) is defined as an inadequacy of a medical device rela ted to its identity, 
quality, durability, reliability, safety or performance, such as malfunction, misuse or use error 
and inadequate labeling. This includes the failure of the device to meet its performance 
specifications or otherwise perform as intended.   Note: performance specifications include all 
claims made in the labeling of the device.  
PRODUCT EXPERIENCE (PE)  
Product Experience (PE) is defined as any expression of customer concern or dissatisfaction, 
including adverse events and patient issues that  occurred during or after the use of a 
commercially available medical device.  
  
Abbott Vascular  Version 17.[ADDRESS_781222] 16, 2018 . APPENDIX III:  SCHEDU LE OF EVENTS  
 
PROCEDURE/TEST  
Baseline  
Baseline  
(within 7 days)  
Pre-Procedure  
(within 48 hours)  
Procedure  
Post-Procedure  
 30 7d, 90 14d, 
180 28d, 270  28d 
Telephone contact 
[CONTACT_592170]  
14 months ± 1 
month  
1, 2, 3, 4 , 5 yrs ( 28 
d), Telephone 
contact [CONTACT_592223]  
62 months ± [ADDRESS_781223] Medical/Clinical 
History (Age, Sex, Risk 
Factors, Angina Status, 
Cardiac History)  ✓          
Subject Informed Consent 
(Must be obtained prior to 
any study related testing or 
procedures)  ✓          
General Inclusion/Exclusion 
Criteria11 ✓          
Angiographic 
Inclusion/Exclusion Criteria     ✓[ADDRESS_781224] (if 
applicable)   ✓         
Hgb, Platelet Count, 
Creatinine, HbA1c, eGFR, 
WBC  ✓1          
CK and CK -MB    ✓2 ✓3 ✓4     ✓7 
Troponin I or T    ✓2 ✓3      ✓7 
12-lead ECG    ✓5  ✓5     ✓7 
Coronary Angiogram     ✓8       
Study device information     ✓       
Per Protocol Medications6   ✓ ✓ ✓ ✓  ✓  ✓ 
Concomitant Medications  ✓   ✓ ✓ ✓  ✓  ✓ 
Adverse Events     ✓ ✓ ✓  ✓  ✓ 
Patient Reported Outcome 
Instruments  ✓9     ✓10  ✓10   
Patient Perception 
Questionnaire      ✓12   ✓12   
SPECT14       ✓   ✓[ADDRESS_781225] Angiogram/Perfusion14     ✓13    ✓ ✓[ADDRESS_781226]  be known prior to index procedure. HbA1c is to be collected in diabetic subjects only, and 
its result is not needed prior to the index procedure.  
2. All patients admitted with the diagnosis of possible acute coronary syndrome (including unstable angina, NSTEMI or 
STEMI) must have at least one and preferably 2 or more complete sets of biomarkers (a set consisting of troponin (I or 
T), CK and CK -MB) measured within [ADDRESS_781227] be 
drawn, but can be obtained during the procedure from the arterial sheath but prior to any angioplasty.  
3. Durin g the procedure, all patients with ACS (including unstable angina, NSTEMI or STEMI) must have troponin, CK 
and CK -MB drawn from the arterial sheath prior to first balloon inflation. For patients with stable coronary artery 
disease, it is strongly recommend ed to have a CK and CK -MB drawn from the arterial sheath prior to the first balloon 
inflation.  
4. At least two post -procedure draws required: 1) [ADDRESS_781228] -procedure; 2) [ADDRESS_781229] -procedure (for hospi[INVESTIGATOR_592018] [ADDRESS_781230] to return to the enrolling institution for their 
second biomarker draw) . If either of the post -procedure CK -MB levels are ≥ [ADDRESS_781231] -procedure: 
prasugrel [ADDRESS_781232] be given for a 
minimum of 12 months, and Aspi[INVESTIGATOR_248] ≥ 75 mg to ≤ [ADDRESS_781233] be taken through 5 years follow up (potentially 
up to 10 years  follow -up) during the study, and should continue to be taken indefinitely. If a subject develops 
hypersensitivity to clopi[INVESTIGATOR_7745], prasugrel or ticagrelor, subject may be switched to ticlo pi[INVESTIGATOR_592080] a dose in accordance 
with standard hospi[INVESTIGATOR_13707].   
7. For unscheduled visits for suspected ischemic cardiac events, sites should make reasonable efforts to obtain cardiac 
enzymes (Troponin I or T), CK and CK -MB, and/or ECG if the site is aware of the visit at the time of its occurrence. In 
all other scenarios (i.e., site does not become aware until after the fact), no protocol deviation will be issued if Troponin  
I or T, CK and CK -MB, and/or ECG were not obtained at the time of the unscheduled v isit. 
8. Baseline (prior to pre -dilatation) and final (after stenting/post dilatation) angiogram must be obtained and sent to the 
core laboratory.  
9. Every effort should be made to have subjects complete all patient reported outcomes questionnaires (EQ -5D and SAQ-
7) prior to the procedure.  However, in situations where this is absolutely not possible, subjects may complete them 
post-procedure, prior to discharge.  Subjects who complete their questionnaires post -procedure should base their 
responses on their cond ition prior to the procedure.    
10. All registered subjects may complete PRO (EQ -5D and SAQ -7) at 30, [ADDRESS_781234]’s eligibility  
12. Administered ≥ 4 hours to ≤ [ADDRESS_781235] Angiogram/Perfusion will be performed up to [ADDRESS_781236] will be completed 
at 14 ± [ADDRESS_781237] will be conducted at 62 ± [ADDRESS_781238] enrolled in the ABSORB -RESOLVe Ischemia Sub -study has a cardiovascular related unscheduled event, 
please follow the procedures outlined in section [IP_ADDRESS] and [IP_ADDRESS].   
Abbott Vascular  Version 17.[ADDRESS_781239] 16, 2018 . APPENDIX IV:  ENROLLM ENT AND REGISTRATION  
PROCESS  
 
Figure 1.  Enrollment, Randomization and Registration  
Subject was screened and met general 
inclusion/exclusion criteria
Enrollment ICF signed*
Angiographic inclusion/exclusion met
Successful  pre-dilatation and vessel 
sizing
RandomizationCall IVRS
Registered in TrialYes
Yes
Yes
Yes
Yes
YesNo Screen failure, 
don’t enroll
No Subject not eligible, 
don’t enroll
No Screen failure, 
don’t call IVRS
ITT populationPRO Questionnaires 
Completed
    YesNoComplete after 
index procedure 
prior to discharge
* The ICF can be signed before or after the general inclusion criteria screening. Once signed, a subject is considered 
enrolled. 
Abbott Vascular  Version 17.[ADDRESS_781240] 16, 2018 . Figure 2. Enrollment through Treatment Flow  
 
Angiographic inclusion/
exclusion met Yes
YesNo
No
Call IVRS
Identify # TL lesionsDocument in eCRFYes
ABSORB BVS arm XIENCE arm Subject 
randomized
Subject is considered registered 
in ITT populationSubject a 
screen failure 
Subject RegistrationNo
Subject is clinically followed:
Telephone/office visit 30, [ADDRESS_781241] TL?Treat 2nd or 3rd TL per 
protocol requirements for 
the assigned deviceIf single TL only or if 2nd or 
3rd TL, follow protocol 
treatment strategy before 
proceeding No1st TL treatment 
successful ?Informed Consent Signed
Complete PRO Questionnaire Must Complete prior 
to discharge
Successful Pre-dilatation of the 
1st target  lesion ( TL)                     
(or multiple target lesions)If Non-target lesion 
(NTL ) present , must be 
treated 1st before 
randomization
NTL treatment 
successful?
Don t randomize 
subjectNoYes
 
Note:  
• The ICF can be signed before or after the general inclusion criteria screening. Once signed, a subject is 
considered enrolled.  
• If there are two or three target lesions, the same vessel sizing modality and treatment requirements must be used 
on all target lesions.  
• Patients in ABSORB IV will potentially  be followed up to 5 years  if it is necessary as determined by [CONTACT_429] . 
• Subjects will be clinically followed up to 5 years  
• Patient Reported Outcomes questionnaires should be completed prior to procedure after signing ICF, but must 
occur prior to discharge. The follow -up PRO questionnaires must be completed at 30  and180 days, and at 1, 3 
and 5 years . 
• Patient Perception Questionnaire will be administered by [CONTACT_592224][INVESTIGATOR_592056] (≥ 4 hours to ≤ 7 days after the procedure) and at [ADDRESS_781242] 16, 2018 . APPENDIX V:  VESSEL T REATMENT & RANDOMIZATION  
 
Figure 1. Single Vessel Treatment  
Visual assessment of lesion to 
be treated
Single Lesion
Vessel Size
Call IVRS 
randomizationMeets size 
Criteria?YesSuccessful 
pre-dil of 
lesion?No
Yes
YesDon’t call IVRS, subject 
is a screen failure
NoDon’t call IVRS, subject 
is a screen failure
Absorb BVS arm XIENCE  arm Subject 
randomized
Subject is considered registered 
in ITT population
Assigned device 
reach/cross TL?Proceed 
with 
subject 
follow-upYes
If assigned Absorb, treat w/
XIENCE; If assigned XIENCE 
treat per standard of careSuccessful 
implant? 
No No
 
Note:   
• The lesion must be successfully pre -dilated and meet vessel sizing criteria prior to randomizing subject.  
• Due to pre -dilatation being required prior to vessel sizing and r andomization, there is the possibility of an 
“unstable” target lesion. Therefore, time period between p re-dilatation and vessel sizing should be 
minimized to being as brief as possible.  
• Vessel sizing is done by [CONTACT_142184].
Abbott Vascular  Version 17.[ADDRESS_781243] 16, 2018 . Figure 2. Vessel Sizing: Multiple Vessel Treatment  
Visual Assessment of up to 
three lesions to be treated
Successful 
pre-dil of 1st or 
all TL(s)?
Vessel Size 1st or all 
TL(s)
yesYes
TL(s) meets 
size criteria?No
Yes
Absorb BVS arm XIENCE  arm Subject 
randomizedCall IVRS 
randomizationDon t 
randomize 
subject
Assigned device 
reach/cross TL?
Successful 
implant ? If assigned to Absorb 
treat with XIENCE and 
if successful addn  l TL 
treat with Absorb 
If assiged to XIENCE 
treat per standard of 
careNo YesSubject is considered registered 
in ITT population
Proceed to additional 
TL(s) treatment per 
protocolYesNoNTL treatment 
successful?yes
No
Don t 
randomize 
subjectTreat NTL Yes
 
 
Note:  
• Non-target lesion treatment can occur only in a non -target vessel. The non -target lesion must be treated first 
(XIENCE only) prior to randomization. Patient may be randomized only if treatment of the non -target 
lesion is successful.  
Abbott Vascular  Version 17.[ADDRESS_781244] 16, 2018 . • In the case of two or three target lesions, if the 1st target lesion was successfully pre -dilated and eligibility  
criteria are still met, the operator may at this point choose to randomize the patient, or pre -dilate other 
lesions. If other lesions are pre -dilated, all such pre -dilatations must be considered successful prior to 
randomization. If there are two target l esions in a single epi[INVESTIGATOR_131270], it is strongly 
recommended that both be successful pre -dilated before the patient is randomized .  
• If pre -dilatation of the 1st target lesion fails (or if pre -dilatation of  any lesion fails if multiple lesions are 
pre-dilated prior to randomization), the patient may not be randomized . 
• If the 1st target lesion was successfully pre -dilated but no longer met eligibility criteria (or if any lesion 
after pre -dilatation no longer met eligibility criteria if multiple l esions are pre -dilated prior to 
randomization), the patient may not be randomized . 
• In the case of two or three target lesions assigned to the Absorb BVS, if any of the target lesions is 
unsuccessfully treated with Absorb BVS, XIENCE must be used. If the ta rget lesion that failed treatment of 
Absorb BVS is treated successfully with XIENCE, the remaining target lesion(s) must  be treated with 
Absorb BVS. If the target lesion failed treatments with both Absorb BVS and XIENCE, all remaining 
target lesion(s) must  be treated per standard of care .  
• Due to pre -dilatation being required prior to vessel sizing and randomization, there is the possibility of an 
“unstable” target lesion. Therefore, time period between p re-dilatation and vessel sizing should be 
minimized t o being as brief as possible.  
• Vessel sizing is done by [CONTACT_142184].   
  
Abbott Vascular  Version 17.[ADDRESS_781245] 16, 2018 . APPENDIX VI: RISK ST RATIFICATION OF CARD IAC 
CATHERIZATION, STENT ING AND PERCUTANEOUS  
TRANSCATHETER CORONA RY ANGIOPLASTY  
Potential risks associated with the study device and everolimus were described in the original 
protocol. Based on additional clinical and commercial experience, and more conservative 
groupi[INVESTIGATOR_592081], Abbott Vascular can now provide a consolidated list of 
anticipated adverse events and, in alignment with ISO14155:2011 requirements, the estimated 
frequencies of those risks.  
There is extensive clinical and commercial experience worldwide with cardiac catheterization 
and interventional pro cedures. It is expected that the risks will not be significantly different with 
the use of the Absorb BVS and XIENCE V stent in this trial. The incidence rates of the known 
complications that may arise from a stenting procedure were obtained from the poole d XIENCE 
V trials conducted by [CONTACT_12227] (Spi[INVESTIGATOR_592019], Spi[INVESTIGATOR_592020], Spi[INVESTIGATOR_592021], Spi[INVESTIGATOR_592022], Spi[INVESTIGATOR_592023] 4.0 mm, 
Spi[INVESTIGATOR_592024], Spi[INVESTIGATOR_17040] V Diabetic, Spi[INVESTIGATOR_17040] V Registry, Spi[INVESTIGATOR_592025], XV [LOCATION_003], XV DAPT, and XV 
India using MedDRA Preferred Terms of site -reported 1 year  adverse events regardless of 
relationship to device or procedure ) and were classified using the frequency categories as below.  
Death and stent thrombosis within [ADDRESS_781246] been observed in < 2.0% of the patients enrolled 
in these trials.  
1. Very common : ≥ 10%: Unstable or stable angina pectoris  
2. Common: ≥ 1.0% to < 10 %: Cardiac, pulmonary or renal failure; a ccess site complications 
including pain, hematoma, or hemorrhage; vascular complication including at the entry site, 
which may require vessel rep air; coronary artery dissection; arrhythmia including atrial and 
ventricular; myocardial infarction, including acute myocardial infarction; nausea and vomiting; 
hypotension; hypertension; restenosis  
3. Uncommon: ≥ 0.1% to < 1.0%: Cardiac arrest; e mergent o r non -emergent surgery; allergic or 
hypersensitivity reactions to contrast agent or platinum, polymer poly (L -lactide) (PLLA), 
polymer poly (D,L -lactide) (PDLLA), and drug reactions to everolimus, antiplatelet drugs or 
contrast agent; bleeding complication s which may require transfusion; coronary artery spasm; 
distal emboli; fever; catheter site infection or pain; myocardial ischemia; palpi[INVESTIGATOR_814]; coronary 
artery perforation; pericarditis; peripheral ischemia (due to vascular injury); pseudoaneurysm; 
pulmo nary edema; stroke /CVA/TIA ; total occlusion of coronary artery; ventricular tachycardia; 
and ventricular fibrillation; vessel dissection  
4. Rare: ≥ 0.01% to < 0.1%:  Arteriovenous fistula; cardiac tamponade; coronary artery 
embolism; arterial injury; proced ural nausea; shock; peripheral artery dissection; peripheral 
nerve injury; renal insufficiency ; pericardial effusion  
5. Very Rare: < 0.01% (including not reported AEs): Abrupt coronary artery closure; coronary 
artery aneurysm; arterial rupture; everolimus IFU risks . 
Some IFU risks, including everolimus risks have not been observed in AV clinical studies. These 
risks are listed in the very rare category. There may be risks related to the device that are 
unknown at present.  Likewise the exact frequency of the  risk might be unknown.  
Abbott Vascular  Version 17.[ADDRESS_781247] 16, 2018 . APPENDIX VII:  CONTACT [CONTACT_7533]  
A list of investigational site co -ordinates can be obtained upon request from the Clinical Project 
Manager for the study. The Clinical Project Manager can be reached at 408 -845-3000.  